<SEC-DOCUMENT>0001439222-22-000040.txt : 20220506
<SEC-HEADER>0001439222-22-000040.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505094655
ACCESSION NUMBER:		0001439222-22-000040
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGIOS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001439222
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36014
		FILM NUMBER:		22894597

	BUSINESS ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-649-8600

	MAIL ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AGIOS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20080703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>agio-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:55e4eac5-1c9c-49df-a9ba-5fe941f4694b,g:196378a3-5ec7-4de3-a864-cc3dd9965fcc,d:a065fc71787b4c5bb0fb689995212901--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:agio="http://agios.com/20220331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agio-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV8zLTEtMS0xLTMxODI0_9579157f-b3ed-4dd1-8586-9bea788e76ff">2022</ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV80LTEtMS0xLTMxODI0_57a45550-da6f-4367-94f3-14e14d2e8aa4">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV81LTEtMS0xLTMxODI0_9e681a45-2812-45c9-a3c9-ac3664736a86">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV82LTEtMS0xLTM0Njg4_bef277d2-68b2-4f6d-ab8f-20d920ad6b7b">0001439222</ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV83LTEtMS0xLTM0Njkw_f06b0560-930b-464f-a841-31795ae3aae6">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="agio-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed2165b94a24217bfa5f7d7525c4828_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i44baacb616534e10bf3e92b51f3ca635_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4ad81482e39040cfa13a399adf4f783f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if275c08a4b1a44d1a150f50c7c881130_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6cc362c4f604b6698f86e13bb3b5e3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbd80b1c38d4e15abafa707e5b10913_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e46f8b9b7c4fa794ef1e57c63f60ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia915565fa9bf49e8a6089229571dfeb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020aaaa8244f4450abf7a489bae1b308_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb58067c996499e8ddfaee3546da6b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia723c5f1bdd7498dab4b5253a5239e6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedff87c239d041ee903730df5ff0e42d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabd827068424d0c94fda806b5666e9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib098b853fd0d4618a37120ad076e9c33_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba6574b9a85494dab7e9c14215a1307_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8b31b9ebd44400b5d964739f3458f3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97bac5a737ae4720be910bf41fbb0e01_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c10b102b3741ac813dad0356a92d49_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fa642d4aed4cbc87a473f75a555d65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3315546551a7412ba1760a313ef1c110_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72df7c6a122499cb275a14c404f6193_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3ef75081e0946589cf01741b601dbb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id99b7f6ad84a4d639bf1a58feafe6ab6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339ff47008914dcb996ae4ba141c02f0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03dffb153674380907acf14bba35d94_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e1016b843348d4859494db7ba331a1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d6c97c0efd4da4aac22b43597a001a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25af98b853e641e0826021863429c9c3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida08a64c245c4eb79187d42287aa92d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f84d4c481cd4ba7be68a72191bcf918_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2f4983539c43e795b959c6ddd43062_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b18b5af79b4bf5aca45b588737fa36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf16b64ad3af4100843dc0cb6c96f297_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia102effd057548618be0c7faa2c14a71_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffde9483458d4f4480d7cedd42c1d1e0_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i091236316b914dbcab5fb5da12dce5a3_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:VorasidenibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75182c507fc84a0aa16c99db2a260ac3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae28c36de4446c380e38079965eb99e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief104d7641164b449e022699db588dd0_D20210405-20210405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6391c1de417d466184f6c9a28dad5e87_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5203cb569ff49ca98a0359fff1bd001_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96cc6c457fc41639d4fc3f4ed2f934c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88992bda51914909b6dd871d292700b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia69dec3d703147e0a24827abbbc23547_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4126d05954e4466c8ed0d02bb4506ffb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0bcdc9702194332ba58fb885ff2771d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a87ede4a0944e6aac0235cba36b26d2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ca3b35d04643e0ad5bb05e77e88126_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7012a29f126a40258af0e6ed5765dbff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie228033d9a0b4b799dd10eaf894a5565_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7413f9c5b84645e38c9f817ef9fc6d59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b75ada5f8f43bea21d6e34291436e7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91bc918915e74396b7fef2d671257ed8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bb9c2460444fceb9a62eea46ed198e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ffcd4120185407dba6ff4635e5381d6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9dbd1b26e91468d9424a22a13ad1978_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4c15c9efd3d4ae6b10bdf6ef9f35bb2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec10babe1b934aab9dcfd367e69adf4f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1163f342e67f4b2b8954b9a8000defec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie75239587a9d477198559b60a4c19637_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i784f84d08b5046fdb42b2d6c383708d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b2447db00040c2874fb5c5e278e3b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9cef39867a74079819ffe0340b554c5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488b85c653fd499fa66acffad102fa83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05325d5c1172404596cff3bf376d9b1f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1cfedca62f472d82be8d85973de1d7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf964a81be38414aa97c9c309c1c2c82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac319395ad2486b9899656e63bb1ef3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79dd4f0c88284fe4badccb9475c4f971_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca711242fee4c6ab4d75442d9612253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i756a2ef1edac4f07b53d1470ef869070_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i855087ce662749b2b547077eb45a8a38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0577f8cd46849f2a8b97982550aea04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be1907947514eb7b13e3dc095194484_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>agio:security</xbrli:measure></xbrli:unit><xbrli:context id="i15c7600459e34951a4cec3ff06faf28f_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i70609af01f924e08961eae93134c2934_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia272dc6363a84ac2ad2bd1fac38e1aab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ae90ff305f4fc99f69ae4834a3f97a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa54a29f6a2c403383d89cfeec3aaf59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b16706b28640548b80c7b1f2d3e403_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d1a1a869b64af6af400f631a1e6c4d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e402691929e44468cadbcc8453e6514_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib271baa482c94d97ac48840b7d361a47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f547c547c3d455d9028f77bd9be80d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f510a7bc35c4acc904d0706efb5488c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c09eceb9aa140f8b2fa149e6232b87f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46afd29a81bf441a99b55105d1a18809_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ddbb4db5e1644ccaa03be39b46f2cb4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3842af82e752402aa7a5fbeedccf54b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9a1d0006454af4aeab6df1c2911d6e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c67bf64fdf4dcc9d2de216530f51c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88173f3394c14c71afab60eef3d941af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328200bab58e48e9be32dfe062e76e09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i538c902f308341ad8db797be144a4c17_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15521d93cb44d6183b8ea908841d562_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefcb67b5c5064fd198f05934740baab6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20bb451b5406436aa3044e6572769236_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd284c57e7c4c53b396b12930ced078_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba1d1e1128ab469a92b7cd44c6db0d2b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce6cd786d794f4ba84de03a86627fd4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8f36b78766499982b48169e8709eec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7ca6a9e8334a34861d3a8cc12a5faa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f5a58c7510e4e6e8d4cb2499cc30bc7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bfd973f33e846f5b7d28e08e0c6e96b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3df74c825b14d068c62180063fd7587_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab52b0c782a64d07b43279f5e7626420_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a401f6a1c148b28af205ff7abe39ac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdafde84e3d3486fbcdf4313d51d80e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia065fc71787b4c5bb0fb689995212901_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV84Mg_a8bcf614-cb25-4576-bc16-78b239cfaad5">10-Q</ix:nonNumeric><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6MDZkNmJhZWMwYTI2NGRhMzk3ZTVjYmNkZWJmMWY2YzIvdGFibGVyYW5nZTowNmQ2YmFlYzBhMjY0ZGEzOTdlNWNiY2RlYmYxZjZjMl8wLTAtMS0xLTMxODI0_f27bb7b6-1db8-4c8b-ad0d-519da949e4c5">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xMzE_d99c26d6-ccd3-469f-b134-de68af06958e">March&#160;31, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6ZTA2MDY2NzIzZjUyNDc0MWFlMzI4NjQ4ZGFlMzcyZTEvdGFibGVyYW5nZTplMDYwNjY3MjNmNTI0NzQxYWUzMjg2NDhkYWUzNzJlMV8wLTAtMS0xLTMxODI0_04b67c0e-dc81-4c8b-837a-8667b236d044">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xNjM_9c013392-be86-421a-aadf-9471167895a4">001-36014</ix:nonNumeric><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xNjg_234f207d-96b0-48b4-8ce1-9e537b88fbec">AGIOS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:20.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8wLTAtMS0xLTMxODI0_9b2e000f-4fbe-4e63-9501-d72b717a3f60">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8wLTMtMS0xLTMxODI0_9a0e06f1-ba08-4a22-ae2d-70803436927e">26-0662915</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>&#160;Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S.&#160;Employer<br/>&#160;Identification&#160;No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTAtMS0xLTMxODI0L3RleHRyZWdpb246MzgzOTMyNjAzMGM2NGRkZjkxYWE2ZjUxMWU5ZjJmMGNfNA_e343a408-aa60-466a-a379-4b6eb8d6826a">88 Sidney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTAtMS0xLTMxODI0L3RleHRyZWdpb246MzgzOTMyNjAzMGM2NGRkZjkxYWE2ZjUxMWU5ZjJmMGNfOA_29cd4338-ecce-4537-a412-9410d1c49db1">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTAtMS0xLTMxODI0L3RleHRyZWdpb246MzgzOTMyNjAzMGM2NGRkZjkxYWE2ZjUxMWU5ZjJmMGNfMTI_bf4b736e-3386-44a9-91c3-7091c0f1552c">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTMtMS0xLTMxODI0_4efe94f8-f029-42cc-82a6-96ed9208fd55">02139</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8yMzI_48f8e9e1-6681-4705-ae93-7c1ef8f9d11e">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8yMzY_2b24b20d-55b7-43fa-90ce-152e288b8353">649-8600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:2pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NzcyNTYwYjhmNjY1NGM4ZGE4MDA2ZjAyMzY1MmYzMTUvdGFibGVyYW5nZTo3NzI1NjBiOGY2NjU0YzhkYTgwMDZmMDIzNjUyZjMxNV8xLTAtMS0xLTMxODI0_88e9a368-15ea-4006-b827-0019b63bca32">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NzcyNTYwYjhmNjY1NGM4ZGE4MDA2ZjAyMzY1MmYzMTUvdGFibGVyYW5nZTo3NzI1NjBiOGY2NjU0YzhkYTgwMDZmMDIzNjUyZjMxNV8xLTEtMS0xLTMxODI0_d4797a4f-7e6e-43a0-81c2-c03eea1876d6">AGIO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NzcyNTYwYjhmNjY1NGM4ZGE4MDA2ZjAyMzY1MmYzMTUvdGFibGVyYW5nZTo3NzI1NjBiOGY2NjU0YzhkYTgwMDZmMDIzNjUyZjMxNV8xLTItMS0xLTMxODI0_b1817fda-9533-4c11-9e50-5659083fde37">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV83ODk_0fe64944-3920-4a8e-931f-9c021399a9d1">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xMTE2_aa1bb049-0435-4d54-a7c6-57ab11b9f083">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:7pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:27.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NWY0MGY2ZTUxYjUxNDgxNzgzNDRhMzAxOTFmNzA0MGYvdGFibGVyYW5nZTo1ZjQwZjZlNTFiNTE0ODE3ODM0NGEzMDE5MWY3MDQwZl8wLTAtMS0xLTMxODI0_f2ac68fa-144b-4be4-8686-42c33e33f730">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NWY0MGY2ZTUxYjUxNDgxNzgzNDRhMzAxOTFmNzA0MGYvdGFibGVyYW5nZTo1ZjQwZjZlNTFiNTE0ODE3ODM0NGEzMDE5MWY3MDQwZl8xLTMtMS0xLTMxODI0_4a469467-34a1-4b00-ab0f-459e429bf439">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NWY0MGY2ZTUxYjUxNDgxNzgzNDRhMzAxOTFmNzA0MGYvdGFibGVyYW5nZTo1ZjQwZjZlNTFiNTE0ODE3ODM0NGEzMDE5MWY3MDQwZl8yLTMtMS0xLTMxODI0_8f64ca72-b7e7-4db4-86f0-fa8aab190324">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:7pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-bottom:7pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xODU4_e6b79305-d337-4887-ae98-259e01ac061d">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of shares of the registrant&#8217;s Common Stock, $0.001 par value, outstanding on April&#160;29, 2022: <ix:nonFraction unitRef="shares" contextRef="i0ed2165b94a24217bfa5f7d7525c4828_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xOTYw_18c0c98b-2039-4012-9b9b-6510ec3243fd">54,788,927</ix:nonFraction> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH 31, 2022 </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_10">PART&#160;I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_16">Condensed Consolidated Balance Sheets as of March 31, 2022 and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_19">Condensed Consolidated Statements of Operations for the Three Months Ended </a>March 31<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_19">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_22">Condensed Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_22">(Loss) </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_22">Income</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_22"> for the Three Months Ended </a>March<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_22"> 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_25">Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended </a>March<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_25"> 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_28">Condensed Consolidated Statements of Cash Flows for the Three Months Ended </a>March<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_28"> 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_67">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_88">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_91">27</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_94">PART&#160;II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_94">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_97">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_97">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_100">56</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_103">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_103">57</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ia065fc71787b4c5bb0fb689995212901_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements (Unaudited)</span></div><div id="ia065fc71787b4c5bb0fb689995212901_16"></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets </span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMy0xLTEtMS0zMTgyNA_62d718ca-3ad3-45f6-b70c-e10aa5cb3699">80,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMy0zLTEtMS0zMTgyNA_cd26dce0-db1f-4542-a9cc-c343c52a4015">203,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNC0xLTEtMS0zMTgyNA_bf9a85b7-d54e-4c60-a8d2-a88bcc6792ef">843,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNC0zLTEtMS0zMTgyNA_9e323fb1-2a9f-4418-8177-3ae1685b5973">816,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNS0xLTEtMS0zMTgyNA_bfa41c2c-4d89-4f82-859a-a930c4853914">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNS0zLTEtMS0zMTgyNA_5ecc5231-2a13-462d-b7a8-0a69f6549559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0xLTEtMS0zNTYxNw_37ec5ba0-1698-4d2f-a9b7-077b0e6fb238">5,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0zLTEtMS0zNTYxMQ_210900e0-ea32-47c7-a814-90ef63c7138d">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0xLTEtMS0zMTgyNA_e5e2e6c9-562d-4a45-98f5-f23ce749699d">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0zLTEtMS0zMTgyNA_8c68ba58-338b-44c6-8243-99b70eb084cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTAtMS0xLTEtMzE4MjQ_3d45d48e-449f-4b9b-8dad-591ba1876c93">43,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTAtMy0xLTEtMzE4MjQ_88a0a3fa-be5b-48f8-8918-37124705b37c">39,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTItMS0xLTEtMzE4MjQ_22792d76-fa21-440b-a2d0-e1ec371cc975">975,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTItMy0xLTEtMzE4MjQ_832d7491-0309-4307-986b-516e62cec159">1,064,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTMtMS0xLTEtMzE4MjQ_e0cc86e7-5c69-4574-a80d-b35ea890fc51">255,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTMtMy0xLTEtMzE4MjQ_e8a4e17a-845a-4654-ac3d-4b6a918d0c31">266,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTQtMS0xLTEtMzE4MjQ_42edc845-5366-47b1-a4e6-ec0500857638">72,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTQtMy0xLTEtMzE4MjQ_9c1fc5ab-147d-4e07-bf83-741ea55b5e38">75,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTUtMS0xLTEtMzE4MjQ_093b2580-3e67-4906-8f6e-316a33a1de78">29,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTUtMy0xLTEtMzE4MjQ_708b6ac3-23c3-475b-8355-57595ef817c1">28,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTYtMS0xLTEtMzE4MjQ_5699380a-24e3-4c9b-93a0-82dd367dedbc">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTYtMy0xLTEtMzE4MjQ_75e6d52c-2510-4f24-b402-fd6aa71b74cc">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTctMS0xLTEtMzE4MjQ_544f2b03-a5c7-415f-a989-f4c14b02dc00">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTctMy0xLTEtMzE4MjQ_6ecf807f-0676-4d1e-a17b-0eecc4feb377">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTktMS0xLTEtMzE4MjQ_eaa4784b-43b6-4f72-8366-6c822e3f72b8">1,335,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTktMy0xLTEtMzE4MjQ_96c2decd-7a0f-4fc5-a39a-df2ffb7d3072">1,437,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjMtMS0xLTEtMzE4MjQ_4d364686-9d2e-4188-bde1-55886b6cd2ef">11,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjMtMy0xLTEtMzE4MjQ_bb34e57b-0a6c-4af3-a1cd-ff2de94ee1b6">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjQtMS0xLTEtMzE4MjQ_bf099442-cbea-4167-8a05-18de238cae15">19,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjQtMy0xLTEtMzE4MjQ_4ff6644d-4db7-4b94-915d-ff4263c11151">31,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjYtMS0xLTEtMzE4MjQ_f3a8271b-3e65-412f-b7f2-eb96ebf2b676">11,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjYtMy0xLTEtMzE4MjQ_3457ce1e-394a-4a87-8d0c-a706206efd17">10,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjctMS0xLTEtMzE4MjQ_472cfa50-55b9-405d-acaa-6013031b5e6e">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjctMy0xLTEtMzE4MjQ_9b1f539c-459e-4800-a188-e0ee1440db3c">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjktMS0xLTEtMzU2MzY_abc5bb20-b1ad-48aa-bb50-eb2807f1737f">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjktMy0xLTEtMzU2NTY_d6e9485b-bac8-45c0-b781-9e1a22751cfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzEtMS0xLTEtMzE4MjQ_3c2c0612-b8e5-4d53-8742-005237f1ea77">45,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzEtMy0xLTEtMzE4MjQ_265bae3f-3879-4b16-ab22-f8a4583cf926">59,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzMtMS0xLTEtMzE4MjQ_7b737ddb-2417-4b33-ace2-c9608c2637f0">82,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzMtMy0xLTEtMzE4MjQ_1e63873a-ce38-4492-9778-8c620ff7a959">85,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzQtMS0xLTEtMzE4MjQ_89bad927-75e1-4e2c-8965-ccfa793b3f4b">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzQtMy0xLTEtMzE4MjQ_4f7d8ffa-3fc2-49a7-b1b0-8f53ffb79978">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzctMS0xLTEtMzE4MjQ_6c5700e7-061a-479a-8313-c1d54ba3b8fd">128,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzctMy0xLTEtMzE4MjQ_97fe49d8-c09e-4b58-b39c-aa80f496f9d9">145,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8yMQ_1d214f80-3154-4d5f-a648-bec6acb00dd4"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8yMQ_e12e2a1d-0911-4ee4-a8f4-4253d4ad3322">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8zNQ_1ee848ef-a468-4224-b662-d63c7683fdd2"><ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8zNQ_3430f1ec-b187-4fcb-b367-18d3fb1f6647">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_10ffdb48-24cc-4573-8518-655c87218b78"><ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_4fe08b35-00ec-4c31-a5d6-06894dbf6cd2"><ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_507b2d21-1694-4b7a-b343-c1b6d7b6df34"><ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_b8020732-47e0-4461-8bc0-28df0e59aead">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMS0xLTEtMzE4MjQ_e0d98215-e05c-45c7-baa8-7334bf69a17b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMy0xLTEtMzE4MjQ_b3dd9f65-3a80-4152-b712-7b4f6e6f4fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8xOA_c3a73faf-3024-4030-9999-1ff69e29cc1c"><ix:nonFraction unitRef="usdPerShare" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8xOA_dfb0d0a8-5f55-4f78-914b-1d0a9299d41b">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8zMg_b1697637-3318-41e6-b7d0-c03505f97a2d"><ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8zMg_be9d7bb2-66f7-42e6-897c-316ed548e016">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV81NA_a4cc14ef-6629-4efd-a426-dedb0721b92a">70,993,277</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8yMTk5MDIzMjU1ODk3_19aa9db0-1cd9-4709-a631-907215d78fe5">54,776,467</ix:nonFraction> shares outstanding at March&#160;31, 2022, and <ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV82MQ_c220b542-1a8c-4257-a00f-af847f7341f5">70,550,631</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8yMTk5MDIzMjU1OTAx_0b0c0018-753b-4ed4-9124-07892373d8f2">54,334,220</ix:nonFraction> shares outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMS0xLTEtMzE4MjQ_3576fc07-667a-4aa5-8a0a-52de30e613d1">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMy0xLTEtMzE4MjQ_abb96413-227f-4206-877c-84e9a1cd0f4d">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDEtMS0xLTEtMzE4MjQ_ee6b038e-d331-4b48-bf3a-efdfb77c98a9">2,351,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDEtMy0xLTEtMzE4MjQ_aa4748b2-ca25-4ba2-bf26-bc47453db470">2,334,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDItMS0xLTEtMzE4MjQ_95b7cb98-88ae-4a2e-8140-5bc5b557a755">7,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDItMy0xLTEtMzE4MjQ_b58961b0-4c6a-420a-b773-29fc71dd7349">1,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMC0xLTEtMzIyODcvdGV4dHJlZ2lvbjo3MGFhZjc5N2NlYjM0YjA1OWU2OWMxMWVjZGQzNjFiNV8yNzQ4Nzc5MDY5NTg2_1ced238c-d8a9-40e1-a240-a23e71fa7d40"><ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMC0xLTEtMzIyODcvdGV4dHJlZ2lvbjo3MGFhZjc5N2NlYjM0YjA1OWU2OWMxMWVjZGQzNjFiNV8yNzQ4Nzc5MDY5NTg2_4a0eece7-1b3b-409f-89ec-0edade0b36ca">16,216,411</ix:nonFraction></ix:nonFraction> shares at March&#160;31, 2022 and December&#160;31, 2021)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMS0xLTEtMzQ1NzA_70fbb7e8-41cd-41ab-b4d5-b180bc907801">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMy0xLTEtMzIzMjQ_37461d91-866b-454c-90db-daa33fcf019e">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMS0xLTEtMzE4MjQ_953297b4-14e7-4a2f-b9ea-67e879e4076e">333,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMy0xLTEtMzE4MjQ_49fe4555-d215-4106-a1cf-5b6a00588c7b">238,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDQtMS0xLTEtMzE4MjQ_533506e7-9157-42e6-bdf6-5feb02d0efb8">1,207,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDQtMy0xLTEtMzE4MjQ_327b585f-3dd7-481a-ab7f-dcee4fa47928">1,291,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDUtMS0xLTEtMzE4MjQ_d2a5d307-2a16-4426-b53e-5a5ef2af820c">1,335,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDUtMy0xLTEtMzE4MjQ_5d88b28e-f457-4d3e-b6ef-f696dbc38c08">1,437,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad81482e39040cfa13a399adf4f783f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMy0xLTEtMS0zMTgyNA_33a583f2-a477-4dec-a7d9-017f3554372f">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if275c08a4b1a44d1a150f50c7c881130_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMy0zLTEtMS0zMTgyNA_ae22ef86-9178-488a-b06d-24ec4fb1753b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfNy0xLTEtMS0zMTgyNA_136ae9fa-e33e-4dc7-84dc-65d04b02b1ed">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfNy0zLTEtMS0zMTgyNA_ac7a3de1-f327-445f-a12b-a024c66a41bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfOS0xLTEtMS0zMTgyNA_8b7dc187-e834-4d79-8b94-b27b9a9d5268">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfOS0zLTEtMS0zMTgyNA_446488b8-dd38-4b64-ab19-f9c4db9a94f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTAtMS0xLTEtMzE4MjQ_063a4e3f-476a-44e3-81a4-38fc27b5122c">70,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTAtMy0xLTEtMzE4MjQ_94eb9c08-580a-4146-acad-dc250ffbddc2">57,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTEtMS0xLTEtMzE4MjQ_1d7521b9-7490-4d9f-9906-1259421543db">31,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTEtMy0xLTEtMzE4MjQ_b8552ae6-1dd5-4589-828c-d90972ad0d81">33,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTItMS0xLTEtMzE4MjQ_542cdda7-d152-4992-a21d-3cbf0ab1736b">101,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTItMy0xLTEtMzE4MjQ_c8682ab1-f9a0-42a0-a193-b9744b0cf809">91,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTMtMS0xLTEtMzE4MjQ_8518329f-a8e9-4452-b911-9c3200b850e3">101,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTMtMy0xLTEtMzE4MjQ_063f7083-8fe4-496e-8d30-68d7bee01502">91,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty income from gain on sale of oncology business </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMS0xLTEtMzU1NzQ_7efcb7a3-6157-4b7f-a188-181d14264eb3">2,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMy0xLTEtMzU1OTA_34f29d06-394b-4e8c-a98d-7ae884f46a55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMS0xLTEtMzE4MjQ_e8c8b405-6546-4b6b-b3f6-a125a70c8c1e">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMy0xLTEtMzE4MjQ_0438c14e-5eae-4fcc-863d-88fcd95fc672">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMS0xLTEtMzU1ODA_4f7674c5-078b-49bf-9a27-0d78b019c21e">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMy0xLTEtMzU1OTY_fa107b2e-e234-4416-8bc1-b7c051be9a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMS0xLTEtMzE4MjQ_8aba767f-904d-4622-b343-768e85b0e3bc">94,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMy0xLTEtMzE4MjQ_d09da321-137d-459d-99a7-12946590914d">90,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTctMS0xLTEtMzE4MjQ_30ee9d27-acbe-4b16-900e-b418aa1b4e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTctMy0xLTEtMzE4MjQ_ecccbb83-a610-479e-8881-52b2a26ebf90">1,965,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTgtMS0xLTEtMzE4MjQ_dd4aae5e-6711-4bdb-bfce-6ec1d8886786">94,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTgtMy0xLTEtMzE4MjQ_41a8969f-0388-4828-9773-b5d82135599f">1,874,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations per share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMS0xLTEtMzE4MjQ_0241a026-4d20-46c6-9014-73b7d92d3add"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMS0xLTEtMzE4MjQ_fc77b9a6-fe40-4feb-9f7f-300377e5b84c">1.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMy0xLTEtMzE4MjQ_434d42e4-2fe1-49d7-9ca8-6e4f5949d3b5"><ix:nonFraction unitRef="usdPerShare" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMy0xLTEtMzE4MjQ_62d1c88a-a39b-4bce-abd2-5308133c93fd">1.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMS0xLTEtMzE4MjQ_1d9f1099-df74-47c8-a64a-9cc41f6a4657"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMS0xLTEtMzE4MjQ_e8973637-a890-4c6e-beb1-b55b5a9ad947">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMy0xLTEtMzE4MjQ_38064d6e-69a9-4da5-bae7-cf5c88eb0e1b"><ix:nonFraction unitRef="usdPerShare" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMy0xLTEtMzE4MjQ_ab5fe4bb-4d9a-4945-8055-62c60b30298c">28.26</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMS0xLTEtMzE4MjQ_5e4db68c-3b06-4193-8a56-77790eac3ea0"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMS0xLTEtMzE4MjQ_ce9d8063-b496-4198-8aef-83f3ae19b689">1.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMy0xLTEtMzE4MjQ_bb9e1a31-6c6c-4873-b71e-9c850dcc277f"><ix:nonFraction unitRef="usdPerShare" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMy0xLTEtMzE4MjQ_f21ea2fe-1c69-42a9-a522-0e8d99913ccf">26.95</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMS0xLTEtMzE4MjQ_0a967ef8-8643-4e3c-9dc3-3a9f98360e02"><ix:nonFraction unitRef="shares" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMS0xLTEtMzE4MjQ_21104ec4-4fe9-49dc-8047-510d4a6d35af">54,555,467</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMy0xLTEtMzE4MjQ_0aa0b955-b295-4891-9441-b007f5c97f06"><ix:nonFraction unitRef="shares" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMy0xLTEtMzE4MjQ_eaf0a060-e717-45fe-971a-2d5c5f5a0387">69,543,510</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive (Loss) Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfMi0xLTEtMS0zMTgyNA_3d64cbfd-0fcb-46bc-80f2-a08d8f9d9b31">94,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfMi0zLTEtMS0zMTgyNA_232458e1-e8b3-4713-924e-f6dd20e1f79c">1,874,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNC0xLTEtMS0zMTgyNA_f97d6d3d-9322-4e97-a9f5-0a2916fda876">6,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNC0zLTEtMS0zMTgyNA_8a5f4225-652c-48ac-9ee3-09d8e2bfc9a1">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNS0xLTEtMS0zMTgyNA_7ba0a35f-8601-4734-91f5-f3c338203d6f">101,321</ix:nonFraction>)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNS0zLTEtMS0zMTgyNA_13c077fb-5895-4eab-a680-f8fc9661ba54">1,874,217</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.436%"></td><td style="width:0.1%"></td></tr><tr style="height:47pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6cc362c4f604b6698f86e13bb3b5e3c_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xLTEtMS0zMTgyNA_d9f76105-e00b-4aa4-8495-e68e2bbd7eea">70,550,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cc362c4f604b6698f86e13bb3b5e3c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0zLTEtMS0zMTgyNA_ca986fec-a424-4aeb-8e21-926f8d5c97ee">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbd80b1c38d4e15abafa707e5b10913_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi01LTEtMS0zMTgyNA_ab51b06a-2d96-414c-86d7-76a09116beae">2,334,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e46f8b9b7c4fa794ef1e57c63f60ec_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi03LTEtMS0zMTgyNA_2c470995-affc-463e-b4e7-ec6fbfc23fbc">1,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia915565fa9bf49e8a6089229571dfeb9_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi05LTEtMS0zMTgyNA_6e0e3539-85a7-44f9-bef6-26e740164974">238,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i020aaaa8244f4450abf7a489bae1b308_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xMS0xLTEtMzQ0NzI_2d979635-c3f4-4f1a-a52f-1e577b6f4637">16,216,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i020aaaa8244f4450abf7a489bae1b308_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xMy0xLTEtMzQ0Nzk_ceee0e74-5190-4886-ba9b-75ae7ef079ac">802,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xMS0xLTEtMzE4MjQ_168d53c9-119a-4a2c-b0ac-f17b46fde7a1">1,291,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cb58067c996499e8ddfaee3546da6b3_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNC0xLTEtMS0zMTgyNA_a9ee233f-0327-424a-934e-fd648a04810f">442,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia723c5f1bdd7498dab4b5253a5239e6a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNC01LTEtMS0zMTgyNA_6a6a387c-e89a-4567-911e-3fbdb5211d66">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNC0xMS0xLTEtMzE4MjQ_8aa48c9f-c7df-4814-a265-b1286e028441">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia723c5f1bdd7498dab4b5253a5239e6a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNS01LTEtMS0zMTgyNA_01e985e4-586e-4db5-9323-6587839cb69c">15,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNS0xMS0xLTEtMzE4MjQ_bfc2d1ae-649f-4acd-9fa5-c2e4e172ee82">15,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedff87c239d041ee903730df5ff0e42d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNi03LTEtMS0zMTgyNA_d9a20c17-1773-4b93-a25d-6a2d30fc96b1">6,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNi0xMS0xLTEtMzE4MjQ_6eb43c66-b065-439f-9713-5f5fc0715042">6,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idabd827068424d0c94fda806b5666e9a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNy05LTEtMS0zMTgyNA_5229dd44-01fd-4b27-8578-b93f9ea8dfda">94,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNy0xMS0xLTEtMzE4MjQ_01841355-e74b-4081-9cc9-d25fb9582a63">94,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib098b853fd0d4618a37120ad076e9c33_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xLTEtMS0zMTgyNA_84417e02-19eb-481d-b343-df68e35b4d79">70,993,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib098b853fd0d4618a37120ad076e9c33_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0zLTEtMS0zMTgyNA_c49bf259-88f8-4c32-a61f-98cecd9e8796">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6574b9a85494dab7e9c14215a1307_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS01LTEtMS0zMTgyNA_0e3e8060-23a9-44a9-b7a5-eff10a117bef">2,351,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa8b31b9ebd44400b5d964739f3458f3_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS03LTEtMS0zMTgyNA_9b20e5d2-bfc9-4f94-85c9-28144aa02b0f">7,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97bac5a737ae4720be910bf41fbb0e01_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS05LTEtMS0zMTgyNA_a5ad190f-082a-4599-be59-79b3a9e2e563">333,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if6c10b102b3741ac813dad0356a92d49_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xMS0xLTEtMzQ1MTM_fe6bd396-348c-4393-918b-d8006242bdeb">16,216,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c10b102b3741ac813dad0356a92d49_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xMy0xLTEtMzQ1MjA_0e291215-365a-4feb-b748-143986472edf">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xMS0xLTEtMzE4MjQ_11eb5a68-e11f-4d6e-bdd2-7d77c49fd0e5">1,207,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3fa642d4aed4cbc87a473f75a555d65_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi0xLTEtMS0zMTgyNA_060cf544-5c7f-4662-a58a-f902ec961ef2">69,293,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fa642d4aed4cbc87a473f75a555d65_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi0zLTEtMS0zMTgyNA_bf8ad4b0-60d5-4a70-b1c2-6f98a465142c">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3315546551a7412ba1760a313ef1c110_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi01LTEtMS0zMTgyNA_b4e05a5d-126e-4825-8e1a-0bb7c4bc81cb">2,242,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72df7c6a122499cb275a14c404f6193_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi03LTEtMS0zMTgyNA_53578bbc-6b6a-48a8-8fb7-426e705e21a5">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3ef75081e0946589cf01741b601dbb9_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi05LTEtMS0zMTgyNA_1cd5da15-f04a-4251-957a-e1ec5444cad5">1,843,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99b7f6ad84a4d639bf1a58feafe6ab6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi0xMS0xLTEtMzE4MjQ_c868f0ea-c305-4021-838a-6bff13deb5c6">399,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i339ff47008914dcb996ae4ba141c02f0_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy0xLTEtMS0zMTgyNA_797d589a-f609-4e11-a905-5ae799772e0d">518,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339ff47008914dcb996ae4ba141c02f0_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy0zLTEtMS0zMTgyNA_f4cfe42f-e126-4291-8cdb-d9d1ca5801a9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03dffb153674380907acf14bba35d94_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy01LTEtMS0zMTgyNA_f934e575-74c4-4090-a601-df454302770f">7,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy0xMS0xLTEtMzE4MjQ_af98b0a2-734a-4bb8-8937-b85b6ff2f5b7">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03dffb153674380907acf14bba35d94_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNC01LTEtMS0zMTgyNA_c41b584a-e8fc-4b50-bbdc-e1a66448f56a">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNC0xMS0xLTEtMzE4MjQ_bc9f42de-66a9-42f1-b5c4-155163a3e7cc">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e1016b843348d4859494db7ba331a1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNS03LTEtMS0zMTgyNA_dda99467-5b19-4daf-ab68-14ccec3678d4">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNS0xMS0xLTEtMzE4MjQ_e9cbcaa4-6183-4755-bd46-603eb6143f8c">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d6c97c0efd4da4aac22b43597a001a_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNy05LTEtMS0zMTgyNA_ee155b2d-8880-4137-9076-242aac88ce0a">1,874,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNy0xMS0xLTEtMzE4MjQ_306d9406-3d10-4d73-9f9a-650fc338e3a0">1,874,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposition of oncology business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03dffb153674380907acf14bba35d94_D20210101-20210331" decimals="-3" sign="-" name="agio:StockholdersEquityDispositionOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOC01LTEtMS0zMTgyNA_e96c00d4-d027-4f1d-babb-da5f4769a969">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="agio:StockholdersEquityDispositionOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOC0xMS0xLTEtMzE4MjQ_6c4d8516-31ab-4edb-a334-ccb667a51c0f">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25af98b853e641e0826021863429c9c3_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS0xLTEtMS0zMTgyNA_a2e77d02-d6d9-4e67-afe1-185045713601">69,812,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25af98b853e641e0826021863429c9c3_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS0zLTEtMS0zMTgyNA_4f6fa828-1964-46ea-a559-6b6778d96e52">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida08a64c245c4eb79187d42287aa92d9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS01LTEtMS0zMTgyNA_27bb8371-11c3-4ae1-950b-e8c6bab89953">2,265,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f84d4c481cd4ba7be68a72191bcf918_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS03LTEtMS0zMTgyNA_1bc728df-26c2-46a7-962e-7b281c09d8dd">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2f4983539c43e795b959c6ddd43062_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS05LTEtMS0zMTgyNA_02ead992-ad20-4128-b780-4d32c7bfa11b">30,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b18b5af79b4bf5aca45b588737fa36_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS0xMS0xLTEtMzE4MjQ_ba23e4c4-0126-4afe-814c-8d6833e78725">2,296,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.<br/><br/>Condensed Consolidated Statements of Cash Flows<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMy0xLTEtMS0zMTgyNA_b2d516bb-c554-428c-adfa-7ed9100d7b61">94,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMy0zLTEtMS0zMTgyNA_a080bda2-766a-4604-8dd8-263cc3d610ff">1,874,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNC0xLTEtMS0zMTgyNA_763e5861-575e-414f-b73e-46767a6eb1eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNC0zLTEtMS0zMTgyNA_38f1a7d2-5aff-4f42-a814-0a76bc272b07">1,965,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNS0xLTEtMS0zMTgyNA_b5ea93dc-f964-42ee-ad75-dbe5831055a6">94,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNS0zLTEtMS0zMTgyNA_f29a2286-50a7-42f6-ba4a-c01207a9fd63">90,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNy0xLTEtMS0zMTgyNA_5cd4c65d-df24-4871-81bc-6b0a92b7cf0e">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNy0zLTEtMS0zMTgyNA_37c4b4a4-168f-4132-8f5a-c6aec4e09765">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOC0xLTEtMS0zMTgyNA_271acf7d-378d-414c-b663-1729d04528e1">15,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOC0zLTEtMS0zMTgyNA_97d4ff25-5996-4013-958f-e4eb4572049c">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amortization of premium (accretion of discount) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOS0xLTEtMS0zMTgyNA_b34dea66-285b-492e-8cb9-3da5e47c3ec3">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOS0zLTEtMS0zMTgyNA_86548893-a470-478e-bc80-61dd9e16b8a1">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTEtMS0xLTEtMzE4MjQ_7ee41d1c-5a5d-41d1-9884-dc2ad9a9d150">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTEtMy0xLTEtMzE4MjQ_4105b3d0-a534-4906-94bf-8a90b1ec78e1">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTgtMS0xLTEtMzE4MjQ_27de165a-846d-489f-b46d-18d45dde38da">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTgtMy0xLTEtMzE4MjQ_599839dd-5e1b-449e-a636-3325bcf16ec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjItMS0xLTEtMzE4MjQ_eb894c2c-7a0e-43a4-bfa4-3a0523564465">2,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjItMy0xLTEtMzE4MjQ_6b001bbd-24cd-4fc8-8e02-9ff84cc905c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMS0xLTEtMzU3MTU_7b1ec498-fb0c-4a35-ac50-53e53b60a41b">987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMy0xLTEtMzU3MjE_00c2c653-da6f-4901-b01f-dab1acafa8d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMS0xLTEtMzE4MjQ_d4748926-86c3-4e62-924e-b170f2c42e99">3,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMy0xLTEtMzE4MjQ_be1104bf-a84b-4a4d-9bab-95ec3c7373eb">3,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjUtMS0xLTEtMzE4MjQ_bba95098-e765-435b-9679-3726b387994b">5,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjUtMy0xLTEtMzE4MjQ_64dd4b35-c986-48a8-9730-525da2245d35">2,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjYtMS0xLTEtMzE4MjQ_c8a94bfa-b36d-4a5b-acec-0bd64ebab2a0">12,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjYtMy0xLTEtMzE4MjQ_b570f57b-3e5c-4868-97fb-3f360aa9585c">12,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjktMS0xLTEtMzU3NTg_3f9dabd2-65bd-4186-ab00-6acd7a7e06a1">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjktMy0xLTEtMzU3NjQ_4200f288-30e3-4368-925f-8d00258aab72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjgtMS0xLTEtMzE4MjQ_6856698e-c032-4122-93db-fb92e51ae6cc">2,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjgtMy0xLTEtMzE4MjQ_5d572b29-980a-455d-810e-b6b97c1b8424">1,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities - continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzAtMS0xLTEtMzE4MjQ_3b90bc75-c73a-482f-a6a1-661928b4b9db">97,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzAtMy0xLTEtMzE4MjQ_8840ac64-d8e8-4f7d-b778-ae25734e8437">90,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities - discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzEtMS0xLTEtMzE4MjQ_de99894c-f5f2-4632-ae23-a8045712254f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzEtMy0xLTEtMzE4MjQ_e6fce83f-5a7b-46a2-b664-4d541c12fc89">30,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzItMS0xLTEtMzE4MjQ_f3f6cec3-fa3d-4611-aa9f-dcb11a6c9b98">97,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzItMy0xLTEtMzE4MjQ_c26987b7-f74d-4295-934b-5131e9c56dcf">120,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzQtMS0xLTEtMzE4MjQ_68b9131f-f159-4dbd-8ecf-77847cd6fcce">355,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzQtMy0xLTEtMzE4MjQ_0e7de1c5-7776-485c-908f-b23eed390cd7">61,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzUtMS0xLTEtMzE4MjQ_acd5ca3a-ab40-4374-b994-084cec87de5a">332,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzUtMy0xLTEtMzE4MjQ_1c943a6d-c711-427d-979c-c09dce5ef85f">134,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzYtMS0xLTEtMzE4MjQ_8480976a-27d6-42e5-9960-d91be46a5393">2,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzYtMy0xLTEtMzE4MjQ_e6f211aa-890b-4c21-9027-cfbdf50d2df8">1,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities - continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzctMS0xLTEtMzE4MjQ_1457f2e3-9ef6-44f3-a85b-32d45bfc3b4e">26,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzctMy0xLTEtMzE4MjQ_b6a55f68-a44d-44fe-ac41-96e9d74980d7">71,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities - discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzgtMS0xLTEtMzE4MjQ_c7a94860-1cf9-464a-aeb8-728781bfc747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzgtMy0xLTEtMzE4MjQ_51b71b37-324f-4478-8072-24b638f4c114">1,802,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzktMS0xLTEtMzE4MjQ_3165259a-cea1-4acc-bbd4-2b963d39024d">26,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzktMy0xLTEtMzE4MjQ_f2691f0d-34b6-4787-9857-d86c8cf42b82">1,874,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on financing lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDEtMS0xLTEtMzE4MjQ_5a63de8b-c9d6-48b5-b9f9-8c55c7205ecb">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDEtMy0xLTEtMzE4MjQ_d0daf0fc-6bb9-462c-9139-5a898d59fd41">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDQtMS0xLTEtMzE4MjQ_51230fb1-13a1-411c-b4ab-a6f8e85336c0">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDQtMy0xLTEtMzE4MjQ_f3e6f393-c5cf-4ad2-9c78-3f561f8bf29e">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities - continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDUtMS0xLTEtMzE4MjQ_a85150c4-d0b1-4c44-9cc0-592473c3ac5d">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDUtMy0xLTEtMzE4MjQ_cc0fabbd-cbc8-4c92-952f-654dbf4c9dbe">7,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities - discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDYtMS0xLTEtMzE4MjQ_3911d3f6-abbf-4569-9855-6b8d2cd27009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDYtMy0xLTEtMzE4MjQ_343ce066-45db-41ef-89d1-eaa380464663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDctMS0xLTEtMzE4MjQ_0183d318-81f6-4557-9958-48018093811c">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDctMy0xLTEtMzE4MjQ_3fed14df-c5cc-40b8-8545-1f0bcfbcfed7">7,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDgtMS0xLTEtMzE4MjQ_b0c0c20d-b484-4814-abe0-a43b48df64ef">123,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDgtMy0xLTEtMzE4MjQ_1a748a91-5920-41c6-b04e-045c401bbc93">1,760,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDktMS0xLTEtMzE4MjQ_5ffc83c5-9bd2-4fa1-884a-b1ef6d224fa3">203,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99b7f6ad84a4d639bf1a58feafe6ab6_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDktMy0xLTEtMzE4MjQ_c271731c-30df-4373-a0b5-ee5d3ee9314d">127,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTAtMS0xLTEtMzE4MjQ_2beacb4b-d553-44c5-8228-543f855b63b4">80,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b18b5af79b4bf5aca45b588737fa36_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTAtMy0xLTEtMzE4MjQ_6abb075e-4fb1-4072-9279-6d6ec573201d">1,888,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing transactions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTItMS0xLTEtMzE4MjQ_ff7388ad-e499-4303-a90d-cb3f8a2d8c5f">1,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTItMy0xLTEtMzE4MjQ_0967ad8d-fe23-495e-9046-902d7c07b78e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNjAtMS0xLTEtMzgzMjY_a2dd34b2-bc35-4487-92e7-fa8f44085e4f">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNjAtMy0xLTEtMzgzNDE_f917debb-69e0-4d3e-8aef-c81c32ac1837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ia065fc71787b4c5bb0fb689995212901_34"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA2MQ_2c3d8a37-64fc-41f9-abbd-dd643161fff7" continuedAt="if2ebec576d1e40aa9e57ca8f54119c46" escape="true">Overview and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="if2ebec576d1e40aa9e57ca8f54119c46" continuedAt="ie66147ed9e374c86abc6ae4e737df8d4"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our Board of Directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for genetically defined diseases, or GDDs. We take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect, while cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for GDDs. We are located in Cambridge, Massachusetts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our GDD portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. On February 17, 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. In June 2021, we submitted a marketing authorization application, or MAA, to the European Medicines Agency, or EMA, for the treatment of adults with PK deficiency in the European Union. The MAA has passed validation, and the regulatory review process is ongoing. In addition, we are currently evaluating PYRUKYND&#174; for the treatment of thalassemia and sickle cell disease, or SCD, in clinical trials. We are also developing AG-946, a novel, next-generation PKR activator, for the potential treatment of hemolytic anemias and other indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, we foster a productive research engine and are seeking to advance multiple novel, investigational therapies in clinical and preclinical development in our focus area of GDDs, based on our scientific leadership in the field of cellular metabolism and adjacent areas of biology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, product liability claims and government investigations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of our Oncology Business to Servier</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $<ix:nonFraction unitRef="usd" contextRef="idf16b64ad3af4100843dc0cb6c96f297_D20210331-20210331" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfODY4_e5e58065-9022-461f-b312-f941e2dd4117">1.8</ix:nonFraction>&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $<ix:nonFraction unitRef="usd" contextRef="ia102effd057548618be0c7faa2c14a71_I20210331" decimals="-6" name="us-gaap:GainContingencyUnrecordedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfOTQ0_4df1a40b-c2b0-4b59-bf7d-c3779f856134">200</ix:nonFraction>&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of <ix:nonFraction unitRef="number" contextRef="iffde9483458d4f4480d7cedd42c1d1e0_D20210331-20210331" decimals="2" name="agio:GainContingencyRoyaltyPercentageOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTQzNw_f7a39a13-203d-4fbc-99a8-0e5f02f57b41">5</ix:nonFraction>% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of <ix:nonFraction unitRef="number" contextRef="i091236316b914dbcab5fb5da12dce5a3_D20210331-20210331" decimals="2" name="agio:GainContingencyRoyaltyPercentageOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTU1MA_4927a16e-8140-4ccb-ab2f-250b5d362fea">15</ix:nonFraction>% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $<ix:nonFraction unitRef="usd" contextRef="i75182c507fc84a0aa16c99db2a260ac3_I20210331" decimals="-5" name="agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTc3Nw_1726241b-9b67-49fa-a57e-980fc95d56fb">25.0</ix:nonFraction>&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#174; development program.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="ie66147ed9e374c86abc6ae4e737df8d4" continuedAt="i4c9a8c9adf2440f583eb2b4f41fd2bdf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded income from royalties of approximately $<ix:nonFraction unitRef="usd" contextRef="icae28c36de4446c380e38079965eb99e_D20220101-20220331" decimals="-5" name="agio:ContingentGainOnDispositionOfBusinessRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTY0OTI2NzQ3NTA2MQ_c30400f3-7f10-4fbf-babe-22f6ec2bf291">2.7</ix:nonFraction> million on U.S. net sales of TIBSOVO&#174; by Servier in the royalty income from gain on sale of oncology business line item within the condensed consolidated statements of operations, for the three months ended March 31, 2022.</span></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA2NA_449f548b-0f70-40ce-b3d0-a594ccd1ac2d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, comprehensive (loss) income and stockholders' equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2022, our results of operations and stockholders' equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2021 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;24, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA3Ng_8bb50db0-b420-4a52-afb0-c263626f7119" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA3Nw_ab4189cf-c5a0-4e1e-a785-fb82a0a24b47" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier, and received approximately $<ix:nonFraction unitRef="usd" contextRef="idf16b64ad3af4100843dc0cb6c96f297_D20210331-20210331" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4NzExNg_e5e58065-9022-461f-b312-f941e2dd4117">1.8</ix:nonFraction>&#160;billion in cash at closing. In connection with the sale, on March 25, 2021, we announced that our Board of Directors authorized the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4NzEwMA_40861fa3-6ce9-4af9-a2dd-e2cd99573259">1.2</ix:nonFraction>&#160;billion of our outstanding shares of common stock, or the Repurchase Program, using the proceeds from the sale of our oncology business to Servier. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with Bristol-Myers Squibb Company, or BMS, to repurchase <ix:nonFraction unitRef="shares" contextRef="ief104d7641164b449e022699db588dd0_D20210405-20210405" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE0Mw_40ba7756-ec21-425a-b9ac-a04ef3486eab">7.1</ix:nonFraction>&#160;million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ief104d7641164b449e022699db588dd0_D20210405-20210405" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE1Ng_fa993b9c-0159-48d7-9980-8ac49d3c9c2b">344.5</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ief104d7641164b449e022699db588dd0_D20210405-20210405" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE3Mg_6ed72c90-839e-4bee-a50d-0fa06058bd9d">48.38</ix:nonFraction> per share. This repurchase was completed on April 5, 2021. Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan pursuant to which we could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6391c1de417d466184f6c9a28dad5e87_I20210402" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE4MA_20597e01-5ad5-49bd-b083-fe4453d70115">600.0</ix:nonFraction>&#160;million of shares of our common stock. On October 5, 2021, we terminated our Rule 10b5-1 share repurchase program and on October 13, 2021 we entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization. As of December 31, 2021 and March 31 2022, we repurchased approximately <ix:nonFraction unitRef="shares" contextRef="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE5NA_08bd6c00-5382-48b9-96f2-9497f6da2dfe">9.1</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODIwNw_94909367-43c9-4595-b2ba-f3293c052b84">458.0</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODIyMw_fdd80240-864f-4ffd-93bf-5743279a7572">50.35</ix:nonFraction> per share, under the Rule 10b5-1 repurchase plan. As of March 31, 2022, we have not repurchased any shares under the Rule 10b-18 repurchase plan. In total, as of December 31, 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODI1NQ_03bdfe9b-b3f5-43d7-81bb-224514b0cbf8">16.2</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODIzMQ_aa5532a7-8270-4ba0-8be7-3f7904161923">802.5</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODI0Nw_cd28b6b9-a04e-45e1-98d0-4ad789497754">49.49</ix:nonFraction> per share, under the Repurchase Program. We have paused our share repurchases for the foreseeable future.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c9a8c9adf2440f583eb2b4f41fd2bdf">As of March 31, 2022, we had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-8" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTY0OTI2NzQ3NTE2NQ_c8c1dd16-11ef-40cf-8038-9b55be549292">1.2</ix:nonFraction> billion. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.</ix:continuation></span></div><div id="ia065fc71787b4c5bb0fb689995212901_37"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfMjg3Nw_046e2257-2777-4ce7-88c4-6446f73c6bbb" continuedAt="i12c9218e3619418d8332254e380316cd" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i12c9218e3619418d8332254e380316cd" continuedAt="i4c5804374ad64a5cac4d3d273bd836a6"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzNg_c2345397-a924-4b66-8838-53044a909d13" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzNw_cc6f0401-028a-4497-bd9d-8cd6835efeeb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, by the FDA on February 17, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the treatment of hemolytic anemia in adults with PK deficiency in the United States, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we began to capitalize inventories of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzOA_0a5e09dc-6cf8-4e5c-9cc7-d0f71131e48b" continuedAt="id205079cd5ee40769c51b3b235668c9e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4c5804374ad64a5cac4d3d273bd836a6"><ix:continuation id="id205079cd5ee40769c51b3b235668c9e"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div></ix:continuation><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzOQ_04ee1505-1f16-4600-badc-a8ee8dd73da6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of sales consists primarily of manufacturing costs of PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ecorded during the three months ended March 31, 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the three months ended March 31, 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfMjg3Mw_ed14ab0b-e36a-4ce5-a741-d6fd601e27f1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="ia065fc71787b4c5bb0fb689995212901_43"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTgyMw_033f916b-d55f-4616-b186-b0e8c98268d0" continuedAt="ib0a6c75ae7ec4f12b4417f9b66e990e2" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib0a6c75ae7ec4f12b4417f9b66e990e2" continuedAt="i13e290809c2c4d2faf9d817d7798c450"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTgxOQ_d66f2469-4874-4b90-b26a-e8115dc6cb10" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="i13e290809c2c4d2faf9d817d7798c450"><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTgyMQ_9dbca96c-a864-4d85-80b5-482c314c01a4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value and by level on a recurring basis as of March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5203cb569ff49ca98a0359fff1bd001_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS0xLTEtMS0zMTgyNA_d350e41a-8082-422a-8f8f-24975e4ad4b7">8,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96cc6c457fc41639d4fc3f4ed2f934c_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS0zLTEtMS0zMTgyNA_3b550aae-16ec-49c2-b597-3ed4300c0fc1">57,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88992bda51914909b6dd871d292700b7_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS01LTEtMS0zMTgyNA_14a68414-57d8-42a6-901e-fd15f0325cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69dec3d703147e0a24827abbbc23547_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS03LTEtMS0zMTgyNA_0aa89dcd-c629-4e21-8512-22944f026b3f">66,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4126d05954e4466c8ed0d02bb4506ffb_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi0xLTEtMS0zMTgyNA_8d59aab8-08b2-4291-9eac-3794fe6a51b7">8,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi0zLTEtMS0zMTgyNA_4d66c5d9-e86d-491e-ac0c-0696d64f14d9">57,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi01LTEtMS0zMTgyNA_125b7091-980e-4eee-9995-a2f5462125ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0bcdc9702194332ba58fb885ff2771d_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi03LTEtMS0zMTgyNA_4c27c81d-d8fb-45f3-bced-46700055b339">66,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a87ede4a0944e6aac0235cba36b26d2_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi0xLTEtMS0zMTgyNA_b32198f1-2f9e-4588-95b8-e48a1f47e246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ca3b35d04643e0ad5bb05e77e88126_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi0zLTEtMS0zMTgyNA_282355f7-d2c6-4558-b8b3-21ae8be8fb30">272,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012a29f126a40258af0e6ed5765dbff_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi01LTEtMS0zMTgyNA_d6db9b69-28f5-4b93-b9ca-b769fa26dab5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie228033d9a0b4b799dd10eaf894a5565_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi03LTEtMS0zMTgyNA_955d15a7-4727-43f9-8770-f57ff4b886bc">272,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7413f9c5b84645e38c9f817ef9fc6d59_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy0xLTEtMS0zMTgyNA_997f2a27-c6f7-4dae-b4ac-3eb0a2169796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b75ada5f8f43bea21d6e34291436e7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy0zLTEtMS0zMTgyNA_71ef2e69-394d-487f-9879-8d6e6943d4c7">170,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bc918915e74396b7fef2d671257ed8_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy01LTEtMS0zMTgyNA_054b6e36-2658-4bb4-870a-8bb148441c06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bb9c2460444fceb9a62eea46ed198e_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy03LTEtMS0zMTgyNA_ac12c1bf-3f25-474d-ae6c-fa6dad88d00c">170,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffcd4120185407dba6ff4635e5381d6_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC0xLTEtMS0zMTgyNA_538f99b3-b10e-4108-a6f2-af0bf9718bb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9dbd1b26e91468d9424a22a13ad1978_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC0zLTEtMS0zMTgyNA_12729ff4-6101-4d8d-bcef-7897d8df2bab">655,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c15c9efd3d4ae6b10bdf6ef9f35bb2_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC01LTEtMS0zMTgyNA_a906ec85-6a05-4c81-9dd2-8061493fdc44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec10babe1b934aab9dcfd367e69adf4f_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC03LTEtMS0zMTgyNA_470742bd-c871-4dfa-94bb-dbaf617c53fc">655,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4126d05954e4466c8ed0d02bb4506ffb_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS0xLTEtMS0zMTgyNA_a4916a94-5d07-497c-aee1-1808b3f7de39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS0zLTEtMS0zMTgyNA_cdd0318d-87da-4781-b486-8fe0367c9e82">1,099,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS01LTEtMS0zMTgyNA_67eb2f88-2c78-4bc4-9516-bb4cce7bd5dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0bcdc9702194332ba58fb885ff2771d_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS03LTEtMS0zMTgyNA_fd4b2123-72d6-47f8-a842-f79bb004803d">1,099,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4126d05954e4466c8ed0d02bb4506ffb_I20220331" decimals="-6" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtMS0xLTEtMzE4MjQ_57ea873f-010e-4e3d-a866-73d24e683408">8,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331" decimals="-6" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtMy0xLTEtMzE4MjQ_714639e4-66e1-4314-b60c-7a7875e8c4f2">1,157,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331" decimals="-6" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtNS0xLTEtMzE4MjQ_65ffbce7-dc50-4f1a-a43e-92723607efa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0bcdc9702194332ba58fb885ff2771d_I20220331" decimals="-6" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtNy0xLTEtMzE4MjQ_81f1ec9c-1144-4f31-8bc9-135e56a8f1fd">1,165,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the three months ended March 31, 2022, and we had <ix:nonFraction unitRef="usd" contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331" decimals="INF" name="us-gaap:FairValueNetAssetLiability" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTcyNQ_2c878bac-450d-422b-ac07-daee02f88e28">no</ix:nonFraction> financial assets or liabilities that were classified as Level 3 at any point during the three months ended March 31, 2022.</span></div></ix:continuation><div id="ia065fc71787b4c5bb0fb689995212901_46"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMjI2NQ_f8014410-1330-410c-88ec-3cef86a07d6d" continuedAt="i1f95cb9b38a6465fb7dff7c3dd3c5c56" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i1f95cb9b38a6465fb7dff7c3dd3c5c56" continuedAt="i9daf5ebf2bb5486a943c153c27c7df6b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMjI2Ng_224f985f-5f98-4041-96e5-57a5efa0e847" continuedAt="ied082cc9a6b74b95a60a413d3290cb7c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive loss in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive (loss) income, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied082cc9a6b74b95a60a413d3290cb7c">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the condensed consolidated balance sheets with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="INF" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfOTI0_563b3331-c9c5-4430-a018-bf018548f02a"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="INF" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfOTI0_c76f4434-eb3d-4a77-9d0c-7aa436bdd444">no</ix:nonFraction></ix:nonFraction> material realized gains or losses on marketable securities for the three months ended March 31, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMjI2OA_2c1ccb4d-0286-468b-954a-aa2db91dbfc9" continuedAt="i5b513279ede24b70801778e1a0c958ef" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at March&#160;31, 2022 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy0xLTEtMS0zMTgyNA_2ecf1f0c-ea95-4c2e-a5d8-deb37ebedbcc">243,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy0zLTEtMS0zMTgyNA_81001bdd-e697-44dd-97d4-8630f03327d6">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy01LTEtMS0zMTgyNA_46308aea-30ce-4f50-b030-8ed5b4c56f25">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy03LTEtMS0zMTgyNA_2bf2d596-8c80-4fda-acba-1b3287bfc59b">243,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie75239587a9d477198559b60a4c19637_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC0xLTEtMS0zMTgyNA_4ffd7a22-12db-4c67-bb17-8adf209e8c8e">24,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie75239587a9d477198559b60a4c19637_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC0zLTEtMS0zMTgyNA_4579ced6-7019-43a2-be18-8b8e06a5e74a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie75239587a9d477198559b60a4c19637_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC01LTEtMS0zMTgyNA_03a81a44-4376-4c1b-839d-51ca14732b73">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie75239587a9d477198559b60a4c19637_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC03LTEtMS0zMTgyNA_fdb30c6d-550c-48b9-9c81-c441ca2aa39c">24,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS0xLTEtMS0zMTgyNA_c18599dd-5dc4-4fcc-bea6-0e9def16aece">577,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS0zLTEtMS0zMTgyNA_7ab5997f-d91d-4b0c-9d91-d7e53aa47916">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS01LTEtMS0zMTgyNA_b6bc604b-3489-45fd-b075-ee65bd7c0d0d">2,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS03LTEtMS0zMTgyNA_5e5c9bcb-e289-4b2c-a918-39bc4e48298e">575,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi0xLTEtMS0zMTgyNA_b9e37683-f588-49db-8e2a-12b8ab3cd518">846,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi0zLTEtMS0zMTgyNA_79464ec4-5a0f-4865-8282-b4de139df009">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi01LTEtMS0zMTgyNA_298d54e4-d415-4b33-9fb4-096d94041dea">2,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi03LTEtMS0zMTgyNA_72c795ae-09ca-4402-999e-345a43ea15b0">843,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtMS0xLTEtMzE4MjQ_c6c83560-f0b7-4947-9228-6edc242ed96c">29,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtMy0xLTEtMzE4MjQ_89001eb5-4789-4839-b2e2-0a81874a18b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtNS0xLTEtMzE4MjQ_55b58257-99a8-42b9-a960-41115fa077ee">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtNy0xLTEtMzE4MjQ_4f0d17c2-f120-427c-899e-20c0bfee8669">29,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488b85c653fd499fa66acffad102fa83_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItMS0xLTEtMzE4MjQ_74826d80-7635-47f5-a94f-666b31f3d8c8">149,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488b85c653fd499fa66acffad102fa83_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItMy0xLTEtMzE4MjQ_d793a738-3526-4266-8dda-bbb6cfd2f102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i488b85c653fd499fa66acffad102fa83_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItNS0xLTEtMzE4MjQ_84de95ac-6848-408c-9728-cb6529aa558e">3,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488b85c653fd499fa66acffad102fa83_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItNy0xLTEtMzE4MjQ_e1e7d496-1156-44d0-8511-988ee10037d1">146,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtMS0xLTEtMzE4MjQ_36120b51-f888-43ab-b146-46ec0f4921dc">81,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtMy0xLTEtMzE4MjQ_4cca41ea-2c55-401e-b3f1-1726327fb342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtNS0xLTEtMzE4MjQ_7e63885a-3e83-44b9-85ba-3140b71e9017">1,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtNy0xLTEtMzE4MjQ_3ea75626-3a8e-42a8-a779-06920289a97d">80,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtMS0xLTEtMzE4MjQ_be72f08e-ca60-4bbc-bc30-17483d35d868">260,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtMy0xLTEtMzE4MjQ_0015a211-23c8-46b2-ac7f-d06ac501fa5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtNS0xLTEtMzE4MjQ_e7ef77bc-8a09-4e5f-a194-12c8332a3b95">5,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtNy0xLTEtMzE4MjQ_dc4db79c-3615-4e3b-88fa-0207b12606a2">255,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtMS0xLTEtMzE4MjQ_34b9bced-dde8-4285-b8a6-1e9d802a4746">1,107,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtMy0xLTEtMzE4MjQ_0597263b-af4f-42e4-bdb3-de7e6913d232">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtNS0xLTEtMzE4MjQ_8cfab3f3-8952-4cda-a1f9-6f9f176287f8">7,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtNy0xLTEtMzE4MjQ_15a9578b-017b-4fd8-aac7-e13f892e3f5e">1,099,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="i9daf5ebf2bb5486a943c153c27c7df6b"><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i5b513279ede24b70801778e1a0c958ef"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2021 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi0xLTEtMS0zMTgyNA_2f170a16-1a0c-4939-ad30-0ba379615e04">269,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi0zLTEtMS0zMTgyNA_4a2461b6-4b94-4f42-aa3c-0c9c8b7b7a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi01LTEtMS0zMTgyNA_b63568cd-3a2d-4dbc-8f5f-2c0de8a637ae">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi03LTEtMS0zMTgyNA_3a4b4027-7451-447d-8792-faa00beab0b9">269,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy0xLTEtMS0zMTgyNA_0076430d-4fe4-457c-87a0-60b7b04d92bb">17,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy0zLTEtMS0zMTgyNA_3aa0482b-ac2c-4b11-86a5-8724479313b3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy01LTEtMS0zMTgyNA_7f8fa5cd-25da-4982-8739-a14fe9ad5a63">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy03LTEtMS0zMTgyNA_fe65bc1f-99d5-4fdb-a524-90d2ef714763">17,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC0xLTEtMS0zMTgyNA_e7d418e4-e571-479d-9b3b-0962175e04b4">530,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC0zLTEtMS0zMTgyNA_cfa9fc37-946d-4a2a-867b-3a67ae31838f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC01LTEtMS0zMTgyNA_6d063576-5380-45e4-b127-27eec9c2dd37">429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC03LTEtMS0zMTgyNA_231efc9c-b4df-480e-8cca-126c8aa92b1b">530,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca711242fee4c6ab4d75442d9612253_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS0xLTEtMS0zMTgyNA_74b7bd60-d80f-4f74-ae74-fa757b8a7c48">817,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca711242fee4c6ab4d75442d9612253_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS0zLTEtMS0zMTgyNA_7c4a5f23-002a-4e03-b62a-f21c1731606f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idca711242fee4c6ab4d75442d9612253_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS01LTEtMS0zMTgyNA_a232245b-fe82-45ab-8dab-bcddc7e69828">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca711242fee4c6ab4d75442d9612253_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS03LTEtMS0zMTgyNA_0fdfb71c-fad8-43cd-ba36-9f6ad78b3136">816,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS0xLTEtMS0zMTgyNA_439d1047-bb5d-43cd-b294-af12c78496f4">40,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS0zLTEtMS0zMTgyNA_2a2284ec-2297-4cfb-83fd-e30b06e7d97c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS01LTEtMS0zMTgyNA_ff9f0104-7bd6-4f83-bf5e-a9bc5dcf474e">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS03LTEtMS0zMTgyNA_041bf45e-2de4-43ef-81f4-a1d81c14a228">40,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855087ce662749b2b547077eb45a8a38_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtMS0xLTEtMzE4MjQ_0ebb081c-40cf-45b5-af25-04d35d77eb0e">148,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855087ce662749b2b547077eb45a8a38_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtMy0xLTEtMzE4MjQ_0bfdcbd5-6a76-4d33-9646-2680d2d29744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855087ce662749b2b547077eb45a8a38_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtNS0xLTEtMzE4MjQ_c701848b-6540-40dd-b462-b80d908d02e2">470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855087ce662749b2b547077eb45a8a38_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtNy0xLTEtMzE4MjQ_5824a61f-274b-4246-8be3-4c2b185d7e13">148,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtMS0xLTEtMzE4MjQ_7f139912-78d7-4547-8779-ef7af4fa132a">77,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtMy0xLTEtMzE4MjQ_df6e02b1-ed3b-4c86-bba7-70072fb0e9ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtNS0xLTEtMzE4MjQ_c2868201-5781-4d89-9593-d62c46d6b01b">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtNy0xLTEtMzE4MjQ_09053cff-d731-4b8f-9af3-030c98363b44">77,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be1907947514eb7b13e3dc095194484_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItMS0xLTEtMzE4MjQ_1260dc40-3948-4fca-87d4-55fc7212a277">267,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be1907947514eb7b13e3dc095194484_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItMy0xLTEtMzE4MjQ_a06dde66-9779-4cc4-be95-aaa893ade93c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2be1907947514eb7b13e3dc095194484_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItNS0xLTEtMzE4MjQ_96d69f48-48fc-4b58-b476-39f1b0164500">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be1907947514eb7b13e3dc095194484_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItNy0xLTEtMzE4MjQ_e484f4a7-b4cf-4840-8e77-5c10df9dd0ea">266,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtMS0xLTEtMzE4MjQ_1cd1c776-8418-4e17-ae88-aae5becfa003">1,084,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtMy0xLTEtMzE4MjQ_9a4802c9-0b13-4b13-b7c1-bd3e1836c217">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtNS0xLTEtMzE4MjQ_3db225dc-7896-4f5c-8805-dabb51e3d928">1,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtNy0xLTEtMzE4MjQ_7a341953-faf1-4211-9eef-3ebdb8d5b792">1,083,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, we held <ix:nonFraction unitRef="security" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTUyOQ_217d62e8-fe48-448f-9771-d6c1c36aa178">307</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTUzNg_84c235a1-9272-4afc-b9af-cc13d71db4c7">294</ix:nonFraction> debt securities, respectively, that were in an unrealized loss position for less than one year. We did <ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTY0Mg_3afcfa02-fcf2-4e34-a573-d1f6142124df"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTY0Mg_705ce8c8-fc73-49d0-973e-c4e21ea96671">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses as of March&#160;31, 2022 and December&#160;31, 2021 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTgyMQ_23119b7d-5b41-4825-a9bf-4a9b60b9da5e">1,066.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTgyOA_ef5e8d3d-7c11-4537-a40c-b36f0d577a31">950.5</ix:nonFraction> million, respectively. There were <ix:nonFraction unitRef="security" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTg1Nw_0b01d3ba-d3a3-4c70-b483-7484812ea7ed"><ix:nonFraction unitRef="security" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTg1Nw_caad5671-dc81-4fb5-b4b6-970be171df96">no</ix:nonFraction></ix:nonFraction> individual securities that were in a significant unrealized loss position as of March&#160;31, 2022 and December&#160;31, 2021. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of March&#160;31, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div id="ia065fc71787b4c5bb0fb689995212901_461"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90ZXh0cmVnaW9uOmQ4MGVkYjA1YmM1ZDQ0ZWU5YjY3MjIwYzhkMmRkMjJhXzY1OTcwNjk3NjY4NTI_4765d616-ee52-42dd-8c68-b8e905f6efb4" continuedAt="iac410c70510e4e7890acef677b3001eb" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="iac410c70510e4e7890acef677b3001eb"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90ZXh0cmVnaW9uOmQ4MGVkYjA1YmM1ZDQ0ZWU5YjY3MjIwYzhkMmRkMjJhXzY1OTcwNjk3NjY4NTM_8a400285-68de-4c77-9f68-2a2d5815ba82" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of PYRUKYND&#174;, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzEtMS0xLTEtMzMyNDk_21342076-883f-4283-970e-085605a0684a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzEtMy0xLTEtMzMyNzg_a7a0e281-53b9-4322-8070-55d8833d425a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzItMS0xLTEtMzMyNTY_3a3acb54-c096-40bc-b6fe-3b5a43daf16e">2,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzItMy0xLTEtMzMyODU_5273ae1f-4ce3-42b6-98c2-7cc3e9b79cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzMtMS0xLTEtMzMyNjM_e8f4a8b4-f37e-4c89-a928-be395625fc61">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzMtMy0xLTEtMzMyOTI_d3f26751-3ea4-4c45-a32c-f5fa3f7d9da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzQtMS0xLTEtMzMyNzA_fd6c30a1-7a1a-4539-aa76-d46ce38bddf3">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzQtMy0xLTEtMzMyOTk_4ba44240-8532-465c-aa2c-bbf4390cbdd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia065fc71787b4c5bb0fb689995212901_49"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTAzNw_55b17ef9-e776-4620-af0d-6500eeeab2d1" continuedAt="i386a0fdccbf14f398df036ea9a4e8a91" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i386a0fdccbf14f398df036ea9a4e8a91" continuedAt="i13c280eb45c2492897ec3b128f96d747"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of <ix:nonNumeric contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTcy_ca19be1a-fc43-4957-94c2-e00b566ebbe2">six years</ix:nonNumeric> and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTAzMw_4cc79f4c-8fd2-479c-b587-62f8cc4f7fc6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense and other information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMi0xLTEtMS0zMTgyNA_4567b280-a666-4723-b4bd-6e4c7258ce7d">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMi0zLTEtMS0zMTgyNA_e7b192de-a4a6-49b7-8133-012ad37645ff">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMy0xLTEtMS0zMTgyNA_fc01ee73-f525-4e8f-a05a-ac6379bd39cb">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMy0zLTEtMS0zMTgyNA_66c25004-eb66-4e27-902f-8bbdf89a265c">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of March&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="i13c280eb45c2492897ec3b128f96d747"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at the operating lease liabilities as of March&#160;31, 2022 and December&#160;31, 2021, we applied the weighted-average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQyMg_829fc209-b3f3-4daf-8058-c3ed8024d052"><ix:nonFraction unitRef="number" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQyMg_9b7de839-de2a-4ee2-89da-31d1c64eba41">5.7</ix:nonFraction></ix:nonFraction>% for both periods over a weighted-average remaining lease term of <ix:nonNumeric contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQ5MQ_014c6079-db66-4372-a345-c29f23bd6f02">5.9</ix:nonNumeric> years and <ix:nonNumeric contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQ5OQ_4aa99f8c-8034-44d3-9317-82550ed24cd9">6.2</ix:nonNumeric> years, respectively.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTAzNQ_c162a271-85b0-457e-af00-934a5357630f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfMS0xLTEtMS0zMTgyNA_9c17392a-ec37-475a-bb29-5f492f043206">11,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfMi0xLTEtMS0zMTgyNA_9e1e9a26-6fbb-43c5-8548-3e2a7f7c8e0b">18,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfMy0xLTEtMS0zMTgyNA_4fcce850-0efe-4d59-ac8a-13705b5b7d6f">18,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNC0xLTEtMS0zMTgyNA_0560ded2-fd6c-4eee-b7b7-3b66883be430">19,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNS0xLTEtMS0zMTgyNA_03a97acc-5800-4dcd-b910-15ae481bd4f8">20,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNi0xLTEtMS0zNTUyMg_e3cd5dbd-2f55-4dbe-bdb3-46a8d3c59bb7">20,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNi0xLTEtMS0zMTgyNA_43ea3aa5-7424-4fc7-8c94-a754623d2a65">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNy0xLTEtMS0zMTgyNA_3f67a52a-ef9d-40cf-be3c-d0f778395f5b">112,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfOC0xLTEtMS0zMTgyNA_21df0939-e33a-46a7-8f8b-726194818802">18,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfOS0xLTEtMS0zMTgyNA_851bd224-9b13-4d4f-8376-ff5a485e6c71">94,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provided our landlord a standby letter of credit of $<ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzkyOA_544f2b03-a5c7-415f-a989-f4c14b02dc00">2.9</ix:nonFraction> million as security for our leases. We are not required to maintain any cash collateral for the standby letter of credit.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a long-term sublease agreement for <ix:nonFraction unitRef="sqft" contextRef="i15c7600459e34951a4cec3ff06faf28f_I20210831" decimals="-3" name="agio:LesseeOperatingSubleaseAreaOfPremisesSubleased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfNjU5NzA2OTc2ODI1OQ_dcf69fcb-3aed-4e21-97b7-2931361c4b82">13,000</ix:nonFraction> square feet of the office space at 38 Sidney Street Cambridge, Massachusetts. The term of the lease runs until December 2024. We recorded operating sublease income of $<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMjE5OTAyMzI1NzExNw_dc4a0a9f-92e3-449b-aac6-4263cccb1be4">0.4</ix:nonFraction>&#160;million for the three months ended March 31, 2022 in other income, net in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfNjU5NzA2OTc2ODI2OA_1b6e633c-6ab0-461d-9fb6-7ec774d42830" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the future minimum lease payments to be received under the long-term sublease agreement were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfMS0xLTEtMS0zNjg4Mw_c3b06c77-d33f-403a-a6ea-afe4e8c6feb9">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfMi0xLTEtMS0zNjg4Mw_f717025b-25fd-401d-8f0d-b2b8da5ad01c">1,152</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfMy0xLTEtMS0zNjg4Mw_49c47cf2-e9cd-472f-aebc-0cb336d03581">1,186</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfNC0xLTEtMS0zODQ0NQ_63696a92-13fe-4d36-aa95-13d981932930">3,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia065fc71787b4c5bb0fb689995212901_52"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RleHRyZWdpb246ZmFjMzcxMzFjZDMzNGI1OWJhZjZmMTg5YWQ2MWNkZjRfNzE_a1c52ba2-a783-43b2-9153-ec6f3d243faf" continuedAt="i8c53da9b02ca46cd995e95a55105bc1f" escape="true">Accrued Expenses</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i8c53da9b02ca46cd995e95a55105bc1f"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RleHRyZWdpb246ZmFjMzcxMzFjZDMzNGI1OWJhZjZmMTg5YWQ2MWNkZjRfNjk_3cb50c25-cd12-42dd-92ed-505b461b7271" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMS0xLTEtMS0zMTgyNA_948151aa-e6e4-4da6-8653-ef20e2669c53">5,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMS0zLTEtMS0zMTgyNA_07b54a4a-7053-4a16-84bc-26013cfa0bd9">19,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMi0xLTEtMS0zMTgyNA_655a1627-defa-404d-a390-c70047c345b4">8,626</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMi0zLTEtMS0zMTgyNA_c7e8fbc6-6eaa-4224-87ff-9ddbaeeac660">5,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMy0xLTEtMS0zMTgyNA_2ae2a4df-5e63-4637-98f5-7b2b634a4753">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMy0zLTEtMS0zMTgyNA_9f43d3d1-c314-4d2e-920c-2a2dd4d61cc6">2,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNC0xLTEtMS0zMTgyNA_95b04af2-cd88-4640-a5c7-7c5283f40e32">3,782</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNC0zLTEtMS0zMTgyNA_826af638-3181-4da9-b9e4-ff302bb3d63f">3,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNS0xLTEtMS0zMTgyNA_b05af587-99a8-4041-b475-1d6265f169f3">19,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNS0zLTEtMS0zMTgyNA_28268d1b-ed94-4bc2-8dde-ad23a42ae954">31,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="ia065fc71787b4c5bb0fb689995212901_471"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTA_11bfa12e-31e3-4708-baee-6dec88dff18c" continuedAt="ied6f8f21b4434aba8a252b716c7c6951" escape="true">Product Revenue</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied6f8f21b4434aba8a252b716c7c6951" continuedAt="i657f8ff829cc4fb181c011b3e9ded2b7">We sell PYRUKYND&#174;, our wholly owned product, to the Customers. The Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="i657f8ff829cc4fb181c011b3e9ded2b7" continuedAt="i5be4315f5a0d4035a3f7f1138045db6e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTE_c2e7458f-4b36-4a8d-bd84-a077fc836e69" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, were as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad81482e39040cfa13a399adf4f783f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTozNzJlNGEyOGQ0NDA0OTg5YTMwNmY0ZWQ3MzRhMmZlZi90YWJsZXJhbmdlOjM3MmU0YTI4ZDQ0MDQ5ODlhMzA2ZjRlZDczNGEyZmVmXzItMS0xLTEtMzM3MDM_33a583f2-a477-4dec-a7d9-017f3554372f">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if275c08a4b1a44d1a150f50c7c881130_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTozNzJlNGEyOGQ0NDA0OTg5YTMwNmY0ZWQ3MzRhMmZlZi90YWJsZXJhbmdlOjM3MmU0YTI4ZDQ0MDQ5ODlhMzA2ZjRlZDczNGEyZmVmXzItMy0xLTEtMzM3MTM_ae22ef86-9178-488a-b06d-24ec4fb1753b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTI_11a692a0-4580-4576-9855-838fcfc29dd6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtMS0xLTEtMzM4MTc_ae8d1f8f-020a-4804-9a10-c0d7324f45c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:ContractWithCustomerRebateReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtMy0xLTEtMzM4MTc_5bd6c452-fadf-478a-bcfb-f30e59f4a61b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtNS0xLTEtMzM4MTc_68a7ee8e-2ba9-44cf-8a80-b55fbe89222c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtNy0xLTEtMzM4MTc_f76354ef-e2ea-4783-b337-a8de21ba9e01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:CurrentYearProvisionForContractualAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItMS0xLTEtMzM4MTc_4493691f-c943-4a33-8419-b0797bd626de">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:CurrentYearProvisionsForRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItMy0xLTEtMzM4MTc_7583e9d3-b34e-4081-a233-134c4c4df349">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ProvisionForRightToRecoverProductInCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItNS0xLTEtMzM4MTc_f4165054-293b-4991-9252-51e42af7db33">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerCurrentYearReserveProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItNy0xLTEtMzM4MTc_1904c3bd-98c0-4f6a-957a-c0cabb61ff20">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:PriorYearProvisionForContractualAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtMS0xLTEtMzM4MTc_e8252e69-f3f8-4057-b935-cc20a2b6d44c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:PriorYearProvisionsForRebateReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtMy0xLTEtMzM4MTc_3cc5e382-3d07-43ac-a814-2890c916bcb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ProvisionForRightToRecoverProductInPriorYears" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtNS0xLTEtMzM4MTc_59b1020e-eb34-4a60-9c46-c2050f0a68e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerPriorYearsReserveProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtNy0xLTEtMzM4MTc_29ab8ef7-4553-4f45-b01c-494ab1ef906b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtMS0xLTEtMzM4MTc_17c1e284-1af8-4800-9892-f3a063eb1bc2">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtMy0xLTEtMzM4MTc_d0562ef6-eec3-4528-aece-852390d361c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtNS0xLTEtMzM4MTc_5f7a0cc4-7354-4aaf-8e06-53ba659abacc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerCurrentYearReserveRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtNy0xLTEtMzM4MTc_ff1288f3-9646-4a8e-885a-28455563d441">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtMS0xLTEtMzM4MTc_878dc9a2-4004-4b2b-9357-9e351f28b141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtMy0xLTEtMzM4MTc_79771181-349c-4260-9573-c6ce7b050b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtNS0xLTEtMzM4MTc_30ba5430-b82d-4ca0-93ca-baee13895ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerPriorYearsReserveRecoveries" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtNy0xLTEtMzM4MTc_8229b6c7-5b21-4710-a249-43b95bcfcabe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtMS0xLTEtMzM4MTc_f64d5d29-f3ca-427a-8705-cd6d7116d18b">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:ContractWithCustomerRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtMy0xLTEtMzM4MTc_367fc71e-4b91-41a6-a523-1fa17280534a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtNS0xLTEtMzM4MTc_edfa1451-e214-4780-803b-878c5f2ff6a1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtNy0xLTEtMzM4MTc_2b0c5eec-450b-41d1-b5da-5ef5cbda8936">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTM_ab8c6838-b184-406e-9559-e5d116ae1818" continuedAt="i6c1309f86fb94585a4924d4556884bf1" escape="true">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="i5be4315f5a0d4035a3f7f1138045db6e" continuedAt="i7f6a1154c6bb4340b6985a38d533f76c"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i6c1309f86fb94585a4924d4556884bf1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzEtMS0xLTEtMzM4ODM_d5f0ab03-c19b-418c-ba07-532cd204812a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzEtMy0xLTEtMzM4ODM_f388e8ee-ecc4-4646-8145-140329578ddd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:ContractWithCustomerAllowanceAndReservesLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzItMS0xLTEtMzM4ODM_cb9e6686-d553-4cc9-8829-a3f0fceac10c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:ContractWithCustomerAllowanceAndReservesLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzItMy0xLTEtMzM4ODM_14680efd-6775-429f-b541-d61401769d98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzMtMS0xLTEtMzM4ODM_b733a89f-41cd-4930-b3a3-5d84840799ec">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzMtMy0xLTEtMzM4ODM_8dfb2358-d20f-4ef6-82c3-23f2bd19d30d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTQ_c0e97e4b-8479-48e2-b5d1-850573552ca4" continuedAt="i9e2c59fdf9f44a50a5ed10b293ab5594" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets during the three months ended March 31, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItMS0xLTEtMzM5NDc_bcd9c9d0-46a2-4cf5-bb30-71ea9eab0f3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItMy0xLTEtMzM5NDc_95e6d006-1b25-4349-b873-d7c1155175ec">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItNS0xLTEtMzM5NDc_6c9709f9-5a08-481f-a2bf-5d7fbc846ac4">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItNy0xLTEtMzM5NDc_97a274ee-efd0-435e-bed2-308930c6ca0d">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i7f6a1154c6bb4340b6985a38d533f76c"><ix:continuation id="i9e2c59fdf9f44a50a5ed10b293ab5594">(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.</ix:continuation></ix:continuation> </span></div><div id="ia065fc71787b4c5bb0fb689995212901_55"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzNw_62a3b9e7-aa3f-4d3b-8570-cc6d49362da3" continuedAt="i2f9e876cb2f74ce1bae6b5f53f7a367f" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i2f9e876cb2f74ce1bae6b5f53f7a367f" continuedAt="i91b139c0cca0467590cdf9012dec0e32"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based share units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of March&#160;31, 2022, the total number of shares reserved under the 2007 Plan and the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="i70609af01f924e08961eae93134c2934_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTQ2_70cdcfe4-c99b-4d18-9193-31acc676a69d">13,027,919</ix:nonFraction>, and we had <ix:nonFraction unitRef="shares" contextRef="ia272dc6363a84ac2ad2bd1fac38e1aab_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTYx_879ad419-9d36-4420-b9d1-138fe6d5ae1e">6,142,929</ix:nonFraction> shares available for future issuance under the 2013 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzOA_b360dae3-7fcc-4e70-b489-e519fea9a92d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock option activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMS0xLTEtMS0zMTgyNA_739aeb3b-0691-477b-8e0a-78e1f94ea25d">4,798,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMS0zLTEtMS0zMTgyNA_9a72de22-c6be-4743-be3c-98e4a5bd1f74">58.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMi0xLTEtMS0zMTgyNA_e10ab490-c6b1-4f5b-8efd-422341b221df">647,713</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMi0zLTEtMS0zMTgyNA_2ff5d277-341f-4c25-82e4-cd47d75af9b9">32.23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMy0xLTEtMS0zMTgyNA_f290d296-cbe6-4f62-89bf-c692a5f5f8e3">3,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMy0zLTEtMS0zMTgyNA_cfcbef49-eff1-4fe2-b2f2-952c8e5a5116">4.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNC0xLTEtMS0zMTgyNA_dfb3e78f-4a2e-418c-8106-76d21f518088">168,145</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNC0zLTEtMS0zMTgyNA_fdaed655-ee62-4340-9a72-06a514f172df">68.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNS0xLTEtMS0zMTgyNA_996be199-92b8-4a89-a3f2-36eec0493090">5,275,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNS0zLTEtMS0zMTgyNA_43d8d2ed-e76f-4e3d-a9e4-549915d6b808">55.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNi0xLTEtMS0zMTgyNA_34b68264-e4e0-4c61-b5dd-92037356c086">3,494,909</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNi0zLTEtMS0zMTgyNA_fffa748c-492f-4827-ba16-6170a959d3c8">59.81</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNy0xLTEtMS0zMTgyNA_f28aa7ea-f67a-4a0c-991f-8043610d81e7">5,275,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNy0zLTEtMS0zMTgyNA_4e1f0a55-f1f4-41d8-a587-05834390875a">55.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ia272dc6363a84ac2ad2bd1fac38e1aab_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMzMy_85ee516d-7387-4560-9fea-111c67d71aaa">44.0</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i83ae90ff305f4fc99f69ae4834a3f97a_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfNDk2_d9ce865c-bc40-421b-8994-707dec7f5f97">2.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzOQ_9dae4146-be97-473c-8892-7963c715eaf5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents RSU activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa54a29f6a2c403383d89cfeec3aaf59_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMS0xLTEtMS0zMTgyNA_8085824d-5b46-47ae-959f-8c85cb676735">1,002,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa54a29f6a2c403383d89cfeec3aaf59_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMS0zLTEtMS0zMTgyNA_427c08e7-fea6-446a-9cc4-83f8ce356b93">51.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMi0xLTEtMS0zMTgyNA_d8f9e97d-9195-4ef1-b319-7125ed61cd4d">634,232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMi0zLTEtMS0zMTgyNA_8f8e9335-5dde-4cea-a80e-59c2fdba3524">32.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMy0xLTEtMS0zMTgyNA_b630645c-9015-4849-8a45-61ef3d30f65b">337,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMy0zLTEtMS0zMTgyNA_a80f60c9-1c2c-4131-9f94-c7a7432f2621">53.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNC0xLTEtMS0zMTgyNA_b2d30d40-ee34-42b8-9ac4-e4d661d715fa">16,156</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNC0zLTEtMS0zMTgyNA_1ffb92c9-28a2-4136-acd3-1671b3164287">46.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNS0xLTEtMS0zMTgyNA_9e037dd6-996a-4fe1-9118-422244aca2eb">1,283,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNS0zLTEtMS0zMTgyNA_25985302-655f-4bd6-998c-705c36839186">41.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfNjEz_e31874dc-9f2e-4514-83fc-a2c03a30da58">43.4</ix:nonFraction> million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfNzUz_7f04d851-b184-489c-89bb-0a266a6a43cc">2.1</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><ix:continuation id="i91b139c0cca0467590cdf9012dec0e32" continuedAt="ife4959163f6244b788c6c13317a722b5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock units </span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjY0MA_d1f35ae4-472f-43b7-80d3-2238ac70d924" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PSU activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92b16706b28640548b80c7b1f2d3e403_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMS0xLTEtMS0zMTgyNA_d4228333-5403-41da-824c-7a8f13500453">234,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i92b16706b28640548b80c7b1f2d3e403_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMS0zLTEtMS0zMTgyNA_d3f90276-60ae-4216-98e4-2fba6a2cdbae">54.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMi0xLTEtMS0zMTgyNA_70cda43b-4619-4db3-8850-a4630d2ec4b7">108,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMi0zLTEtMS0zMTgyNA_2c3c0fd9-4dcd-4f13-afdf-1fed7b54b2b8">32.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMy0xLTEtMS0zMTgyNA_360e3fef-633d-4fec-9fdf-d60ee1380d51">53,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMy0zLTEtMS0zMTgyNA_a1bb0cdf-49c6-45e6-a625-a08bdc5638fd">54.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNC0xLTEtMS0zMTgyNA_1b11ea95-97fa-4620-86f7-1419fd3405d1">5,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNC0zLTEtMS0zMTgyNA_465bf7c0-29bb-41cf-a937-49a177ac3b6e">61.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d1a1a869b64af6af400f631a1e6c4d_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNS0xLTEtMS0zMTgyNA_d0932528-5e9a-4bc6-8ae1-8c9a75c20e0e">283,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65d1a1a869b64af6af400f631a1e6c4d_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNS0zLTEtMS0zMTgyNA_1f33d7d0-00ef-4842-a214-d831dd08627b">45.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was <ix:nonFraction unitRef="usd" contextRef="i8e402691929e44468cadbcc8453e6514_I20220331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTA1NQ_8585cbdc-98d2-4be3-9e12-9b1f3ee51d3b">no</ix:nonFraction> unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $<ix:nonFraction unitRef="usd" contextRef="i65d1a1a869b64af6af400f631a1e6c4d_I20220331" decimals="-5" name="agio:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTE5Nw_c5ade234-0db2-4005-ba8e-d8982c2654b1">13.0</ix:nonFraction> million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjY0Mg_d3edf4ab-e86f-4800-81bd-c86d67ee833d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib271baa482c94d97ac48840b7d361a47_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMS0xLTEtMS0zMTgyNA_a499572e-19b1-4f9c-902e-f908b975221c">42,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib271baa482c94d97ac48840b7d361a47_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMS0zLTEtMS0zMTgyNA_aebc66f2-75b4-40dc-b19d-a3ec569115b4">41.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f547c547c3d455d9028f77bd9be80d6_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMi0xLTEtMS0zMTgyNA_8e75aa0b-23e6-44dd-931e-efcbbc0b8823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f547c547c3d455d9028f77bd9be80d6_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMi0zLTEtMS0zMTgyNA_c726da41-7bfd-45b4-9bd7-62142bf62fff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f510a7bc35c4acc904d0706efb5488c_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfNS0xLTEtMS0zMTgyNA_406a031b-9266-4cf6-854e-b40577da4542">42,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f510a7bc35c4acc904d0706efb5488c_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfNS0zLTEtMS0zMTgyNA_38390fe6-58e1-4ae6-9d5c-8f36d9e62722">41.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of March&#160;31, 2022, there was <ix:nonFraction unitRef="usd" contextRef="i3f510a7bc35c4acc904d0706efb5488c_I20220331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTc0NQ_673720a9-1894-4fbe-afcc-0e1b91cec7a9">no</ix:nonFraction> remaining unrecognized compensation expense related to MSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold <ix:nonFraction unitRef="shares" contextRef="i6c09eceb9aa140f8b2fa149e6232b87f_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjAwOQ_041411e2-89fe-46ed-bfb3-0224f6a50ae1">48,156</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i46afd29a81bf441a99b55105d1a18809_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjAxNg_5833f9d0-2713-414f-b4da-c164b8565db2">59,401</ix:nonFraction> shares of common stock during the three months ended March 31, 2022 and 2021, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6c09eceb9aa140f8b2fa149e6232b87f_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjIwMQ_e7e12aea-c685-42fe-b161-37aaa1df1a3f">1,854,545</ix:nonFraction> shares of our common stock. As of March&#160;31, 2022, we had <ix:nonFraction unitRef="shares" contextRef="i3ddbb4db5e1644ccaa03be39b46f2cb4_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjI0OQ_d5a98ca2-8320-4907-ad57-d34d3673430f">1,346,491</ix:nonFraction> shares of common stock available for future issuance under the 2013 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzNQ_bd65d64a-12e1-4396-b57a-d15463a0c1c1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3842af82e752402aa7a5fbeedccf54b5_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMi0xLTEtMS0zMTgyNA_482fd66c-c068-42dc-9a0f-f085f1296ff4">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9a1d0006454af4aeab6df1c2911d6e_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMi0zLTEtMS0zMTgyNA_a6e3b937-1a3d-4fb4-a01d-0a7ac763b017">8,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMy0xLTEtMS0zMTgyNA_e66fad00-bfd7-4692-8990-791052c99d26">6,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c67bf64fdf4dcc9d2de216530f51c1_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMy0zLTEtMS0zMTgyNA_71290dbd-173e-45a7-9737-f01faed158f4">6,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNC0xLTEtMS0zMTgyNA_f53f425f-c67c-4c41-affe-c011cfc99058">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88173f3394c14c71afab60eef3d941af_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNC0zLTEtMS0zMTgyNA_7577d4e0-6c70-4aac-ae6a-3b086b4f02cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328200bab58e48e9be32dfe062e76e09_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNS0xLTEtMS0zMTgyNA_8a959e2d-97b3-432c-9fc9-c5801bcce582">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c902f308341ad8db797be144a4c17_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNS0zLTEtMS0zMTgyNA_7ec62eae-d52e-4030-ba87-89fd68c32426">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15521d93cb44d6183b8ea908841d562_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNi0xLTEtMS0zMTgyNA_616e75e2-2896-423a-8ede-23a29ece2f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcb67b5c5064fd198f05934740baab6_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNi0zLTEtMS0zMTgyNA_80ad2a9d-5ba4-46e7-a072-1fada51dd635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNy0xLTEtMS0zMTgyNA_b8c0308b-421b-41e4-9173-5efaeb256cc5">15,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNy0zLTEtMS0zMTgyNA_56371e2e-899c-40f7-ac6e-6fb0768bc780">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="ife4959163f6244b788c6c13317a722b5"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzNA_4e7c6ac0-4b5d-427b-90bf-859cea22bbf1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20bb451b5406436aa3044e6572769236_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMi0xLTEtMS0zMTgyNA_d1674c9a-d242-48ed-a878-90ffe8dff8e0">6,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd284c57e7c4c53b396b12930ced078_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMi0zLTEtMS0zMTgyNA_b5b3217a-f559-47c7-b7d1-343dcebb5308">6,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba1d1e1128ab469a92b7cd44c6db0d2b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMy0xLTEtMS0zMTgyNA_7d3f5452-77cb-4e3d-934f-9da533e775c4">8,854</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce6cd786d794f4ba84de03a86627fd4_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMy0zLTEtMS0zMTgyNA_5c93d820-4f0a-4015-a2e4-02cd27e4137d">7,881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfNC0xLTEtMS0zMTgyNA_05f41a23-0b38-4465-b475-bb178b33911b">15,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfNC0zLTEtMS0zMTgyNA_f7153fb7-b9ad-4ec8-be13-c032c15f9555">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="ia065fc71787b4c5bb0fb689995212901_58"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RleHRyZWdpb246YmY4ZTRkNzM0NzdlNGMxY2IzNWYyYWYxNmFmMTBlYmZfMTgzOA_e71de198-4b64-4762-b68f-003cfdf3249c" continuedAt="i1293a337f4b140eba7cac64b5ae47ae5" escape="true">Loss per Share</ix:nonNumeric></span></div><ix:continuation id="i1293a337f4b140eba7cac64b5ae47ae5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RleHRyZWdpb246YmY4ZTRkNzM0NzdlNGMxY2IzNWYyYWYxNmFmMTBlYmZfMTgzOQ_8bc31fd9-870e-4887-bdac-ea5aa40b62aa" escape="true">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2022 are not considered to be common stock equivalents.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss for continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income from discontinued operations per share. Basic and diluted net loss per share was the same for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RleHRyZWdpb246YmY4ZTRkNzM0NzdlNGMxY2IzNWYyYWYxNmFmMTBlYmZfMTg0MQ_17c6f97e-dcf0-4281-81f5-7495827e6f21" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:71.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a8f36b78766499982b48169e8709eec_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMi0xLTEtMS0zMTgyNA_10b0fca0-8a8f-4f99-b3ff-1d45a8ebc936">5,275,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d7ca6a9e8334a34861d3a8cc12a5faa_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMi0zLTEtMS0zMTgyNA_a92d514e-c304-4326-8304-da93bc2e4c56">6,181,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f5a58c7510e4e6e8d4cb2499cc30bc7_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMy0xLTEtMS0zMTgyNA_420224af-7166-486b-a3e5-5314ff362e2c">1,283,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bfd973f33e846f5b7d28e08e0c6e96b_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMy0zLTEtMS0zMTgyNA_aa88e8a5-b4b7-4557-a1ae-0059f66fd92d">1,263,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3df74c825b14d068c62180063fd7587_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNC0xLTEtMS0zMTgyNA_06a2cf00-6bb1-4ba5-8577-8bea896fa2ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab52b0c782a64d07b43279f5e7626420_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNC0zLTEtMS0zMTgyNA_d0d42eb2-a62d-49da-9842-096b25d1de4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73a401f6a1c148b28af205ff7abe39ac_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNS0xLTEtMS0zMTgyNA_81e4bd8b-93a4-4b6f-9ab2-4f0054ad8316">12,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdafde84e3d3486fbcdf4313d51d80e9_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNS0zLTEtMS0zMTgyNA_a887b321-8cc8-4db5-94a9-4ed507f5eb02">7,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNi0xLTEtMS0zMTgyNA_1892c6f6-a211-40f1-afbf-da26cffe20c5">6,571,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNi0zLTEtMS0zMTgyNA_50100873-d1da-4826-9374-ec2d8b7d080b">7,452,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia065fc71787b4c5bb0fb689995212901_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfNDY3_2e3d3474-93f2-4204-9b13-fe1411203bb3" continuedAt="ifc5d07769b444ac48b55b5f352a13004" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc5d07769b444ac48b55b5f352a13004">We recorded <ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="INF" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfNjU5NzA2OTc2NzYzNQ_71ccd94f-e5bd-4923-bcbc-26406d0c5c07">no</ix:nonFraction> provision for income taxes for the three months ended March&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfMjc0ODc3OTA3MDA5Mg_3a5ced50-e247-4e5a-b34b-8f9e76152848">12.9</ix:nonFraction>&#160;million income tax provision for the three months ended March&#160;31, 2021. The tax provision for the three months ended March&#160;31, 2021 has been recorded within discontinued operations as it relates to the income tax impact on the sale of its oncology business to Servier. There is <ix:nonFraction unitRef="usd" contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfMzQ2_c215b643-2152-4bd1-939f-252f7adb5aa1"><ix:nonFraction unitRef="usd" contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfMzQ2_f9cd7ea2-216e-444b-aa0f-eb06baa938b6">no</ix:nonFraction></ix:nonFraction> income tax expense recorded in continuing operations for the three months ended March&#160;31, 2022 and 2021, respectively.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-looking Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements as of March&#160;31, 2022 and for the three months ended March 31, 2022 and 2021, and related notes included in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on February&#160;24, 2022. This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, forecasts and projections, and the beliefs and assumptions of our management, and include, without limitation, statements with respect to our expectations regarding our research, development and commercialization plans and prospects, results of operations, selling, general and administrative expenses, research and development expenses, the sufficiency of our cash for future operations and business activity disruption due to the COVID-19 pandemic. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;vision&#8221; and similar statements or variation of these terms or the negative of those terms and similar expressions are intended to identify these forward-looking statements. Readers are cautioned that these forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading &#8220;Risk Factors&#8221; in Part II, Item&#160;1A and elsewhere in this report, and in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_70"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for genetically defined diseases, or GDDs. We take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect, while cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for GDDs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our GDD portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. On February 17, 2022, the FDA approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. In June 2021, we submitted a marketing authorization application, or MAA, to the European Medicines Agency, or EMA, for PYRUKYND&#174; for the treatment of adults with PK deficiency in the European Union. The MAA has passed validation, and the regulatory review process is ongoing. In addition, we are currently evaluating PYRUKYND&#174; for the treatment of thalassemia and sickle cell disease, or SCD, in the clinical trials described below and we intend to evaluate PYRUKYND&#174; in pediatric patients with PK deficiency in the planned clinical trials described below. We are also developing AG-946, a novel, next-generation PKR activator, for the potential treatment of hemolytic anemias and other indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the aforementioned development programs, we foster a productive research engine and are seeking to advance multiple novel, investigational therapies in clinical and preclinical development in our focus area of GDDs, based on our scientific leadership in the field of cellular metabolism and adjacent areas of biology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of our Oncology Business to Servier</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IDHIFA&#174; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#174; development program.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_76"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 on our Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we have not experienced a significant financial or supply chain impact directly related to the COVID-19 pandemic but have experienced some disruptions to clinical operations, including timelines to complete patient enrollment in some of our clinical trials, and we may in the future experience further such disruptions. In addition, we have experienced disruptions to certain research activities at our contract research organizations, or CROs, based in China, due to the recent COVID-19 surge in China. We are continuing to serve our customers while taking precautions to provide a safe work environment for our employees and customers. Our lab-based employees who need to be onsite to fulfill their job responsibilities have been onsite since late May 2020, and since September 2020 we have opened our Cambridge office to limited numbers of employees who prefer to work onsite. Our field-based employees continue to engage with healthcare providers and other third parties on a primarily remote basis and, where local regulations and other conditions allow, on a limited in-person basis. We are conducting our return to work program under strict guidelines as required by federal, state, and local authorities. Effective November 8, 2021, we require all employees, regardless of role or work location, to be fully vaccinated against COVID-19, as defined by the Center of Disease Control and Prevention's guidelines, subject to limited exception. We have been monitoring our supply chain network for disruptions due to the COVID-19 pandemic, and our third-party manufacturers, other than the China-based CROs discussed above, remain largely unaffected, with any campaign delays experienced to date being limited to a few days in duration. Although global shipping continues to be disrupted due to the pandemic, we have not experienced a supply impact.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the pandemic&#8217;s effect on our operational and financial performance will depend in large part on future developments, which cannot be predicted with confidence at this time. Future developments include changes in the duration, scope and severity of the pandemic, including any variant strains of the COVID-19 virus, the actions taken to contain or mitigate its impact, the impact on governmental programs and budgets, the supply, distribution and efficacy of vaccines, and the resumption of widespread economic activity. Any prolonged material disruption of our employees, suppliers, manufacturing, or customers could negatively impact our consolidated financial position, results of operations and cash flows. As a result, we may have to take further actions that we determine are in the best interests of our employees or as required by federal, state, or local authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have primarily focused on organizing and staffing our company, business planning, raising capital, assembling our core capabilities in cellular metabolism, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, establishing a commercial infrastructure, preparing for the commercial launch of PYRUKYND&#174; and, prior to the sale of our oncology business to Servier on March 31, 2021, marketing TIBSOVO&#174; and IDHIFA&#174;. Through March 31, 2021, we have financed our operations primarily through proceeds from the sale of our royalty rights, commercial sales of TIBSOVO&#174;, funding received from our collaboration agreements, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings. Following the sale of our oncology business to Servier on March 31, 2021, we have financed and expect to finance our operations primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174;, the potential milestone payment and royalties from Servier if vorasidenib is approved by the FDA, and potential sales of PYRUKYND&#174; if successfully launched by us and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically incurred operating losses. Our net loss for the three months ended March 31, 2022 was $94.8&#160;million and our net income for the three months ended March 31, 2021 was $1,874.3 million. As of March&#160;31, 2022, we had an accumulated deficit of $333.5 million. The net income we generated in the three months ended March 31, 2021 was primarily due to the sale of our oncology business to Servier, which was consummated on March 31, 2021. Following the consummation of the sale of our oncology business, we expect to incur significant expenses and net losses until such time we are able to report profitable results. Our net losses may fluctuate significantly from year to year. We expect that we will continue to incur significant expenses as we continue to advance and expand clinical development activities for our lead programs: PYRUKYND&#174;, and AG-946; continue to discover and validate novel targets and drug product candidates; expand and protect our intellectual property portfolio; and hire additional commercial, development and scientific personnel.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Revenues<br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly owned product, PYRUKYND&#174;, received approval from the FDA on February 17, 2022, for the treatment of hemolytic anemia in adults with PK deficiency in the United States. Upon FDA approval of PYRUKYND&#174; in the United States, we began generating product revenue from sales of PYRUKYND&#174;. We sell PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;. For further discussion of our revenue recognition policy, see Note 2, Summary of Significant Accounting Polices and Note 8, Product Revenue, to the condensed consolidated financial statements in this Form 10-Q.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the future, we expect to continue to generate revenue from a combination of product sales, royalties on product sales, cost reimbursements, milestone payments, and upfront payments to the extent we enter into future collaborations or licensing agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; recorded during the three months ended March 31, 2022 were expensed prior to February 17, 2022, and, therefore, are not included in costs of sales during the three months ended March 31, 2022.<br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs related to our GDD portfolio to increase significantly for the foreseeable future as our product candidate development programs progress. However, the successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development and to commercialize these product candidates. We are unable to predict the amount of net cash inflows from PYRUKYND&#174; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any of our product candidates. This is due to the numerous risks and uncertainties associated with developing medicines, including the uncertainty of:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing an appropriate safety profile with an investigational new drug application, or IND, and/or NDA-enabling toxicology and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the successful enrollment in, and completion of, clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing compliant commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining an acceptable safety profile of the products following approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">employee-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with third parties, including CROs, that conduct research and development and both preclinical and clinical activities on our behalf, and the cost of consultants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of lab supplies and acquiring, developing and manufacturing preclinical and clinical study materials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and the maintenance of facilities, insurance and other operating costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our most advanced programs:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PYRUKYND&#174; (mitapivat): First-in-Class PK Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing PYRUKYND&#174; for the treatment of PK deficiency and other hemolytic anemias such as thalassemia and SCD. PYRUKYND&#174; is an orally available small molecule and a potent activator of the wild-type and mutated PKR enzymes. To date, we have demonstrated in clinical trials that treatment with PYRUKYND&#174; can lead to durable sustained increases in hemoglobin in patients with amenable mutations in the PKR gene and a statistically significant and clinically meaningful reduction in transfusion burden in regularly transfused patients with PK deficiency, and we have observed in clinical trials of PYRUKYND&#174; durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoeiesis in both &#945;- and &#946;- thalassemia patients and reductions in 2,3-DPG and increases in ATP in SCD patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the FDA approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In June 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we submitted an MAA to the EMA for the treatment of adults with PK deficiency the European Union. The MAA has passed validation, and the regulatory review process is ongoing. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have worldwide development and commercial rights to PYRUKYND&#174; and expect to fund the future development and commercialization costs related to this program. PYRUKYND&#174; has been granted orphan drug designation for the treatment of PK deficiency by the FDA and the EMA. Additionally, PYRUKYND&#174; has received orphan drug designation from the FDA for the treatment of thalassemia and SCD. We have built our US commercial infrastructure to support the commercial launch of PYRUKYND&#174; in the United States and continue to evaluate all options for the commercialization and continued development of PYRUKYND&#174; outside of the United States in order to maximize the benefit to patients and value to our shareholders, including through exploring potential partnership opportunities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating PYRUKYND&#174; in the following clinical trials:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ENERGIZE, a phase 3, double-blind, randomized, placebo-controlled multicenter study evaluating the efficacy and safety of PYRUKYND&#174; as a potential treatment for adults with non-transfusion-dependent &#945;- or &#946;-thalassemia, defined as &#8804;5 red blood cell, or RBC, units during the 24-week period before randomization and no RBC transfusions &#8804;8 weeks before providing informed consent or during the screening period. The primary endpoint of the trial is percentage of patients with hemoglobin response, defined as a &#8805;1.0 g/dL increase in average hemoglobin concentration from Week 12 through Week 24 compared with baseline. Secondary endpoints include markers of hemolysis and ineffective </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erythropoiesis, as well as patient-reported outcome measures. This trial is enrolling patients, and we expect to enroll a meaningful portion of the patients by the end of 2022. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ENERGIZE-T, a phase 3, double-blind, randomized, placebo-controlled multicenter study evaluating the efficacy and safety of PYRUKYND&#174; as a potential treatment for adults with transfusion-dependent &#945;- or &#946;-thalassemia, defined as 6 to 20 RBC units transfused and &#8804;6-week transfusion-free period during the 24-week period before randomization. The primary endpoint of the trial is percentage of patients with transfusion reduction response, defined as a &#8805;50% reduction in transfused RBC units with a reduction of &#8805;2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline. Secondary endpoints include additional transfusion reduction measures and percentage of participants with transfusion-independence. This trial is enrolling patients, and we expect to enroll a meaningful portion of the patients by the end of 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">RISE UP, a phase 2/3 study evaluating the efficacy and safety of PYRUKYND&#174; in SCD patients who are 16 years of age or older, have had between two and 10 sickle cell pain crises in the past 12 months, and have hemoglobin within the range of 5.5 to 10.5 g/dL during screening. The phase 2 portion of the trial, which has initiated, includes a 12-week randomized, placebo-controlled period in which participants will be randomized in a 1:1:1 ratio to receive 50 mg PYRUKYND&#174; twice daily, 100 mg PYRUKYND&#174; twice daily or matched placebo. The primary endpoints are hemoglobin response, defined as &#8805;1 g/dL increase in average hemoglobin concentration from Week 10 through Week 12 compared to baseline, and safety. These data will be used to establish a clear dosing paradigm for the phase 3 portion. The phase 3 portion includes a 52-week randomized, placebo-controlled period in which participants will be randomized in a 2:1 ratio to receive the recommended PYRUKYND&#174; dose level or placebo. The primary endpoints are hemoglobin response, defined as &#8805;1 g/dL increase in average hemoglobin from baseline to Week 52, and annualized rate of sickle cell pain crises. Participants who complete either the phase 2 or phase 3 portion will have the option to move into a 216-week open-label extension period to continue to receive PYRUKYND&#174;. The phase 2 portion of this trial is enrolling patients, and we expect to complete enrollment in the phase 2 portion of the trial by the end of 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from ACTIVATE and ACTIVATE-T, our completed pivotal trials of PYRUKYND&#174; in not regularly transfused and regularly transfused patients with PK deficiency. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from DRIVE PK, our completed global phase 2, first-in-patient, open-label safety and efficacy clinical trial of PYRUKYND&#174; in adult, not regularly transfused patients with PK deficiency.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from our completed phase 2, open-label safety and efficacy clinical trial of PYRUKYND&#174; in adults with non-transfusion-dependent &#945;- and &#946;-thalassemia. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with the National Institutes of Health, or NIH, we are evaluating PYRUKYND&#174; in a phase 1 trial in patients with SCD pursuant to a cooperative research and development agreement. The core trial period has completed. The long-term extension study is ongoing. In June 2020, clinical proof of concept was established based on a preliminary analysis of the data from this trial.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with UMC Utrecht, or UMC, we are evaluating PYRUKYND&#174; in patients with SCD pursuant to an investigator sponsored trial agreement. The trial has completed enrollment and patient follow-up is ongoing, and a 2-year extension study has been activated for patients who complete the follow-up period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to initiate two phase 3 trials of PYRUKYND&#174;, ACTIVATE-kids and ACTIVATE-kidsT, in not regularly transfused and regularly transfused pediatric patients with PK deficiency in mid-2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AG-946: Novel, Next-generation PKR Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing AG-946, a novel, next-generation PKR activator, for the potential treatment of hemolytic anemias. We are evaluating AG-946, in a phase 1 trial of AG-946 in healthy volunteers and in patients with SCD. The trial has completed the healthy volunteer cohort, and we have initiated the SCD patient cohort of this trial. We expect to initiate a phase 2a study of AG-946 in adults with L-IR MDS by year-end 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other research and platform programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other research and platform programs include activities related to exploratory efforts, target validation and lead optimization for our discovery and follow-on programs, and our proprietary metabolomics platform. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, business development, commercial, legal and human resources functions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other significant costs include facility-related costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our selling, general and administrative expenses will increase in the future to support continued research and development activities and ongoing and future commercialization activities related to our GDD portfolio, including the commercialization of PYRUKYND&#174; and any of our other product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_73"></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">Critical Accounting  Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our critical accounting estimates are those which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We have determined that our most critical accounting estimates are those relating to revenue recognition, accrued research and development expenses and stock-based compensation. Except those that have been disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the notes to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no significant changes to our existing critical accounting estimates discussed in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended March 31, 2022 and 2021</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Total Revenue &#8211; First Quarter of 2022 vs. First Quarter of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The increase in total revenue of $0.8&#160;million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was due to product revenue associated with PYRUKYND&#174;, which was approved in February 2022.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Operating Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Operating Expenses - First Quarter of 2022 vs. First Quarter of 2021 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total operating expenses of $10.8 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily due an increase in research and development expenses of $12.5 million which is described below under Research and Development Expenses, partially offset by a decrease in selling, general and administrative expenses of $2.0 million due to a reduction in workforce-related expenses. Included in selling, general and administrative expenses is approximately $1.1 million of reimbursable transition related services we provided to Servier related to the sale of the oncology business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses, by major program, are outlined in the table below: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK activator (PYRUKYND&#174;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel PK activator (AG-946)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and platform programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,349&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Facilities and IT related expenses &amp; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other expenses - transition services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Total Research and Development Expenses - First Quarter of 2022 vs. First Quarter of 2021 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase in total research and development expenses of $12.5 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily due to a $10.2 million increase in our direct expenses. The increase in direct expenses was primarily due to a $4.8 million increase in PYRUKYND&#174; costs and a $3.7 million increase in other research and platform programs. The increase in PYRUKYND&#174; costs was primarily due to startup costs for the initiated phase 3 trials of PYRUKYND&#174; in patients with thalassemia, ENERGIZE and ENERGIZE-T, and the phase 2/3 trial of PYRUKYND&#174; in patients with SCD, RISE UP, offset by closeouts of ACTIVATE and ACTIVATE-T studies. The increase in other research and platform programs was primarily driven by planned increased activity on various exploratory activities. Included in total indirect research and development expenses was $1.5&#160;million of reimbursable transition related services we provided to Servier related to the sale of the oncology business for discovery, clinical development, technical operations, and related activities which were completed during the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income and Expense</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty income from gain on  sale of  oncology business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other Income and Expense - First Quarter of 2022 vs. First Quarter of 2021 -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The increase in other income, net in the three months ended March 31, 2022 compared to the three months ended March 31, 2021 primarily relates to approximately $2.6&#160;million of reimbursable transition related services and fees for the sale of the oncology business for the three months ended March 31, 2022. The increase in royalty income from gain on sale of oncology business relates to income from royalties on U.S. net sales of TIBSOVO&#174; by Servier of approximately $2.7&#160;million for the three months ended March 31, 2022. The increase in interest income, net is primarily attributable to an increase in interest rates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss from Operations and Net (Loss) Income</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,774)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,877)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,965,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,774)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loss from Operations and Net Income (Loss) &#8211; First Quarter of 2022 vs. First Quarter of 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; The increase in net loss from continuing operations for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily driven by the higher research and development expenses discussed above under Research and Development Expenses, partially offset by approximately $2.6&#160;million of reimbursable transition related services and fees for the sale of the oncology business and $2.7&#160;million of royalty income from gain on sale of oncology business related to income from royalties on U.S. net sales of TIBSOVO&#174; by Servier. The change in net income from discontinued operations and net (loss) income for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily driven by the sale </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our oncology business to Servier for approximately $1.8&#160;billion in cash in the first quarter of 2021, which is included within net income from discontinued operations.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since our inception, and through March&#160;31, 2022, we have funded our operations through proceeds from the sale of our royalty rights, commercial sales of TIBSOVO&#174;, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">funding received from our collaboration agreements, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings. Following the sale of our oncology business to Servier on March 31, 2021, we have financed and expect to continue to finance our operations primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174;, the potential milestone payment and royalties from Servier if vorasidenib is approved by the FDA, potential sales of PYRUKYND&#174;, if successfully launched by us and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 31, 2021, we completed the sale of our oncology business to Servier. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted NDA approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $25.0 million potential milestone payment under our prior collaboration agreement with Celgene, and following the sale Servier is responsible for conducting certain clinical development activities within the IDHIFA&#174; development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 25, 2021, we announced that our Board of Directors authorized the repurchase of up to $1.2 billion of our outstanding shares of common stock, or the Repurchase Program, using the proceeds from the sale of our oncology business to Servier. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with Bristol-Myers Squibb Company, or BMS, to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $344.5&#160;million, or $48.38 per share. This repurchase was completed on April 5, 2021. Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan pursuant to which we could repurchase up to $600.0&#160;million of shares of our common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2021, we  repurchased approximately 9.1&#160;million shares of common stock for $458.0&#160;million, or $50.35 per share, under the Rule 10b5-1 repurchase plan. On October 5, 2021, we terminated our Rule 10b5-1 share repurchase program and on October 13, 2021 entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization under the Repurchase Program. In total, as of December 31, 2021 and March 31, 2022, we repurchased 16.2&#160;million shares of common stock for $802.5&#160;million, or $49.49 per share, under the Repurchase Program. We have paused our share repurchases and for the foreseeable future, we expect that our capital allocation will be prioritized towards opportunities to accelerate programs in our development pipeline and/or pursue potential complementary business development opportunities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive a $200.0&#160;million milestone payment and royalty payments under our transaction agreement with Servier. Our right to such payments under our transaction agreement with Servier is our only committed potential external source of funds. Whether the regulatory approval milestone for vorasidenib will be achieved is subject to various risks and uncertainties, many of which are outside our control, including adverse clinical developments with respect to vorasidenib. Furthermore, we cannot predict what success, if any, Servier may have in the United States with respect to sales of TIBSOVO&#174; and, if approved, vorasidenib and consequently we cannot estimate the amount of royalty payments that we can expect to receive from Servier under the Purchase Agreement prior to the loss of exclusivity of these products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,735)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,749)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,573)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,100)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760,589&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Net cash used in operating activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Cash used in operating activities of $97.7 million during the three months ended March 31, 2022, of which all was used by continuing operations, was primarily due to operating expenses driven by research and development costs described above under Research and Development Expenses, offset by cash received of $4.4 million from Servier for reimbursable transition related services and fees, and royalties on U.S. net sales of TIBSOVO&#174;. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash used in operating activities of $120.7 million during the three months ended March 31, 2021, of which $90.2&#160;million was used by continuing operations and $30.5&#160;million was used by discontinued operations, was primarily due to operating expenses driven by research and development costs described above under Research and Development Expenses and selling, general and administrative costs described above under Total Operating Expenses. These amounts were offset by cash received of $39.5 million from sales of TIBSOVO&#174;, and $1.2 million in cost reimbursements related to our collaboration agreements with Celgene.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Net cash (used in) provided by investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Cash used in investing activities of $26.6&#160;million during the three months ended March 31, 2022, of which all was used by continuing operations, was primarily due to higher purchases of marketable securities than proceeds from maturities and sales of marketable securities. Cash provided by investing activities of $1.9&#160;billion for the three months ended March 31, 2021, of which $71.1&#160;million was provided by operating activities and $1.8&#160;billion was provided by discontinued operations, was primarily due to the approximately $1.8 billion in cash proceeds received from the sale of our oncology business to Servier that was completed on March 31, 2021. We also received higher proceeds from maturities and sales of marketable securities than purchases of marketable securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cash provided by financing activities for the three months ended March 31, 2022, of which all was provided by continuing operations, was primarily the result of the $1.3 million of proceeds received from stock option exercises and purchases made pursuant to our 2013 Employee Stock Purchase Plan, or 2013 ESPP. Cash provided by financing activities for the three months ended March 31, 2021, of which all was provided by continuing operations, was primarily the result of the $7.3 million of proceeds received from stock option exercises and purchases made pursuant to our 2013 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although our expenses decreased following the completion of the sale of our oncology business to Servier on March 31, 2021, we anticipated that this decrease will be offset as we continue the research, development and clinical trials of, seek marketing approvals for, and commercialize our product candidates in our GDD portfolio, including as we commercialize PYRUKYND&#174;. If we obtain marketing approval for PYRUKYND&#174; in other indications outside of the United States or for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash, cash equivalents and marketable securities as of&#160;March&#160;31, 2022, will enable us to execute our operating plan through major catalysts and to cash-flow positivity without the need to raise additional equity. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of contingent consideration we ultimately receive in connection with the sale of our oncology business to Servier;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount and timing of future revenue, if any, received from commercial sales of PYRUKYND&#174; or any of our product candidates for which we may receive marketing approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of our ongoing commercialization activities, including product manufacturing, sales, marketing and distribution for PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to successfully execute on our strategic plans; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operational delays due to the ongoing COVID-19 pandemic; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we acquire or in-license, or monitor or out-license, other medicines and technologies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174;, a potential milestone payment and royalties from Servier if vorasidenib is approved by the FDA and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, in connection with potential future strategic transactions, we may pursue opportunistic debt offerings, and equity or equity-linked offerings. We do not have any committed external source of funds other than the potential milestone and royalty payments that we are eligible to receive under our purchase agreement with Servier. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_85"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there were no significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_88"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of March&#160;31, 2022 and December&#160;31, 2021, we had cash, cash equivalents and marketable securities of $1.2 billion and $1.3&#160;billion, respectively. Our marketable securities consist primarily of investments in U.S. Treasuries, government securities and corporate debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are primarily in short-term marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we do not believe an immediate and uniform 100 basis point change in interest rates would have a material effect on the fair market value of our investment portfolio.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to market risk related to changes in foreign currency exchange rates. We have contracts with CROs located in Asia and Europe that are denominated in foreign currencies, and we are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk. As of March&#160;31, 2022 and December&#160;31, 2021, liabilities denominated in foreign currencies were immaterial.</span></div><div id="ia065fc71787b4c5bb0fb689995212901_91"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of March&#160;31, 2022, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 17, 2022, the FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. As a result, during the fiscal quarter ended March 31, 2022, we made the following modifications to our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, including changes to accounting policies and procedures, operational processes, and documentation practices that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">updated our policies and procedures, and added documentation processes related to accounting for accounts receivable, inventory, revenue recognition and cost of sales</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">added internal controls over accounts receivable, inventory, revenue recognition and cost of sales</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">added controls to address related disclosures for accounts receivable, inventory, revenue recognition and cost of sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other than the items described above, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div><span><br/></span></div><div id="ia065fc71787b4c5bb0fb689995212901_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page 1 of this Quarterly Report on Form 10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not successfully commercialize PYRUKYND&#174; and other products for which we receive approval, our prospects may be substantially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, we obtained marketing approval from the FDA for PYRUKYND&#174; (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. PYRUKYND&#174; is the first product for which we have received marketing approval following the sale of our oncology business to Servier in March 2021 and PYRUKYND&#174; is the first product in our GDD portfolio that has received marketing approval. As of the date of this Quarterly Report on Form 10-Q, we are in the process of commercially launching</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PYRUKYND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#174;. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to generate revenue from PYRUKYND&#174; will depend heavily on our successful development and commercialization of the product.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of PYRUKYND&#174; could be unsuccessful if:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medical community and third-party payors do not accept PYRUKYND&#174; as safe, efficacious and cost-effective for the treatment of hemolytic anemia in adults with PK deficiency;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to maintain the necessary financial resources and expertise to manufacture, market and sell PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to develop, implement and maintain effective marketing, sales and distribution strategies and operations for the development and commercialization of PYRUKYND&#174;; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to continue to develop, validate and maintain a commercially viable manufacturing process for PYRUKYND&#174; that is compliant with current good manufacturing practices, or cGMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to successfully obtain third party reimbursement and generate commercial demand that results in sales of PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PYRUKYND&#174; or any product candidate that we commercialize, may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to commercialize PYRUKYND&#174; are impeded by the effects of the COVID-19 pandemic;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we encounter any third-party patent interference, derivation, inter partes review, post-grant review, reexamination or patent infringement claims with respect to PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to comply with regulatory and legal requirements applicable to the sale of PYRUKYND&#174;; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing drug products are approved for the same indications as PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to approve marketing approval of PYRUKYND&#174; in jurisdictions other than the United States; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new significant safety risks are identified; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a significant number of eligible patients with PK deficiency do not end up being prescribed PYRUKYND&#174; and, if they are, such patients do not stay on treatment; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PYRUKYND&#174; does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory standards for approval in indications other than currently approved indications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience significant delays or an inability to successfully develop and commercialize PYRUKYND&#174; our business would be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of our clinical product candidates, including our lead product candidate PYRUKYND&#174; for use in indications other than PK deficiency and in other jurisdictions. Clinical trials of our product candidates may not be successful for a number of important reasons. If we or our collaborators are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the identification of our product candidates and development of our most advanced clinical programs, including PYRUKYND&#174;. Our ability to generate product revenue will depend heavily on the successful clinical development and eventual commercialization of our current and any future product candidates, including PYRUKYND&#174; for use in indications other than PK deficiency and in jurisdictions outside of the United States. In February 2022, the FDA approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In June 2021, we submitted a MAA to the EMA for the treatment of adults with PK deficiency the European Union.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and any collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements in foreign jurisdictions. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product development. Moreover, we, or any collaborators, may experience any of a number of possible unforeseen adverse events in connection with clinical trials, many of which are beyond our control, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our collaborators, may fail to demonstrate efficacy in a clinical trial or across a broad population of patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. For example, many compounds that initially showed promise in earlier stage testing for treating specific disease indications have later been found to cause side effects that prevented further development of the compound;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics or otherwise expose participants to unacceptable health risks, causing us, our collaborators or our investigators, regulators or institutional review boards or the data safety monitoring board for such trial to halt, delay, interrupt, suspend or terminate the trials or cause us, or any collaborators, to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our product candidates have undesirable side effects, it could result in a more restrictive label, or it could result in the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we, or our collaborators, may decide, or regulators may require us, to conduct additional clinical trials, including testing in more subjects, or abandon product development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may not authorize us, our collaborators or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate; enrollment in these clinical trials, which may be particularly challenging for some of the orphan diseases we target in our GDD programs, may be slower than we anticipate; or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors used by us or our collaborators may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant preclinical study or clinical trial delays could shorten any periods during which we, or any collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any collaborators, to bring products to market before we, or any collaborators, do;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than anticipated; and,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we withdrew our IND for AG-519, our second PKR activator, following verbal notification of a clinical hold from the FDA relating to a previously disclosed case of drug-induced cholestatic hepatitis which occurred in our phase 1 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial of AG-519 in healthy volunteers. Although these decisions and this hepatic adverse event finding do not affect our ongoing clinical trials for PYRUKYND&#174;, our first PKR activator, we cannot provide any assurances that there will not be similar or other treatment-related severe adverse events in our other clinical trials of PYRUKYND&#174;, that our other trials will not be placed on clinical hold in the future, or that patient recruitment for our other trials will not be adversely impacted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully begin and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates could result in additional costs to us, or any collaborators, would impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties and would significantly harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover potential product candidates or to develop medicines of commercial value and we may not achieve our goals included in our strategic vision.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to identify and test compounds that target cellular metabolism and adjacent areas of biology in a variety of different types of GDDs. A significant portion of the research that we are conducting involves new compounds and drug discovery methods, including our proprietary technology. The drug discovery that we are conducting using our proprietary technology may not be successful in identifying compounds in our therapeutic areas. In addition, our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the research methodology used may not be successful in identifying appropriate biomarkers or potential product candidates; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to identify suitable compounds for preclinical and clinical development, or any medicines we develop do not effectively correct metabolic pathways or alter the metabolic state of immune cells, we will not be able to achieve our strategic vision and our specific long-term goals and will not be able generate product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has and may continue to affect our ability to initiate or continue our planned, ongoing and future clinical trials, disrupt regulatory activities, disrupt our ability to maintain a commercial infrastructure for our product or have other adverse effects on our business and operations. In addition, this pandemic may continue to adversely impact economies worldwide, which could result in adverse effects on our business and operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we were temporarily required to close our facilities except for a limited number of essential facilities and laboratory staff. Our Cambridge office reopened, with appropriate safety precautions in place that are aligned with local and CDC guidelines. Operations have maintained productivity, while allowing employees who prefer to work onsite to do so all or some of the time. Additionally, our field-based employees engage with healthcare providers and other third parties remotely and, where local regulations allow, on a limited in-person basis. In November 2021, we began requiring all employees, regardless of role or work location, to be fully vaccinated against COVID-19, as defined by CDC guidelines, subject to limited exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face disruptions that may affect our ability to initiate and complete clinical trials including disruptions in procuring items that are essential for our research and development activities, including, for example, raw materials used in the manufacturing of our product candidates and laboratory supplies for planned and ongoing clinical trials, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. We have experienced disruptions to certain research activities at our contract research organizations, or CROs, based in China, due to the recent COVID-19 surge in China. We have enrolled, and seek to enroll, patients in our clinical trials at sites located both in the United States and internationally. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis has been and may continue to be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. We have faced and may continue to face difficulties recruiting or retaining patients in our ongoing clinical trials because of the pandemic. Patients enrolled in our clinical trials may be unable or unwilling to visit clinical trial sites which may impact the collection of important clinical trial data and has, and may continue to, necessitate remote data verification. In addition, limitations in the ability to visit sites has affected, and may continue to affect, our enrollment timelines for our clinical trials, and may adversely affect the timing of completion of our clinical trials or our ability to complete clinical trials in a fully compliant manner. Additionally, the potential suspension of clinical trial activity at clinical trial sites may have an adverse impact on our clinical trial plans and timelines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have faced and may continue to face disruptions in our ability to prepare and submit applications to regulatory authorities for drug approvals and to build and maintain a commercial infrastructure for our product and product candidates. We may face manufacturing disruptions or disruptions related to the ability to obtain necessary institutional review board or other necessary site approvals, as well as other delays at clinical trial sites.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may continue to significantly impact economies and financial markets worldwide, which could result in adverse effects on our business and operations, impact our ability to raise additional funds through public offerings and impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business in the future and a continuation of the pandemic has the potential to adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may not be able to initiate, continue or complete clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. Furthermore, enrollment has been and may continue to be particularly challenging in light of the ongoing COVID-19 pandemic and even more so for some of the orphan diseases we target in our GDD programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of the disease under investigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability and efficacy of approved medications for the disease under investigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria for the study in question;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing our precision medicine approach, we generally focus our development activities on genetically or biomarker defined patients most likely to respond to our therapies. As a result, the potential patient populations for our clinical trials are narrowed, and we may experience difficulties in identifying and enrolling a sufficient number of patients in our clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or planned clinical trials for product candidates that would treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. For example, Rocket Pharma LTD, or Rocket Pharma, is developing a gene therapy targeting PK deficiency; Vertex Pharmaceuticals Incorporated, or Vertex, is developing a gene therapy targeting SCD; Forma Therapeutics Holdings, Inc., or Forma, is developing molecules for the treatment of beta thalassemia and SCD; Global Blood Therapeutics is developing molecules for the treatment of SCD; Fibrogen, Inc. is developing Roxadustat for the treatment of anemia in MDS patients; and Geron Corporation is developing imetelstat for the treatment of low-risk MDS. Roivant Sciences is developing RVT-2001 (licensed from Eisai Co., Ltd.) for the treatment of transfusion-dependent anemia in patients with lower-risk MDS. Competition for eligible patients may make it particularly difficult for us to enroll a sufficient number of patients to complete our clinical trials for our product candidates in a timely and cost-effective manner. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on contract research organization, or CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. Our or our collaborators&#8217; inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies and early clinical trials may not be predictive of results of later-stage clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier stages of development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. While we obtained marketing approval of PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States, we cannot be certain that we will obtain marketing approval of PYRUKYND&#174; in other indications. The results of clinical trials of PYRUKYND&#174; for the treatment of PK deficiency do not predict that PYRUKYND&#174; will be efficacious in our ongoing clinical trials in other indications. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any collaborators, to market the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our clinical trials, or those of any collaborators, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, including PYRUKYND&#174;, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any collaborators, could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PYRUKYND&#174;, or any of our product candidates that may receive marketing approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PYRUKYND&#174;, or any of our product candidates that may receive marketing approval in the future, may fail to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If PYRUKYND&#174; or any of our product candidates that may receive marketing approval do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of PYRUKYND&#174; and any of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efficacy and potential advantages compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our medicines for sale at competitive prices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring uninterrupted product supply;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party coverage or reimbursement; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing PYRUKYND&#174; or our product candidates if they are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for approved medicines for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. Although we had established sales and marketing capabilities to support our co-promotion efforts for IDHIFA&#174; and our sales of TIBSOVO&#174; prior to the sale of our oncology business to Servier, we are again in the process of building our sales and marketing infrastructure to support our commercial launch and sell PYRUKYND&#174; for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. We may need to further build our sales and marketing infrastructure to commercialize PYRUKYND&#174; in other indications or outside of the United States or to commercialize any of our other product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our medicines on our own include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of product revenue to us are likely to be lower than if we were to market and sell any medicines that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing PYRUKYND&#174; or any of our product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition with respect to PYRUKYND&#174; and our current product candidates, and we will face competition with respect to any product candidates that we or they may seek to develop or commercialize in the future. Potential competitors include major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product or our product candidates, such as PK deficiency, thalassemia, SCD and L-IR MDS. For example, Acceleron Pharma Inc. (in collaboration with Bristol-Myers Squibb Company) and bluebird bio, Inc., or bluebird, are each marketing therapies to treat beta thalassemia, Novartis International AG, Emmaus Life Sciences and Global Blood Therapeutics are each marketing therapies to treat SCD, Rocket Pharma is conducting a clinical trial of a gene therapy targeting PK deficiency, and a number of other biotechnology companies have product candidates in clinical development in similar indications as ours. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a variety of treatment options available, including a number of marketed enzyme replacement therapies, for treating patients with GDDs. In addition to currently marketed therapies, there are also a number of products that are either enzyme replacement therapies, gene therapies or PK activators in various stages of clinical development to treat GDDs. These products in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies or for which there are no approved treatments. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also a number of product candidates in preclinical or clinical development by third parties to treat GDDs by targeting similar mechanisms of action as our product candidates. These companies include large pharmaceutical companies, such as Novartis, as well as biotechnology companies of various sizes, such as BioMarin Pharmaceutical Inc., bluebird, Forma, PTC Therapeutics, Inc., Rocket Pharma, and Vertex. Our competitors may develop products that are more effective, safer, more convenient or less costly than PYRUKYND&#174; or any product candidates that we are developing or that would render PYRUKYND&#174; or our product candidates obsolete or non-competitive. In addition, our competitors may discover biomarkers that more efficiently measure metabolic pathways than our methods, which may give them a competitive advantage in developing potential products. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and clinical stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA does not grant our products, if and when approved, appropriate periods of data exclusivity before approving generic or follow-on versions of our products, the sales of our products could be adversely affected. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With FDA approval of an NDA, the product covered by the application is specified as a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any reference-listed drug may be typically lost to the generic product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, that references the FDA&#8217;s prior approval of the innovator product or preclinical studies and/or clinical trials that were not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. A 505(b)(2) NDA product, or follow-product, may be for a new or improved version of the original reference listed drug. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA or 505(b)(2) NDA until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The FDCA provides a period of five years of new chemical entity exclusivity for a new drug containing a new active moiety. Specifically, in cases where such exclusivity has been granted, an ANDA or a 505(b)(2) NDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed drug. The FDCA also provides a period of three years of new clinical investigation data exclusivity in connection with the approval of a supplemental indication for the product for which a clinical trial is deemed by the FDA as essential for approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a generic or follow-on manufacturer is somehow able to obtain FDA approval without adherence to these periods of data exclusivity, the competition that our approved products may face from generic and follow-on versions could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if there are patents listed for our drug products in the Orange Book, ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the applicant intends to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic or follow-on competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us or any collaborators could cause us or our collaborators to incur substantial liabilities and could limit commercialization of any medicines that we or they may develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any collaborators face a risk of product liability exposure related to our product candidates in human clinical trials and face an even greater risk as we or they commercially sell any medicines, including PYRUKYND&#174;. If we or any collaborators cannot successfully defend ourselves or themselves against claims that our product candidates or medicines caused injuries, we or they could incur substantial costs and liabilities. Regardless of merit or eventual outcome, liability claims may also result in, among other thing, decreased demand for any product candidates or medicines that we may develop, reputational harm and lost revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of any third parties with which we contract, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from computer viruses, worms and other destructive or disruptive software, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber incidents by malicious third parties. Cyber incidents are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber incidents could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber incidents also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company, including personal information of our employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System failures, accidents, cyber incidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical and commercialization activities and business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions, in addition to possibly requiring substantial expenditures of resources to remedy. For example, the loss of clinical trial data from completed or future trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and our product research, development and commercialization efforts could be delayed. In addition, we may not have adequate insurance coverage to provide compensation for any losses associated with such events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a material breach of our security or that of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed, we could lose business and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to EU General Data Protection Regulation, or the GDPR, which applies to all member states of the European Economic Area, or EEA. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data. The GDPR imposes significant obligations on us with respect to clinical trials conducted in the EEA. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of GDPR, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#8217;s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the EU. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal information could expose us to fines and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by GDPR, though the California Consumer Privacy Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with current and any future federal and state laws regarding privacy and security of personal information could expose us to fines and penalties. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face new challenges as a smaller, less diversified company following the sale of our oncology business to Servier.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the sale of our oncology business to Servier in March 2021, we have focused our resources and efforts on product and product candidates for the treatment of GDDs. The success of the GDD business is subject to various risks and uncertainties, including the possibility that we may not be able to successfully commercialize PYRUKYND&#174;, which only recently was approved by the FDA for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, the possibility of adverse clinical and other developments in respect of PYRUKYND&#174; or our other product candidates of the GDD business, and unanticipated changes in applicable laws and regulations that may adversely affect the GDD business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed most of our initial products and product candidates for the treatment of various types of cancer. The sale of our oncology business to Servier, including our approved products at the time of sale, TIBSOVO&#174; and IDHIFA&#174;, has resulted in us being a smaller, less diversified company with a more limited business concentrated on products and product candidates for the treatment of GDDs. As a result, we may be more susceptible to changing market conditions, including fluctuations and risks particular to the markets for patients with GDDs, than a more diversified company, which could adversely affect our business, financial condition and results of operations. In addition, even with the FDA approval of PYRUKYND&#174;, the diversification of our revenues, costs and cash flows has diminished following the transaction. Our results of operations, cash flows, working capital and financing requirements may be subject to increased volatility and our ability to fund capital expenditures and investments or satisfy other financial commitments may be diminished.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion as to the use of the proceeds from the sale of our oncology business to Servier, and we may not use the proceeds effectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have broad discretion with respect to the use of proceeds of the sale of our oncology business to Servier. The results and effectiveness of the use of proceeds, including the repurchase of shares of our common stock, are uncertain, and we could spend the proceeds in ways that do not improve our remaining business, financial condition or results of operations. Our failure to apply these funds effectively could have an adverse effect on its business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, including from sales of PYRUKYND&#174;, we expect to finance our cash needs primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174;, a potential milestone payment and royalties from Servier if vorasidenib is approved by the FDA and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, in connection with potential future strategic transactions, we may pursue opportunistic debt offerings, and equity or equity-linked offerings. We do not have any committed external source of funds other than the potential milestone and royalty payments that we are eligible to receive under our purchase agreement with Servier. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may require us to enter into agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our existing capital is insufficient to execute our operating plan through major catalysts and to cash-flow positivity, we will need to raise capital, and if we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses as we continue to advance our ongoing activities. We expect to execute our operating plan through major catalysts and to cash-flow positivity without the need to raise additional equity. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operating plan is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of future revenue received from commercial sales of PYRUKYND&#174; and any of our other product candidates for which we may receive marketing approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of contingent consideration we ultimately receive in connection with the sale of our oncology business to Servier;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of our ongoing commercialization activities, including product manufacturing, sales, marketing and distribution, for PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;  </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully execute on our strategic plans;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operational delays due to the COVID-19 pandemic; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license, or monitor or out-license, other medicines and technologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a history of incurring operating losses. Our net loss for the three months ended March 31, 2022 was $94.8 million, and our net income for the three months ended March 31, 2021 was $1,874.3 million, which was due to the sale of our oncology business to Servier on March 31, 2021. As of March&#160;31, 2022, we had an accumulated deficit of $333.5 million. Prior to the sale of our oncology business to Servier, we had generated only modest revenue from sales of TIBSOVO&#174; and, prior to our sale to Royalty Pharma of our royalty rights to IDHIFA&#174;, from royalties on sales of IDHIFA&#174;. We have only recently obtained marketing approval and have begun to commercialize PYRUKYND&#174; for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. PYRUKYND&#174; is the first product we have received marketing approval for following the sale of our oncology business, including approved products TIBSOVO&#174; and IDHIFA&#174;, to Servier in March 2021. We have neither obtained marketing approval for PYRUKYND&#174; in any other indications or for any indication outside of the United States nor have we obtained marketing approval for any of our other product candidates, all of which are in preclinical or clinical development stages. In June 2021, we submitted a MAA for PYRUKYND&#174; in adults with PK deficiency to the EMA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of our oncology business to Servier, we financed our operations primarily through public offerings of our common stock and our collaboration agreements with Celgene and have devoted substantially all of our efforts to research and development. Following the sale of our oncology business to Servier on March 31, 2021, we have financed and expect to finance our operations primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174;, a potential milestone payment from Servier if vorasidenib is approved by the FDA, potential sales of PYRUKYND&#174; and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. We expect to continue to incur significant expenses and net losses until such time as we are able to report profitable results. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that we will incur significant expenses if and as we:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercially launch PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to establish and maintain a sales, marketing and distribution infrastructure to commercialize PYRUKYND&#174; and other product candidates for which we may obtain marketing approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate and continue clinical trials for our products and product candidates, including PYRUKYND&#174; in other indications; continue our research and preclinical development of our product candidates and seek to identify additional product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for our product candidates that successfully complete clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the manufacture of larger quantities of product candidates for clinical development and commercialization;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add additional personnel to support our product research and development and planned future commercialization efforts and our operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other medicines and technologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and successfully commercialize one or more medicines with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those medicines for which we may obtain marketing approval and satisfying any post-marketing requirements. Notwithstanding the extent to which we may succeed in any of these activities, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of contingent consideration we will receive from the sale of our oncology business to Servier is subject to various risks and uncertainties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the sale of our oncology business to Servier, Servier assumed certain liabilities with respect to the oncology business and paid to us: approximately $1.8 billion in cash, net of certain adjustments for the working capital of the oncology business at the time of closing of the transaction and amounts for a representation and warranty insurance policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Servier will pay to us:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$200.0 million in cash if, prior to January 1, 2027, vorasidenib is granted approval for a new drug application, or NDA, from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an IDH1 or IDH2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a royalty payment of 5% of the U.S. net sales (as defined in the purchase agreement with Servier) of TIBSOVO&#174; from the completion of the transaction through loss of exclusivity of TIBSOVO&#174;; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a royalty payment of 15% of the U.S. net sales (as defined in the purchase agreement with Servier) of vorasidenib from its first commercial sale through loss of exclusivity of vorasidenib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration described above is subject to various risks and uncertainties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether the regulatory approval milestone will be achieved prior to January 1, 2027 is subject to various risks and uncertainties, many of which are outside of the control of the parties, including adverse clinical developments with respect to vorasidenib. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot predict what success, if any, Servier may have in the United States with respect to sales of TIBSOVO&#174; and vorasidenib, if approved, and, therefore, the amount of royalty payments that we can expect to receive from Servier under the terms of the purchase agreement prior to the loss of exclusivity of these products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty payments are also subject to deductions and other adjustments under the terms of the purchase agreement, the amounts of which are uncertain as of the date of this report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax law may adversely affect our business or financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act, or the Tax Act, which significantly reformed the U.S. Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, contained significant changes to corporate taxation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Congress&#8217; response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted on March 27, 2020, COVID-19 relief provisions were included in the Consolidated Appropriations Act, 2021, or CAA, which was enacted on December 27, 2020 and the American Rescue Plan Act of 2021, or ARPA, was enacted on March 11, 2021. All contain numerous tax provisions. Regulatory guidance under the Tax Act, the FFCR Act, the CARES Act, the CAA and the ARPA is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. It is possible that Congress will enact additional legislation in connection with the COVID-19 pandemic. Furthermore, as a result of the changes in the U.S. presidential administration and control of the U.S. Senate, it is possible that additional tax legislation will be enacted. Such legislation could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the FFCR Act, the CARES Act, the CAA or the ARPA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek collaborations for the development and commercialization of our product candidates with large and mid-size pharmaceutical companies and biotechnology companies. We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. Collaborators may have rights that restrict us from entering into future agreements on certain terms with potential collaborators.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into any such arrangements with collaborators, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities. Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing, which may result in a need for additional capital to pursue further development or commercialization of the applicable product candidate. Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. Disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our medicines or product candidates or that result in costly litigation or arbitration that diverts management attention and resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not independently conduct clinical trials of any of our product candidates. We rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. In addition, we currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time. If any of our relationships with these third parties terminate, we may not be able to enter into similar arrangements with alternative third-parties or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. As a result, delays may occur in our product development activities. Although we seek to carefully manage our relationships with our CROs, we could encounter such challenges or delays that could have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such standards. We and these third parties are required to comply with current good clinical practices, or cGCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you a given regulatory authority will determine that any of our clinical trials comply with cGCP regulations. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. We are exposed to risk of fraud or other misconduct by such third parties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely and expect to continue to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercialization. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the materials and manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND&#174; and any product candidate for which we or our collaborators obtain marketing approval. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have entered into long-term supply agreements for commercial supply of PYRUKYND&#174; with third-party manufacturers, we may be unable to establish similar long-term supply agreements with third-party manufacturers with respect to our other GDD product candidates or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reliance on the third party for regulatory compliance, quality assurance, environmental and safety and pharmacovigilance reporting;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possible breach of the manufacturing agreement by the third party; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMPs. regulations or similar regulatory requirements on a global basis. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been monitoring our supply chain network for any disruptions due to the COVID-19 pandemic, and our manufacturers have remained largely unaffected, with any campaign delays experienced to date being limited to a few days in duration. Although global shipping continues to be disrupted due to the pandemic, we have not yet experienced a supply impact. If either we or any third parties on which we rely are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and research and development operations and our product for commercialization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development, marketing approval or our commercialization efforts. We do not currently have arrangements in place for redundant supply for drug product. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product or our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent or trade secret protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary medicines and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business. We do not yet have issued patents for all our most advanced product candidates in all markets in which we intend to commercialize but we continue to actively pursue patent protection for our assets around the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is costly and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify and/or file patent applications on every aspect of our research and development output that is or may be eligible for patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who may have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent protection. There is also the possibility that loss or theft of data or records may jeopardize the ability to seek patent protection or impede the progress or drafting of patent applications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed patent rights, and in the future may license additional patent rights, from third parties. Such licenses may be accompanied by milestone and/or royalty payment obligations. These licensed patent rights may be valuable to our business, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or medicines underlying such licenses. We cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties also apply to patent rights we own.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or medicines or that effectively prevent others from commercializing competitive technologies and medicines. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming the other requirements for patentability are met, prior to March 2013, in the United States, the first to make the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. Beginning in March 2013, the United States transitioned to a first inventor to file system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize medicines without infringing third-party patent rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of the patent or in one or more patent claims being narrowed or invalidated, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and medicines. Given the significant amount of time required for the discovery, development, preclinical and clinical testing and regulatory review and approval of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In such circumstances we would be relying primarily on regulatory or marketing exclusivity to exclude others from commercializing a generic version of our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we or our collaborators are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product and product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We have in the past and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, including opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings before the USPTO or other patent offices around the world. For example, in 2011, The Leonard and Madlyn Abramson Family Cancer Research Institute at the Abramson Cancer Center of the University of Pennsylvania initiated a lawsuit against us, one of our founders, Craig B. Thompson, M.D., and Celgene, alleging misappropriation of intellectual property and, in 2012, the Trustees of the University of Pennsylvania initiated a similar lawsuit against us and Dr. Thompson. Each of these lawsuits was settled in 2012. We are not aware of any other legal proceedings having been filed against us to date. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we or one of our collaborators are found to infringe a third party&#8217;s intellectual property rights, we or they could be required to obtain a license from such third party to continue developing and marketing our medicines and technology. However, we or our collaborators may not be able to obtain any required license on commercially reasonable terms or at all. Even if we or our collaborators were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We or our collaborators could be forced, including by court order, to cease developing and commercializing the infringing technology or medicine. In addition, we or our collaborators could be found liable for monetary damages. A finding of infringement could prevent us or our collaborators from commercializing our product and product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we or our collaborators have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants or advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and medicines, we also rely on maintaining the confidentiality of unpatented know-how, technology and other proprietary information, to maintain our competitive position. For example, we consider the confidential information and know-how related to our cellular metabolism technology platform to be our primary intellectual property assets in this space. Unpatented proprietary technical information and know-how can be difficult to protect. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect this proprietary technical information and know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our proprietary technical information and know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Moreover, we anticipate that with respect to this platform, at least some of this technical information and know-how will, over time, be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and comparable regulatory authorities in other countries. With the exception of the FDA approval of PYRUKYND&#174;, for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, we have not received approval to market any of our current product candidates from regulatory authorities in any jurisdiction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, EMA and other foreign regulatory authorities have substantial discretion in the approval process. Accordingly, it is possible that the FDA or EMA may refuse to accept for substantive review any NDA, sNDA or MAA that we submit for our product candidates, or may conclude after review of our data that our marketing application is insufficient to obtain marketing approval of our product candidates, including with respect to the MAA for PYRUKYND&#174; that is currently under review by the EMA. If the FDA or EMA does not accept or approve our applications for any of our product candidates, the applicable regulator may require that we conduct additional clinical trials, preclinical studies or manufacturing validation studies and submit that data before reconsidering our applications. Depending on the extent of these or any other FDA- or EMA-required trials or studies, approval of any marketing applications that we submit may be delayed by several years, or may require us to expend more resources than we planned. It is also possible that additional trials or studies, if performed and completed, may not be considered sufficient by the FDA or EMA to approve any marketing applications. We may not be successful in obtaining FDA or EMA approval of our product candidates on a timely basis, or ever. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process, and failure to obtain marketing approval for our product candidates will prevent us from commercializing the product candidate in the applicable jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we or our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic may continue to disrupt the U.S. and international healthcare and regulatory systems. These disruptions could materially delay the review of, and/or decision making with respect to, marketing approvals for our product candidates. Any delay in regulatory review or decision making resulting from such disruptions could materially affect the development of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may prolong the time necessary for regulatory submissions to be reviewed and/or new drugs to be approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown were to occur, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Should the FDA determine that an inspection is necessary for approval of a regulatory submission and an inspection cannot be completed during the review cycle due to restrictions on travel due to COVID-19, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue a complete response letter or defer action on the regulatory submission until an inspection can be completed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of our medicines that are approved for marketing in such jurisdiction will be subject to risk associated with foreign operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our medicines in the EU and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country. We or our collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the EU on December 31, 2020, commonly referred to as Brexit. On December 24, 2020, the United Kingdom and EU entered into a Trade and Cooperation Agreement, which sets out certain procedures for approval and recognition of medical products in each jurisdiction, and the United Kingdom and EU continue to work on the rules for implementation. Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, the consequences of Brexit and the impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing any product candidates in the United Kingdom and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability, which could significantly and materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States. In addition, we do not have experience commercializing products outside of the United States and such efforts may depend on our ability to find a suitable collaborator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast track designation and/or priority review designation by the FDA or PRIME designation in the EU may not actually lead to a faster development or regulatory review or approval process, nor does it assure approval of the product candidate by the FDA or the EMA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek fast track designation, priority review designation and/or PRIME designation for our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate is intended for the treatment of a serious or life-threatening disease or condition and the product candidate demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion on whether to grant fast track designation and/or priority review designation to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Even if our product candidates receive fast track designation and/or priority review designation, we may not experience a faster development process, review or approval, if at all, compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the EU, the PRIME designation program focuses on product candidates that target conditions for which there exists no satisfactory method of treatment in the EU or product candidates that may offer a major therapeutic advantage over existing treatments. The benefits of a PRIME designation include, among other things, the potential to qualify product for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME designation enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if our product candidates receive PRIME designation, we may not experience a faster development process, review or approval compared to conventional EMA procedures and it does not assure or increase the likelihood of the EMA&#8217;s grant of a marketing authorization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or any collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Moreover, even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. The FDA may reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product or product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product or product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and record keeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our medicines for uses other than their respective approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which violations may result in the imposition of significant administrative, civil and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians and third-party payors are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of PYRUKYND&#174; and any product candidates for which we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute PYRUKYND&#174; and any other medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals and other covered recipients; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and transparency statutes, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PYRUKYND&#174; or any product candidate that we commercialize may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of PYRUKYND&#174; or of any of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not available, or reimbursement is available only to limited levels, we, or any collaborators, may not be able to successfully commercialize PYRUKYND&#174; or our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we, or any collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any collaborators, to commercialize PYRUKYND&#174; or any of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any collaborators to sell PYRUKYND&#174; or our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenue. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for PYRUKYND&#174; or any product candidate that we, or any collaborator, may commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for PYRUKYND&#174; or any of our product candidates for which we, or any collaborator, may obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to obtain reimbursement and commercialize our drug candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell PYRUKYND&#174; or any other product for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This legislation resulted in aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through 2031. However, pursuant to the CARES Act and subsequent legislation, these Medicare sequester reductions were suspended through the end of March 2022 and from April 2022 through June 2022, a 1% cut will be in effect, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On November 10, 2020, the Supreme Court heard oral arguments as to whether the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On February 10, 2021, the Biden Administration withdrew the federal government&#8217;s support for overturning the ACA. On June 17, 2021, the Supreme Court struck down the lower court rulings, finding that the plaintiffs did not have standing to challenge the ACA&#8217;s minimum essential coverage provision at issue in the case.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked these Orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. This Executive Order also directs the U.S. Department of Health and Human Services to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic. We cannot predict how federal agencies will respond to such Executive Orders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The costs of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for products. To those ends, President Trump issued several executive orders intended to lower the costs of prescription drug products. Certain of these orders are reflected in recently promulgated regulations, including an interim final rule implementing President Trump&#8217;s most favored nation model, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries effective, but such final rule is currently subject to a nationwide preliminary injunction. On August 21, 2021, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a proposed rule to rescind President Trump&#8217;s interim final rule, following public notice and comment, and CMS stated it will explore all options to incorporate value into payments for Medicare Part B drugs and improve beneficiaries&#8217; access to evidence-based care. The Biden Administration has frozen certain of the Trump Administration&#8217;s measures to reform drug prices. It remains to be seen whether the orders and resulting regulations put in place during the Trump Administration will remain in force. Further, on September 24, 2020, the Trump Administration finalized a rulemaking allowing states or certain other non-federal government entities to submit importation program proposals to the FDA for review and approval. Applicants are required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant cost savings for consumers. The FDA has issued draft guidance that would allow manufacturers to import their own FDA-approved drugs that are authorized for sale in other countries (multi-market approved products). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product or product candidates or additional pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and foreign export control, import, sanctions, anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with such laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our key executives and scientific leadership and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management and scientific teams, each of whom is employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. We cannot predict the likelihood, timing or effect of future transitions among our executive leadership. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and universities and research institutions for similar personnel. Our consultants and advisors, including our scientific co-founders, who assist us in formulating our research and development and commercialization strategy may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Furthermore, the ongoing COVID-19 pandemic and our flexible workplace policy allowing employees to work from home may make it difficult for us to maintain our corporate culture.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to experience growth in the number of our employees as we expand our development, regulatory and future sales and marketing capabilities. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations or regulations in other jurisdictions, provide accurate information to the FDA or other regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, disclose unauthorized activities to us, or comply with securities laws. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, including for illegal insider trading activities, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may enter into transactions to acquire other businesses, products or technologies. Because we have not made any acquisitions to date, our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and Other Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our Board of Directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board of Directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is likely to be volatile, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. For example, since January 1, 2015 the closing price of our common stock on the Nasdaq Global Select Market has ranged from $22.70 per share to $138.85 per share. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. While the full extent of the economic impact and the duration of the COVID-19 pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in launching and commercializing PYRUKYND&#174;; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the sale of our oncology business to Servier on our business;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of our repurchases of shares of common stock from our stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and results of clinical trials of product candidates, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions with respect to our product or product candidates or our competitors&#8217; products and product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of collaborations for our development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our products, product candidates or development programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to develop additional product candidates and products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results or development timelines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our insiders or other stockholders, including shares issuable upon exercise of outstanding stock options and upon vesting of stock units under our stock incentive plans;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or results of companies that are perceived to be similar to us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates, evaluations or recommendations by securities analysts, that cover our stock or the failure by one or more securities analysts to continue to cover our stock;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the societal and economic impact of public health epidemics, such as the ongoing COVID-19 pandemic and any recession, depression or sustained market event resulting from the pandemic;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company's securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert managements' attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot guarantee that an active trading market for our shares will be sustained. An inactive trading market for our common stock may impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results also may fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned shares representing a significant percentage of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Code and corresponding provisions of state law, if a company undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership by certain stockholders over a three-year period, the company&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income may be limited. Our prior equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. We completed a review of our changes in ownership through December 31, 2021, and determined that we did not have a qualified ownership change since our last review as of December 31, 2020. Future ownership changes under Section 382 may limit the amount of net operating loss and tax credit carryforwards that we could potentially utilize to reduce future tax liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. The Tax Act, as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different from previous periods or our current expectations due to numerous factors, including as a result of changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and will continue to incur significant legal, accounting and other expenses as a public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations. Our management and other personnel devote, and will need to continue to devote, a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will repurchase shares of our common stock or that we will repurchase shares at favorable prices.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 25, 2021, we announced that our Board of Directors authorized the Repurchase Program for the repurchase of up to $1.2 billion of our outstanding shares of common stock. In April 2021, in connection with the Repurchase Program, we repurchased from BMS 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $344.5 million, or $48.38 per share. Further, in April 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan pursuant to which we repurchased approximately 9.1 million shares of common stock for $458.0 million, or $50.35 per share, under the plan. In total, as of December 31, 2021, we repurchased 16.2 million shares of common stock for $802.5 million under the Repurchase Program. In October 2021, we terminated our Rule 10b5-1 share repurchase program and entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization. We have paused our share repurchases and for the foreseeable future, we expect that our capital allocation will be prioritized towards opportunities to accelerate programs in our development pipeline and/or pursue potential complementary business development opportunities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount and timing of share repurchases are subject to capital availability, our cash balances and future capital requirements and our determination that share repurchases are in the best interest of our stockholders and are in compliance with all respective laws and our applicable agreements. A reduction in repurchases under, or the completion of, our Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File&#160;Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date of Filing</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 30, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312518353307/d653738dex31.htm">Second Amended and Restated By-Laws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 19, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1x03x31x22.htm#i7529373f46b849319bc12ffca96e17a5_1">Certification of principal executive officer pursuant to Rule&#160;13a 14(a)/15d 14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2x03x31x22.htm#iad8148e171084a099795d873c58c06fb_1">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1x03x31x22.htm#i6184396c02924f9f8d67c44e59fde07f_1">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2x03x31x22.htm#i77b15f5769e34d0cb41d3514471a2dfb_1">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">* This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ia065fc71787b4c5bb0fb689995212901_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">Table of Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia065fc71787b4c5bb0fb689995212901_7">&#160;&#160;&#160;&#160;</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AGIOS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jacqualyn A. Fouse</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jonathan Biller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller<br/>Chief Financial Officer and Head of Corporate Affairs<br/>(principal financial officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1x03x31x22.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7529373f46b849319bc12ffca96e17a5_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqualyn A. Fouse, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2x03x31x22.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iad8148e171084a099795d873c58c06fb_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jonathan Biller, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Chief Financial Officer and Head of Corporate Affairs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1x03x31x22.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6184396c02924f9f8d67c44e59fde07f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jacqualyn A. Fouse, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2x03x31x22.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i77b15f5769e34d0cb41d3514471a2dfb_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jonathan Biller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to his knowledge on the date hereof&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Chief Financial Officer and Head of Corporate Affairs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>agio-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:55e4eac5-1c9c-49df-a9ba-5fe941f4694b,g:196378a3-5ec7-4de3-a864-cc3dd9965fcc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agio="http://agios.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agios.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://agios.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewandBasisofPresentation" roleURI="http://agios.com/role/OverviewandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Overview and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewandBasisofPresentationDetails" roleURI="http://agios.com/role/OverviewandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Overview and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://agios.com/role/FairValueMeasurements">
        <link:definition>2105103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://agios.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2407402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2408403 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://agios.com/role/MarketableSecurities">
        <link:definition>2109104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://agios.com/role/MarketableSecuritiesTables">
        <link:definition>2310302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>2411404 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofMarketableSecuritiesDetails" roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails">
        <link:definition>2412405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://agios.com/role/Inventory">
        <link:definition>2113105 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://agios.com/role/InventoryTables">
        <link:definition>2314303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetails" roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails">
        <link:definition>2415406 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://agios.com/role/Leases">
        <link:definition>2116106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://agios.com/role/LeasesTables">
        <link:definition>2317304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://agios.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2418407 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseExpenseandOtherInformationDetails" roleURI="http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails">
        <link:definition>2419408 - Disclosure - Leases - Schedule of Lease Expense and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails">
        <link:definition>2420409 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2420409 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentstobeReceivedDetails" roleURI="http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails">
        <link:definition>2421410 - Disclosure - Leases - Future Minimum Lease Payments to be Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://agios.com/role/AccruedExpenses">
        <link:definition>2122107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://agios.com/role/AccruedExpensesTables">
        <link:definition>2323305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryofAccruedExpensesDetails" roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails">
        <link:definition>2424411 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenue" roleURI="http://agios.com/role/ProductRevenue">
        <link:definition>2125108 - Disclosure - Product Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueTables" roleURI="http://agios.com/role/ProductRevenueTables">
        <link:definition>2326306 - Disclosure - Product Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails">
        <link:definition>2427412 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails">
        <link:definition>2428413 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofRevenueRelatedReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails">
        <link:definition>2429414 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails">
        <link:definition>2430415 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://agios.com/role/ShareBasedPayments">
        <link:definition>2131109 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://agios.com/role/ShareBasedPaymentsTables">
        <link:definition>2332307 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>2433416 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofStockOptionActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails">
        <link:definition>2434417 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails">
        <link:definition>2435418 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails">
        <link:definition>2436419 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails">
        <link:definition>2437420 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails">
        <link:definition>2438421 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShare" roleURI="http://agios.com/role/LossperShare">
        <link:definition>2139110 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareTables" roleURI="http://agios.com/role/LossperShareTables">
        <link:definition>2340308 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>2441422 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://agios.com/role/IncomeTaxes">
        <link:definition>2142111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://agios.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2443423 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="agio_CurrentYearProvisionsForRebateReserve" abstract="false" name="CurrentYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveRecoveries" abstract="false" name="ContractWithCustomerCurrentYearReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" abstract="false" name="ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="agio_RepurchaseProgramMember" abstract="true" name="RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_AgiosOncologyBusinessMember" abstract="true" name="AgiosOncologyBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_Agreement2010Member" abstract="true" name="Agreement2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_VorasidenibMember" abstract="true" name="VorasidenibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_OtherStockAwardsMember" abstract="true" name="OtherStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_ProductReturnsRollForward" abstract="true" name="ProductReturnsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_TwoThousandAndThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerAllowanceAndReservesLiability" abstract="false" name="ContractWithCustomerAllowanceAndReservesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractualAdjustmentsRollForward" abstract="true" name="ContractualAdjustmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_PriorYearProvisionForContractualAdjustments" abstract="false" name="PriorYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserve" abstract="false" name="ContractWithCustomerRebateReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInCurrentYear" abstract="false" name="ProvisionForRightToRecoverProductInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_MarketBasedStockUnitsMember" abstract="true" name="MarketBasedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_ChangeInContractWithCustomerAssetRollForward" abstract="true" name="ChangeInContractWithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveProvisions" abstract="false" name="ContractWithCustomerCurrentYearReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerTotalAllowancesAndReserves" abstract="false" name="ContractWithCustomerTotalAllowancesAndReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" abstract="false" name="ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" abstract="true" name="March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductPriorYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PerformanceStockUnitMember" abstract="true" name="PerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetRevenueRecognized" abstract="false" name="ContractWithCustomerAssetRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContingentGainOnDispositionOfBusinessRecognized" abstract="false" name="ContingentGainOnDispositionOfBusinessRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CurrentYearProvisionForContractualAdjustments" abstract="false" name="CurrentYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" abstract="false" name="ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="agio_EmployeeStockPurchasePlan2013Member" abstract="true" name="EmployeeStockPurchasePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_March252021RepurchaseProgramRule10b51RepurchaseMember" abstract="true" name="March252021RepurchaseProgramRule10b51RepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInPriorYears" abstract="false" name="ProvisionForRightToRecoverProductInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveRecoveries" abstract="false" name="ContractWithCustomerPriorYearsReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" abstract="false" name="LesseeOperatingSubleaseAreaOfPremisesSubleased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_GainContingencyRoyaltyPercentageOfNetSales" abstract="false" name="GainContingencyRoyaltyPercentageOfNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerContractualAdjustmentReserve" abstract="false" name="ContractWithCustomerContractualAdjustmentReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_EmployeePurchasePlanMember" abstract="true" name="EmployeePurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveProvisions" abstract="false" name="ContractWithCustomerPriorYearsReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_GovernmentRebatesRollForward" abstract="true" name="GovernmentRebatesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" abstract="false" name="PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" abstract="false" name="ContractWithCustomerAssetProceedsFromCollectionOfReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_StockholdersEquityDispositionOfBusiness" abstract="false" name="StockholdersEquityDispositionOfBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductReserve" abstract="false" name="ContractWithCustomerRightToRecoverProductReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CurrentAssetMember" abstract="true" name="CurrentAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_TIBSOVOMember" abstract="true" name="TIBSOVOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_PriorYearProvisionsForRebateReserve" abstract="false" name="PriorYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>agio-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:55e4eac5-1c9c-49df-a9ba-5fe941f4694b,g:196378a3-5ec7-4de3-a864-cc3dd9965fcc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_54267276-947c-48cf-9dd7-0e6f3803fcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_54267276-947c-48cf-9dd7-0e6f3803fcbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_98eb0f19-e8ca-4334-afc4-1716138cd2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_98eb0f19-e8ca-4334-afc4-1716138cd2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0450caf2-8a30-43c4-b79e-563196444cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0450caf2-8a30-43c4-b79e-563196444cea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1df551cc-4351-4f24-8000-aae904b1c279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:to="loc_us-gaap_AssetsCurrent_1df551cc-4351-4f24-8000-aae904b1c279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2a224423-8492-4270-ba72-3e729f49e3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2a224423-8492-4270-ba72-3e729f49e3e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a627269e-10fa-4e41-8f9b-adb75a05e7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f29aafc-1efb-4a43-ad2c-08f505add7c7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a627269e-10fa-4e41-8f9b-adb75a05e7b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0e948b85-c3c4-48de-9532-4357cbdfb971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_94db4041-aa13-4b72-a749-971cde18044d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e948b85-c3c4-48de-9532-4357cbdfb971" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_94db4041-aa13-4b72-a749-971cde18044d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4caaf8e5-4013-47b9-815b-189fbc484492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e948b85-c3c4-48de-9532-4357cbdfb971" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4caaf8e5-4013-47b9-815b-189fbc484492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d1883614-fff5-4dfe-a3ca-fd32c994daed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e948b85-c3c4-48de-9532-4357cbdfb971" xlink:to="loc_us-gaap_AccountsPayableCurrent_d1883614-fff5-4dfe-a3ca-fd32c994daed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_807cf181-b2fd-4767-bd26-920cf1985ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e948b85-c3c4-48de-9532-4357cbdfb971" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_807cf181-b2fd-4767-bd26-920cf1985ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b0975a34-0a9d-4ab7-a719-be0a3e81f24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0e948b85-c3c4-48de-9532-4357cbdfb971" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b0975a34-0a9d-4ab7-a719-be0a3e81f24b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9074e71a-6099-4af3-9f87-8099b37a0686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9074e71a-6099-4af3-9f87-8099b37a0686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_8bc9916c-43d7-44e1-a760-ab9777735e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_8bc9916c-43d7-44e1-a760-ab9777735e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae92b547-e004-4686-aca1-0645fb3da898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae92b547-e004-4686-aca1-0645fb3da898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9875406a-edb8-4efb-8cca-9cce7339ab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9875406a-edb8-4efb-8cca-9cce7339ab13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a381d76f-3fae-4e6e-a33f-0f564364def0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:to="loc_us-gaap_InventoryNet_a381d76f-3fae-4e6e-a33f-0f564364def0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_bcf1e091-f0b9-4cd5-b225-43e71c093079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df342353-c8b8-4ffd-849f-17464a19e73a" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_bcf1e091-f0b9-4cd5-b225-43e71c093079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_51c52f78-f5c8-4853-af45-7bd91e8e7111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a532135-97b0-42f7-807a-634b6eee1c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51c52f78-f5c8-4853-af45-7bd91e8e7111" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a532135-97b0-42f7-807a-634b6eee1c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b61da21-4d65-471b-bed5-09d7fa831ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51c52f78-f5c8-4853-af45-7bd91e8e7111" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b61da21-4d65-471b-bed5-09d7fa831ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64166abe-9f72-4f4b-b262-dc319b576670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51c52f78-f5c8-4853-af45-7bd91e8e7111" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64166abe-9f72-4f4b-b262-dc319b576670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f5624984-67aa-4d55-8b9d-6074df854bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:to="loc_us-gaap_PreferredStockValue_f5624984-67aa-4d55-8b9d-6074df854bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43b158a9-e53f-4724-8960-f72e14cda4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43b158a9-e53f-4724-8960-f72e14cda4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cee080f2-e13b-4cb9-8e9a-94f00c9cfa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:to="loc_us-gaap_CommonStockValue_cee080f2-e13b-4cb9-8e9a-94f00c9cfa7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a77f4555-4e4a-43f7-adf6-0ba2250e7470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a77f4555-4e4a-43f7-adf6-0ba2250e7470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d7b2201b-da8e-4ccf-bbb5-8c942b814d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d7b2201b-da8e-4ccf-bbb5-8c942b814d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_992774f2-0d89-4323-9ae5-6267b17276bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3597f2d6-afde-4a32-bbf0-4bc1b80c9b75" xlink:to="loc_us-gaap_TreasuryStockValue_992774f2-0d89-4323-9ae5-6267b17276bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_64a4c497-3eca-4144-83f7-e88ff8ccbe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5c29cb2-b7c4-41ee-b8c0-117be323514a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_64a4c497-3eca-4144-83f7-e88ff8ccbe1f" xlink:to="loc_us-gaap_Liabilities_d5c29cb2-b7c4-41ee-b8c0-117be323514a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25fd6b21-5826-4e4c-9161-46f9eaf8cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_64a4c497-3eca-4144-83f7-e88ff8ccbe1f" xlink:to="loc_us-gaap_StockholdersEquity_25fd6b21-5826-4e4c-9161-46f9eaf8cf2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_592c4292-8848-4138-80a2-05a6b522c913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da124b38-ad0b-4fc9-9409-d6e95fd1db2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_592c4292-8848-4138-80a2-05a6b522c913" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da124b38-ad0b-4fc9-9409-d6e95fd1db2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b8c2b8dd-19da-45a7-b373-a738cac4335f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_592c4292-8848-4138-80a2-05a6b522c913" xlink:to="loc_us-gaap_CostsAndExpenses_b8c2b8dd-19da-45a7-b373-a738cac4335f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_befddab5-8ae1-4e83-910f-b7b0c5ce1577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_06d9afc9-40c1-4254-9d1d-a4312ea18bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_befddab5-8ae1-4e83-910f-b7b0c5ce1577" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_06d9afc9-40c1-4254-9d1d-a4312ea18bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3e633ac8-20b7-4843-af4a-e76c92828a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_befddab5-8ae1-4e83-910f-b7b0c5ce1577" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3e633ac8-20b7-4843-af4a-e76c92828a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2099081e-2e35-46e3-a6b2-3f66a981c5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_7fe8d5c3-7fb9-4be3-825d-23a8f4b6237d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2099081e-2e35-46e3-a6b2-3f66a981c5f8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_7fe8d5c3-7fb9-4be3-825d-23a8f4b6237d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_771b2c93-6acf-4128-b871-3538872c702b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2099081e-2e35-46e3-a6b2-3f66a981c5f8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_771b2c93-6acf-4128-b871-3538872c702b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_65035645-b46e-4289-a13e-0019103be971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_15f5001d-b0ca-4f40-91f8-58ccb212adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_65035645-b46e-4289-a13e-0019103be971" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_15f5001d-b0ca-4f40-91f8-58ccb212adb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0a1c404d-c72a-4e72-9e45-d157c591d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_65035645-b46e-4289-a13e-0019103be971" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0a1c404d-c72a-4e72-9e45-d157c591d5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_42afbf35-653e-4540-a41d-abad05cd69fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_65035645-b46e-4289-a13e-0019103be971" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_42afbf35-653e-4540-a41d-abad05cd69fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d31c5009-4bbf-43a7-9be3-564aa7f43a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_43812b3c-2b77-4781-af43-e56e73ddd187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d31c5009-4bbf-43a7-9be3-564aa7f43a01" xlink:to="loc_us-gaap_OperatingIncomeLoss_43812b3c-2b77-4781-af43-e56e73ddd187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a2c55a28-32fa-4684-b0cb-8e0f8249ab07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d31c5009-4bbf-43a7-9be3-564aa7f43a01" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a2c55a28-32fa-4684-b0cb-8e0f8249ab07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f23d0120-09b0-4aea-b35e-9068e6616261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d31c5009-4bbf-43a7-9be3-564aa7f43a01" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f23d0120-09b0-4aea-b35e-9068e6616261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_cb196255-4896-45bc-b525-732714286a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d31c5009-4bbf-43a7-9be3-564aa7f43a01" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_cb196255-4896-45bc-b525-732714286a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3883c6ef-578e-4e3f-ace6-0091dd51f0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_21c776be-d28e-4856-b7a2-a3b59d912514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_3883c6ef-578e-4e3f-ace6-0091dd51f0cd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_21c776be-d28e-4856-b7a2-a3b59d912514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f84c81ea-6cdf-4397-8c3f-41da943a00c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_3883c6ef-578e-4e3f-ace6-0091dd51f0cd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f84c81ea-6cdf-4397-8c3f-41da943a00c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6e2785a-35cb-4df2-9c21-082177a855e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e1299d7c-71cd-4f59-8f93-fae239144bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6e2785a-35cb-4df2-9c21-082177a855e4" xlink:to="loc_us-gaap_NetIncomeLoss_e1299d7c-71cd-4f59-8f93-fae239144bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_363b6ecf-d411-421a-9464-5ef1103d6990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6e2785a-35cb-4df2-9c21-082177a855e4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_363b6ecf-d411-421a-9464-5ef1103d6990" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f5f9734-2289-4260-a5c6-3df6b58211c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1c60a9ff-7bfa-4649-9657-547dbbc93de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f5f9734-2289-4260-a5c6-3df6b58211c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1c60a9ff-7bfa-4649-9657-547dbbc93de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c855bf32-6e79-4cd0-a056-07c5bff36b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f5f9734-2289-4260-a5c6-3df6b58211c7" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c855bf32-6e79-4cd0-a056-07c5bff36b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_672b6b8d-f30b-4833-8f31-fff7ea7e052d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_faadc676-cc5a-405a-8d6f-9bd0376e2279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_672b6b8d-f30b-4833-8f31-fff7ea7e052d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_faadc676-cc5a-405a-8d6f-9bd0376e2279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_3b644977-68c0-445b-9c76-03b51bca615f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_672b6b8d-f30b-4833-8f31-fff7ea7e052d" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_3b644977-68c0-445b-9c76-03b51bca615f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_37dcb812-c1e7-43c6-bdc1-425b8c6b1f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_8ea9f08a-8f33-4a57-8871-a7406de3ea86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_37dcb812-c1e7-43c6-bdc1-425b8c6b1f4b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_8ea9f08a-8f33-4a57-8871-a7406de3ea86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0dedbadb-f2c0-4a53-a165-67f0e1fda9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_37dcb812-c1e7-43c6-bdc1-425b8c6b1f4b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0dedbadb-f2c0-4a53-a165-67f0e1fda9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59acf433-d2e0-46bb-ab65-f60d3f3f4911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b071c56-6d3d-497e-ba3d-2ff2a86e60be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59acf433-d2e0-46bb-ab65-f60d3f3f4911" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b071c56-6d3d-497e-ba3d-2ff2a86e60be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cba61778-f614-4b07-89f1-f6dfa3ec9877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59acf433-d2e0-46bb-ab65-f60d3f3f4911" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cba61778-f614-4b07-89f1-f6dfa3ec9877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a96e9fb4-2e83-452e-ba1f-44c03d488d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59acf433-d2e0-46bb-ab65-f60d3f3f4911" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a96e9fb4-2e83-452e-ba1f-44c03d488d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_abdd8992-23a6-4506-9f2c-f99cc6b270ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24fa7299-65c7-4218-a26f-1c13ebd464cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_abdd8992-23a6-4506-9f2c-f99cc6b270ee" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24fa7299-65c7-4218-a26f-1c13ebd464cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_107164f6-be4c-4b08-a518-175f27a1313e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_abdd8992-23a6-4506-9f2c-f99cc6b270ee" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_107164f6-be4c-4b08-a518-175f27a1313e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0633120f-af72-42d7-9125-80b78aebf918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_abdd8992-23a6-4506-9f2c-f99cc6b270ee" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0633120f-af72-42d7-9125-80b78aebf918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_176076a2-bf39-45f4-ae6d-8a51b0dce23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_176076a2-bf39-45f4-ae6d-8a51b0dce23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_73eaa034-39d4-4ad6-a542-15858fcfc198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_73eaa034-39d4-4ad6-a542-15858fcfc198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_130382d8-2121-4595-980f-601ec127ab92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_ShareBasedCompensation_130382d8-2121-4595-980f-601ec127ab92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8906014e-fd88-4ba8-9314-60da5b376a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8906014e-fd88-4ba8-9314-60da5b376a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_76996f5f-86c8-48d2-aa73-0848cf715d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_76996f5f-86c8-48d2-aa73-0848cf715d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_790c22b9-25f6-447f-8768-8374bf8406c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_790c22b9-25f6-447f-8768-8374bf8406c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e68eb817-f7f5-4a50-b03c-e07550daf187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e68eb817-f7f5-4a50-b03c-e07550daf187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1ce8201f-47c4-4fac-b0a7-d9af13b89db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1ce8201f-47c4-4fac-b0a7-d9af13b89db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2848f034-b0a8-470a-ae0a-b4194af59470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2848f034-b0a8-470a-ae0a-b4194af59470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_ff99a749-4363-4515-bfb0-9db7276aa2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_ff99a749-4363-4515-bfb0-9db7276aa2b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_67a54546-8345-4b6c-b8fb-9a458cd20cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_67a54546-8345-4b6c-b8fb-9a458cd20cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7a994106-7087-4c7d-86a6-69f1c8a00b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7a994106-7087-4c7d-86a6-69f1c8a00b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d2a8f5a5-a1ce-4b41-81d7-634137a5d450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f70e407a-f575-4e83-ba09-e8b1bd971dc2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d2a8f5a5-a1ce-4b41-81d7-634137a5d450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_768e9586-dd50-46ed-89b6-17d588bc093a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3d983f10-8f36-4a84-b9c3-a577689a4fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_768e9586-dd50-46ed-89b6-17d588bc093a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3d983f10-8f36-4a84-b9c3-a577689a4fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5789901c-fa9c-478d-ac96-d599c3ca231a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_768e9586-dd50-46ed-89b6-17d588bc093a" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5789901c-fa9c-478d-ac96-d599c3ca231a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_b5f5451b-8650-4cbd-8afe-9e5445d6a7cd" xlink:href="agio-20220331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_01518a7c-d9f5-4611-806a-5591d8b7f9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_b5f5451b-8650-4cbd-8afe-9e5445d6a7cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_01518a7c-d9f5-4611-806a-5591d8b7f9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_853e8f17-0664-43f8-8ace-54f049469a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_b5f5451b-8650-4cbd-8afe-9e5445d6a7cd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_853e8f17-0664-43f8-8ace-54f049469a08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2fdee75-8870-4bd1-ace4-36e1bedd8f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_39913dc7-7894-40f3-b2a8-414e47fe29d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2fdee75-8870-4bd1-ace4-36e1bedd8f94" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_39913dc7-7894-40f3-b2a8-414e47fe29d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62312ef6-5a7a-4601-90f9-cfc82e1a0215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2fdee75-8870-4bd1-ace4-36e1bedd8f94" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62312ef6-5a7a-4601-90f9-cfc82e1a0215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_320ac31a-e540-49c7-aa3a-104d90115517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d2fdee75-8870-4bd1-ace4-36e1bedd8f94" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_320ac31a-e540-49c7-aa3a-104d90115517" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#InventoryScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d5f4b134-4308-4f9e-b5b4-1a057df0125b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_55fd0229-8d9d-4cd7-b47a-cda11d6649b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d5f4b134-4308-4f9e-b5b4-1a057df0125b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_55fd0229-8d9d-4cd7-b47a-cda11d6649b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a9a1b535-5a71-4d28-a9e7-0d797587e87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d5f4b134-4308-4f9e-b5b4-1a057df0125b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a9a1b535-5a71-4d28-a9e7-0d797587e87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_71a1fbc8-6caa-4c78-8c04-6f32868aca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d5f4b134-4308-4f9e-b5b4-1a057df0125b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_71a1fbc8-6caa-4c78-8c04-6f32868aca5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6214daa9-2adb-4d08-b585-9a50b8033c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2ef42928-9534-4108-92d0-94d4fe0016a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6214daa9-2adb-4d08-b585-9a50b8033c36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2ef42928-9534-4108-92d0-94d4fe0016a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2f8aee5f-39dd-435c-98a3-e717d1069f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6214daa9-2adb-4d08-b585-9a50b8033c36" xlink:to="loc_us-gaap_OperatingLeaseLiability_2f8aee5f-39dd-435c-98a3-e717d1069f2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df738b53-c01b-4115-823a-dcfb9a8d7f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df738b53-c01b-4115-823a-dcfb9a8d7f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20f881f3-bb8e-433e-a538-b91ac68054ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20f881f3-bb8e-433e-a538-b91ac68054ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7189b1f8-6229-4fc1-a6b1-ca2fd148b9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7189b1f8-6229-4fc1-a6b1-ca2fd148b9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_770d97c7-97ad-4113-b7fc-2bd6d631d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_770d97c7-97ad-4113-b7fc-2bd6d631d9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_adb565a7-8e69-488c-8c32-dca9b9577307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_adb565a7-8e69-488c-8c32-dca9b9577307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cfc2f0ac-a458-4b84-a57a-c59f595c572d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cfc2f0ac-a458-4b84-a57a-c59f595c572d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e98412a8-b6d9-41b1-bf99-a0c365f2a0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fed4c880-a0e3-44f2-bd95-4cd7c114d8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e98412a8-b6d9-41b1-bf99-a0c365f2a0a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesFutureMinimumLeasePaymentstobeReceivedDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_69180641-7213-4f16-9528-cfc651dbc00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_5a69634f-8c7d-4651-acc7-c78d43d95676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_69180641-7213-4f16-9528-cfc651dbc00d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_5a69634f-8c7d-4651-acc7-c78d43d95676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_748372a4-3635-4896-be86-21f80906e1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_69180641-7213-4f16-9528-cfc651dbc00d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_748372a4-3635-4896-be86-21f80906e1d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_d0522bcc-b576-495e-973f-bfdf58389806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_69180641-7213-4f16-9528-cfc651dbc00d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_d0522bcc-b576-495e-973f-bfdf58389806" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_319034d7-bbbf-44f9-83ef-8091113f0adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1e532ad7-7651-467a-b5ea-85f79654b140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_319034d7-bbbf-44f9-83ef-8091113f0adf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1e532ad7-7651-467a-b5ea-85f79654b140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_8ab2ccaf-e12d-443e-b7d6-5ea717970a37" xlink:href="agio-20220331.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_319034d7-bbbf-44f9-83ef-8091113f0adf" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_8ab2ccaf-e12d-443e-b7d6-5ea717970a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_97c69bdc-ddcf-4aeb-8c0d-41f5bb20ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_319034d7-bbbf-44f9-83ef-8091113f0adf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_97c69bdc-ddcf-4aeb-8c0d-41f5bb20ca19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4b2f19f7-418e-4a1b-82b3-fddff29c4016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_319034d7-bbbf-44f9-83ef-8091113f0adf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4b2f19f7-418e-4a1b-82b3-fddff29c4016" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_e593aee9-412f-4682-9143-e388429af393" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_04c8ff56-1ae9-4e4c-9d53-9108bdc60786" xlink:href="agio-20220331.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_e593aee9-412f-4682-9143-e388429af393" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_04c8ff56-1ae9-4e4c-9d53-9108bdc60786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_e01ebfb7-5b11-4df1-a86e-d552bf5af81a" xlink:href="agio-20220331.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_e593aee9-412f-4682-9143-e388429af393" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_e01ebfb7-5b11-4df1-a86e-d552bf5af81a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_c84ea321-0ed4-4c61-9d3d-e6c780dc60fa" xlink:href="agio-20220331.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_e593aee9-412f-4682-9143-e388429af393" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_c84ea321-0ed4-4c61-9d3d-e6c780dc60fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_335c7f79-49ac-416b-9121-41950308d0cf" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_82246509-c3f7-43fa-a442-a19ddb240059" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_335c7f79-49ac-416b-9121-41950308d0cf" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_82246509-c3f7-43fa-a442-a19ddb240059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_710aa206-502e-42fa-bf49-538b75cec60a" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_335c7f79-49ac-416b-9121-41950308d0cf" xlink:to="loc_agio_ContractWithCustomerRebateReserve_710aa206-502e-42fa-bf49-538b75cec60a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_9cf44b81-717d-4d9e-a2e5-ad99dc96768b" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_335c7f79-49ac-416b-9121-41950308d0cf" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_9cf44b81-717d-4d9e-a2e5-ad99dc96768b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_6ee3dd57-6001-4e3b-a079-2c8f26b7599f" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_cab8001e-1a94-4aea-a28a-b8838d93581e" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_6ee3dd57-6001-4e3b-a079-2c8f26b7599f" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_cab8001e-1a94-4aea-a28a-b8838d93581e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_5a2e4af9-a56e-4814-9f7c-342fb015e1d2" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_6ee3dd57-6001-4e3b-a079-2c8f26b7599f" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_5a2e4af9-a56e-4814-9f7c-342fb015e1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_2a00ce8a-be7d-4781-bacb-810af655c48e" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_6ee3dd57-6001-4e3b-a079-2c8f26b7599f" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_2a00ce8a-be7d-4781-bacb-810af655c48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_78123a58-87dd-4f67-b8f6-8cfa71c6bbb0" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_177416c8-df2e-4721-a4de-2ce4d71768b4" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_78123a58-87dd-4f67-b8f6-8cfa71c6bbb0" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_177416c8-df2e-4721-a4de-2ce4d71768b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_445ec430-19d5-4c03-bec4-50126fcaf185" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_78123a58-87dd-4f67-b8f6-8cfa71c6bbb0" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_445ec430-19d5-4c03-bec4-50126fcaf185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_c85d6865-6a13-4810-a6e3-491132921de0" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_78123a58-87dd-4f67-b8f6-8cfa71c6bbb0" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_c85d6865-6a13-4810-a6e3-491132921de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_812e2bba-b6ac-45cf-af4d-c4f9bb23e7b8" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_18e26abe-ed7a-4860-aaed-c9157272ed3c" xlink:href="agio-20220331.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_812e2bba-b6ac-45cf-af4d-c4f9bb23e7b8" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_18e26abe-ed7a-4860-aaed-c9157272ed3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_2abebd9e-b003-4261-89fe-c5396ea47d19" xlink:href="agio-20220331.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_812e2bba-b6ac-45cf-af4d-c4f9bb23e7b8" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_2abebd9e-b003-4261-89fe-c5396ea47d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_a024a7aa-6275-41a8-864e-990e76a3af8f" xlink:href="agio-20220331.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_812e2bba-b6ac-45cf-af4d-c4f9bb23e7b8" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_a024a7aa-6275-41a8-864e-990e76a3af8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_c779efeb-1693-41dd-8730-6735848622ef" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_543afb98-235b-4877-a071-fae57b2f8d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_c779efeb-1693-41dd-8730-6735848622ef" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_543afb98-235b-4877-a071-fae57b2f8d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_df580f15-33ee-4a9a-91f7-9c9d2b79b7a2" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_c779efeb-1693-41dd-8730-6735848622ef" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_df580f15-33ee-4a9a-91f7-9c9d2b79b7a2" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>agio-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:55e4eac5-1c9c-49df-a9ba-5fe941f4694b,g:196378a3-5ec7-4de3-a864-cc3dd9965fcc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="iebb5ce5af0f0452ab5389cb942774160_CondensedConsolidatedStatementsofOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee38e022-7af5-4f27-ae24-fc397ff4d00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee38e022-7af5-4f27-ae24-fc397ff4d00a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b096ac25-cfa7-4f2a-97c8-a38f9fd1fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee38e022-7af5-4f27-ae24-fc397ff4d00a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b096ac25-cfa7-4f2a-97c8-a38f9fd1fc37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1671a93f-52ff-43e4-b48c-2bd94bd0ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1671a93f-52ff-43e4-b48c-2bd94bd0ac9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_55d060fe-75fe-4fad-a2c7-a8ec138af2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_55d060fe-75fe-4fad-a2c7-a8ec138af2e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58509f41-c8de-4ac3-a529-816325940f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58509f41-c8de-4ac3-a529-816325940f9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_23628f06-999b-4c3d-919a-c631a355d841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_CostsAndExpenses_23628f06-999b-4c3d-919a-c631a355d841" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8272222d-4748-4537-8eb6-e4fb2492935d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_OperatingIncomeLoss_8272222d-4748-4537-8eb6-e4fb2492935d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_54509f01-b19a-4c64-be1a-e111e21e5d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_54509f01-b19a-4c64-be1a-e111e21e5d3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d7a50bc1-88b5-48ea-bac3-7b57abff747b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d7a50bc1-88b5-48ea-bac3-7b57abff747b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_ac4d47bf-fb85-41a2-a74e-7957b6a556e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_ac4d47bf-fb85-41a2-a74e-7957b6a556e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_70246002-508a-4c06-a91b-71aaeb85076a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_70246002-508a-4c06-a91b-71aaeb85076a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c67a6177-2af0-4ecc-ae58-fa1ad51e5769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c67a6177-2af0-4ecc-ae58-fa1ad51e5769" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_daecbb54-95ec-4739-a882-9afad6582ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_NetIncomeLoss_daecbb54-95ec-4739-a882-9afad6582ebf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ccd1ddd3-18c2-4796-9b65-f90ba06afc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ccd1ddd3-18c2-4796-9b65-f90ba06afc2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b5c047aa-c4f5-49c7-84f9-cd1fb3627140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b5c047aa-c4f5-49c7-84f9-cd1fb3627140" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d81f0c31-025a-4c4b-b23f-0685f5117423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d81f0c31-025a-4c4b-b23f-0685f5117423" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6883d129-9f4b-46e9-8d5b-9b8f078ebe10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6883d129-9f4b-46e9-8d5b-9b8f078ebe10" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a87cf9cf-de49-444d-b076-9e80777d4b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_EarningsPerShareBasic_a87cf9cf-de49-444d-b076-9e80777d4b99" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fd5df976-18b1-45e2-97c8-13cc91329c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fd5df976-18b1-45e2-97c8-13cc91329c48" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a5931f6-2bb9-4f48-be6b-2cf38944a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a5931f6-2bb9-4f48-be6b-2cf38944a07a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4eb5bcf7-368b-4522-86ec-b24c61ff3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4eb5bcf7-368b-4522-86ec-b24c61ff3aff" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:to="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2853ba40-ff8a-4d19-8862-e623da1d0b1e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:to="loc_srt_ProductsAndServicesDomain_2853ba40-ff8a-4d19-8862-e623da1d0b1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ca2243c-201b-46f9-9f11-95385a4468d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:to="loc_srt_ProductsAndServicesDomain_9ca2243c-201b-46f9-9f11-95385a4468d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5fdafb2a-f765-4a8e-b531-f45524a4c10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ca2243c-201b-46f9-9f11-95385a4468d4" xlink:to="loc_us-gaap_ProductMember_5fdafb2a-f765-4a8e-b531-f45524a4c10d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="ia1ca8db263da4c8885d6a10a78ad7ea3_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7144309e-a1cf-4a1a-969b-215c6600d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7144309e-a1cf-4a1a-969b-215c6600d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6ceec79a-92d0-4a6a-a60d-5aaf6d110681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_SharesOutstanding_6ceec79a-92d0-4a6a-a60d-5aaf6d110681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7de00d9-7778-4548-982b-2a089dac28fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockholdersEquity_b7de00d9-7778-4548-982b-2a089dac28fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85546f80-81f0-4bfa-a1c9-352b81466cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85546f80-81f0-4bfa-a1c9-352b81466cef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_179a9d64-3ae2-450c-b161-a7e4ac18e2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_179a9d64-3ae2-450c-b161-a7e4ac18e2f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc640c04-cfec-430d-a2ed-76da87024177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc640c04-cfec-430d-a2ed-76da87024177" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_da6a3211-a498-474f-be8d-bad77505bd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_da6a3211-a498-474f-be8d-bad77505bd0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e1e1faf-dd96-4acf-989e-ee6bc7157b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_NetIncomeLoss_4e1e1faf-dd96-4acf-989e-ee6bc7157b3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_StockholdersEquityDispositionOfBusiness_a0912a10-4bd3-4ae5-af95-1fa9f3dba09e" xlink:href="agio-20220331.xsd#agio_StockholdersEquityDispositionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_agio_StockholdersEquityDispositionOfBusiness_a0912a10-4bd3-4ae5-af95-1fa9f3dba09e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dad6f4a3-c4a4-4815-a0d1-4c03f7c6c583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f4f474d2-fa3b-4406-821a-b4b84f5c4737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7144309e-a1cf-4a1a-969b-215c6600d71f" xlink:to="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08c423b6-35d6-4f08-9500-37f40f659992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:to="loc_us-gaap_EquityComponentDomain_08c423b6-35d6-4f08-9500-37f40f659992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:to="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7576e3d5-f631-4976-a5dc-4ae08a3adb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_CommonStockMember_7576e3d5-f631-4976-a5dc-4ae08a3adb28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_42c12894-e5f0-419d-8076-e90b1ea1a362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_42c12894-e5f0-419d-8076-e90b1ea1a362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_477598a0-179d-4955-8346-7fe1d46ab718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_477598a0-179d-4955-8346-7fe1d46ab718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_91ab59f5-908d-4cc9-aa2b-d05774f31668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_RetainedEarningsMember_91ab59f5-908d-4cc9-aa2b-d05774f31668" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_a945b413-b4d0-4a40-91a3-02bcb1dd35f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_TreasuryStockMember_a945b413-b4d0-4a40-91a3-02bcb1dd35f5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#OverviewandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationDetails" xlink:type="extended" id="i285b89caffdf4267a9c9b077c6cbdd17_OverviewandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_18c71007-6fa4-4608-8c7b-654ab9a67957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_18c71007-6fa4-4608-8c7b-654ab9a67957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_f8d9d40c-9844-4105-8daf-0ec7381c3f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_f8d9d40c-9844-4105-8daf-0ec7381c3f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_8b358af3-08ce-4411-9a05-adbadf0a08f1" xlink:href="agio-20220331.xsd#agio_GainContingencyRoyaltyPercentageOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_8b358af3-08ce-4411-9a05-adbadf0a08f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_5a28a6ff-0463-4e15-a0f1-45e600c0062d" xlink:href="agio-20220331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_5a28a6ff-0463-4e15-a0f1-45e600c0062d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_f0136caa-0eb0-47e9-8af6-78073c8f2c00" xlink:href="agio-20220331.xsd#agio_ContingentGainOnDispositionOfBusinessRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_f0136caa-0eb0-47e9-8af6-78073c8f2c00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d9f1bba-0e7d-4084-87c7-2e009b725613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d9f1bba-0e7d-4084-87c7-2e009b725613" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_54f262d6-0000-4796-ab3e-d8fc35f10b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_54f262d6-0000-4796-ab3e-d8fc35f10b4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6d0fe075-06c3-4798-bb3f-5a98e15b1fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6d0fe075-06c3-4798-bb3f-5a98e15b1fea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_cc78d85c-9990-4e6a-8b0f-64fc8406d152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_cc78d85c-9990-4e6a-8b0f-64fc8406d152" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f1750fc4-411e-427a-b86a-2fb07b963a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f1750fc4-411e-427a-b86a-2fb07b963a14" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_94283119-0f88-4e64-8438-b89e2a6ba46e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_94283119-0f88-4e64-8438-b89e2a6ba46e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_07c574c3-fa63-42d0-a095-e4c366c27e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_07c574c3-fa63-42d0-a095-e4c366c27e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f990ffa7-ec52-4271-a493-4b6563237a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_07c574c3-fa63-42d0-a095-e4c366c27e4e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f990ffa7-ec52-4271-a493-4b6563237a1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71939df9-1460-495b-ac86-f2d583d10fca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71939df9-1460-495b-ac86-f2d583d10fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54fd1773-3c47-4ef9-8313-f647f67f12da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54fd1773-3c47-4ef9-8313-f647f67f12da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_838262b1-c437-4584-952f-b1a20b877c6e" xlink:href="agio-20220331.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54fd1773-3c47-4ef9-8313-f647f67f12da" xlink:to="loc_agio_AgiosOncologyBusinessMember_838262b1-c437-4584-952f-b1a20b877c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7d24719a-7802-4314-82d3-72391de6464e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:to="loc_srt_ProductsAndServicesDomain_7d24719a-7802-4314-82d3-72391de6464e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:to="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TIBSOVOMember_79d77379-04fa-4169-a76e-d3082f7d69ef" xlink:href="agio-20220331.xsd#agio_TIBSOVOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:to="loc_agio_TIBSOVOMember_79d77379-04fa-4169-a76e-d3082f7d69ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_VorasidenibMember_b9bf7df7-2570-4c03-91d1-e154ab12264c" xlink:href="agio-20220331.xsd#agio_VorasidenibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:to="loc_agio_VorasidenibMember_b9bf7df7-2570-4c03-91d1-e154ab12264c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e465cf2-a1d2-4da0-85cc-a34f5675dc37_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:to="loc_srt_SegmentGeographicalDomain_8e465cf2-a1d2-4da0-85cc-a34f5675dc37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2ea97eed-6259-477d-8c3f-9c4d81f0d21c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:to="loc_srt_SegmentGeographicalDomain_2ea97eed-6259-477d-8c3f-9c4d81f0d21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c7185a57-0c92-4dee-b530-cd2d0463fa01" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2ea97eed-6259-477d-8c3f-9c4d81f0d21c" xlink:to="loc_country_US_c7185a57-0c92-4dee-b530-cd2d0463fa01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_baa01126-b043-4d73-9a32-944a6d82e327_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_baa01126-b043-4d73-9a32-944a6d82e327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfcea4ba-0cad-43ec-8cb8-15d6ecafcbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfcea4ba-0cad-43ec-8cb8-15d6ecafcbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_e5983c29-d572-4abc-aa6e-1cf0bd08a26a" xlink:href="agio-20220331.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfcea4ba-0cad-43ec-8cb8-15d6ecafcbe7" xlink:to="loc_agio_Agreement2010Member_e5983c29-d572-4abc-aa6e-1cf0bd08a26a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f267a48b-6b8f-4cc2-8102-d95f79f22e1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f267a48b-6b8f-4cc2-8102-d95f79f22e1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_c0b99d3a-cbc9-461d-8eeb-590979479d0d" xlink:href="agio-20220331.xsd#agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:to="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_c0b99d3a-cbc9-461d-8eeb-590979479d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_58573417-8a34-4c63-a1b6-eb9916ab6c55" xlink:href="agio-20220331.xsd#agio_March252021RepurchaseProgramRule10b51RepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:to="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_58573417-8a34-4c63-a1b6-eb9916ab6c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RepurchaseProgramMember_f140b1b1-0cf0-48fd-8967-aece991b5bb9" xlink:href="agio-20220331.xsd#agio_RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:to="loc_agio_RepurchaseProgramMember_f140b1b1-0cf0-48fd-8967-aece991b5bb9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ide760b1d0c014668b5bc373204aaa965_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d34af212-ec6b-4213-892e-f155f05c9967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d34af212-ec6b-4213-892e-f155f05c9967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8958a4ee-1b01-4513-8c37-e6f3e4291b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8958a4ee-1b01-4513-8c37-e6f3e4291b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_217af0e4-cba9-42df-bfa6-3cd6ceff14af" xlink:href="agio-20220331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_217af0e4-cba9-42df-bfa6-3cd6ceff14af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b12bcbba-a300-477d-a0e8-e236b1d12f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b12bcbba-a300-477d-a0e8-e236b1d12f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3e4df45d-9dfd-4a2e-a44e-0a9f1ab077f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b12bcbba-a300-477d-a0e8-e236b1d12f25" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3e4df45d-9dfd-4a2e-a44e-0a9f1ab077f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5578d392-3378-4d3d-b38f-6857401221ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5578d392-3378-4d3d-b38f-6857401221ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd05875f-f6a9-41af-be6a-9a1478745aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd05875f-f6a9-41af-be6a-9a1478745aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_96482db5-cb7a-4b43-9133-f454bf229ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_96482db5-cb7a-4b43-9133-f454bf229ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a43d2975-600d-484c-9ec1-62b1d093d1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a43d2975-600d-484c-9ec1-62b1d093d1df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3077a6f9-6d36-45f9-a485-4cd479c62ae9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3077a6f9-6d36-45f9-a485-4cd479c62ae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_18cd71c1-9a81-4280-a1df-3c071dd9f7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_CashEquivalentsMember_18cd71c1-9a81-4280-a1df-3c071dd9f7c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_3b8efe09-d401-40a1-a5a0-17f07c3dca12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_3b8efe09-d401-40a1-a5a0-17f07c3dca12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b2c5d04-8784-4420-911f-156090be7dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b2c5d04-8784-4420-911f-156090be7dcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ba3ff8e-a1a4-45ea-9865-0ca3173941f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ba3ff8e-a1a4-45ea-9865-0ca3173941f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="ib4c445196e4a4c2589e58847e9fa4a7b_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91642325-f821-4a59-910a-b7f84aba4890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_9c127d2e-993f-46d2-bb21-800c3031327f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91642325-f821-4a59-910a-b7f84aba4890" xlink:to="loc_us-gaap_FairValueNetAssetLiability_9c127d2e-993f-46d2-bb21-800c3031327f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91642325-f821-4a59-910a-b7f84aba4890" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1934b7f4-3841-4fa8-bac9-48bf052053d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1934b7f4-3841-4fa8-bac9-48bf052053d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ed6bfa0-d78e-44fe-b189-464790b4874c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ed6bfa0-d78e-44fe-b189-464790b4874c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cd10ef1b-423e-4723-b87f-4eeb4f0629dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ed6bfa0-d78e-44fe-b189-464790b4874c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cd10ef1b-423e-4723-b87f-4eeb4f0629dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2acdd51c-40f7-4b21-a0fb-377735428a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2acdd51c-40f7-4b21-a0fb-377735428a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8c7e26e6-0f58-49f9-933e-e0ae0624c095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2acdd51c-40f7-4b21-a0fb-377735428a35" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8c7e26e6-0f58-49f9-933e-e0ae0624c095" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended" id="ib4b2005526534642bb7f6a69b0ffe9a3_MarketableSecuritiesSummaryofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe1738ce-6f44-4e8f-946b-b72aae583358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe1738ce-6f44-4e8f-946b-b72aae583358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d0f9d16-9288-44d9-9d8c-de00412701f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d0f9d16-9288-44d9-9d8c-de00412701f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f658c7e3-0450-4327-94bc-e30df73f827d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f658c7e3-0450-4327-94bc-e30df73f827d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d132f68-2f1d-4c75-b475-3fd75f1c7be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d132f68-2f1d-4c75-b475-3fd75f1c7be8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_85aabfc4-8d67-4e65-b66c-599e6c7f624e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_85aabfc4-8d67-4e65-b66c-599e6c7f624e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_921cb8de-d0c2-4568-a9c8-a82ef95b564e" xlink:href="agio-20220331.xsd#agio_CurrentAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:to="loc_agio_CurrentAssetMember_921cb8de-d0c2-4568-a9c8-a82ef95b564e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_3452b56d-90cd-4b2d-9147-f84aaafc4157" xlink:href="agio-20220331.xsd#agio_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:to="loc_agio_NonCurrentAssetsMember_3452b56d-90cd-4b2d-9147-f84aaafc4157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d162bdb-625e-479e-b52b-347d254ff624_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d162bdb-625e-479e-b52b-347d254ff624_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f7228a28-1d5f-466b-b2ba-b4c7021a07c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f7228a28-1d5f-466b-b2ba-b4c7021a07c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95d81bb7-00d2-4af2-81f3-dfb964249da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95d81bb7-00d2-4af2-81f3-dfb964249da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_64dd54db-e279-4bcf-b78b-26b5b7e5ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_64dd54db-e279-4bcf-b78b-26b5b7e5ee53" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended" id="i12843c7c79e44274b2d1fff8ea797a09_ProductRevenueScheduleofProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_60d6fee2-fa0f-4f94-8154-52557d4fa3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f31508-45f1-46d1-8931-d0b4c2abd5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_60d6fee2-fa0f-4f94-8154-52557d4fa3ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f31508-45f1-46d1-8931-d0b4c2abd5c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_60d6fee2-fa0f-4f94-8154-52557d4fa3ff" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:to="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:to="loc_srt_ProductsAndServicesDomain_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e7c4655-d6b3-4ebf-bd92-3b6c635c5d4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:to="loc_srt_ProductsAndServicesDomain_1e7c4655-d6b3-4ebf-bd92-3b6c635c5d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4081e341-25de-4178-ba13-5491d5c6e2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1e7c4655-d6b3-4ebf-bd92-3b6c635c5d4b" xlink:to="loc_us-gaap_ProductMember_4081e341-25de-4178-ba13-5491d5c6e2d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended" id="i38c4c7431e6a495fb3e415b2f4e5d7d4_ShareBasedPaymentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a16dddf-a529-4d8a-adbe-3441a991aba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a16dddf-a529-4d8a-adbe-3441a991aba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac2dcdf6-63ff-407a-9cdd-5b1cd59e8ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac2dcdf6-63ff-407a-9cdd-5b1cd59e8ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d621cd40-41d5-4e4e-a1e8-47bef86b656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d621cd40-41d5-4e4e-a1e8-47bef86b656e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d14fc7bf-4b52-447e-b939-0047a708b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d14fc7bf-4b52-447e-b939-0047a708b42b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5c97a5ec-bc46-44ab-9a8c-8846da949f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5c97a5ec-bc46-44ab-9a8c-8846da949f29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d110dd2e-2e98-4a44-a10e-a6b8f6eccda1" xlink:href="agio-20220331.xsd#agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d110dd2e-2e98-4a44-a10e-a6b8f6eccda1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6be8d794-5a5a-4b4d-ad1f-7ca7d46a9010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6be8d794-5a5a-4b4d-ad1f-7ca7d46a9010" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_39a447e4-6a07-436d-bcda-494fdd2a91cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_39a447e4-6a07-436d-bcda-494fdd2a91cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:to="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:to="loc_us-gaap_PlanNameDomain_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:to="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_2a348d6f-5505-4ca6-a156-fdcfb69fcbe5" xlink:href="agio-20220331.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_2a348d6f-5505-4ca6-a156-fdcfb69fcbe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_a36f7601-c31d-4ef0-b749-58a069ed8721" xlink:href="agio-20220331.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_a36f7601-c31d-4ef0-b749-58a069ed8721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_fc906992-04de-4bfb-b7ee-15431ed5cea7" xlink:href="agio-20220331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_fc906992-04de-4bfb-b7ee-15431ed5cea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:to="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a07dac99-edac-4b26-ab9d-6e08a5d008d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a07dac99-edac-4b26-ab9d-6e08a5d008d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_65c6da33-3eb2-4e97-97c1-1365dbb7bd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_65c6da33-3eb2-4e97-97c1-1365dbb7bd1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e25a6fa4-d88f-4ff0-9aa6-9d4707d3f4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e25a6fa4-d88f-4ff0-9aa6-9d4707d3f4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_5f67b117-7d8a-437e-add5-87e2a32cd20f" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_agio_PerformanceStockUnitMember_5f67b117-7d8a-437e-add5-87e2a32cd20f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_e56fcbf8-5d5c-4790-885b-3c2033e9f910" xlink:href="agio-20220331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_agio_MarketBasedStockUnitsMember_e56fcbf8-5d5c-4790-885b-3c2033e9f910" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended" id="i4ff9517d415b41828856bde4857db46d_ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a66fd2b-3b61-4ea7-99ef-2eed67912bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a66fd2b-3b61-4ea7-99ef-2eed67912bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f464229b-dc48-49c6-a11c-c3a6fb27208b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f464229b-dc48-49c6-a11c-c3a6fb27208b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccfbba9e-cf6c-444c-b759-04870b920d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccfbba9e-cf6c-444c-b759-04870b920d55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5da18b73-50da-441d-85f3-d7fada0f0713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5da18b73-50da-441d-85f3-d7fada0f0713" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f021a279-f8c7-4015-a0f5-96afa6cb14d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94918936-88af-405e-a78c-411ee4856efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94918936-88af-405e-a78c-411ee4856efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_086061ad-7eb7-4a04-a0c6-3667389e2c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_086061ad-7eb7-4a04-a0c6-3667389e2c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_66e261c9-1cbf-47be-a2f8-bb7f10e5001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_66e261c9-1cbf-47be-a2f8-bb7f10e5001b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d83d843c-aca5-4757-9707-05e4ac7bc215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d83d843c-aca5-4757-9707-05e4ac7bc215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66f2bb5d-edef-47f1-907d-51f18d4f745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:to="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7376ed-7325-4692-8b84-71c762d80402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7376ed-7325-4692-8b84-71c762d80402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2af6d5c-15df-4a59-b658-2acbb7d3b3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7376ed-7325-4692-8b84-71c762d80402" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2af6d5c-15df-4a59-b658-2acbb7d3b3fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended" id="i240728151dbf40398fba14e6e1bc9a5c_ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80c4b8be-1408-4c24-9183-f89f1f6d7e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80c4b8be-1408-4c24-9183-f89f1f6d7e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60d70813-a361-4b0b-9d88-af78fa1437e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60d70813-a361-4b0b-9d88-af78fa1437e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e631d9d-8611-4d5b-8932-6f47e2c73adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e631d9d-8611-4d5b-8932-6f47e2c73adf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_eb6067e9-636e-4c5b-90e0-cce1281fb205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_eb6067e9-636e-4c5b-90e0-cce1281fb205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26c2f7d3-1bd5-4a55-a47e-9718e6737874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_340a658e-7f87-4752-98b4-5356a588e005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_340a658e-7f87-4752-98b4-5356a588e005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff086553-a5cf-451b-9086-fc2c16729d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff086553-a5cf-451b-9086-fc2c16729d3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a721e14a-f86b-4165-8b5b-8a4ed7b7940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a721e14a-f86b-4165-8b5b-8a4ed7b7940e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9070e221-73bf-4656-bc2f-41f6ddfb5e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9070e221-73bf-4656-bc2f-41f6ddfb5e91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16102e64-b8c8-41ee-9656-8e5da9dde866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:to="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0794726a-d02b-495c-93e5-50d769bfd25b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0794726a-d02b-495c-93e5-50d769bfd25b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_f6fa01db-0c97-4bdc-b62f-0d31f7b4e9ea" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:to="loc_agio_PerformanceStockUnitMember_f6fa01db-0c97-4bdc-b62f-0d31f7b4e9ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_6f0351c2-d730-438c-9867-c92d4689a096" xlink:href="agio-20220331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:to="loc_agio_MarketBasedStockUnitsMember_6f0351c2-d730-438c-9867-c92d4689a096" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended" id="i10b690b5c3f449caa0129dcfc5bb6763_ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2c27fb7-9352-4bec-95b9-e4e9a059374e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6081818-f6ef-42d8-948c-36b434f62dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2c27fb7-9352-4bec-95b9-e4e9a059374e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6081818-f6ef-42d8-948c-36b434f62dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2c27fb7-9352-4bec-95b9-e4e9a059374e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:to="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7682526f-8ae2-42dc-b98a-abe570c88fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7682526f-8ae2-42dc-b98a-abe570c88fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_958c3940-f780-491b-821d-3bbc5d7fa67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_958c3940-f780-491b-821d-3bbc5d7fa67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_00d93c9a-a4c6-41eb-8810-2b2e5c37c703" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_agio_PerformanceStockUnitMember_00d93c9a-a4c6-41eb-8810-2b2e5c37c703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_6b515964-abd2-44bb-bf65-938a03f9ddc1" xlink:href="agio-20220331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_agio_EmployeePurchasePlanMember_6b515964-abd2-44bb-bf65-938a03f9ddc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember_b19f2214-bf7f-47fa-a48d-3acddefc0a16" xlink:href="agio-20220331.xsd#agio_OtherStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_agio_OtherStockAwardsMember_b19f2214-bf7f-47fa-a48d-3acddefc0a16" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended" id="id9fd5f7390324f6590d2647fc2e97301_ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c3ef22-c4cd-4a30-b822-7d574ce3dde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e4c361e-6d47-4117-9625-564505ff4585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c3ef22-c4cd-4a30-b822-7d574ce3dde3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e4c361e-6d47-4117-9625-564505ff4585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c3ef22-c4cd-4a30-b822-7d574ce3dde3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e53b230d-add8-4d68-83dd-ef1887ad3480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e53b230d-add8-4d68-83dd-ef1887ad3480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e4f31350-f5ea-4afc-b197-6e00d9e91ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e4f31350-f5ea-4afc-b197-6e00d9e91ef2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i186f54ef391f4fd99d260ba1c239d6f2_LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06184e00-088b-418c-ba04-eb33de3c85b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407519dd-6d00-4908-af95-0cf8789b3f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06184e00-088b-418c-ba04-eb33de3c85b6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407519dd-6d00-4908-af95-0cf8789b3f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06184e00-088b-418c-ba04-eb33de3c85b6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bbbe6606-527d-4a5c-8b44-0d815aa8c657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bbbe6606-527d-4a5c-8b44-0d815aa8c657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13082be5-d97b-4549-aedf-4a6a40832e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13082be5-d97b-4549-aedf-4a6a40832e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cca4032b-4c1b-4fff-ac04-00b9e323e090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cca4032b-4c1b-4fff-ac04-00b9e323e090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_0d0614b2-5e7a-4dcb-99ff-67fe8e549dde" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_agio_PerformanceStockUnitMember_0d0614b2-5e7a-4dcb-99ff-67fe8e549dde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_7fcad6df-033b-4c91-9be5-61518479f695" xlink:href="agio-20220331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_agio_EmployeePurchasePlanMember_7fcad6df-033b-4c91-9be5-61518479f695" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>agio-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:55e4eac5-1c9c-49df-a9ba-5fe941f4694b,g:196378a3-5ec7-4de3-a864-cc3dd9965fcc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4d36e0e1-d292-46a3-a53d-fb6f2d123ecf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9177f851-3fd4-4f71-8e09-b2435f2adc14_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5f63723a-d5f0-4dcb-847c-28f480fdf394_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b8deaf0-5f5d-4ae8-8ef3-946e656f3176_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_66aaeb16-8451-457c-8566-538bc7c0ed54_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fb35fdea-9488-43ea-a0cc-5aa326cbce74_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a7025b40-6e5c-495a-abee-1125d0369d91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b472e8fa-5757-4795-8694-6930b48ef551_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0a258954-7762-4d23-aa38-406eef75d5c2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87ee852d-caae-4fed-a059-640f44e0e71c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2d9d8128-712f-43b8-81ed-6fd092fcb433_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContingentGainOnDispositionOfBusinessRecognized_d8adf058-75db-40b5-ad98-2c096205a322_terseLabel_en-US" xlink:label="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out revenue for royalties</link:label>
    <link:label id="lab_agio_ContingentGainOnDispositionOfBusinessRecognized_label_en-US" xlink:label="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Gain On Disposition Of Business Recognized</link:label>
    <link:label id="lab_agio_ContingentGainOnDispositionOfBusinessRecognized_documentation_en-US" xlink:label="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Gain On Disposition Of Business Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:href="agio-20220331.xsd#agio_ContingentGainOnDispositionOfBusinessRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:to="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_dd4f9c3a-d925-48cb-9635-4843c767ca59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6ed37667-cbe4-4329-b722-bb7f1bb2d00a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_476d9393-768e-4f64-9de9-bfb1ed3f5b0a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2657a020-7de8-4701-a7a1-711b5831c069_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_cf8ddb37-3f8b-4efc-ad2f-6aaaca6e968a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opportunity to purchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_d8255d84-5566-43fb-86f8-1aba0e27daef_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_589c0393-d42b-4b02-82cc-7155eb31eb62_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3c245e78-1bf8-4d11-af5c-3734d1c60590_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_948174e9-9279-491b-9eb3-8a90dda6284e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7b8893eb-4cc9-40ea-b111-62525838fe08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3028e55-701e-4c3e-a7ea-ab3136088a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ce2a99c-f152-4031-a98a-5e213153f087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_672a952f-f4e0-48d0-8e1c-287c6eac9a8d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b734f19e-18ae-4e5e-99b9-78fb71316981_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_12331307-4734-4a17-b042-617d135fa20d_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0953b24e-c15d-4227-9036-6ad63fbc3766_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_Agreement2010Member_ee79dcce-ab92-4209-8149-909eb690af0b_terseLabel_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Agreement</link:label>
    <link:label id="lab_agio_Agreement2010Member_label_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement 2010 [Member]</link:label>
    <link:label id="lab_agio_Agreement2010Member_documentation_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement 2010</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member" xlink:href="agio-20220331.xsd#agio_Agreement2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_Agreement2010Member" xlink:to="lab_agio_Agreement2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_a0c700ab-f7ec-4ad9-ad18-c8ec9331ae7c_terseLabel_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Plan and 2013 Plan</link:label>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:href="agio-20220331.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_7ac27c31-ba93-4ca7-8efc-431a8f2ec80f_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_02a0a765-d4e8-4557-b323-af2fd2580dba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa8b4fae-b1d3-428b-8a02-af5453393465_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8d912ce5-f51f-4dd1-875d-ba90f474c805_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_53b35ac7-7a23-4d76-b8b1-b24b9ad3772b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_StockholdersEquityDispositionOfBusiness_bab5c163-22db-4dd3-89c2-7575f3a55a11_negatedTerseLabel_en-US" xlink:label="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposition of oncology business</link:label>
    <link:label id="lab_agio_StockholdersEquityDispositionOfBusiness_label_en-US" xlink:label="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Disposition Of Business</link:label>
    <link:label id="lab_agio_StockholdersEquityDispositionOfBusiness_documentation_en-US" xlink:label="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Disposition Of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_StockholdersEquityDispositionOfBusiness" xlink:href="agio-20220331.xsd#agio_StockholdersEquityDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_StockholdersEquityDispositionOfBusiness" xlink:to="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_VorasidenibMember_960d42b6-fd57-43cd-8a4f-acc114496662_terseLabel_en-US" xlink:label="lab_agio_VorasidenibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vorasidenib</link:label>
    <link:label id="lab_agio_VorasidenibMember_label_en-US" xlink:label="lab_agio_VorasidenibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vorasidenib [Member]</link:label>
    <link:label id="lab_agio_VorasidenibMember_documentation_en-US" xlink:label="lab_agio_VorasidenibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vorasidenib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_VorasidenibMember" xlink:href="agio-20220331.xsd#agio_VorasidenibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_VorasidenibMember" xlink:to="lab_agio_VorasidenibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc4ad0d3-b0e5-45f2-8a23-df815b0c5cae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OtherStockAwardsMember_3c96ef3e-e9d5-41a9-9f4e-dad3052575df_terseLabel_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other stock awards</link:label>
    <link:label id="lab_agio_OtherStockAwardsMember_label_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards [Member]</link:label>
    <link:label id="lab_agio_OtherStockAwardsMember_documentation_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember" xlink:href="agio-20220331.xsd#agio_OtherStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OtherStockAwardsMember" xlink:to="lab_agio_OtherStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a108e535-223c-4c38-b7e1-b04e54024704_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b06b1580-811d-40db-bd76-e437f3e77068_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e6a5a6-7e7f-4131-a9f8-8903dac3d690_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_c854d5c0-3c92-4f4c-b59a-1201926f7387_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_951c435b-1787-4fbb-be62-1f71c1adf7ac_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7ef5ee0f-272d-4a51-bb4a-ecd33bf31da0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e69d152b-efdb-4ea3-b198-0f405078aa0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60c38dab-6060-4eff-983e-137352f27537_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dbbd9320-01c0-4238-ae49-a4e66b724046_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_f0f0ee3b-a51c-4181-8fa2-0f3e35fb5b0f_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue-related reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_label_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Total Allowances And Reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:to="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cffcca17-82fd-4247-a79d-b36a3a0d9f38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_b60009b3-ebee-47b0-8548-c9ae31888247_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_48a8a66d-8200-4b6a-829c-a703459171e0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4079f0c5-1583-4011-a9ea-691417d34e99_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b11e4b3-7313-4a97-9798-a1dd75d5c52c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25a06bbd-07bb-4a15-a03c-54e952d7523c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0bcb981e-945f-4e8b-84df-84ed9d86d09f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d048e43b-cef2-4a9a-9251-a56085de735f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64f528dc-3378-495e-bb58-bf500b829769_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_35f74a05-234c-4d1a-8885-28829fff6491_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Current Year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:href="agio-20220331.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:to="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_367eda94-b8cb-4d9d-b5eb-2117ae91586e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes recorded in discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_053a0925-f566-4240-bb16-0e4dfb120900_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_04727562-65e0-4526-b74c-897685758601_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ab119bf9-5d37-4058-b06a-aacb1c737f0b_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_bcda479c-1dd1-4fe0-bc18-0aab301cfd3a_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty income from gain on sale of oncology business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_ad8c6378-afd4-4c31-929a-11e99011eaeb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37e722b2-f8db-47ae-a36b-46f338c7a3e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_af256ea9-4c34-462f-8acb-68f4b14008e4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_bf01d41b-07bf-408a-99da-659da459307f_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8805a23c-f79e-427a-a10c-8b1ed6ba08e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_259461cd-e241-4334-b66d-b3ec951fbfaf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GovernmentRebatesRollForward_d4fdbb78-5cf5-4bdc-995c-6fc4dcd25cfd_terseLabel_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_label_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates [Roll Forward]</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_documentation_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward" xlink:href="agio-20220331.xsd#agio_GovernmentRebatesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GovernmentRebatesRollForward" xlink:to="lab_agio_GovernmentRebatesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0237e626-18ff-459f-906b-98e79e58c746_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8e6ff9f1-3d46-4968-bcc2-1ce064be7790_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Stock&#160;Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_cbf08773-fc50-4a58-9de2-09422c0b0701_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_8193da93-3f9b-49cb-9a38-d974f98e21d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Market-Based Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_68dff733-8616-427d-a9f6-c03d8e987233_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_f8fe52ea-1ce8-4c7b-8c9b-e404f2db1064_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5afa9303-40a6-4324-bf34-870c5ad9b39d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0b44d57a-209c-4e73-b70e-8ab3890c5de6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9b75839a-2a7e-4fc0-bac2-7571e8fc4d94_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_df007832-8a17-44aa-a85b-f276c424921c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_24a8e52a-b38d-4bef-a92b-bf0a393bf947_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_2d8bacc1-a746-4be1-9114-a348edbaa247_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractWithCustomerAssetProceedsFromCollectionOfReceivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:to="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_210dc269-f1ea-409a-9519-e36acd3ebad7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_75c9ef5c-02d9-4c3d-89eb-e2cbe0a546a9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_80e3303a-34ef-4a9b-8d58-ffee596231e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0a64e9bc-638f-4df2-a574-7eb7b663d928_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_ad964370-fb50-48f7-812f-617fa07fc1f9_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f79b6aa5-90bb-4809-a5aa-a65da46da58b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_63c7dc07-68be-4007-8f3b-f15f14e68130_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bc97b268-c9c2-477c-87bb-7c660ea24fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5c67cbd5-06b3-4c86-97d9-fb1eb68fe69e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_2572344e-1bd3-4281-9a7b-51130dafb9ed_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_label_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Allowance And Reserves, Liability</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:to="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_9685603e-b737-456b-9a9e-521e233e216c_terseLabel_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_label_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2013 [Member]</link:label>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_documentation_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2013</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:href="agio-20220331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:to="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2cb0a8c6-eec5-444c-86e7-8e0abc2ba46a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_90baf2f8-e300-46e5-9001-2804a33f1140_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7fce5e25-aeb2-4c37-8bb6-0143d5925bf5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5443f902-202c-46b0-8114-6eb7ff2dc86e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_218f6ffb-25d3-4e15-a6c7-e321ffa52c23_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased, aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_48074957-4c0c-4269-9763-5735a6055b26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_632920ab-f0ae-481b-8d30-62f0d2532c38_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ae9cd5ed-87d3-4b77-a824-7031cf044f4a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_a729485d-3b3b-4bfc-8454-39330410406c_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Revenue Recognized</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:to="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a8d490ed-df7b-4254-9db5-9ab02af8eb00_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0e8bf097-7d61-4825-aea0-5d0f51e9e749_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8543997a-07f9-4fea-95d4-cf4740af2ff1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_723c3cc9-f341-4950-b928-828d42914ade_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_178cb08b-b7ad-45c0-90cb-f5982932d360_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5d0bc42b-1258-4934-8d18-8be60f6779de_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f5de79fb-b753-44ff-b9f8-04ec0f353ae9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_4cb81ea4-9fed-4ab4-b962-e73a556e4f52_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payment</link:label>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_label_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:to="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3b08ae15-d728-460e-a378-010276a734cb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5f258648-f9db-4ad0-ba11-9358f4ffcb27_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_753e64dd-d98c-4e9b-a125-f79c798cbb1c_terseLabel_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment for achievement of specified ex-U.S. commercial milestone event</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_label_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_documentation_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:href="agio-20220331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:to="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_24d2ca8d-8b56-4cd6-9920-097b2ea5c63c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5686fcf6-6904-4226-8a2b-1b8d7a66c825_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_a49d4716-714c-42d0-bc71-c2a565d2948b_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_6ee3d594-dc4f-4675-8f6f-ac8d0bbca118_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d2ed75f1-6689-448b-bebf-136a31e57ff6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_02d31064-b708-4e22-b84a-cc3911afb187_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_f683b4ea-e9b5-4bf5-8453-0921bfec4476_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_864b9778-994a-42d3-a89d-6835ecc072f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_722328dc-220a-4f53-a92b-51044e005e5e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1f0ef2a5-48d8-497a-a31b-84931c7bd23e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9098ab26-ea43-418f-8b17-3fa78cb25fad_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8b0868b1-7948-4315-b072-f5a11eaeae75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_29d3b429-c07c-4beb-8c33-5ee0fff8e053_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5bb7a144-7d65-44a8-916e-7e080740a35b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_500b73b8-8e27-4751-a4c5-e344349169e6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_98057f73-8cd3-4b66-80d7-33ac383cbad9_terseLabel_en-US" xlink:label="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost not expected to be recognized</link:label>
    <link:label id="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_label_en-US" xlink:label="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount</link:label>
    <link:label id="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_documentation_en-US" xlink:label="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:href="agio-20220331.xsd#agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:to="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_a84cbcd9-14b9-4016-a26f-d8998bbeb7ed_terseLabel_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="agio-20220331.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0aae88a4-5a5e-46d9-8324-4f3aa75cb02e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_4e597c90-5029-4446-9fa3-f9db9a91cc9a_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_6fb4dc55-7c0f-436b-8a18-a73acacd0413_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Right To Recover Product, Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7553d161-e78b-4632-aa15-738cce4e4361_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0910f198-acf8-4ea9-b6c2-ffadf47e16de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0b2d0cdb-adeb-480e-8d3c-7985c1a09249_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_71d21133-6c7d-4666-85e7-eca99d76db86_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_78caacc4-7503-4589-a7b7-e68bbc8d0d94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_172daabc-b9e5-454b-b050-a86046d94808_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized; 70,993,277 shares issued and 54,776,467 shares outstanding at March&#160;31, 2022, and 70,550,631 shares issued and 54,334,220 shares outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_aeb94d07-0900-49d8-bb2a-cffc0720c442_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a2c2a32-05ba-4219-ba12-f41e3266be91_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize compensation expense (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3434e07-4e07-4045-8380-d2ae680302b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_718fd8b0-677a-48d4-affc-971034ba3367_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_27aae8a6-8f9d-4c6a-b763-a27c9f1bcb3b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitMember_b5bcdbe5-ddcc-476c-8c57-d04031970ea6_terseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_531da36b-3235-4fe2-a281-105b488374b2_verboseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit [Member]</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_documentation_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitMember" xlink:to="lab_agio_PerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_cd40319b-0dec-4111-8c49-c18d1271eaa3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8cfa46b5-d2e4-4554-b841-84fb3eaa4402_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0838f01d-842d-452c-8b3a-362cce9215f0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_0603b7b1-4056-4236-96cc-d9b4047a891d_terseLabel_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Thirteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Thirteen Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:href="agio-20220331.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ee52367-7363-43e0-a385-b52bed0afe0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_7015c3e7-1877-4cfd-b568-e69c4e5d8d69_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0f7cf378-a4f6-4187-bc56-75fdfb06f3a4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8b7f3eb1-228a-4f60-b092-adbd7c8aab64_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_23b9b8cc-87c8-4a38-b763-646cb8f545d6_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_635362a5-6df4-4584-aff1-bf4d1517302a_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_ccb228cc-cfa3-460e-8799-4669659c44ff_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_66666646-cdea-4f1a-ba48-2edfe686f10a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0fcdbdfb-fe6f-4be8-9d49-cc81dcab5cd1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_093f917e-f3ce-4942-983a-a98201f539eb_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_89eac2fe-85ff-42a1-8af9-58d61ae59aff_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_9c84eb5a-a236-4f4e-9625-ae883e4cbf17_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c3d087c1-8d3a-400f-a978-48d4af01f239_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d27d2f05-a79d-42a6-b748-1eb5fb038414_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_def3983c-2e80-4bc3-b406-a7da55c351b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7ca198cf-164c-415f-9481-1ae2de69d89e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d5543b1a-c360-4b61-b033-adfba2def580_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9fbdddcd-3bcf-4de7-ad4e-9c5395cad403_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_50c985d1-3ba1-4894-bb32-95dfa2df4544_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5d09d7a5-322c-4d90-958a-5ed20fbf0721_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6448eb4-7812-40b1-9021-80edde7a49af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a0d53c73-8e0b-4781-af80-84c286438e55_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_fbd69b36-e8a2-4ca5-b8d8-ae1c51b71934_terseLabel_en-US" xlink:label="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 repurchase plan</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_label_en-US" xlink:label="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase [Member]</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_documentation_en-US" xlink:label="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:href="agio-20220331.xsd#agio_March252021RepurchaseProgramRule10b51RepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:to="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2a6d87c4-a024-406d-bc16-7292aab2b3e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c5a170ed-08a5-4648-971a-0f13c940a012_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_461f2adc-9ed8-4604-be1c-006851d06139_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a256baf-99b4-4d1f-8a32-c4e27d125f13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9e6ddca1-7b9b-4d83-9ab0-ee4d36cba867_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_444f86e8-97a7-444e-b15a-5d02024ea53f_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_475b86f3-dd8b-4960-8d69-381fe50e0731_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1c43f876-65d7-4f35-ad69-442b619d99be_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_962ab687-9db9-4265-963b-16c4e8298059_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4803461c-071c-4fc2-bff2-bf1d24b605be_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5186be38-3654-4ae3-90d3-98f4da7c9753_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_cb47c224-a3b9-43dd-b14c-8cbf28b2681d_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities, Product Revenue</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_f232b9e0-b09c-4b46-a26f-e676be8935b1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_63e9177b-cb52-4064-b07e-25631864bafb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85a85308-37a6-47c0-936c-54c3f72bd2db_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_860782d4-f8fe-4b7f-b86f-57ed9662ab16_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_aeb1ddfc-3df6-42f9-808a-32283d7a50d0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_fc3717ca-a0ed-4049-8065-d8317db51713_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5932939c-82eb-4dd9-a3ba-59a2f48bcb34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_904a0dfb-0df6-4b4b-ae46-298f6fedf4d0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48f63dea-c5a2-4bb0-b219-e031729a9751_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9007e108-c588-464e-9e3f-dbb30dc3128d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_310e1c08-e444-416b-a170-a75059de40a8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_360b9852-8abf-48e3-80e2-32d5bca4c867_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a776fe45-2b52-4bb8-ba31-7da7fce74e9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ef1e773d-41e7-4fcf-8b24-d524a7ba1be6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b10d9876-b638-46ed-87d0-743cc2354fd4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_47a3db26-d302-461d-bb36-addb6d16f7a3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_b28b815a-2460-40cd-aa3b-5164dc3c82b5_terseLabel_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_label_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units [Member]</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_documentation_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember" xlink:href="agio-20220331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_MarketBasedStockUnitsMember" xlink:to="lab_agio_MarketBasedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_eb61fd98-0da5-4730-a994-508aa735f5fa_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract adjustments, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_ef034aba-2cde-4140-a5d0-e214ebd61beb_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract adjustments, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contractual Adjustment Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:to="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_04029592-16d3-462b-a489-91585c2090bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c3598b01-1377-435c-9bb2-4c8c4580b279_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5bc854a5-6ff1-4c22-b928-9fc9a30585bd_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f43663d4-7d00-4f10-8896-8111d0867221_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a2786f41-074b-448a-aa08-a5f92ac9178d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bff36378-8075-4620-8c16-36f0b18e6ba8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_6c2418f2-20a5-402c-becb-9ff84a25231f_terseLabel_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_label_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_documentation_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward" xlink:href="agio-20220331.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractualAdjustmentsRollForward" xlink:to="lab_agio_ContractualAdjustmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_344851fe-8e4f-4c41-8bc1-461a015ea346_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e982864f-2aeb-454b-bd76-3fb4e4ea15c7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1d953302-fc91-41b6-8144-320d772df0f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ad973a18-f6d9-463a-905b-960b987afb2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under 2013 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_02ba74d8-111b-4227-a007-08dfaa55ffc8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_04307705-3c7f-4f7b-8d0b-062c864f2e83_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_c3fc1d34-3832-4ab1-ab8c-25c31d75b68a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_29993b2f-49a0-4720-a285-4917b2787196_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fdc913a3-2831-46ad-8d43-bb16467e239f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_ff60ae23-821d-4e43-91a5-34c4a7118fe7_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, adjustments relating to prior year</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:href="agio-20220331.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:to="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RepurchaseProgramMember_f6bdbe84-3a1f-48ca-b442-5f9eed86d1ba_terseLabel_en-US" xlink:label="lab_agio_RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Program</link:label>
    <link:label id="lab_agio_RepurchaseProgramMember_label_en-US" xlink:label="lab_agio_RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Program [Member]</link:label>
    <link:label id="lab_agio_RepurchaseProgramMember_documentation_en-US" xlink:label="lab_agio_RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RepurchaseProgramMember" xlink:href="agio-20220331.xsd#agio_RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RepurchaseProgramMember" xlink:to="lab_agio_RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a65e131c-9501-4219-8086-8df73c7a492b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes recorded in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4a34be8d-53d5-41c8-9ae9-58f73fa5515e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d7dde904-2993-4b57-9687-996e03f24ce2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_de81766f-ec6b-43b2-87cb-3ef9325fe7ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9c2d122e-a83a-41c0-9850-d2c8e817da80_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_fd80e78d-b8a6-4665-8274-61eb0313de08_totalLabel_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="agio-20220331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d56e8079-4e9c-4c5f-8ba5-0d166ff57ba7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e0ad800f-840a-46d8-be11-c8bf53ebc1df_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9a9cb357-2181-423a-b2de-a7d691c36b4c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_cbbfd20e-b173-433f-96e1-186d87807616_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5751768f-a213-4d2b-9163-4317e39fe4b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fda115dc-4f4a-4653-a3a4-b46846fef760_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted minimum rental commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_99c3f0cd-5ab4-4bc5-a371-eb43754b9f18_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_15716af1-7423-4b41-a011-91ce321ea8da_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8ca01fc1-5f2d-49b4-b664-7038904cd74b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3a7e747-55d7-4853-9b14-bbfa130a810a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d8660c03-bdcf-41ef-8bae-072a6466e01a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_cd5b24eb-bd35-4ab4-972a-974a862a5cf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b6f1d676-5402-4c48-a24a-88b988ab8b34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f2743eb6-4676-4735-8002-f5d9d1c9a8ae_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_d60c79b7-c2ec-4765-b4fc-2584097aadc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2708fda2-6acf-4b6c-b779-6a8403546a49_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_16f6d14e-a41e-488b-a1db-9cab824f0e76_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d3a72564-fcf6-4897-9040-498908ed8a3d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3dc230af-6990-4a8f-bba4-1e2aceca918e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense excluding options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ab51b689-f0c3-49d7-a5c8-9967ac93fe55_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bd17f8fc-f49e-40f1-b8a7-baffdbb74d4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0bb9e991-01f7-4fc2-9b31-f93ac81ba2b8_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8f2b6db9-b710-4e88-adbe-7508625cd73e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_7f6ff73e-1949-415b-8b02-7e9e5ef23e0b_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b30f0490-480a-46bb-9852-0e5ad63b3568_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a7eb2476-9be9-4652-af62-4170bff9f96a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_65d09fbe-b84e-48f1-9b5d-26dba9211c63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5ebb6ae1-3b3d-4ba7-ac7a-ba4d66126b53_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2bd9b28f-1eff-44a5-ae6c-eff5847a6e07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_23ab0e1a-4cf4-4040-849c-9497ef8484a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0c337705-d5c5-40dd-b508-6b1254a7ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f6b54eb-2e43-46ca-806d-9d177a09d18a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89e21e19-8086-42e0-84cf-7a552bf7e85b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9bfa322b-7ad0-4a44-a8b7-b1c42d6138cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_591b0eb0-cbe8-475c-8b6c-45d450198405_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_cfdc339e-80ca-4d08-8828-f1ff392b164c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_431ed277-b7cd-412d-98b8-0cc003cb9a50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e9aef3d7-87e7-4d74-82d8-da922dd54589_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of debt securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_88101436-419e-4ad7-b951-f112efe7ab3c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2c17cd4e-75b7-44ff-af25-5ecaa9d8f9c8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1892e62d-c804-4df0-b6ab-91078c8d8fe4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_744b8345-9e4a-4e91-b0d5-eef3b3a19a17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_da900be8-3066-42aa-ba19-55b6f37242d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7b483b5c-0f31-4e37-b012-0f5e69f936d3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b79fae00-7137-406a-b670-e64e61f4e255_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b9e92044-4b08-45c8-8af9-8312cd56a0a3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_edf63898-c61e-4a3c-bfe5-2ed964c6c3c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_40f14dec-d1e1-4397-aff6-d51c6e9eabb4_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:href="agio-20220331.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:to="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3a9cb785-a766-4055-bf9b-2d03779d790c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9120dacb-9295-460d-b00c-992805499e0a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_8db06357-6ba9-4689-b9c1-b75eb0957e32_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve" xlink:href="agio-20220331.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionsForRebateReserve" xlink:to="lab_agio_PriorYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_96172714-45c9-4ad6-b8ad-14489cc9d2c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9f9c0bfd-462f-44ef-aece-a68aed5d3a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7ea71fb7-0be4-4d26-ba63-66f3f0bd9b20_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_b4eaed83-a527-4a77-ada7-08ed26c832e8_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e4436aa4-e619-4fb4-a929-00c694b0d9f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue Allowance and Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_dc1159eb-3a34-4f98-abf3-bbb562ac0a6c_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec74a953-7c05-446e-afdc-6ac8006142c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_683f729b-5c77-4743-afd7-865cf3286aee_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5578b23c-e752-4349-aa79-ebe97d915ad0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_31deeafe-809d-468f-a8d2-a6dce7a351d8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_870f0532-0c26-4e00-bd15-84256c5e3247_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_66f8dd4d-45d2-408b-9e49-3ee5bf49972f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense and Other Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_44f2b425-bffd-4147-9cac-6caec7ecb2cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e550c1c2-edb6-4e43-a92e-675723ef86f9_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d042d0f-2831-455c-adfa-996a3cd3835a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ae8488e7-e43e-4d74-9261-e143a9e0f525_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8d2331f6-ea6b-4f98-8512-9c7b3fef737f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_56397c51-6b18-405a-b025-43392258dc23_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9a7d95f3-54d0-417b-a828-523892e2bcbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_66800fe4-5885-4d1f-9a11-07ee6e3df0f4_terseLabel_en-US" xlink:label="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Repurchase</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_label_en-US" xlink:label="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase [Member]</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_documentation_en-US" xlink:label="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:href="agio-20220331.xsd#agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:to="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GainContingencyRoyaltyPercentageOfNetSales_a8bcbe26-dca6-46c3-b1fd-4586961873fd_terseLabel_en-US" xlink:label="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty payment</link:label>
    <link:label id="lab_agio_GainContingencyRoyaltyPercentageOfNetSales_label_en-US" xlink:label="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Royalty Percentage Of Net Sales</link:label>
    <link:label id="lab_agio_GainContingencyRoyaltyPercentageOfNetSales_documentation_en-US" xlink:label="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Royalty Percentage Of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:href="agio-20220331.xsd#agio_GainContingencyRoyaltyPercentageOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:to="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1cbf7fad-8acf-4b58-8fc5-1d2948b32803_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d5f2b9c-23ff-493b-aede-b971c96ca88b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_61f7024f-eb11-4fc1-8b21-4cca07e82b13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_59559745-f5a9-4c2c-acc5-3f3883308997_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (16,216,411 shares at March&#160;31, 2022 and December&#160;31, 2021)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_610f7114-0180-4117-b2d4-3586b934843f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9714eb51-3dbf-40dc-9d3f-ab1cc42945bc_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_513148cf-13a5-47a2-9226-b0d7c3f1b472_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_619794bf-7cf8-480a-8cce-3bc4fbf45c1a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_da285409-53d4-435d-8d4b-c8131ee35376_terseLabel_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_label_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset [Roll Forward]</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward" xlink:href="agio-20220331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward" xlink:to="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0d3b801a-c14a-44bb-a4a5-2cbc324fc67a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_8fba141e-d063-4ad0-98f6-6ef7b148f1e1_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Related Reserves</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:href="agio-20220331.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:to="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34469493-0020-433a-a185-80d9dc1c7fe9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9fefbfbd-ee2b-4602-b730-c4569c6edeac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_2d9c11a4-aaa7-465f-959c-86a9f52d635d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_f9f4b3b9-712d-40ac-baa6-189947007ed2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5c407f53-ce56-47d8-a84e-53c473f55be4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_cf0f2ce7-42cb-4621-8a13-bb8335d4a636_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a4ae1ed-fcd3-4a03-a627-2c4b0552b4d2_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c69c3465-07f9-4984-8bae-94d7eb90e1e7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AgiosOncologyBusinessMember_5fdb91c9-052d-410d-b33c-bfef497a9c93_terseLabel_en-US" xlink:label="lab_agio_AgiosOncologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agios Oncology Business</link:label>
    <link:label id="lab_agio_AgiosOncologyBusinessMember_label_en-US" xlink:label="lab_agio_AgiosOncologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agios Oncology Business [Member]</link:label>
    <link:label id="lab_agio_AgiosOncologyBusinessMember_documentation_en-US" xlink:label="lab_agio_AgiosOncologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agios Oncology Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember" xlink:href="agio-20220331.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AgiosOncologyBusinessMember" xlink:to="lab_agio_AgiosOncologyBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_044b8a72-2006-47a7-b8f6-a7c3d756abe4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_d90b8270-6059-4fd8-96bb-6056e5ccc26d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities in unrealized loss position for less than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_77725bfd-598c-40d3-b051-d594cc556b5b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dfb96b07-51e9-47f2-99c7-2b20a7b6fef9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6ed463d7-cb48-4046-a793-6cae9fa08e90_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8288b35a-b95c-4e0d-990b-659bf3640f5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Stock&#160;Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c220bc08-0e60-4cb4-8ace-efb368714340_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_51442361-1a6a-4959-9b0b-ea87ba6d00a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0be4b712-6b04-49c6-aa5c-6ca8bd76bcc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_b5723c36-2e7c-40f2-9dac-549d9748e457_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cf2769a9-e05a-45fc-9591-617f94c53907_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_54cbea76-78fb-41bc-8d5b-079b2eee84e7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fe8b037f-44d5-4e9d-804e-593a9971f16d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_549117ba-cffb-472a-a21a-4ada79ccea2b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_873d20ac-15b8-495e-a647-1a74e990ebeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_6da37bcd-bdb0-43f8-be14-7c7bc29194e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_347c9d0a-a610-4f50-8718-982e2641ff57_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f4cf565-6b8d-4746-b410-e2fea4ad8651_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8fbe294f-2ee3-4852-9f1f-2f1e8ead459a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities in significant unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ed795111-df5d-4b39-bd34-2ab6b591f876_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_a73fe5b1-ee99-4328-b6d7-1ddfd0559653_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Prior Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_ede66525-f657-4036-af63-669aba0a89e6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_fa94a1ce-d2f8-4724-868e-5d5340a06c2b_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Prior Years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentAssetMember_dc18f251-1a3a-4d26-a044-55987408e1e8_terseLabel_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_agio_CurrentAssetMember_label_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Asset [Member]</link:label>
    <link:label id="lab_agio_CurrentAssetMember_documentation_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember" xlink:href="agio-20220331.xsd#agio_CurrentAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentAssetMember" xlink:to="lab_agio_CurrentAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cf26aece-5a1d-4aa1-9e16-fac35a849948_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_df03c3b5-7224-4731-a191-c34347223257_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_af549d08-25b1-4cf5-9a46-e5c14c491d9b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6a4e068a-03b6-4694-bd72-d66495717d31_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of premium (accretion of discount) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41d65898-686c-490d-b9e8-7b8decea391c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bfa5f69e-b017-4837-99c9-baf9fd3ded72_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_3b658f41-4698-4bf7-8df2-f0e2c135556d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_66bcfe7c-c6a6-4ac3-a1fe-82a5b92d8439_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8bfcdac1-46de-4015-ac19-7da262d24425_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_91125fe0-bec4-45ea-ac96-0a80a2a8e4ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_335b172d-cbc2-45f4-bc5b-591614e409b4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c10caf0e-fce1-41ad-acef-ab07e1bcc416_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_85fc928c-fb2d-4f49-ad8e-2dd13872f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance-Based Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e22dcfbd-4ce1-48a2-a36f-572cf9a9d579_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_3fb0d02e-b3ec-46a5-862b-798f1d861b78_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_3b62ed5a-ff03-4952-8cd8-dab8c2e2f1a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d60591b1-afdb-4bc4-8ad8-f6f887bcfe84_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3cc5a8d2-2d7e-458f-83ed-909a850b56fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7e3ebbe0-b7c3-4c40-b6c8-c0962d5d841f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cf93219-1c2a-445d-bfe4-e507ef635c5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5b0ceeb5-dc9c-4dac-8323-a78d3d5ec6b6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3fd76876-bc54-45a2-b018-85421d5d34be_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2f67f7b-6ce7-4325-8abb-e1cddc9c3a4a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b4e49a84-0e9a-4c5a-904f-848f58cddbce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_bbc4c6a4-c69a-467a-a6af-e23af0ea38c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_c39cd51f-df1e-4b51-9002-70c19ef06718_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0c8f2467-0b1e-434f-ac27-3cd2acd5c477_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TIBSOVOMember_dcffb112-74e4-444d-bf01-640c3b78bcb2_terseLabel_en-US" xlink:label="lab_agio_TIBSOVOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TIBSOVO</link:label>
    <link:label id="lab_agio_TIBSOVOMember_label_en-US" xlink:label="lab_agio_TIBSOVOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TIBSOVO [Member]</link:label>
    <link:label id="lab_agio_TIBSOVOMember_documentation_en-US" xlink:label="lab_agio_TIBSOVOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TIBSOVO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TIBSOVOMember" xlink:href="agio-20220331.xsd#agio_TIBSOVOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TIBSOVOMember" xlink:to="lab_agio_TIBSOVOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_613da8c8-44b4-42bc-aa3f-fca27121b12a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Excluded from Calculation of Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_1b6b1d35-aa86-454f-b62b-4424c806a4f1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9eb37d0f-3b9e-4c84-bf75-3370a101c889_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b544de0b-dc01-4862-8f94-eb7bb76720ee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ee98cf64-c86d-4cf1-a4f1-4bf08f7aa6c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeePurchasePlanMember_601e7239-c0d3-4cbd-96e6-d47cfaea2970_terseLabel_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_18b09038-0960-494e-95c4-39a981e2392f_verboseLabel_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan shares</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_label_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Purchase Plan [Member]</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_documentation_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember" xlink:href="agio-20220331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeePurchasePlanMember" xlink:to="lab_agio_EmployeePurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fdbe18ac-9e69-4b68-8798-ae76e8d4a0b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f048dcf9-fbdd-4884-b2ea-60a917aec2f1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_aef75067-8441-42bd-b53a-d552733a148e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9174ba58-bb3d-4b71-b60b-b10c22547f4c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3b240e1d-1753-4247-a34e-263304ce45d4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_89a3ebf7-bf58-4422-a891-657ff8f17886_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the prior year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Prior Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_59acbdd1-0537-447f-ad9e-9d4fe1f8b840_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_2fa3c3a3-e8d6-407c-b12f-47372c458117_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_4f7bf172-d7c4-472a-a503-2d201b572d58_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_688734e8-5e6f-444e-be2f-866643c7017a_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebate Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserve" xlink:to="lab_agio_ContractWithCustomerRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_181d3f56-30e6-4466-9fad-ace09b97dc96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93b7d75b-1096-431a-860f-d223f75ab88e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_59836e88-3ca9-4ea8-b07d-9a4e2650fc67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_e1e36dd0-5743-458b-928d-b863a666affd_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Prior Years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:href="agio-20220331.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:to="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_05ff70c2-72d8-4f43-8c37-49190b124698_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_99a920c4-69b4-462a-89ca-b97dd8ed4389_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Current Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProductReturnsRollForward_3992d988-4fa8-4cf1-a503-b6b2e42e0c8b_terseLabel_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_label_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Roll Forward]</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_documentation_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward" xlink:href="agio-20220331.xsd#agio_ProductReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProductReturnsRollForward" xlink:to="lab_agio_ProductReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_c681c32b-a706-4a9d-a1ff-fee8ee3edb00_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of premises subleased (in square feet)</link:label>
    <link:label id="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_label_en-US" xlink:label="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Area Of Premises Subleased</link:label>
    <link:label id="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_documentation_en-US" xlink:label="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Area Of Premises Subleased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:href="agio-20220331.xsd#agio_LesseeOperatingSubleaseAreaOfPremisesSubleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:to="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0ab4f9e1-1ecc-43fb-a840-7df78fb8b6b7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0214e5da-c36d-4677-8fea-825e55ca599d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a1d569bf-969d-4b5b-a5ac-1b6ed3f79f3e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_90073d70-abb4-492e-8f9e-138c9c5c39cd_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:href="agio-20220331.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:to="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NonCurrentAssetsMember_1d9424af-c384-463b-a62d-4621a9bc9c4b_terseLabel_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current:</link:label>
    <link:label id="lab_agio_NonCurrentAssetsMember_label_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Assets [Member]</link:label>
    <link:label id="lab_agio_NonCurrentAssetsMember_documentation_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember" xlink:href="agio-20220331.xsd#agio_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NonCurrentAssetsMember" xlink:to="lab_agio_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>agio-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:55e4eac5-1c9c-49df-a9ba-5fe941f4694b,g:196378a3-5ec7-4de3-a864-cc3dd9965fcc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_86aec6da-d3cb-4493-8b6c-10f96467ae4e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_DocumentType_86aec6da-d3cb-4493-8b6c-10f96467ae4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e088ffc1-05cd-4298-b869-db76eaa66b6a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_DocumentQuarterlyReport_e088ffc1-05cd-4298-b869-db76eaa66b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_37b7fcf7-b87a-4b53-8aa1-eb506a4fecec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_DocumentPeriodEndDate_37b7fcf7-b87a-4b53-8aa1-eb506a4fecec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fa8b92e4-8d44-4faf-a91a-73d37e1ece25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_DocumentTransitionReport_fa8b92e4-8d44-4faf-a91a-73d37e1ece25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_02795aff-4e0a-4a8d-8557-fb3befecb4ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityFileNumber_02795aff-4e0a-4a8d-8557-fb3befecb4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d2216180-9851-47e7-9f9e-80d6a5f02708" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityRegistrantName_d2216180-9851-47e7-9f9e-80d6a5f02708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3e70d8bd-eb5c-4d19-915d-654cdefa49f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3e70d8bd-eb5c-4d19-915d-654cdefa49f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ef18687f-1ab8-4519-8091-187fd1aa1336" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityTaxIdentificationNumber_ef18687f-1ab8-4519-8091-187fd1aa1336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_795ce1c4-e802-49d8-8707-ec449a67de40" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityAddressAddressLine1_795ce1c4-e802-49d8-8707-ec449a67de40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e366033d-1d2d-472d-9575-f3d2ebc5fb48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityAddressCityOrTown_e366033d-1d2d-472d-9575-f3d2ebc5fb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0b34f99d-5ae0-46af-9d39-5906f46d068f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityAddressStateOrProvince_0b34f99d-5ae0-46af-9d39-5906f46d068f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ecc446ca-8d14-4fce-b428-0b5aa31f8497" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityAddressPostalZipCode_ecc446ca-8d14-4fce-b428-0b5aa31f8497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_23f58c8f-cdd5-49f1-bc83-29806e394c75" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_CityAreaCode_23f58c8f-cdd5-49f1-bc83-29806e394c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_49e059c6-4c7c-41c5-a016-641f692adedb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_LocalPhoneNumber_49e059c6-4c7c-41c5-a016-641f692adedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bbf7a8cc-73bc-46c9-bf33-ca3cf8707eef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_Security12bTitle_bbf7a8cc-73bc-46c9-bf33-ca3cf8707eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a5d90b6b-d8a4-4ae3-9068-8a64bcd290b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_TradingSymbol_a5d90b6b-d8a4-4ae3-9068-8a64bcd290b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cae9d3c7-ac23-454f-bf11-c03db6d38686" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_SecurityExchangeName_cae9d3c7-ac23-454f-bf11-c03db6d38686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_234366ba-b42d-4fa9-8604-0c7d4af76c9b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityCurrentReportingStatus_234366ba-b42d-4fa9-8604-0c7d4af76c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d8e66184-118c-4490-82d7-08891b2b4ac0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityInteractiveDataCurrent_d8e66184-118c-4490-82d7-08891b2b4ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7181e215-9024-4f54-a80c-c0e227ca7f19" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityFilerCategory_7181e215-9024-4f54-a80c-c0e227ca7f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_47155197-81e5-40d9-912b-3b992b8a1c65" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntitySmallBusiness_47155197-81e5-40d9-912b-3b992b8a1c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3e7a312d-cf29-4a64-89d6-21ca8b7837b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityEmergingGrowthCompany_3e7a312d-cf29-4a64-89d6-21ca8b7837b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2b0f5500-7bb2-414b-ac62-6b4480128eac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityShellCompany_2b0f5500-7bb2-414b-ac62-6b4480128eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f0afc0a0-2829-4a42-80cb-b0fcdd27ba4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f0afc0a0-2829-4a42-80cb-b0fcdd27ba4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bc0b79ee-506b-44c5-a007-c9aaca1549c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_DocumentFiscalYearFocus_bc0b79ee-506b-44c5-a007-c9aaca1549c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5691e5ea-1cba-454a-87c6-b6177652c162" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5691e5ea-1cba-454a-87c6-b6177652c162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_23e23032-ff0a-4a4b-a5d0-22b26d3baa8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_AmendmentFlag_23e23032-ff0a-4a4b-a5d0-22b26d3baa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b89c19f3-a8b1-4345-99fe-5f22e827a4c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_EntityCentralIndexKey_b89c19f3-a8b1-4345-99fe-5f22e827a4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_71e22088-9fa9-4178-a05a-439f232b5e80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_edbf0eb7-0056-4c62-a873-7c55d8f3d53e" xlink:to="loc_dei_CurrentFiscalYearEndDate_71e22088-9fa9-4178-a05a-439f232b5e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_910c24d2-834d-4615-ba03-1a10c2c7d8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_910c24d2-834d-4615-ba03-1a10c2c7d8b6" xlink:to="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4dbeef83-82da-45d2-8e22-3fc07e282f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4dbeef83-82da-45d2-8e22-3fc07e282f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ca2bdb4b-b7c7-4398-b617-3b93ef787f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ca2bdb4b-b7c7-4398-b617-3b93ef787f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c7f8e636-e595-4fad-b512-7eb5d6cb6890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c7f8e636-e595-4fad-b512-7eb5d6cb6890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_95048b7e-8744-4bb1-aa9e-f11c33643ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_95048b7e-8744-4bb1-aa9e-f11c33643ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e2ae32a7-fcb1-469b-9f83-c45412a6c845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_InventoryNet_e2ae32a7-fcb1-469b-9f83-c45412a6c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4bdfb537-22cf-42a4-a086-bc67befeb781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4bdfb537-22cf-42a4-a086-bc67befeb781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7a0d4299-1a37-4b26-afbd-7a6d11d86ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_587605bd-c0f5-41c1-ad0a-1c80ff183f3b" xlink:to="loc_us-gaap_AssetsCurrent_7a0d4299-1a37-4b26-afbd-7a6d11d86ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eedcff7a-7c44-4921-8369-20334db66f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eedcff7a-7c44-4921-8369-20334db66f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e46f6f2-6280-4689-a11f-63afc379c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e46f6f2-6280-4689-a11f-63afc379c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f17cf575-b6de-4d4c-9f64-d5675f9aeda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f17cf575-b6de-4d4c-9f64-d5675f9aeda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_bc076baf-abbf-432d-a5cc-b8664113e269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_bc076baf-abbf-432d-a5cc-b8664113e269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_01b3e38b-28a9-42af-8c01-65dd97a4a4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_01b3e38b-28a9-42af-8c01-65dd97a4a4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6e893fbb-a4ab-4584-81c0-2435200b3ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5737798e-d194-4425-bf46-cd01489f6471" xlink:to="loc_us-gaap_Assets_6e893fbb-a4ab-4584-81c0-2435200b3ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_910c24d2-834d-4615-ba03-1a10c2c7d8b6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0b735023-07e6-4ee7-a333-0ef7356dfb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:to="loc_us-gaap_AccountsPayableCurrent_0b735023-07e6-4ee7-a333-0ef7356dfb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bd0e10e2-0f15-44da-b5e2-cfa41faece9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bd0e10e2-0f15-44da-b5e2-cfa41faece9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6fc1c580-10e8-469f-9fcb-f9f61debe6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6fc1c580-10e8-469f-9fcb-f9f61debe6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c0dd5c84-4522-480d-8b40-472d449d65a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c0dd5c84-4522-480d-8b40-472d449d65a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9063b121-adf7-4eff-9080-0f9e53720d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9063b121-adf7-4eff-9080-0f9e53720d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bc1c0136-bf59-4ae6-ae24-ed6f4af7c9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_938401d1-98b0-4a48-a960-a42a25b5c4b3" xlink:to="loc_us-gaap_LiabilitiesCurrent_bc1c0136-bf59-4ae6-ae24-ed6f4af7c9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f498065c-6755-4b08-ad59-adacf6e33856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f498065c-6755-4b08-ad59-adacf6e33856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_03e5fb92-0692-4877-8887-59cb824dadb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_03e5fb92-0692-4877-8887-59cb824dadb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_90b1aedb-37a7-4fd4-83e8-c2583b4ecad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:to="loc_us-gaap_Liabilities_90b1aedb-37a7-4fd4-83e8-c2583b4ecad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:to="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_491c6765-8082-4ab0-8340-2c02152f52c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_PreferredStockValue_491c6765-8082-4ab0-8340-2c02152f52c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_459e14f5-8933-4566-ae41-5e0e0640a653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_CommonStockValue_459e14f5-8933-4566-ae41-5e0e0640a653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dbe424bf-f6c2-4286-80a9-cad6b4ec6cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dbe424bf-f6c2-4286-80a9-cad6b4ec6cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9a2cd440-83c3-4125-88f7-0bcf25d359ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9a2cd440-83c3-4125-88f7-0bcf25d359ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_94541df4-903f-4623-bf66-c4e09b94f636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_TreasuryStockValue_94541df4-903f-4623-bf66-c4e09b94f636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c39ffb3e-efca-4e5b-bc08-5e9379dc7ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c39ffb3e-efca-4e5b-bc08-5e9379dc7ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b2b5675-d46e-43ea-8685-de13a79e8510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_939c3f04-5ef7-45ca-b237-c327b0aec276" xlink:to="loc_us-gaap_StockholdersEquity_9b2b5675-d46e-43ea-8685-de13a79e8510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7ef1c36-1633-42ad-9dd4-faba0237bbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beb838bd-777e-4d02-8248-f2c5f9ae3117" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7ef1c36-1633-42ad-9dd4-faba0237bbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_838fa58d-dbaf-404c-a64b-18607051c491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_838fa58d-dbaf-404c-a64b-18607051c491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f85c852c-b0d3-4a24-b488-df2dd92a5c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f85c852c-b0d3-4a24-b488-df2dd92a5c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_499edd17-7bd6-455a-9387-7ec6000eabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_PreferredStockSharesIssued_499edd17-7bd6-455a-9387-7ec6000eabe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ef3c101a-973d-4ffe-926c-a1a09030695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ef3c101a-973d-4ffe-926c-a1a09030695c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_29ecd026-7006-4aaa-8fe0-ec77db8717ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_29ecd026-7006-4aaa-8fe0-ec77db8717ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_97799167-fe95-45aa-8017-de563322154f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_97799167-fe95-45aa-8017-de563322154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ca3067eb-f581-4a0e-933f-57cc9ad9ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_CommonStockSharesIssued_ca3067eb-f581-4a0e-933f-57cc9ad9ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c16037a9-9efb-497a-8296-be0d680e6017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c16037a9-9efb-497a-8296-be0d680e6017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2185ee5e-d653-418e-90ab-864b5953af5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f60e006-5fa4-4c48-9090-f5aaf93a0613" xlink:to="loc_us-gaap_TreasuryStockShares_2185ee5e-d653-418e-90ab-864b5953af5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cee5a15a-cecc-411e-88e5-7967e6ac9a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cee5a15a-cecc-411e-88e5-7967e6ac9a85" xlink:to="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:to="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ca2243c-201b-46f9-9f11-95385a4468d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2853ba40-ff8a-4d19-8862-e623da1d0b1e" xlink:to="loc_srt_ProductsAndServicesDomain_9ca2243c-201b-46f9-9f11-95385a4468d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5fdafb2a-f765-4a8e-b531-f45524a4c10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ca2243c-201b-46f9-9f11-95385a4468d4" xlink:to="loc_us-gaap_ProductMember_5fdafb2a-f765-4a8e-b531-f45524a4c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_553b8e81-9bad-4ec8-9aca-d1f9a4fc1416" xlink:to="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee38e022-7af5-4f27-ae24-fc397ff4d00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee38e022-7af5-4f27-ae24-fc397ff4d00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b096ac25-cfa7-4f2a-97c8-a38f9fd1fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee38e022-7af5-4f27-ae24-fc397ff4d00a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b096ac25-cfa7-4f2a-97c8-a38f9fd1fc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1671a93f-52ff-43e4-b48c-2bd94bd0ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1671a93f-52ff-43e4-b48c-2bd94bd0ac9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_55d060fe-75fe-4fad-a2c7-a8ec138af2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_55d060fe-75fe-4fad-a2c7-a8ec138af2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58509f41-c8de-4ac3-a529-816325940f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58509f41-c8de-4ac3-a529-816325940f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_23628f06-999b-4c3d-919a-c631a355d841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0e044fa0-d423-4f13-afaf-38fcbf779e0c" xlink:to="loc_us-gaap_CostsAndExpenses_23628f06-999b-4c3d-919a-c631a355d841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8272222d-4748-4537-8eb6-e4fb2492935d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_OperatingIncomeLoss_8272222d-4748-4537-8eb6-e4fb2492935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_54509f01-b19a-4c64-be1a-e111e21e5d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_54509f01-b19a-4c64-be1a-e111e21e5d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d7a50bc1-88b5-48ea-bac3-7b57abff747b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d7a50bc1-88b5-48ea-bac3-7b57abff747b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_ac4d47bf-fb85-41a2-a74e-7957b6a556e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_ac4d47bf-fb85-41a2-a74e-7957b6a556e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_70246002-508a-4c06-a91b-71aaeb85076a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_70246002-508a-4c06-a91b-71aaeb85076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c67a6177-2af0-4ecc-ae58-fa1ad51e5769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c67a6177-2af0-4ecc-ae58-fa1ad51e5769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_daecbb54-95ec-4739-a882-9afad6582ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_NetIncomeLoss_daecbb54-95ec-4739-a882-9afad6582ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ccd1ddd3-18c2-4796-9b65-f90ba06afc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ccd1ddd3-18c2-4796-9b65-f90ba06afc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b5c047aa-c4f5-49c7-84f9-cd1fb3627140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b5c047aa-c4f5-49c7-84f9-cd1fb3627140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d81f0c31-025a-4c4b-b23f-0685f5117423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d81f0c31-025a-4c4b-b23f-0685f5117423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6883d129-9f4b-46e9-8d5b-9b8f078ebe10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_6883d129-9f4b-46e9-8d5b-9b8f078ebe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a87cf9cf-de49-444d-b076-9e80777d4b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_EarningsPerShareBasic_a87cf9cf-de49-444d-b076-9e80777d4b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fd5df976-18b1-45e2-97c8-13cc91329c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fd5df976-18b1-45e2-97c8-13cc91329c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a5931f6-2bb9-4f48-be6b-2cf38944a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a5931f6-2bb9-4f48-be6b-2cf38944a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4eb5bcf7-368b-4522-86ec-b24c61ff3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07105fc5-81ce-420b-8362-1f445687f549" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4eb5bcf7-368b-4522-86ec-b24c61ff3aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f349ab1c-c1cf-40b4-960b-ee030fa8eb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_def9f942-8f17-494a-9014-afaf0dbd5f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f349ab1c-c1cf-40b4-960b-ee030fa8eb5f" xlink:to="loc_us-gaap_NetIncomeLoss_def9f942-8f17-494a-9014-afaf0dbd5f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4c08c61f-ce13-49c7-9182-89216671c115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f349ab1c-c1cf-40b4-960b-ee030fa8eb5f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4c08c61f-ce13-49c7-9182-89216671c115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bd05dd0a-b0a8-4e1b-999c-f0e089fa7928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4c08c61f-ce13-49c7-9182-89216671c115" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bd05dd0a-b0a8-4e1b-999c-f0e089fa7928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb1e6db0-34b3-49b5-8594-120ccd9ef081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f349ab1c-c1cf-40b4-960b-ee030fa8eb5f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb1e6db0-34b3-49b5-8594-120ccd9ef081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_42f05dcf-d862-452e-a0ab-1539d048c569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_42f05dcf-d862-452e-a0ab-1539d048c569" xlink:to="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_08c423b6-35d6-4f08-9500-37f40f659992" xlink:to="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7576e3d5-f631-4976-a5dc-4ae08a3adb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_CommonStockMember_7576e3d5-f631-4976-a5dc-4ae08a3adb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_42c12894-e5f0-419d-8076-e90b1ea1a362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_42c12894-e5f0-419d-8076-e90b1ea1a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_477598a0-179d-4955-8346-7fe1d46ab718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_477598a0-179d-4955-8346-7fe1d46ab718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_91ab59f5-908d-4cc9-aa2b-d05774f31668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_RetainedEarningsMember_91ab59f5-908d-4cc9-aa2b-d05774f31668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_a945b413-b4d0-4a40-91a3-02bcb1dd35f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e0ec0cda-c9af-4a34-9e6a-76cdbe2b8d10" xlink:to="loc_us-gaap_TreasuryStockMember_a945b413-b4d0-4a40-91a3-02bcb1dd35f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7144309e-a1cf-4a1a-969b-215c6600d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3dfa8bb-fe10-4590-b005-f265ef89417c" xlink:to="loc_us-gaap_StatementLineItems_7144309e-a1cf-4a1a-969b-215c6600d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7144309e-a1cf-4a1a-969b-215c6600d71f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6ceec79a-92d0-4a6a-a60d-5aaf6d110681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_SharesOutstanding_6ceec79a-92d0-4a6a-a60d-5aaf6d110681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7de00d9-7778-4548-982b-2a089dac28fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockholdersEquity_b7de00d9-7778-4548-982b-2a089dac28fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85546f80-81f0-4bfa-a1c9-352b81466cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85546f80-81f0-4bfa-a1c9-352b81466cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_179a9d64-3ae2-450c-b161-a7e4ac18e2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_179a9d64-3ae2-450c-b161-a7e4ac18e2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc640c04-cfec-430d-a2ed-76da87024177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fc640c04-cfec-430d-a2ed-76da87024177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_da6a3211-a498-474f-be8d-bad77505bd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_da6a3211-a498-474f-be8d-bad77505bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e1e1faf-dd96-4acf-989e-ee6bc7157b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_NetIncomeLoss_4e1e1faf-dd96-4acf-989e-ee6bc7157b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_StockholdersEquityDispositionOfBusiness_a0912a10-4bd3-4ae5-af95-1fa9f3dba09e" xlink:href="agio-20220331.xsd#agio_StockholdersEquityDispositionOfBusiness"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_agio_StockholdersEquityDispositionOfBusiness_a0912a10-4bd3-4ae5-af95-1fa9f3dba09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dad6f4a3-c4a4-4815-a0d1-4c03f7c6c583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_SharesOutstanding_dad6f4a3-c4a4-4815-a0d1-4c03f7c6c583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f4f474d2-fa3b-4406-821a-b4b84f5c4737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1e2acbab-fb7b-4bf0-835c-a9e6c3a4062b" xlink:to="loc_us-gaap_StockholdersEquity_f4f474d2-fa3b-4406-821a-b4b84f5c4737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="agio-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0638a8f4-340d-40d4-9d89-e02ca6095c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_NetIncomeLoss_0638a8f4-340d-40d4-9d89-e02ca6095c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_08b77826-bce6-407d-ad09-3b18aea6aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_08b77826-bce6-407d-ad09-3b18aea6aba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_6f0b1672-bef7-49a2-8783-d64a8d527c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_6f0b1672-bef7-49a2-8783-d64a8d527c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_87104e52-3aca-41e5-a5b8-a724e2c87d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_87104e52-3aca-41e5-a5b8-a724e2c87d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1779329f-0a39-458d-a351-1c5b1202ac27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:to="loc_us-gaap_ShareBasedCompensation_1779329f-0a39-458d-a351-1c5b1202ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4e9011fe-d34b-4e45-b2f9-396660d67091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4e9011fe-d34b-4e45-b2f9-396660d67091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4a43b228-1876-4d5b-80a5-38dbb3d93165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4a43b228-1876-4d5b-80a5-38dbb3d93165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a64bd7eb-dd4c-4133-8a7f-ce0dc558ab12" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_df909bd7-571f-4f91-9002-c5b284b47643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_df909bd7-571f-4f91-9002-c5b284b47643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e2d1b886-2f98-4e3e-b00f-dad9db7f40af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e2d1b886-2f98-4e3e-b00f-dad9db7f40af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e135f598-4b04-4ea3-a425-000d95bf663e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e135f598-4b04-4ea3-a425-000d95bf663e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b08d0249-8042-4ca5-8b74-71eb1ac71324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b08d0249-8042-4ca5-8b74-71eb1ac71324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_220bfbcc-ddd4-45db-82e9-b739e7fe3ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_220bfbcc-ddd4-45db-82e9-b739e7fe3ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c8a81ef7-6044-4952-b62c-8e719001dfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c8a81ef7-6044-4952-b62c-8e719001dfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_847a1c7c-a1d2-47e0-a9ab-22d2400a1750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_847a1c7c-a1d2-47e0-a9ab-22d2400a1750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7212f88e-6b55-4a91-adfa-d8021af92424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0068483d-3f87-41fd-99a3-bbefa2a31138" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7212f88e-6b55-4a91-adfa-d8021af92424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7acf0cab-1208-49d0-9f98-3043c9b6c071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7acf0cab-1208-49d0-9f98-3043c9b6c071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_283b39dc-9cfe-4128-87f4-c356a5f3e0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_283b39dc-9cfe-4128-87f4-c356a5f3e0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_769f2e25-f9f8-4b6e-8383-6485ccf8ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d9c2d4e-e1c4-498b-bd19-c8aaf152abf1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_769f2e25-f9f8-4b6e-8383-6485ccf8ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f4df06dd-31cd-403c-91b1-47018d6be9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f4df06dd-31cd-403c-91b1-47018d6be9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dfdf4d07-aefd-42fc-b45e-91b8e842c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dfdf4d07-aefd-42fc-b45e-91b8e842c00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7db62e27-6b53-4e3b-8bee-2aba70fc1d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7db62e27-6b53-4e3b-8bee-2aba70fc1d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_ca000630-87b8-46bf-90d2-a13a58114b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_ca000630-87b8-46bf-90d2-a13a58114b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_ae2f7dd7-0265-4733-8c2b-b1498408e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_ae2f7dd7-0265-4733-8c2b-b1498408e6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2b36003-623d-4abc-b509-8f19c8a7cff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9147cd08-50cf-409f-9eff-165521f1928f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2b36003-623d-4abc-b509-8f19c8a7cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_8df72e14-c70a-49b5-97c4-4986d3efa789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_8df72e14-c70a-49b5-97c4-4986d3efa789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_647b5c1b-bb63-47ba-90b3-1ad42ce02244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_647b5c1b-bb63-47ba-90b3-1ad42ce02244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_89c95f35-68b1-427c-bfa9-2ce7fc0d142d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_89c95f35-68b1-427c-bfa9-2ce7fc0d142d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_b8089616-d7f5-44dd-8fc3-15cdea0533b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_b8089616-d7f5-44dd-8fc3-15cdea0533b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_90bfeee5-9bad-435a-addc-7636c1a74c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_4d5d2195-eb65-43ba-8cec-d124cfb9cfb2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_90bfeee5-9bad-435a-addc-7636c1a74c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5080368-cf88-47fb-9649-02cbdcc9e587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5080368-cf88-47fb-9649-02cbdcc9e587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7d8a06a-bfee-47e4-8eb6-7996c2bd5d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7d8a06a-bfee-47e4-8eb6-7996c2bd5d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b620364d-498f-4624-b034-0a2f8174b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b620364d-498f-4624-b034-0a2f8174b9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1c0a8304-87b1-4f48-9608-4605a201b079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e53d3e1-0bde-42c0-a1fb-84226f07cc8a" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1c0a8304-87b1-4f48-9608-4605a201b079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ae63ed08-97c5-4f51-b8a3-2e508d6bf21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1c0a8304-87b1-4f48-9608-4605a201b079" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ae63ed08-97c5-4f51-b8a3-2e508d6bf21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_77d5a60a-c878-459c-9657-2dcfff761ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1c0a8304-87b1-4f48-9608-4605a201b079" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_77d5a60a-c878-459c-9657-2dcfff761ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20220331.xsd#OverviewandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5af0cc86-6b81-479a-b704-a2e222d22bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ca7f9e37-3f10-4306-8188-f6fda27bfc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5af0cc86-6b81-479a-b704-a2e222d22bf5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ca7f9e37-3f10-4306-8188-f6fda27bfc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#OverviewandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1c2c849-3580-484a-9a66-ba11e09fe69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1c2c849-3580-484a-9a66-ba11e09fe69b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_07c574c3-fa63-42d0-a095-e4c366c27e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_94283119-0f88-4e64-8438-b89e2a6ba46e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_07c574c3-fa63-42d0-a095-e4c366c27e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f990ffa7-ec52-4271-a493-4b6563237a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_07c574c3-fa63-42d0-a095-e4c366c27e4e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f990ffa7-ec52-4271-a493-4b6563237a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54fd1773-3c47-4ef9-8313-f647f67f12da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71939df9-1460-495b-ac86-f2d583d10fca" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54fd1773-3c47-4ef9-8313-f647f67f12da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_838262b1-c437-4584-952f-b1a20b877c6e" xlink:href="agio-20220331.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_54fd1773-3c47-4ef9-8313-f647f67f12da" xlink:to="loc_agio_AgiosOncologyBusinessMember_838262b1-c437-4584-952f-b1a20b877c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7d24719a-7802-4314-82d3-72391de6464e" xlink:to="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TIBSOVOMember_79d77379-04fa-4169-a76e-d3082f7d69ef" xlink:href="agio-20220331.xsd#agio_TIBSOVOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:to="loc_agio_TIBSOVOMember_79d77379-04fa-4169-a76e-d3082f7d69ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_VorasidenibMember_b9bf7df7-2570-4c03-91d1-e154ab12264c" xlink:href="agio-20220331.xsd#agio_VorasidenibMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f9c8d208-f4bf-4b8f-9944-c263a44507a9" xlink:to="loc_agio_VorasidenibMember_b9bf7df7-2570-4c03-91d1-e154ab12264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2ea97eed-6259-477d-8c3f-9c4d81f0d21c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8e465cf2-a1d2-4da0-85cc-a34f5675dc37" xlink:to="loc_srt_SegmentGeographicalDomain_2ea97eed-6259-477d-8c3f-9c4d81f0d21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c7185a57-0c92-4dee-b530-cd2d0463fa01" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2ea97eed-6259-477d-8c3f-9c4d81f0d21c" xlink:to="loc_country_US_c7185a57-0c92-4dee-b530-cd2d0463fa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfcea4ba-0cad-43ec-8cb8-15d6ecafcbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_baa01126-b043-4d73-9a32-944a6d82e327" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfcea4ba-0cad-43ec-8cb8-15d6ecafcbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_e5983c29-d572-4abc-aa6e-1cf0bd08a26a" xlink:href="agio-20220331.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfcea4ba-0cad-43ec-8cb8-15d6ecafcbe7" xlink:to="loc_agio_Agreement2010Member_e5983c29-d572-4abc-aa6e-1cf0bd08a26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f267a48b-6b8f-4cc2-8102-d95f79f22e1a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_c0b99d3a-cbc9-461d-8eeb-590979479d0d" xlink:href="agio-20220331.xsd#agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:to="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_c0b99d3a-cbc9-461d-8eeb-590979479d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_58573417-8a34-4c63-a1b6-eb9916ab6c55" xlink:href="agio-20220331.xsd#agio_March252021RepurchaseProgramRule10b51RepurchaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:to="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_58573417-8a34-4c63-a1b6-eb9916ab6c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RepurchaseProgramMember_f140b1b1-0cf0-48fd-8967-aece991b5bb9" xlink:href="agio-20220331.xsd#agio_RepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f67c955-7c6f-4cde-a299-1d19b9940c3f" xlink:to="loc_agio_RepurchaseProgramMember_f140b1b1-0cf0-48fd-8967-aece991b5bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_425da599-33a7-4498-ada2-d453779d519e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_18c71007-6fa4-4608-8c7b-654ab9a67957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_18c71007-6fa4-4608-8c7b-654ab9a67957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_f8d9d40c-9844-4105-8daf-0ec7381c3f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_f8d9d40c-9844-4105-8daf-0ec7381c3f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_8b358af3-08ce-4411-9a05-adbadf0a08f1" xlink:href="agio-20220331.xsd#agio_GainContingencyRoyaltyPercentageOfNetSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_8b358af3-08ce-4411-9a05-adbadf0a08f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_5a28a6ff-0463-4e15-a0f1-45e600c0062d" xlink:href="agio-20220331.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_5a28a6ff-0463-4e15-a0f1-45e600c0062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_f0136caa-0eb0-47e9-8af6-78073c8f2c00" xlink:href="agio-20220331.xsd#agio_ContingentGainOnDispositionOfBusinessRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_f0136caa-0eb0-47e9-8af6-78073c8f2c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d9f1bba-0e7d-4084-87c7-2e009b725613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d9f1bba-0e7d-4084-87c7-2e009b725613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_54f262d6-0000-4796-ab3e-d8fc35f10b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_54f262d6-0000-4796-ab3e-d8fc35f10b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6d0fe075-06c3-4798-bb3f-5a98e15b1fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6d0fe075-06c3-4798-bb3f-5a98e15b1fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_cc78d85c-9990-4e6a-8b0f-64fc8406d152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_cc78d85c-9990-4e6a-8b0f-64fc8406d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f1750fc4-411e-427a-b86a-2fb07b963a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9dd43d04-dbfc-4a4e-a747-5238e73ca113" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f1750fc4-411e-427a-b86a-2fb07b963a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ab44ded-e0ab-4415-93a2-c0a3f7935b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bb0b3410-5130-4b8b-8857-07254ca3cade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ab44ded-e0ab-4415-93a2-c0a3f7935b34" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bb0b3410-5130-4b8b-8857-07254ca3cade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eed64bd6-10bd-4ad3-a700-40c45fa7ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eed64bd6-10bd-4ad3-a700-40c45fa7ef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4dcc7c54-567c-4266-8c84-9dc4d84c63ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4dcc7c54-567c-4266-8c84-9dc4d84c63ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_964c4e94-d5cb-441d-885d-0b4a040602fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_UseOfEstimates_964c4e94-d5cb-441d-885d-0b4a040602fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_19ac00b4-b37c-4123-9318-a9381fae102b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_19ac00b4-b37c-4123-9318-a9381fae102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_f5a2fd51-5c8f-49d3-aea8-97ffd183fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_f5a2fd51-5c8f-49d3-aea8-97ffd183fd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9c8b6c77-d473-4a42-9502-0927146645ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9c8b6c77-d473-4a42-9502-0927146645ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_2de0929c-e5b9-400d-b8a6-0f61461dba9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_2de0929c-e5b9-400d-b8a6-0f61461dba9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5bc79fb1-3ad9-4dff-954e-21c88ae8d22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5bc79fb1-3ad9-4dff-954e-21c88ae8d22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1f8d8590-a736-4f57-80d5-e5a80f9b62b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1f8d8590-a736-4f57-80d5-e5a80f9b62b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_208e8420-97b7-40da-a7b4-c475ee0d4354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_208e8420-97b7-40da-a7b4-c475ee0d4354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0badd440-190e-4266-b934-24d09a35b7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f94cf34-3445-4e94-bb61-82b1b9881e02" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0badd440-190e-4266-b934-24d09a35b7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_572d6518-3633-4976-8273-16e69b65e5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_508e83d2-b019-4994-9627-2860eb0bceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_572d6518-3633-4976-8273-16e69b65e5be" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_508e83d2-b019-4994-9627-2860eb0bceb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0a675067-bf3b-4240-92f3-101f894cd2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f5c37c79-505f-45fc-8bdf-e387d1551b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0a675067-bf3b-4240-92f3-101f894cd2fe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f5c37c79-505f-45fc-8bdf-e387d1551b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1fa5a76b-65fc-45ea-aa59-dbcdde1d95c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1fa5a76b-65fc-45ea-aa59-dbcdde1d95c9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b12bcbba-a300-477d-a0e8-e236b1d12f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dae41570-87d7-4c2e-a2d0-41cf1d1e7c48" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b12bcbba-a300-477d-a0e8-e236b1d12f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3e4df45d-9dfd-4a2e-a44e-0a9f1ab077f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b12bcbba-a300-477d-a0e8-e236b1d12f25" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3e4df45d-9dfd-4a2e-a44e-0a9f1ab077f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5578d392-3378-4d3d-b38f-6857401221ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd05875f-f6a9-41af-be6a-9a1478745aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd05875f-f6a9-41af-be6a-9a1478745aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_96482db5-cb7a-4b43-9133-f454bf229ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_96482db5-cb7a-4b43-9133-f454bf229ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a43d2975-600d-484c-9ec1-62b1d093d1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f572ed87-39ba-4b58-9fc1-1a19ab9e3f58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a43d2975-600d-484c-9ec1-62b1d093d1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3077a6f9-6d36-45f9-a485-4cd479c62ae9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_18cd71c1-9a81-4280-a1df-3c071dd9f7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_CashEquivalentsMember_18cd71c1-9a81-4280-a1df-3c071dd9f7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_3b8efe09-d401-40a1-a5a0-17f07c3dca12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_3b8efe09-d401-40a1-a5a0-17f07c3dca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b2c5d04-8784-4420-911f-156090be7dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b2c5d04-8784-4420-911f-156090be7dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ba3ff8e-a1a4-45ea-9865-0ca3173941f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a3d7e7ee-db9b-4cc0-b4b1-469cfed504d9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ba3ff8e-a1a4-45ea-9865-0ca3173941f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cc853487-c681-4994-9f29-f004cf442169" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d34af212-ec6b-4213-892e-f155f05c9967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d34af212-ec6b-4213-892e-f155f05c9967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8958a4ee-1b01-4513-8c37-e6f3e4291b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8958a4ee-1b01-4513-8c37-e6f3e4291b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_217af0e4-cba9-42df-bfa6-3cd6ceff14af" xlink:href="agio-20220331.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_752df952-206d-4075-9c6a-21ffb974d52d" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_217af0e4-cba9-42df-bfa6-3cd6ceff14af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7de0b6a4-b984-4c65-8429-0e013753d401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7de0b6a4-b984-4c65-8429-0e013753d401" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ed6bfa0-d78e-44fe-b189-464790b4874c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1934b7f4-3841-4fa8-bac9-48bf052053d5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ed6bfa0-d78e-44fe-b189-464790b4874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cd10ef1b-423e-4723-b87f-4eeb4f0629dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ed6bfa0-d78e-44fe-b189-464790b4874c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cd10ef1b-423e-4723-b87f-4eeb4f0629dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2acdd51c-40f7-4b21-a0fb-377735428a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0f1064e8-d8f6-40db-acbf-7fccf3de0f1d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2acdd51c-40f7-4b21-a0fb-377735428a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8c7e26e6-0f58-49f9-933e-e0ae0624c095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2acdd51c-40f7-4b21-a0fb-377735428a35" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8c7e26e6-0f58-49f9-933e-e0ae0624c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91642325-f821-4a59-910a-b7f84aba4890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e52742f9-3cdf-418f-8c4f-cbcb348c9abe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91642325-f821-4a59-910a-b7f84aba4890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_9c127d2e-993f-46d2-bb21-800c3031327f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91642325-f821-4a59-910a-b7f84aba4890" xlink:to="loc_us-gaap_FairValueNetAssetLiability_9c127d2e-993f-46d2-bb21-800c3031327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20220331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_011b6958-bb34-4e69-9626-badc8f426646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_68bb4ff2-5e0f-47cf-bcf9-6ae0ace34026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_011b6958-bb34-4e69-9626-badc8f426646" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_68bb4ff2-5e0f-47cf-bcf9-6ae0ace34026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20220331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01db45b0-3f4f-4a55-b3c5-15bd200ffd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d4382db4-f314-49e2-8e14-887fbf448364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01db45b0-3f4f-4a55-b3c5-15bd200ffd34" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d4382db4-f314-49e2-8e14-887fbf448364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c5ab488-b432-4d82-97db-435f470d5e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_2a51531d-4e7b-4558-b927-dfe1b9efe190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c5ab488-b432-4d82-97db-435f470d5e22" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_2a51531d-4e7b-4558-b927-dfe1b9efe190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_d328a672-a7c2-456b-ac26-8864a00a3b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c5ab488-b432-4d82-97db-435f470d5e22" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_d328a672-a7c2-456b-ac26-8864a00a3b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cf750ff4-4b49-430b-a239-25d29ea76ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c5ab488-b432-4d82-97db-435f470d5e22" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cf750ff4-4b49-430b-a239-25d29ea76ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_91ba6e0a-66f6-4772-af36-6aec171fca30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c5ab488-b432-4d82-97db-435f470d5e22" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_91ba6e0a-66f6-4772-af36-6aec171fca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dfe56e7b-6da6-4a19-a285-4a7e8195e482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c5ab488-b432-4d82-97db-435f470d5e22" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dfe56e7b-6da6-4a19-a285-4a7e8195e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a39bccd4-8a76-4f70-bec5-29682bdaf094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a39bccd4-8a76-4f70-bec5-29682bdaf094" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_85aabfc4-8d67-4e65-b66c-599e6c7f624e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_921cb8de-d0c2-4568-a9c8-a82ef95b564e" xlink:href="agio-20220331.xsd#agio_CurrentAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:to="loc_agio_CurrentAssetMember_921cb8de-d0c2-4568-a9c8-a82ef95b564e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_3452b56d-90cd-4b2d-9147-f84aaafc4157" xlink:href="agio-20220331.xsd#agio_NonCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b0d00cf2-a000-4b15-bc48-37d310de7ec1" xlink:to="loc_agio_NonCurrentAssetsMember_3452b56d-90cd-4b2d-9147-f84aaafc4157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9d162bdb-625e-479e-b52b-347d254ff624" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f7228a28-1d5f-466b-b2ba-b4c7021a07c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f7228a28-1d5f-466b-b2ba-b4c7021a07c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95d81bb7-00d2-4af2-81f3-dfb964249da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_95d81bb7-00d2-4af2-81f3-dfb964249da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_64dd54db-e279-4bcf-b78b-26b5b7e5ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_172e78e3-832f-4b1f-8f24-a001d6df8abd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_64dd54db-e279-4bcf-b78b-26b5b7e5ee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a4a7b94-b39a-4c23-8ea7-142561ae321a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe1738ce-6f44-4e8f-946b-b72aae583358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe1738ce-6f44-4e8f-946b-b72aae583358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d0f9d16-9288-44d9-9d8c-de00412701f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d0f9d16-9288-44d9-9d8c-de00412701f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f658c7e3-0450-4327-94bc-e30df73f827d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f658c7e3-0450-4327-94bc-e30df73f827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d132f68-2f1d-4c75-b475-3fd75f1c7be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2da0197-1ed7-4fce-933f-11aeb465e341" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d132f68-2f1d-4c75-b475-3fd75f1c7be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20220331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b9040253-fb94-4841-a2ca-7c532abea255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_09729e48-96c5-474c-afb2-0b6f0b57fca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b9040253-fb94-4841-a2ca-7c532abea255" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_09729e48-96c5-474c-afb2-0b6f0b57fca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20220331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_59e6f50c-06c7-4a19-ac55-322c3ff77482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ef113d40-9c7c-4fd6-9e45-4b20fe1d7042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_59e6f50c-06c7-4a19-ac55-322c3ff77482" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ef113d40-9c7c-4fd6-9e45-4b20fe1d7042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#InventoryScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_237d2571-b658-4f1e-a8d3-6376ae7e927e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2f5e0e69-4029-426f-9f9b-5a0fd457ca50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_237d2571-b658-4f1e-a8d3-6376ae7e927e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2f5e0e69-4029-426f-9f9b-5a0fd457ca50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8f6c66d2-a421-44c8-bf53-b4422c7463cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_237d2571-b658-4f1e-a8d3-6376ae7e927e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8f6c66d2-a421-44c8-bf53-b4422c7463cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c078b96c-8c00-42af-93d4-6823f605cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_237d2571-b658-4f1e-a8d3-6376ae7e927e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c078b96c-8c00-42af-93d4-6823f605cf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_58859092-7f59-4927-a43a-93b0e72b1cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_237d2571-b658-4f1e-a8d3-6376ae7e927e" xlink:to="loc_us-gaap_InventoryNet_58859092-7f59-4927-a43a-93b0e72b1cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://agios.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2bcf6368-bc75-4dd5-ac2e-aa4ea486f661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a325c250-e7b7-4698-9030-bbb153694dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bcf6368-bc75-4dd5-ac2e-aa4ea486f661" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a325c250-e7b7-4698-9030-bbb153694dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_89ed7ee6-5132-4abb-8702-26f941d200de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_48281452-ecd1-41e0-aec9-36b3ff5966e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_89ed7ee6-5132-4abb-8702-26f941d200de" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_48281452-ecd1-41e0-aec9-36b3ff5966e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b55c8cc0-bf20-464b-9c07-aab300c53869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_89ed7ee6-5132-4abb-8702-26f941d200de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b55c8cc0-bf20-464b-9c07-aab300c53869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_c45a2439-1532-4b62-86da-88a5e80e6b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_89ed7ee6-5132-4abb-8702-26f941d200de" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_c45a2439-1532-4b62-86da-88a5e80e6b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_46dc66e2-4ff6-4777-b5ab-6595e2e4a0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_46dc66e2-4ff6-4777-b5ab-6595e2e4a0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a222b432-c2b2-4977-a496-ff19c531473e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a222b432-c2b2-4977-a496-ff19c531473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2386f0b4-381a-48e7-ab6b-d01aca82ceac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2386f0b4-381a-48e7-ab6b-d01aca82ceac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f3c4e6cf-830d-40ae-9b8c-5e54c901a123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f3c4e6cf-830d-40ae-9b8c-5e54c901a123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_07252cd5-83fa-47b9-8ced-f0948186540f" xlink:href="agio-20220331.xsd#agio_LesseeOperatingSubleaseAreaOfPremisesSubleased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:to="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_07252cd5-83fa-47b9-8ced-f0948186540f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_fe442b4d-43cb-4963-b0fc-eef2eb8ae38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3c210d1-7da3-4531-a2cd-fb15dab79304" xlink:to="loc_us-gaap_SubleaseIncome_fe442b4d-43cb-4963-b0fc-eef2eb8ae38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesScheduleofLeaseExpenseandOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_df5fe856-5280-44e2-9007-79f54fc56eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_178658b6-6713-42cd-9230-d46ec69fe22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df5fe856-5280-44e2-9007-79f54fc56eee" xlink:to="loc_us-gaap_OperatingLeaseCost_178658b6-6713-42cd-9230-d46ec69fe22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_115ccb89-95e9-4d56-ae46-70ef63238960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df5fe856-5280-44e2-9007-79f54fc56eee" xlink:to="loc_us-gaap_OperatingLeasePayments_115ccb89-95e9-4d56-ae46-70ef63238960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8af8972c-53f7-48f1-8337-0d95459ae09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8af8972c-53f7-48f1-8337-0d95459ae09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cbccd56d-f4a0-4e63-8fcd-2c62a33b3b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cbccd56d-f4a0-4e63-8fcd-2c62a33b3b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6660778d-4e38-4a12-b145-76fc931412ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6660778d-4e38-4a12-b145-76fc931412ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2601e264-a1de-4ec3-adba-cddb0838764d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2601e264-a1de-4ec3-adba-cddb0838764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_57e6f18e-3174-4ba0-9d4e-1a50b390a759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_57e6f18e-3174-4ba0-9d4e-1a50b390a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fd8c3185-6d66-46e3-a595-71c1010f485d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fd8c3185-6d66-46e3-a595-71c1010f485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f4f9fd2-82ea-43e5-9a46-e99fca10c75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f4f9fd2-82ea-43e5-9a46-e99fca10c75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64e8b31e-9929-4896-9398-015711ec4f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64e8b31e-9929-4896-9398-015711ec4f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dfca8d8e-5511-4978-892e-3398ba8a4702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dfca8d8e-5511-4978-892e-3398ba8a4702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_52280938-63c5-4751-b9e3-7a62843a9fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67d30d5c-2e9e-45c2-9449-746022064d81" xlink:to="loc_us-gaap_OperatingLeaseLiability_52280938-63c5-4751-b9e3-7a62843a9fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LeasesFutureMinimumLeasePaymentstobeReceivedDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d9c6c81c-9537-4fe8-9f3f-1de09cc9e03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_e1d634ef-11df-4cba-b47d-45346f9344f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d9c6c81c-9537-4fe8-9f3f-1de09cc9e03c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_e1d634ef-11df-4cba-b47d-45346f9344f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_021c6dc2-6fed-46d9-8dec-9ddc6d785292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d9c6c81c-9537-4fe8-9f3f-1de09cc9e03c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_021c6dc2-6fed-46d9-8dec-9ddc6d785292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_bdbf6cf4-7322-401e-9244-2552420b70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d9c6c81c-9537-4fe8-9f3f-1de09cc9e03c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_bdbf6cf4-7322-401e-9244-2552420b70b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_120ac20a-1ec4-42a8-822f-df15948016a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d9c6c81c-9537-4fe8-9f3f-1de09cc9e03c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_120ac20a-1ec4-42a8-822f-df15948016a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20220331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_420dbfc9-6342-45c2-9a70-4cc59ba11375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_97268e4c-4f2e-4322-8d32-57ecea2d44ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_420dbfc9-6342-45c2-9a70-4cc59ba11375" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_97268e4c-4f2e-4322-8d32-57ecea2d44ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20220331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_cea5cd5e-c63a-4a00-b163-f4aea56030c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ada4eca4-cc37-49ca-b59c-27947bad6842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cea5cd5e-c63a-4a00-b163-f4aea56030c9" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ada4eca4-cc37-49ca-b59c-27947bad6842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d3063a4f-0d53-4aaa-b857-351da3904da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b16430a3-5113-48fe-8894-68c4e3f92eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3063a4f-0d53-4aaa-b857-351da3904da9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b16430a3-5113-48fe-8894-68c4e3f92eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_a6d1e1c7-6c0f-4076-b56a-a40466e626b9" xlink:href="agio-20220331.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3063a4f-0d53-4aaa-b857-351da3904da9" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_a6d1e1c7-6c0f-4076-b56a-a40466e626b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_66280da6-22b9-4cf8-8298-4d8960b7a430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3063a4f-0d53-4aaa-b857-351da3904da9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_66280da6-22b9-4cf8-8298-4d8960b7a430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8ffc1c85-d016-45e8-b28c-ebce69d7a757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3063a4f-0d53-4aaa-b857-351da3904da9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8ffc1c85-d016-45e8-b28c-ebce69d7a757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c42ea1ad-1489-4642-bc69-9199d721d6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3063a4f-0d53-4aaa-b857-351da3904da9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c42ea1ad-1489-4642-bc69-9199d721d6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenue"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c46dbb1-8322-4694-a58e-d36f3382e538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_f1358ce4-a762-4259-a1ee-ec255653c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c46dbb1-8322-4694-a58e-d36f3382e538" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_f1358ce4-a762-4259-a1ee-ec255653c8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2e51602-1f40-4996-a9a7-affe66bf5598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1350e77a-e8c9-4c5a-95ce-e4d32b735734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2e51602-1f40-4996-a9a7-affe66bf5598" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1350e77a-e8c9-4c5a-95ce-e4d32b735734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_58c36a66-c56b-4d3d-94c8-93c2868e5c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2e51602-1f40-4996-a9a7-affe66bf5598" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_58c36a66-c56b-4d3d-94c8-93c2868e5c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_a7f5666f-b5ea-4097-bc31-7317a91a7bda" xlink:href="agio-20220331.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2e51602-1f40-4996-a9a7-affe66bf5598" xlink:to="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_a7f5666f-b5ea-4097-bc31-7317a91a7bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_2b3a932c-6c3b-48e7-8daa-68f55dd6ac8b" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2e51602-1f40-4996-a9a7-affe66bf5598" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_2b3a932c-6c3b-48e7-8daa-68f55dd6ac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ff2c8b2e-6272-46b0-a143-a2b0c6a1711a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ff2c8b2e-6272-46b0-a143-a2b0c6a1711a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:to="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e7c4655-d6b3-4ebf-bd92-3b6c635c5d4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ebd76e48-8c20-431e-90a9-cd09e2e4ccfd" xlink:to="loc_srt_ProductsAndServicesDomain_1e7c4655-d6b3-4ebf-bd92-3b6c635c5d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4081e341-25de-4178-ba13-5491d5c6e2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1e7c4655-d6b3-4ebf-bd92-3b6c635c5d4b" xlink:to="loc_us-gaap_ProductMember_4081e341-25de-4178-ba13-5491d5c6e2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_60d6fee2-fa0f-4f94-8154-52557d4fa3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9916f60c-5ba0-48c7-8b22-f9a4364b47ae" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_60d6fee2-fa0f-4f94-8154-52557d4fa3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f31508-45f1-46d1-8931-d0b4c2abd5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_60d6fee2-fa0f-4f94-8154-52557d4fa3ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66f31508-45f1-46d1-8931-d0b4c2abd5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b6075868-9ef7-413d-9a2d-09441ac9d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:href="agio-20220331.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b6075868-9ef7-413d-9a2d-09441ac9d5b7" xlink:to="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_94cd7c12-40b3-47a2-9b95-92bdaffa5950" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_94cd7c12-40b3-47a2-9b95-92bdaffa5950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_3aa2faef-eb5d-47e9-856e-a1e55e0ada7f" xlink:href="agio-20220331.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_3aa2faef-eb5d-47e9-856e-a1e55e0ada7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_bdfac95e-acaa-44ba-917d-9009eef7cd35" xlink:href="agio-20220331.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_bdfac95e-acaa-44ba-917d-9009eef7cd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_3e28ee63-d0ed-432e-8df1-0da6fcb90b82" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_3e28ee63-d0ed-432e-8df1-0da6fcb90b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_7071f502-8a1e-4997-b477-204016059b3d" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_7071f502-8a1e-4997-b477-204016059b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_5fd76c9a-cdc5-4ddd-846d-22a601de8b23" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_a2f18850-539b-4dc7-b386-0f93ab874024" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_5fd76c9a-cdc5-4ddd-846d-22a601de8b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:href="agio-20220331.xsd#agio_GovernmentRebatesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b6075868-9ef7-413d-9a2d-09441ac9d5b7" xlink:to="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_01cc83b5-364d-4592-8b91-6121e725f603" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:to="loc_agio_ContractWithCustomerRebateReserve_01cc83b5-364d-4592-8b91-6121e725f603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_dd45ac72-59eb-4a72-aa72-da3ef38c5ac6" xlink:href="agio-20220331.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_dd45ac72-59eb-4a72-aa72-da3ef38c5ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_a775ef05-99c0-4956-9bc3-b2f16dd1a27b" xlink:href="agio-20220331.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_a775ef05-99c0-4956-9bc3-b2f16dd1a27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_bf6dac37-113a-4a00-ac96-10477545a75a" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_bf6dac37-113a-4a00-ac96-10477545a75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_22179f37-88b9-430c-bf7e-faddc1e179d9" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_22179f37-88b9-430c-bf7e-faddc1e179d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_39c252a2-0e6f-4190-8795-f7e5c7bf4125" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_8cf1428e-6f29-4253-aa6f-d005756ca43c" xlink:to="loc_agio_ContractWithCustomerRebateReserve_39c252a2-0e6f-4190-8795-f7e5c7bf4125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:href="agio-20220331.xsd#agio_ProductReturnsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b6075868-9ef7-413d-9a2d-09441ac9d5b7" xlink:to="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_bee89324-527a-4773-a80d-a3a96d72e592" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_bee89324-527a-4773-a80d-a3a96d72e592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_c7a5d5ff-b995-4205-9c7f-8b3045373034" xlink:href="agio-20220331.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_c7a5d5ff-b995-4205-9c7f-8b3045373034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_17b201cb-5530-4972-8c0c-2ee63b44c3a8" xlink:href="agio-20220331.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_17b201cb-5530-4972-8c0c-2ee63b44c3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_6528924a-e037-4d05-b3c5-3282024526bb" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_6528924a-e037-4d05-b3c5-3282024526bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_7f0695a8-31de-4c3f-894b-67170a697858" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_7f0695a8-31de-4c3f-894b-67170a697858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_6cb2010a-1aa6-4dc4-a531-f6a67cd27dcf" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_22c21797-81cb-43ae-a68b-8ffd8d7e102e" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_6cb2010a-1aa6-4dc4-a531-f6a67cd27dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b6075868-9ef7-413d-9a2d-09441ac9d5b7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_3872843e-e5a3-4523-a3f6-c1e0675990ed" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_3872843e-e5a3-4523-a3f6-c1e0675990ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_f5283860-3682-4998-a0f5-8d8b62cc8be3" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_f5283860-3682-4998-a0f5-8d8b62cc8be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_a5011c39-e740-428e-9dbc-f35def14bcb5" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_a5011c39-e740-428e-9dbc-f35def14bcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_2eb0c029-dd50-4e37-9fcb-29894c00aa2d" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_2eb0c029-dd50-4e37-9fcb-29894c00aa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_c7e0d524-c11b-4314-ba78-794d13d2488a" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_497d5a2c-20be-4efa-9198-18ae923f2412" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_c7e0d524-c11b-4314-ba78-794d13d2488a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_80dc0b26-61d5-4701-83d2-5e4699a73a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_72901fe6-1d18-43d9-b741-8b38847c6190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_80dc0b26-61d5-4701-83d2-5e4699a73a36" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_72901fe6-1d18-43d9-b741-8b38847c6190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_fda2bc10-e1aa-478e-9414-a5d68af87b23" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_80dc0b26-61d5-4701-83d2-5e4699a73a36" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_fda2bc10-e1aa-478e-9414-a5d68af87b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_4fc0c3a5-d9f4-46e8-81f6-79e5f83b83e8" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_80dc0b26-61d5-4701-83d2-5e4699a73a36" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_4fc0c3a5-d9f4-46e8-81f6-79e5f83b83e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f00d69c-ed17-47ca-a530-cb5f67e77f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_d9ecf223-5d75-4883-b2d0-dab3db870a4b" xlink:href="agio-20220331.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f00d69c-ed17-47ca-a530-cb5f67e77f40" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_d9ecf223-5d75-4883-b2d0-dab3db870a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_36e2a562-4ea7-4aa5-ac88-4b0a407d7a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_d9ecf223-5d75-4883-b2d0-dab3db870a4b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_36e2a562-4ea7-4aa5-ac88-4b0a407d7a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_69dedf4b-b45a-49ad-a31b-fbd4733acdec" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_d9ecf223-5d75-4883-b2d0-dab3db870a4b" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_69dedf4b-b45a-49ad-a31b-fbd4733acdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_90208b1b-7d97-47af-8b88-b42b6047e8e3" xlink:href="agio-20220331.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_d9ecf223-5d75-4883-b2d0-dab3db870a4b" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_90208b1b-7d97-47af-8b88-b42b6047e8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4b05fb57-2d74-44f6-b0e6-71cf01bfbad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_d9ecf223-5d75-4883-b2d0-dab3db870a4b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_4b05fb57-2d74-44f6-b0e6-71cf01bfbad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e587b21f-73d8-4a69-99c4-e22ef440f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_10b8be4d-0604-4d75-af69-c02a38e570bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e587b21f-73d8-4a69-99c4-e22ef440f6e4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_10b8be4d-0604-4d75-af69-c02a38e570bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_754c8ffc-b926-4540-a58d-a332492473f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_754c8ffc-b926-4540-a58d-a332492473f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a3930d14-1d45-4729-b2ad-a924f703dbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a3930d14-1d45-4729-b2ad-a924f703dbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_e421c994-4bf0-4727-83f9-bb94ad2f7152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_e421c994-4bf0-4727-83f9-bb94ad2f7152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_9c544fe7-f687-48f3-aabe-23f3b12b0500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_9c544fe7-f687-48f3-aabe-23f3b12b0500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_96a88600-b975-45ac-b2c9-b56ec69938be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_96a88600-b975-45ac-b2c9-b56ec69938be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b60686f-b522-46f6-8ab6-f15214c919c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa106b-7f91-405e-ae3b-f514c4867ec8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b60686f-b522-46f6-8ab6-f15214c919c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_114fd0b9-a5fe-4bce-b744-b9727ac00b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_114fd0b9-a5fe-4bce-b744-b9727ac00b2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:to="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6b8fd9b8-f971-4c4b-95d8-ad870a625aa3" xlink:to="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_2a348d6f-5505-4ca6-a156-fdcfb69fcbe5" xlink:href="agio-20220331.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_2a348d6f-5505-4ca6-a156-fdcfb69fcbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_a36f7601-c31d-4ef0-b749-58a069ed8721" xlink:href="agio-20220331.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_a36f7601-c31d-4ef0-b749-58a069ed8721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_fc906992-04de-4bfb-b7ee-15431ed5cea7" xlink:href="agio-20220331.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_95c43582-f3b3-46bd-ad71-154749087575" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_fc906992-04de-4bfb-b7ee-15431ed5cea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:to="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a07dac99-edac-4b26-ab9d-6e08a5d008d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_65c6da33-3eb2-4e97-97c1-1365dbb7bd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_65c6da33-3eb2-4e97-97c1-1365dbb7bd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e25a6fa4-d88f-4ff0-9aa6-9d4707d3f4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e25a6fa4-d88f-4ff0-9aa6-9d4707d3f4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_5f67b117-7d8a-437e-add5-87e2a32cd20f" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_agio_PerformanceStockUnitMember_5f67b117-7d8a-437e-add5-87e2a32cd20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_e56fcbf8-5d5c-4790-885b-3c2033e9f910" xlink:href="agio-20220331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913c0973-a96c-4baa-9f85-0ba91cbed2f6" xlink:to="loc_agio_MarketBasedStockUnitsMember_e56fcbf8-5d5c-4790-885b-3c2033e9f910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6efd201-0818-40fe-b42d-51e0209737d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a16dddf-a529-4d8a-adbe-3441a991aba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a16dddf-a529-4d8a-adbe-3441a991aba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac2dcdf6-63ff-407a-9cdd-5b1cd59e8ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ac2dcdf6-63ff-407a-9cdd-5b1cd59e8ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d621cd40-41d5-4e4e-a1e8-47bef86b656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d621cd40-41d5-4e4e-a1e8-47bef86b656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d14fc7bf-4b52-447e-b939-0047a708b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d14fc7bf-4b52-447e-b939-0047a708b42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5c97a5ec-bc46-44ab-9a8c-8846da949f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5c97a5ec-bc46-44ab-9a8c-8846da949f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d110dd2e-2e98-4a44-a10e-a6b8f6eccda1" xlink:href="agio-20220331.xsd#agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d110dd2e-2e98-4a44-a10e-a6b8f6eccda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6be8d794-5a5a-4b4d-ad1f-7ca7d46a9010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6be8d794-5a5a-4b4d-ad1f-7ca7d46a9010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_39a447e4-6a07-436d-bcda-494fdd2a91cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79f43878-29d2-4fde-a8b9-e88b005910a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_39a447e4-6a07-436d-bcda-494fdd2a91cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69e9bb03-9486-4466-99c4-977f274bf3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69e9bb03-9486-4466-99c4-977f274bf3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3e890482-62b5-4172-9b82-176b5954c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3e890482-62b5-4172-9b82-176b5954c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a94a8486-a76f-41e7-b582-2eb1e0b147c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a94a8486-a76f-41e7-b582-2eb1e0b147c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_aae65667-bd83-4136-a42c-57cdecbce266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_aae65667-bd83-4136-a42c-57cdecbce266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8f35fe6-6c9c-43e7-98f2-f7ec41336f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7e337b-696a-4efb-b47a-d87d7c0a2302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8f35fe6-6c9c-43e7-98f2-f7ec41336f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_de9e09b6-2f56-4438-8c33-f3997a5cc81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_de9e09b6-2f56-4438-8c33-f3997a5cc81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2b7921cd-aa3d-4e6d-83ce-a3a80a175e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2b7921cd-aa3d-4e6d-83ce-a3a80a175e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d89fc7b-7306-453b-9337-a987878fcda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d89fc7b-7306-453b-9337-a987878fcda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7af9801d-ac76-44a4-9ab4-1a152c928149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7af9801d-ac76-44a4-9ab4-1a152c928149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20509165-c5e9-4846-9f8b-fb9f3829b93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20509165-c5e9-4846-9f8b-fb9f3829b93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a5a13318-1d56-4e5c-9759-e41f0436cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a5a13318-1d56-4e5c-9759-e41f0436cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee105625-16b2-4d30-abdd-13cc9c9b037a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fbc0c68-013c-41a3-a0f9-c8d0c4cfbf3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee105625-16b2-4d30-abdd-13cc9c9b037a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_87472d6f-0a61-4dd5-af96-7f64c47ef973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_87472d6f-0a61-4dd5-af96-7f64c47ef973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a42d8834-c8b7-4091-9c2a-44849dcff984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8ddb7ed-6ab1-4bb7-8067-6cef3e0c66d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a42d8834-c8b7-4091-9c2a-44849dcff984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdc0017c-5b68-4490-bfd4-d534473e7bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdc0017c-5b68-4490-bfd4-d534473e7bce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:to="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7376ed-7325-4692-8b84-71c762d80402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_433d6912-a47a-4a29-8a7a-5a1fd8f11bbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7376ed-7325-4692-8b84-71c762d80402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2af6d5c-15df-4a59-b658-2acbb7d3b3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e7376ed-7325-4692-8b84-71c762d80402" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2af6d5c-15df-4a59-b658-2acbb7d3b3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c4646e-c14d-4316-bad9-eef739368572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a66fd2b-3b61-4ea7-99ef-2eed67912bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a66fd2b-3b61-4ea7-99ef-2eed67912bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f464229b-dc48-49c6-a11c-c3a6fb27208b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f464229b-dc48-49c6-a11c-c3a6fb27208b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccfbba9e-cf6c-444c-b759-04870b920d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccfbba9e-cf6c-444c-b759-04870b920d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5da18b73-50da-441d-85f3-d7fada0f0713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5da18b73-50da-441d-85f3-d7fada0f0713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f021a279-f8c7-4015-a0f5-96afa6cb14d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_454669b1-c2f1-4abc-ae92-ce0d86b66d10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f021a279-f8c7-4015-a0f5-96afa6cb14d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c566a291-8768-4949-ba03-ace0f6db3381" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94918936-88af-405e-a78c-411ee4856efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94918936-88af-405e-a78c-411ee4856efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_086061ad-7eb7-4a04-a0c6-3667389e2c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_086061ad-7eb7-4a04-a0c6-3667389e2c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_66e261c9-1cbf-47be-a2f8-bb7f10e5001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_66e261c9-1cbf-47be-a2f8-bb7f10e5001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d83d843c-aca5-4757-9707-05e4ac7bc215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d83d843c-aca5-4757-9707-05e4ac7bc215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66f2bb5d-edef-47f1-907d-51f18d4f745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e5b3f7c8-6f60-4107-aecc-f46fb93999c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66f2bb5d-edef-47f1-907d-51f18d4f745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4587146b-5c2a-40c1-89db-21104492512c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4587146b-5c2a-40c1-89db-21104492512c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:to="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0794726a-d02b-495c-93e5-50d769bfd25b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_f6fa01db-0c97-4bdc-b62f-0d31f7b4e9ea" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:to="loc_agio_PerformanceStockUnitMember_f6fa01db-0c97-4bdc-b62f-0d31f7b4e9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_6f0351c2-d730-438c-9867-c92d4689a096" xlink:href="agio-20220331.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40e590e8-686d-4211-8d32-5f3a4211417a" xlink:to="loc_agio_MarketBasedStockUnitsMember_6f0351c2-d730-438c-9867-c92d4689a096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2b5009-1fce-4568-be15-dd97120e6608" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80c4b8be-1408-4c24-9183-f89f1f6d7e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80c4b8be-1408-4c24-9183-f89f1f6d7e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60d70813-a361-4b0b-9d88-af78fa1437e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60d70813-a361-4b0b-9d88-af78fa1437e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e631d9d-8611-4d5b-8932-6f47e2c73adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e631d9d-8611-4d5b-8932-6f47e2c73adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_eb6067e9-636e-4c5b-90e0-cce1281fb205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_eb6067e9-636e-4c5b-90e0-cce1281fb205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26c2f7d3-1bd5-4a55-a47e-9718e6737874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1f40d88e-8aa4-4579-8629-c15ec70e2564" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26c2f7d3-1bd5-4a55-a47e-9718e6737874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca615e0-9d72-4fed-9216-7aef48579aa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_340a658e-7f87-4752-98b4-5356a588e005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_340a658e-7f87-4752-98b4-5356a588e005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff086553-a5cf-451b-9086-fc2c16729d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff086553-a5cf-451b-9086-fc2c16729d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a721e14a-f86b-4165-8b5b-8a4ed7b7940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a721e14a-f86b-4165-8b5b-8a4ed7b7940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9070e221-73bf-4656-bc2f-41f6ddfb5e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9070e221-73bf-4656-bc2f-41f6ddfb5e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16102e64-b8c8-41ee-9656-8e5da9dde866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba053490-314a-40f9-bb3c-ae5bd35f6edf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16102e64-b8c8-41ee-9656-8e5da9dde866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4eaecd0-408c-4ce6-a0bd-c302bdb5f625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4eaecd0-408c-4ce6-a0bd-c302bdb5f625" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:to="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_60a8ace1-9bce-4bb3-a98f-9eb775fbf6e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7682526f-8ae2-42dc-b98a-abe570c88fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7682526f-8ae2-42dc-b98a-abe570c88fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_958c3940-f780-491b-821d-3bbc5d7fa67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_958c3940-f780-491b-821d-3bbc5d7fa67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_00d93c9a-a4c6-41eb-8810-2b2e5c37c703" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_agio_PerformanceStockUnitMember_00d93c9a-a4c6-41eb-8810-2b2e5c37c703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_6b515964-abd2-44bb-bf65-938a03f9ddc1" xlink:href="agio-20220331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_agio_EmployeePurchasePlanMember_6b515964-abd2-44bb-bf65-938a03f9ddc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember_b19f2214-bf7f-47fa-a48d-3acddefc0a16" xlink:href="agio-20220331.xsd#agio_OtherStockAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374c6424-ce57-423b-be97-b07909034cda" xlink:to="loc_agio_OtherStockAwardsMember_b19f2214-bf7f-47fa-a48d-3acddefc0a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2c27fb7-9352-4bec-95b9-e4e9a059374e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aed903a0-06c3-448e-bb1a-c923ee9f7aa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2c27fb7-9352-4bec-95b9-e4e9a059374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6081818-f6ef-42d8-948c-36b434f62dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2c27fb7-9352-4bec-95b9-e4e9a059374e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6081818-f6ef-42d8-948c-36b434f62dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4638f5a5-4237-4f12-b5e7-f26cf79914f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4638f5a5-4237-4f12-b5e7-f26cf79914f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2cd61aaf-6e56-460b-8cc4-70aba3cff1cd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e53b230d-add8-4d68-83dd-ef1887ad3480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e53b230d-add8-4d68-83dd-ef1887ad3480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e4f31350-f5ea-4afc-b197-6e00d9e91ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52cb84d4-ed0c-4993-92a7-f703f69627c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e4f31350-f5ea-4afc-b197-6e00d9e91ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c3ef22-c4cd-4a30-b822-7d574ce3dde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06a3c125-2084-4795-9ae3-e2b760d3ee51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c3ef22-c4cd-4a30-b822-7d574ce3dde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e4c361e-6d47-4117-9625-564505ff4585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c3ef22-c4cd-4a30-b822-7d574ce3dde3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e4c361e-6d47-4117-9625-564505ff4585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20220331.xsd#LossperShare"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4fb2d708-c336-48e4-8e25-483cacda8451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6c1254db-9220-4a24-80d8-d7b3ffc32166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4fb2d708-c336-48e4-8e25-483cacda8451" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6c1254db-9220-4a24-80d8-d7b3ffc32166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20220331.xsd#LossperShareTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_daa987d9-fc10-4f6d-88b4-33ec4f06f5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e5b86019-a07c-41e1-a8b9-14326e7045fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_daa987d9-fc10-4f6d-88b4-33ec4f06f5c6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e5b86019-a07c-41e1-a8b9-14326e7045fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b30f2d60-420e-4e90-845f-4ea9712138be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b30f2d60-420e-4e90-845f-4ea9712138be" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bbbe6606-527d-4a5c-8b44-0d815aa8c657" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13082be5-d97b-4549-aedf-4a6a40832e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13082be5-d97b-4549-aedf-4a6a40832e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cca4032b-4c1b-4fff-ac04-00b9e323e090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cca4032b-4c1b-4fff-ac04-00b9e323e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_0d0614b2-5e7a-4dcb-99ff-67fe8e549dde" xlink:href="agio-20220331.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_agio_PerformanceStockUnitMember_0d0614b2-5e7a-4dcb-99ff-67fe8e549dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_7fcad6df-033b-4c91-9be5-61518479f695" xlink:href="agio-20220331.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba98ca4e-43f0-441c-9209-cd8639fcac92" xlink:to="loc_agio_EmployeePurchasePlanMember_7fcad6df-033b-4c91-9be5-61518479f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06184e00-088b-418c-ba04-eb33de3c85b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b43d3872-df2b-4e52-b2b8-b2561d379313" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06184e00-088b-418c-ba04-eb33de3c85b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407519dd-6d00-4908-af95-0cf8789b3f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06184e00-088b-418c-ba04-eb33de3c85b6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407519dd-6d00-4908-af95-0cf8789b3f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxes" xlink:type="simple" xlink:href="agio-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_610d3601-9e23-4ad0-afb8-f2f8995aa5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9953fbd8-f61d-4789-bbb9-220014712b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_610d3601-9e23-4ad0-afb8-f2f8995aa5a5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9953fbd8-f61d-4789-bbb9-220014712b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20220331.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f9447874-30f6-4845-a02b-816f4f0ea331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5aa6c091-fbe8-4bda-8f8a-ee7f93db2af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9447874-30f6-4845-a02b-816f4f0ea331" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_5aa6c091-fbe8-4bda-8f8a-ee7f93db2af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0469ea34-484f-4dfe-8663-e6156cb4103b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9447874-30f6-4845-a02b-816f4f0ea331" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0469ea34-484f-4dfe-8663-e6156cb4103b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927240615416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AGIOS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0662915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">88 Sidney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-8600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,788,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242786056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 80,026<span></span>
</td>
<td class="nump">$ 203,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">843,503<span></span>
</td>
<td class="nump">816,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">5,365<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">43,226<span></span>
</td>
<td class="nump">39,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">975,145<span></span>
</td>
<td class="nump">1,064,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">255,836<span></span>
</td>
<td class="nump">266,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">72,688<span></span>
</td>
<td class="nump">75,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">29,195<span></span>
</td>
<td class="nump">28,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease assets</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,335,859<span></span>
</td>
<td class="nump">1,437,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,551<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">19,747<span></span>
</td>
<td class="nump">31,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">11,744<span></span>
</td>
<td class="nump">10,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,792<span></span>
</td>
<td class="nump">59,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">82,338<span></span>
</td>
<td class="nump">85,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, net of current portion</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">128,406<span></span>
</td>
<td class="nump">145,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 70,993,277 shares issued and 54,776,467 shares outstanding at March&#160;31, 2022, and 70,550,631 shares issued and 54,334,220 shares outstanding at December&#160;31, 2021</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,351,147<span></span>
</td>
<td class="nump">2,334,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7,745)<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost (16,216,411 shares at March&#160;31, 2022 and December&#160;31, 2021)</a></td>
<td class="num">(802,486)<span></span>
</td>
<td class="num">(802,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(333,534)<span></span>
</td>
<td class="num">(238,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,207,453<span></span>
</td>
<td class="nump">1,291,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,335,859<span></span>
</td>
<td class="nump">$ 1,437,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242802072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">70,993,277<span></span>
</td>
<td class="nump">70,550,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">54,776,467<span></span>
</td>
<td class="nump">54,334,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">16,216,411<span></span>
</td>
<td class="nump">16,216,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927244334248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">70,123<span></span>
</td>
<td class="nump">57,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">31,515<span></span>
</td>
<td class="nump">33,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">101,977<span></span>
</td>
<td class="nump">91,217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(101,145)<span></span>
</td>
<td class="num">(91,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Royalty income from gain on sale of oncology business</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="nump">2,973<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(94,774)<span></span>
</td>
<td class="num">(90,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,965,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (94,774)<span></span>
</td>
<td class="nump">$ 1,874,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss from continuing operations per share - basic (in usd per share)</a></td>
<td class="num">$ (1.74)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss from continuing operations per share - diluted (in usd per share)</a></td>
<td class="num">(1.74)<span></span>
</td>
<td class="num">(1.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Net income from discontinued operations per share - basic (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Net income from discontinued operations per share - diluted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28.26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share - basic (in usd per share)</a></td>
<td class="num">(1.74)<span></span>
</td>
<td class="nump">26.95<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share - diluted (in usd per share)</a></td>
<td class="num">$ (1.74)<span></span>
</td>
<td class="nump">$ 26.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share - basic (in shares)</a></td>
<td class="nump">54,555,467<span></span>
</td>
<td class="nump">69,543,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share - diluted (in shares)</a></td>
<td class="nump">54,555,467<span></span>
</td>
<td class="nump">69,543,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242816024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (94,774)<span></span>
</td>
<td class="nump">$ 1,874,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(6,547)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (101,321)<span></span>
</td>
<td class="nump">$ 1,874,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927241574824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,293,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 399,500<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 2,242,801<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="num">$ (1,843,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">14,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">1,874,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,874,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_StockholdersEquityDispositionOfBusiness', window );">Disposition of oncology business</a></td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,812,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">2,296,630<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">2,265,713<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">30,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,550,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,216,411,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,291,975<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">2,334,348<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
<td class="num">(238,760)<span></span>
</td>
<td class="nump">$ 802,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">442,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">15,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(6,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(94,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,993,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,216,411,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 1,207,453<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 2,351,147<span></span>
</td>
<td class="num">$ (7,745)<span></span>
</td>
<td class="num">$ (333,534)<span></span>
</td>
<td class="nump">$ 802,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_StockholdersEquityDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Disposition Of Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_StockholdersEquityDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927244377160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (94,774)<span></span>
</td>
<td class="nump">$ 1,874,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Less: Net income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,965,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(94,774)<span></span>
</td>
<td class="num">(90,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">15,510<span></span>
</td>
<td class="nump">14,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premium (accretion of discount) on marketable securities</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,436<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Accounts receivable, net</a></td>
<td class="num">(540)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,485)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(987)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="num">(3,391)<span></span>
</td>
<td class="num">(3,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(5,007)<span></span>
</td>
<td class="num">(2,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(12,220)<span></span>
</td>
<td class="num">(12,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,405)<span></span>
</td>
<td class="num">(1,504)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities - continuing operations</a></td>
<td class="num">(97,735)<span></span>
</td>
<td class="num">(90,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,523)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(97,735)<span></span>
</td>
<td class="num">(120,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(355,916)<span></span>
</td>
<td class="num">(61,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">332,147<span></span>
</td>
<td class="nump">134,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,804)<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) provided by investing activities - continuing operations</a></td>
<td class="num">(26,573)<span></span>
</td>
<td class="nump">71,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by investing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,802,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(26,573)<span></span>
</td>
<td class="nump">1,874,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on financing lease obligations</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from stock option exercises and employee stock purchase plan</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities - continuing operations</a></td>
<td class="nump">1,208<span></span>
</td>
<td class="nump">7,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash provided by financing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,208<span></span>
</td>
<td class="nump">7,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(123,100)<span></span>
</td>
<td class="nump">1,760,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">203,126<span></span>
</td>
<td class="nump">127,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">80,026<span></span>
</td>
<td class="nump">1,888,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions to property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash taxes paid</a></td>
<td class="nump">$ 1,842<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927244448328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Overview and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Overview and Basis of Presentation</a></td>
<td class="text">Overview and Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our Board of Directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for genetically defined diseases, or GDDs. We take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect, while cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for GDDs. We are located in Cambridge, Massachusetts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our GDD portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. On February 17, 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. In June 2021, we submitted a marketing authorization application, or MAA, to the European Medicines Agency, or EMA, for the treatment of adults with PK deficiency in the European Union. The MAA has passed validation, and the regulatory review process is ongoing. In addition, we are currently evaluating PYRUKYND&#174; for the treatment of thalassemia and sickle cell disease, or SCD, in clinical trials. We are also developing AG-946, a novel, next-generation PKR activator, for the potential treatment of hemolytic anemias and other indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, we foster a productive research engine and are seeking to advance multiple novel, investigational therapies in clinical and preclinical development in our focus area of GDDs, based on our scientific leadership in the field of cellular metabolism and adjacent areas of biology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, product liability claims and government investigations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of our Oncology Business to Servier</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#174; development program.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded income from royalties of approximately $2.7 million on U.S. net sales of TIBSOVO&#174; by Servier in the royalty income from gain on sale of oncology business line item within the condensed consolidated statements of operations, for the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, comprehensive (loss) income and stockholders' equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2022, our results of operations and stockholders' equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2021 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;24, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier, and received approximately $1.8&#160;billion in cash at closing. In connection with the sale, on March 25, 2021, we announced that our Board of Directors authorized the repurchase of up to $1.2&#160;billion of our outstanding shares of common stock, or the Repurchase Program, using the proceeds from the sale of our oncology business to Servier. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with Bristol-Myers Squibb Company, or BMS, to repurchase 7.1&#160;million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $344.5&#160;million, or $48.38 per share. This repurchase was completed on April 5, 2021. Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan pursuant to which we could repurchase up to $600.0&#160;million of shares of our common stock. On October 5, 2021, we terminated our Rule 10b5-1 share repurchase program and on October 13, 2021 we entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization. As of December 31, 2021 and March 31 2022, we repurchased approximately 9.1&#160;million shares of common stock for $458.0&#160;million, or $50.35 per share, under the Rule 10b5-1 repurchase plan. As of March 31, 2022, we have not repurchased any shares under the Rule 10b-18 repurchase plan. In total, as of December 31, 2021, we repurchased 16.2&#160;million shares of common stock for $802.5&#160;million, or $49.49 per share, under the Repurchase Program. We have paused our share repurchases for the foreseeable future.</span></div>As of March 31, 2022, we had cash, cash equivalents and marketable securities of $1.2 billion. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243362024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, by the FDA on February 17, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the treatment of hemolytic anemia in adults with PK deficiency in the United States, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we began to capitalize inventories of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of sales consists primarily of manufacturing costs of PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ecorded during the three months ended March 31, 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the three months ended March 31, 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243533704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value and by level on a recurring basis as of March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the three months ended March 31, 2022, and we had no financial assets or liabilities that were classified as Level 3 at any point during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243408808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive loss in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive (loss) income, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the condensed consolidated balance sheets with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three months ended March 31, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at March&#160;31, 2022 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,698)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,760)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2021 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, we held 307 and 294 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of March&#160;31, 2022 and December&#160;31, 2021 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2022 and December&#160;31, 2021 was $1,066.8 million and $950.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2022 and December&#160;31, 2021. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243587768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of PYRUKYND&#174;, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243578920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of six years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense and other information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at the operating lease liabilities as of March&#160;31, 2022 and December&#160;31, 2021, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 5.9 years and 6.2 years, respectively.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provided our landlord a standby letter of credit of $2.9 million as security for our leases. We are not required to maintain any cash collateral for the standby letter of credit.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a long-term sublease agreement for 13,000 square feet of the office space at 38 Sidney Street Cambridge, Massachusetts. The term of the lease runs until December 2024. We recorded operating sublease income of $0.4&#160;million for the three months ended March 31, 2022 in other income, net in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the future minimum lease payments to be received under the long-term sublease agreement were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243505768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243368984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue</a></td>
<td class="text">Product RevenueWe sell PYRUKYND&#174;, our wholly owned product, to the Customers. The Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, were as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets during the three months ended March 31, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927247334088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based share units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of March&#160;31, 2022, the total number of shares reserved under the 2007 Plan and the 2013 Plan was 13,027,919, and we had 6,142,929 shares available for future issuance under the 2013 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock option activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,713&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,145)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,494,909&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.81&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was approximately $44.0 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.6 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents RSU activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,156)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was approximately $43.4 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 2.1 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock units </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PSU activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.78&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $13.0 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of March&#160;31, 2022, there was no remaining unrecognized compensation expense related to MSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 48,156 and 59,401 shares of common stock during the three months ended March 31, 2022 and 2021, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 1,854,545 shares of our common stock. As of March&#160;31, 2022, we had 1,346,491 shares of common stock available for future issuance under the 2013 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243551432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text">Loss per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2022 are not considered to be common stock equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss for continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income from discontinued operations per share. Basic and diluted net loss per share was the same for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,181,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,571,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,452,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927244444744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesWe recorded no provision for income taxes for the three months ended March&#160;31, 2022 and $12.9&#160;million income tax provision for the three months ended March&#160;31, 2021. The tax provision for the three months ended March&#160;31, 2021 has been recorded within discontinued operations as it relates to the income tax impact on the sale of its oncology business to Servier. There is no income tax expense recorded in continuing operations for the three months ended March&#160;31, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242722056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, comprehensive (loss) income and stockholders' equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2022, our results of operations and stockholders' equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2021 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;24, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts receivable, net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, by the FDA on February 17, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the treatment of hemolytic anemia in adults with PK deficiency in the United States, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we began to capitalize inventories of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of sales consists primarily of manufacturing costs of PYRUKYND&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ecorded during the three months ended March 31, 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the three months ended March 31, 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive loss in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive (loss) income, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span>, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the condensed consolidated balance sheets with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2022 are not considered to be common stock equivalents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243534264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value and by level on a recurring basis as of March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927244456024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at March&#160;31, 2022 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,698)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,760)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2021 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927247253064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of PYRUKYND&#174;, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927247284936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense and Other Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense and other information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the future minimum lease payments to be received under the long-term sublease agreement were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243394504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927246260488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, were as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Product Revenue Allowance and Reserves</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock', window );">Schedule of Revenue Related Reserves</a></td>
<td class="text">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities, Product Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets during the three months ended March 31, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927240560568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock option activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,713&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,145)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,494,909&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.81&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Unvested Stock Unit Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents RSU activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,156)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Performance-Based Units</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PSU activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.78&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Market-Based Units Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,854&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243563224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Excluded from Calculation of Diluted Earnings Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,181,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,571,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,452,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927237728520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Overview and Basis of Presentation (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember', window );">BMS Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased, aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramRule10b51RepurchaseMember', window );">Rule 10b5-1 repurchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased, aggregate purchase price</a></td>
<td class="nump">$ 458.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in usd per share)</a></td>
<td class="nump">$ 50.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=agio_RepurchaseProgramMember', window );">Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased, aggregate purchase price</a></td>
<td class="nump">$ 802.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in usd per share)</a></td>
<td class="nump">$ 49.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication', window );">Milestone payment for achievement of specified ex-U.S. commercial milestone event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_TIBSOVOMember', window );">TIBSOVO | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContingentGainOnDispositionOfBusinessRecognized', window );">Earn-out revenue for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Agios Oncology Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Contingent milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Agios Oncology Business | TIBSOVO | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_GainContingencyRoyaltyPercentageOfNetSales', window );">Contingent royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Agios Oncology Business | Vorasidenib | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_GainContingencyRoyaltyPercentageOfNetSales', window );">Contingent royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContingentGainOnDispositionOfBusinessRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Gain On Disposition Of Business Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContingentGainOnDispositionOfBusinessRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GainContingencyRoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Royalty Percentage Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GainContingencyRoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramRule10b51RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramRule10b51RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=agio_RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=agio_RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_TIBSOVOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_TIBSOVOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_VorasidenibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_VorasidenibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927241284456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 1,099,339<span></span>
</td>
<td class="nump">$ 1,083,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">66,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">1,099,339,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">1,165,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">66,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">272,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">170,626,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">655,953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">8,092,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">8,092,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">8,092,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">1,099,339,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">1,157,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">272,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">170,626,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">655,953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Available For Sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927241516328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value of assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243667592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain (loss) on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of debt securities in unrealized loss position for less than one year | security</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of debt securities in unrealized loss position</a></td>
<td class="nump">$ 1,066,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities in significant unrealized loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927237367304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,107,084<span></span>
</td>
<td class="nump">$ 1,084,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7,760)<span></span>
</td>
<td class="num">(1,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,099,339<span></span>
</td>
<td class="nump">1,083,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">846,186<span></span>
</td>
<td class="nump">817,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(2,698)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">843,503<span></span>
</td>
<td class="nump">816,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current: | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">243,892<span></span>
</td>
<td class="nump">269,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">243,554<span></span>
</td>
<td class="nump">269,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current: | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,753<span></span>
</td>
<td class="nump">17,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">24,589<span></span>
</td>
<td class="nump">17,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">577,541<span></span>
</td>
<td class="nump">530,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(2,182)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">575,360<span></span>
</td>
<td class="nump">530,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">260,898<span></span>
</td>
<td class="nump">267,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5,062)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">255,836<span></span>
</td>
<td class="nump">266,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current: | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,695<span></span>
</td>
<td class="nump">40,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(489)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">29,206<span></span>
</td>
<td class="nump">40,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current: | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">149,378<span></span>
</td>
<td class="nump">148,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3,341)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">146,037<span></span>
</td>
<td class="nump">148,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">81,825<span></span>
</td>
<td class="nump">77,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 80,593<span></span>
</td>
<td class="nump">$ 77,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927246010312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242548808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased', window );">Area of premises subleased (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Area Of Premises Subleased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingSubleaseAreaOfPremisesSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242710616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Expense and Other Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242550840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining 2022</a></td>
<td class="nump">$ 11,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">18,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">18,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">19,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">20,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">20,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted minimum rental commitments</a></td>
<td class="nump">112,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="num">(18,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 94,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927240836968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments to be Received (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">Remaining 2022</a></td>
<td class="nump">$ 842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2024</a></td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total</a></td>
<td class="nump">$ 3,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242775400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 5,387<span></span>
</td>
<td class="nump">$ 19,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">8,626<span></span>
</td>
<td class="nump">5,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">3,782<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 19,747<span></span>
</td>
<td class="nump">$ 31,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927242767064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927244341928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractualAdjustmentsRollForward', window );"><strong>Contractual Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contract adjustments, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CurrentYearProvisionForContractualAdjustments', window );">Contractual adjustments, current provisions relating to sales in the current year</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PriorYearProvisionForContractualAdjustments', window );">Contractual adjustments, adjustments relating to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear', window );">Contractual adjustments, payments/returns relating to sales in the current year</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear', window );">Contractual adjustments, payments/returns relating to sales in the prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contract adjustments, ending balance</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_GovernmentRebatesRollForward', window );"><strong>Government Rebates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CurrentYearProvisionsForRebateReserve', window );">Government rebates, current provisions relating to sales in the current year</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PriorYearProvisionsForRebateReserve', window );">Government rebates, adjustments relating to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear', window );">Government rebates, payments/returns relating to sales in the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears', window );">Government rebates, payments/returns relating to sales in the prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, ending balance</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProductReturnsRollForward', window );"><strong>Returns</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInCurrentYear', window );">Returns, current provisions relating to sales in the current year</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInPriorYears', window );">Returns, adjustments relating to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries', window );">Returns, payments/returns relating to sales in the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries', window );">Returns, payments/returns relating to sales in the prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveProvisions', window );">Total allowances and reserves, current provisions relating to sales in the current year</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveProvisions', window );">Total allowances and reserves, adjustments relating to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the current year</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the prior years</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractualAdjustmentReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractualAdjustmentReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractualAdjustmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractualAdjustmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GovernmentRebatesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GovernmentRebatesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProductReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProductReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927240836680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Revenue - Schedule of Revenue-Related Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Reduction of accounts receivable</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAllowanceAndReservesLiability', window );">Component of accrued expenses</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAllowanceAndReservesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAllowanceAndReservesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927332832968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927240917656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense excluding options</a></td>
<td class="nump">$ 43,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount', window );">Unrecognized compensation cost not expected to be recognized</a></td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense excluding options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember', window );">2007 Plan and 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">13,027,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">6,142,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to options</a></td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan | Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense excluding options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">1,346,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under 2013 ESPP (in shares)</a></td>
<td class="nump">48,156<span></span>
</td>
<td class="nump">59,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Opportunity to purchase of common stock (in shares)</a></td>
<td class="nump">1,854,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927237601560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Stock&#160;Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">4,798,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">647,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(3,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/expired (in shares) | shares</a></td>
<td class="num">(168,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">5,275,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options, exercisable (in shares) | shares</a></td>
<td class="nump">3,494,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of stock options, vested and expected to vest (in shares) | shares</a></td>
<td class="nump">5,275,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 58.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">32.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">4.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/expired (in usd per share) | $ / shares</a></td>
<td class="nump">68.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">55.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">59.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 55.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927241712248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Unvested RSUs Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Stock&#160;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">1,002,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">634,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(337,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(16,156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">1,283,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 51.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">32.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">53.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">46.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927241727752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Stock&#160;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">234,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">108,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(53,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(5,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">283,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">32.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">54.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">61.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 45.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Stock&#160;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927241747224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,510<span></span>
</td>
<td class="nump">$ 14,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,201<span></span>
</td>
<td class="nump">8,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,165<span></span>
</td>
<td class="nump">6,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_EmployeePurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember', window );">Other stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_EmployeePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_EmployeePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927243668328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Expenses Related to Equity-Based Awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,510<span></span>
</td>
<td class="nump">$ 14,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,656<span></span>
</td>
<td class="nump">6,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,854<span></span>
</td>
<td class="nump">$ 7,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927237616280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">6,571,153<span></span>
</td>
<td class="nump">7,452,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">5,275,144<span></span>
</td>
<td class="nump">6,181,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">1,283,537<span></span>
</td>
<td class="nump">1,263,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember', window );">Employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents (in shares)</a></td>
<td class="nump">12,472<span></span>
</td>
<td class="nump">7,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139927247054616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for income taxes recorded in discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes recorded in continuing operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>agio-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:agio="http://agios.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="agio-20220331.xsd" xlink:type="simple"/>
    <context id="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ed2165b94a24217bfa5f7d7525c4828_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i44baacb616534e10bf3e92b51f3ca635_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c86e4fe16a543c093349fd84ce7ee87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ad81482e39040cfa13a399adf4f783f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if275c08a4b1a44d1a150f50c7c881130_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6cc362c4f604b6698f86e13bb3b5e3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cbd80b1c38d4e15abafa707e5b10913_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48e46f8b9b7c4fa794ef1e57c63f60ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia915565fa9bf49e8a6089229571dfeb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i020aaaa8244f4450abf7a489bae1b308_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cb58067c996499e8ddfaee3546da6b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia723c5f1bdd7498dab4b5253a5239e6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iedff87c239d041ee903730df5ff0e42d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idabd827068424d0c94fda806b5666e9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib098b853fd0d4618a37120ad076e9c33_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icba6574b9a85494dab7e9c14215a1307_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa8b31b9ebd44400b5d964739f3458f3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97bac5a737ae4720be910bf41fbb0e01_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if6c10b102b3741ac813dad0356a92d49_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3fa642d4aed4cbc87a473f75a555d65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3315546551a7412ba1760a313ef1c110_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id72df7c6a122499cb275a14c404f6193_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3ef75081e0946589cf01741b601dbb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id99b7f6ad84a4d639bf1a58feafe6ab6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i339ff47008914dcb996ae4ba141c02f0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if03dffb153674380907acf14bba35d94_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i72e1016b843348d4859494db7ba331a1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia8d6c97c0efd4da4aac22b43597a001a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i25af98b853e641e0826021863429c9c3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ida08a64c245c4eb79187d42287aa92d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0f84d4c481cd4ba7be68a72191bcf918_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e2f4983539c43e795b959c6ddd43062_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i70b18b5af79b4bf5aca45b588737fa36_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idf16b64ad3af4100843dc0cb6c96f297_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia102effd057548618be0c7faa2c14a71_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iffde9483458d4f4480d7cedd42c1d1e0_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i091236316b914dbcab5fb5da12dce5a3_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:VorasidenibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75182c507fc84a0aa16c99db2a260ac3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icae28c36de4446c380e38079965eb99e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief104d7641164b449e022699db588dd0_D20210405-20210405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-04-05</endDate>
        </period>
    </context>
    <context id="i6391c1de417d466184f6c9a28dad5e87_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5203cb569ff49ca98a0359fff1bd001_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if96cc6c457fc41639d4fc3f4ed2f934c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i88992bda51914909b6dd871d292700b7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia69dec3d703147e0a24827abbbc23547_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4126d05954e4466c8ed0d02bb4506ffb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie0bcdc9702194332ba58fb885ff2771d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a87ede4a0944e6aac0235cba36b26d2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8ca3b35d04643e0ad5bb05e77e88126_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7012a29f126a40258af0e6ed5765dbff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie228033d9a0b4b799dd10eaf894a5565_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7413f9c5b84645e38c9f817ef9fc6d59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i46b75ada5f8f43bea21d6e34291436e7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i91bc918915e74396b7fef2d671257ed8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i48bb9c2460444fceb9a62eea46ed198e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ffcd4120185407dba6ff4635e5381d6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib9dbd1b26e91468d9424a22a13ad1978_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4c15c9efd3d4ae6b10bdf6ef9f35bb2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec10babe1b934aab9dcfd367e69adf4f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1163f342e67f4b2b8954b9a8000defec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie75239587a9d477198559b60a4c19637_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i784f84d08b5046fdb42b2d6c383708d1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i44b2447db00040c2874fb5c5e278e3b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib9cef39867a74079819ffe0340b554c5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i488b85c653fd499fa66acffad102fa83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05325d5c1172404596cff3bf376d9b1f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa1cfedca62f472d82be8d85973de1d7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibf964a81be38414aa97c9c309c1c2c82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieac319395ad2486b9899656e63bb1ef3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79dd4f0c88284fe4badccb9475c4f971_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idca711242fee4c6ab4d75442d9612253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i756a2ef1edac4f07b53d1470ef869070_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i855087ce662749b2b547077eb45a8a38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0577f8cd46849f2a8b97982550aea04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2be1907947514eb7b13e3dc095194484_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15c7600459e34951a4cec3ff06faf28f_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i70609af01f924e08961eae93134c2934_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia272dc6363a84ac2ad2bd1fac38e1aab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83ae90ff305f4fc99f69ae4834a3f97a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa54a29f6a2c403383d89cfeec3aaf59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i92b16706b28640548b80c7b1f2d3e403_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i65d1a1a869b64af6af400f631a1e6c4d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8e402691929e44468cadbcc8453e6514_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib271baa482c94d97ac48840b7d361a47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f547c547c3d455d9028f77bd9be80d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f510a7bc35c4acc904d0706efb5488c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c09eceb9aa140f8b2fa149e6232b87f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46afd29a81bf441a99b55105d1a18809_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3ddbb4db5e1644ccaa03be39b46f2cb4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3842af82e752402aa7a5fbeedccf54b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a9a1d0006454af4aeab6df1c2911d6e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26c67bf64fdf4dcc9d2de216530f51c1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i88173f3394c14c71afab60eef3d941af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i328200bab58e48e9be32dfe062e76e09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i538c902f308341ad8db797be144a4c17_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib15521d93cb44d6183b8ea908841d562_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iefcb67b5c5064fd198f05934740baab6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20bb451b5406436aa3044e6572769236_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iabd284c57e7c4c53b396b12930ced078_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iba1d1e1128ab469a92b7cd44c6db0d2b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibce6cd786d794f4ba84de03a86627fd4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a8f36b78766499982b48169e8709eec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d7ca6a9e8334a34861d3a8cc12a5faa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f5a58c7510e4e6e8d4cb2499cc30bc7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2bfd973f33e846f5b7d28e08e0c6e96b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia3df74c825b14d068c62180063fd7587_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab52b0c782a64d07b43279f5e7626420_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i73a401f6a1c148b28af205ff7abe39ac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibdafde84e3d3486fbcdf4313d51d80e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>agio:security</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV8zLTEtMS0xLTMxODI0_9579157f-b3ed-4dd1-8586-9bea788e76ff">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV80LTEtMS0xLTMxODI0_57a45550-da6f-4367-94f3-14e14d2e8aa4">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV81LTEtMS0xLTMxODI0_9e681a45-2812-45c9-a3c9-ac3664736a86">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV82LTEtMS0xLTM0Njg4_bef277d2-68b2-4f6d-ab8f-20d920ad6b7b">0001439222</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80L2ZyYWc6MjAzZDQzMDEwODlhNGU5NGJkNDJmY2EwNTQ3ZWJhNGIvdGFibGU6MDYzM2Y2NjI2MjA1NGJjYjk0ZGEyYzhmNjNmOTE0NTEvdGFibGVyYW5nZTowNjMzZjY2MjYyMDU0YmNiOTRkYTJjOGY2M2Y5MTQ1MV83LTEtMS0xLTM0Njkw_f06b0560-930b-464f-a841-31795ae3aae6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV84Mg_a8bcf614-cb25-4576-bc16-78b239cfaad5">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6MDZkNmJhZWMwYTI2NGRhMzk3ZTVjYmNkZWJmMWY2YzIvdGFibGVyYW5nZTowNmQ2YmFlYzBhMjY0ZGEzOTdlNWNiY2RlYmYxZjZjMl8wLTAtMS0xLTMxODI0_f27bb7b6-1db8-4c8b-ad0d-519da949e4c5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xMzE_d99c26d6-ccd3-469f-b134-de68af06958e">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6ZTA2MDY2NzIzZjUyNDc0MWFlMzI4NjQ4ZGFlMzcyZTEvdGFibGVyYW5nZTplMDYwNjY3MjNmNTI0NzQxYWUzMjg2NDhkYWUzNzJlMV8wLTAtMS0xLTMxODI0_04b67c0e-dc81-4c8b-837a-8667b236d044">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xNjM_9c013392-be86-421a-aadf-9471167895a4">001-36014</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xNjg_234f207d-96b0-48b4-8ce1-9e537b88fbec">AGIOS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8wLTAtMS0xLTMxODI0_9b2e000f-4fbe-4e63-9501-d72b717a3f60">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8wLTMtMS0xLTMxODI0_9a0e06f1-ba08-4a22-ae2d-70803436927e">26-0662915</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTAtMS0xLTMxODI0L3RleHRyZWdpb246MzgzOTMyNjAzMGM2NGRkZjkxYWE2ZjUxMWU5ZjJmMGNfNA_e343a408-aa60-466a-a379-4b6eb8d6826a">88 Sidney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTAtMS0xLTMxODI0L3RleHRyZWdpb246MzgzOTMyNjAzMGM2NGRkZjkxYWE2ZjUxMWU5ZjJmMGNfOA_29cd4338-ecce-4537-a412-9410d1c49db1">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTAtMS0xLTMxODI0L3RleHRyZWdpb246MzgzOTMyNjAzMGM2NGRkZjkxYWE2ZjUxMWU5ZjJmMGNfMTI_bf4b736e-3386-44a9-91c3-7091c0f1552c">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6OTU0MTU4NmIzNzEyNGU1OTlkZmViOTMzYTg1OGQ0ZjIvdGFibGVyYW5nZTo5NTQxNTg2YjM3MTI0ZTU5OWRmZWI5MzNhODU4ZDRmMl8zLTMtMS0xLTMxODI0_4efe94f8-f029-42cc-82a6-96ed9208fd55">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8yMzI_48f8e9e1-6681-4705-ae93-7c1ef8f9d11e">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8yMzY_2b24b20d-55b7-43fa-90ce-152e288b8353">649-8600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NzcyNTYwYjhmNjY1NGM4ZGE4MDA2ZjAyMzY1MmYzMTUvdGFibGVyYW5nZTo3NzI1NjBiOGY2NjU0YzhkYTgwMDZmMDIzNjUyZjMxNV8xLTAtMS0xLTMxODI0_88e9a368-15ea-4006-b827-0019b63bca32">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NzcyNTYwYjhmNjY1NGM4ZGE4MDA2ZjAyMzY1MmYzMTUvdGFibGVyYW5nZTo3NzI1NjBiOGY2NjU0YzhkYTgwMDZmMDIzNjUyZjMxNV8xLTEtMS0xLTMxODI0_d4797a4f-7e6e-43a0-81c2-c03eea1876d6">AGIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NzcyNTYwYjhmNjY1NGM4ZGE4MDA2ZjAyMzY1MmYzMTUvdGFibGVyYW5nZTo3NzI1NjBiOGY2NjU0YzhkYTgwMDZmMDIzNjUyZjMxNV8xLTItMS0xLTMxODI0_b1817fda-9533-4c11-9e50-5659083fde37">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV83ODk_0fe64944-3920-4a8e-931f-9c021399a9d1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xMTE2_aa1bb049-0435-4d54-a7c6-57ab11b9f083">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NWY0MGY2ZTUxYjUxNDgxNzgzNDRhMzAxOTFmNzA0MGYvdGFibGVyYW5nZTo1ZjQwZjZlNTFiNTE0ODE3ODM0NGEzMDE5MWY3MDQwZl8wLTAtMS0xLTMxODI0_f2ac68fa-144b-4be4-8686-42c33e33f730">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NWY0MGY2ZTUxYjUxNDgxNzgzNDRhMzAxOTFmNzA0MGYvdGFibGVyYW5nZTo1ZjQwZjZlNTFiNTE0ODE3ODM0NGEzMDE5MWY3MDQwZl8xLTMtMS0xLTMxODI0_4a469467-34a1-4b00-ab0f-459e429bf439">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGFibGU6NWY0MGY2ZTUxYjUxNDgxNzgzNDRhMzAxOTFmNzA0MGYvdGFibGVyYW5nZTo1ZjQwZjZlNTFiNTE0ODE3ODM0NGEzMDE5MWY3MDQwZl8yLTMtMS0xLTMxODI0_8f64ca72-b7e7-4db4-86f0-fa8aab190324">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xODU4_e6b79305-d337-4887-ae98-259e01ac061d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0ed2165b94a24217bfa5f7d7525c4828_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xL2ZyYWc6YzhkOWE1MWIyZDc1NDBkYWE4ODhlNTNiMTI5ODE5ZjUvdGV4dHJlZ2lvbjpjOGQ5YTUxYjJkNzU0MGRhYTg4OGU1M2IxMjk4MTlmNV8xOTYw_18c0c98b-2039-4012-9b9b-6510ec3243fd"
      unitRef="shares">54788927</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMy0xLTEtMS0zMTgyNA_62d718ca-3ad3-45f6-b70c-e10aa5cb3699"
      unitRef="usd">80026000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMy0zLTEtMS0zMTgyNA_cd26dce0-db1f-4542-a9cc-c343c52a4015"
      unitRef="usd">203126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNC0xLTEtMS0zMTgyNA_bf9a85b7-d54e-4c60-a8d2-a88bcc6792ef"
      unitRef="usd">843503000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNC0zLTEtMS0zMTgyNA_9e323fb1-2a9f-4418-8177-3ae1685b5973"
      unitRef="usd">816892000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNS0xLTEtMS0zMTgyNA_bfa41c2c-4d89-4f82-859a-a930c4853914"
      unitRef="usd">540000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNS0zLTEtMS0zMTgyNA_5ecc5231-2a13-462d-b7a8-0a69f6549559"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0xLTEtMS0zNTYxNw_37ec5ba0-1698-4d2f-a9b7-077b0e6fb238"
      unitRef="usd">5365000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0zLTEtMS0zNTYxMQ_210900e0-ea32-47c7-a814-90ef63c7138d"
      unitRef="usd">4378000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0xLTEtMS0zMTgyNA_e5e2e6c9-562d-4a45-98f5-f23ce749699d"
      unitRef="usd">2485000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfOS0zLTEtMS0zMTgyNA_8c68ba58-338b-44c6-8243-99b70eb084cd"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTAtMS0xLTEtMzE4MjQ_3d45d48e-449f-4b9b-8dad-591ba1876c93"
      unitRef="usd">43226000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTAtMy0xLTEtMzE4MjQ_88a0a3fa-be5b-48f8-8918-37124705b37c"
      unitRef="usd">39835000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTItMS0xLTEtMzE4MjQ_22792d76-fa21-440b-a2d0-e1ec371cc975"
      unitRef="usd">975145000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTItMy0xLTEtMzE4MjQ_832d7491-0309-4307-986b-516e62cec159"
      unitRef="usd">1064231000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTMtMS0xLTEtMzE4MjQ_e0cc86e7-5c69-4574-a80d-b35ea890fc51"
      unitRef="usd">255836000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTMtMy0xLTEtMzE4MjQ_e8a4e17a-845a-4654-ac3d-4b6a918d0c31"
      unitRef="usd">266375000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTQtMS0xLTEtMzE4MjQ_42edc845-5366-47b1-a4e6-ec0500857638"
      unitRef="usd">72688000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTQtMy0xLTEtMzE4MjQ_9c1fc5ab-147d-4e07-bf83-741ea55b5e38"
      unitRef="usd">75124000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTUtMS0xLTEtMzE4MjQ_093b2580-3e67-4906-8f6e-316a33a1de78"
      unitRef="usd">29195000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTUtMy0xLTEtMzE4MjQ_708b6ac3-23c3-475b-8355-57595ef817c1"
      unitRef="usd">28923000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTYtMS0xLTEtMzE4MjQ_5699380a-24e3-4c9b-93a0-82dd367dedbc"
      unitRef="usd">95000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTYtMy0xLTEtMzE4MjQ_75e6d52c-2510-4f24-b402-fd6aa71b74cc"
      unitRef="usd">183000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTctMS0xLTEtMzE4MjQ_544f2b03-a5c7-415f-a989-f4c14b02dc00"
      unitRef="usd">2900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTctMy0xLTEtMzE4MjQ_6ecf807f-0676-4d1e-a17b-0eecc4feb377"
      unitRef="usd">2900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTktMS0xLTEtMzE4MjQ_eaa4784b-43b6-4f72-8366-6c822e3f72b8"
      unitRef="usd">1335859000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMTktMy0xLTEtMzE4MjQ_96c2decd-7a0f-4fc5-a39a-df2ffb7d3072"
      unitRef="usd">1437736000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjMtMS0xLTEtMzE4MjQ_4d364686-9d2e-4188-bde1-55886b6cd2ef"
      unitRef="usd">11551000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjMtMy0xLTEtMzE4MjQ_bb34e57b-0a6c-4af3-a1cd-ff2de94ee1b6"
      unitRef="usd">16700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjQtMS0xLTEtMzE4MjQ_bf099442-cbea-4167-8a05-18de238cae15"
      unitRef="usd">19747000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjQtMy0xLTEtMzE4MjQ_4ff6644d-4db7-4b94-915d-ff4263c11151"
      unitRef="usd">31967000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjYtMS0xLTEtMzE4MjQ_f3a8271b-3e65-412f-b7f2-eb96ebf2b676"
      unitRef="usd">11744000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjYtMy0xLTEtMzE4MjQ_3457ce1e-394a-4a87-8d0c-a706206efd17"
      unitRef="usd">10828000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjctMS0xLTEtMzE4MjQ_472cfa50-55b9-405d-acaa-6013031b5e6e"
      unitRef="usd">250000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjctMy0xLTEtMzE4MjQ_9b1f539c-459e-4800-a188-e0ee1440db3c"
      unitRef="usd">331000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjktMS0xLTEtMzU2MzY_abc5bb20-b1ad-48aa-bb50-eb2807f1737f"
      unitRef="usd">2500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMjktMy0xLTEtMzU2NTY_d6e9485b-bac8-45c0-b781-9e1a22751cfb"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzEtMS0xLTEtMzE4MjQ_3c2c0612-b8e5-4d53-8742-005237f1ea77"
      unitRef="usd">45792000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzEtMy0xLTEtMzE4MjQ_265bae3f-3879-4b16-ab22-f8a4583cf926"
      unitRef="usd">59826000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzMtMS0xLTEtMzE4MjQ_7b737ddb-2417-4b33-ace2-c9608c2637f0"
      unitRef="usd">82338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzMtMy0xLTEtMzE4MjQ_1e63873a-ce38-4492-9778-8c620ff7a959"
      unitRef="usd">85659000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzQtMS0xLTEtMzE4MjQ_89bad927-75e1-4e2c-8965-ccfa793b3f4b"
      unitRef="usd">276000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzQtMy0xLTEtMzE4MjQ_4f7d8ffa-3fc2-49a7-b1b0-8f53ffb79978"
      unitRef="usd">276000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzctMS0xLTEtMzE4MjQ_6c5700e7-061a-479a-8313-c1d54ba3b8fd"
      unitRef="usd">128406000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzctMy0xLTEtMzE4MjQ_97fe49d8-c09e-4b58-b39c-aa80f496f9d9"
      unitRef="usd">145761000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8yMQ_1d214f80-3154-4d5f-a648-bec6acb00dd4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8yMQ_e12e2a1d-0911-4ee4-a8f4-4253d4ad3322"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8zNQ_1ee848ef-a468-4224-b662-d63c7683fdd2"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV8zNQ_3430f1ec-b187-4fcb-b367-18d3fb1f6647"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_10ffdb48-24cc-4573-8518-655c87218b78"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_4fe08b35-00ec-4c31-a5d6-06894dbf6cd2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_507b2d21-1694-4b7a-b343-c1b6d7b6df34"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjo3NTRhOTM0ZDI4M2U0MWNjYWExNTFmZWI1YjgyNzhiYV81Nw_b8020732-47e0-4461-8bc0-28df0e59aead"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMS0xLTEtMzE4MjQ_e0d98215-e05c-45c7-baa8-7334bf69a17b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfMzktMy0xLTEtMzE4MjQ_b3dd9f65-3a80-4152-b712-7b4f6e6f4fd7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8xOA_c3a73faf-3024-4030-9999-1ff69e29cc1c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8xOA_dfb0d0a8-5f55-4f78-914b-1d0a9299d41b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8zMg_b1697637-3318-41e6-b7d0-c03505f97a2d"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8zMg_be9d7bb2-66f7-42e6-897c-316ed548e016"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV81NA_a4cc14ef-6629-4efd-a426-dedb0721b92a"
      unitRef="shares">70993277</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8yMTk5MDIzMjU1ODk3_19aa9db0-1cd9-4709-a631-907215d78fe5"
      unitRef="shares">54776467</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV82MQ_c220b542-1a8c-4257-a00f-af847f7341f5"
      unitRef="shares">70550631</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMC0xLTEtMzE4MjQvdGV4dHJlZ2lvbjpkN2RjNzFkZDZlMDQ0MGRhOTkwNGZhYzgyNTkxYjYyOV8yMTk5MDIzMjU1OTAx_0b0c0018-753b-4ed4-9124-07892373d8f2"
      unitRef="shares">54334220</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMS0xLTEtMzE4MjQ_3576fc07-667a-4aa5-8a0a-52de30e613d1"
      unitRef="usd">71000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDAtMy0xLTEtMzE4MjQ_abb96413-227f-4206-877c-84e9a1cd0f4d"
      unitRef="usd">71000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDEtMS0xLTEtMzE4MjQ_ee6b038e-d331-4b48-bf3a-efdfb77c98a9"
      unitRef="usd">2351147000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDEtMy0xLTEtMzE4MjQ_aa4748b2-ca25-4ba2-bf26-bc47453db470"
      unitRef="usd">2334348000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDItMS0xLTEtMzE4MjQ_95b7cb98-88ae-4a2e-8140-5bc5b557a755"
      unitRef="usd">-7745000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDItMy0xLTEtMzE4MjQ_b58961b0-4c6a-420a-b773-29fc71dd7349"
      unitRef="usd">-1198000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMC0xLTEtMzIyODcvdGV4dHJlZ2lvbjo3MGFhZjc5N2NlYjM0YjA1OWU2OWMxMWVjZGQzNjFiNV8yNzQ4Nzc5MDY5NTg2_1ced238c-d8a9-40e1-a240-a23e71fa7d40"
      unitRef="shares">16216411</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMC0xLTEtMzIyODcvdGV4dHJlZ2lvbjo3MGFhZjc5N2NlYjM0YjA1OWU2OWMxMWVjZGQzNjFiNV8yNzQ4Nzc5MDY5NTg2_4a0eece7-1b3b-409f-89ec-0edade0b36ca"
      unitRef="shares">16216411</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMS0xLTEtMzQ1NzA_70fbb7e8-41cd-41ab-b4d5-b180bc907801"
      unitRef="usd">802486000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMy0xLTEtMzIzMjQ_37461d91-866b-454c-90db-daa33fcf019e"
      unitRef="usd">802486000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMS0xLTEtMzE4MjQ_953297b4-14e7-4a2f-b9ea-67e879e4076e"
      unitRef="usd">-333534000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDMtMy0xLTEtMzE4MjQ_49fe4555-d215-4106-a1cf-5b6a00588c7b"
      unitRef="usd">-238760000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDQtMS0xLTEtMzE4MjQ_533506e7-9157-42e6-bdf6-5feb02d0efb8"
      unitRef="usd">1207453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDQtMy0xLTEtMzE4MjQ_327b585f-3dd7-481a-ab7f-dcee4fa47928"
      unitRef="usd">1291975000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDUtMS0xLTEtMzE4MjQ_d2a5d307-2a16-4426-b53e-5a5ef2af820c"
      unitRef="usd">1335859000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xNi9mcmFnOjRkOTFmOGY3MTg5MjQ4Yzc5ZWMyYjU5ZjViYzUwZTIyL3RhYmxlOjVhYjQ5YzAwNzhiMTRhNjE5ODNmYmVhMjhjZDk1YzUyL3RhYmxlcmFuZ2U6NWFiNDljMDA3OGIxNGE2MTk4M2ZiZWEyOGNkOTVjNTJfNDUtMy0xLTEtMzE4MjQ_5d88b28e-f457-4d3e-b6ef-f696dbc38c08"
      unitRef="usd">1437736000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ad81482e39040cfa13a399adf4f783f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMy0xLTEtMS0zMTgyNA_33a583f2-a477-4dec-a7d9-017f3554372f"
      unitRef="usd">832000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if275c08a4b1a44d1a150f50c7c881130_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMy0zLTEtMS0zMTgyNA_ae22ef86-9178-488a-b06d-24ec4fb1753b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfNy0xLTEtMS0zMTgyNA_136ae9fa-e33e-4dc7-84dc-65d04b02b1ed"
      unitRef="usd">832000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfNy0zLTEtMS0zMTgyNA_ac7a3de1-f327-445f-a12b-a024c66a41bb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfOS0xLTEtMS0zMTgyNA_8b7dc187-e834-4d79-8b94-b27b9a9d5268"
      unitRef="usd">339000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfOS0zLTEtMS0zMTgyNA_446488b8-dd38-4b64-ab19-f9c4db9a94f7"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTAtMS0xLTEtMzE4MjQ_063a4e3f-476a-44e3-81a4-38fc27b5122c"
      unitRef="usd">70123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTAtMy0xLTEtMzE4MjQ_94eb9c08-580a-4146-acad-dc250ffbddc2"
      unitRef="usd">57667000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTEtMS0xLTEtMzE4MjQ_1d7521b9-7490-4d9f-9906-1259421543db"
      unitRef="usd">31515000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTEtMy0xLTEtMzE4MjQ_b8552ae6-1dd5-4589-828c-d90972ad0d81"
      unitRef="usd">33550000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTItMS0xLTEtMzE4MjQ_542cdda7-d152-4992-a21d-3cbf0ab1736b"
      unitRef="usd">101977000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTItMy0xLTEtMzE4MjQ_c8682ab1-f9a0-42a0-a193-b9744b0cf809"
      unitRef="usd">91217000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTMtMS0xLTEtMzE4MjQ_8518329f-a8e9-4452-b911-9c3200b850e3"
      unitRef="usd">-101145000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTMtMy0xLTEtMzE4MjQ_063f7083-8fe4-496e-8d30-68d7bee01502"
      unitRef="usd">-91217000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMS0xLTEtMzU1NzQ_7efcb7a3-6157-4b7f-a188-181d14264eb3"
      unitRef="usd">2704000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMy0xLTEtMzU1OTA_34f29d06-394b-4e8c-a98d-7ae884f46a55"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMS0xLTEtMzE4MjQ_e8c8b405-6546-4b6b-b3f6-a125a70c8c1e"
      unitRef="usd">694000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTQtMy0xLTEtMzE4MjQ_0438c14e-5eae-4fcc-863d-88fcd95fc672"
      unitRef="usd">340000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMS0xLTEtMzU1ODA_4f7674c5-078b-49bf-9a27-0d78b019c21e"
      unitRef="usd">2973000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMy0xLTEtMzU1OTY_fa107b2e-e234-4416-8bc1-b7c051be9a51"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMS0xLTEtMzE4MjQ_8aba767f-904d-4622-b343-768e85b0e3bc"
      unitRef="usd">-94774000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTYtMy0xLTEtMzE4MjQ_d09da321-137d-459d-99a7-12946590914d"
      unitRef="usd">-90877000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTctMS0xLTEtMzE4MjQ_30ee9d27-acbe-4b16-900e-b418aa1b4e95"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTctMy0xLTEtMzE4MjQ_ecccbb83-a610-479e-8881-52b2a26ebf90"
      unitRef="usd">1965202000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTgtMS0xLTEtMzE4MjQ_dd4aae5e-6711-4bdb-bfce-6ec1d8886786"
      unitRef="usd">-94774000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTgtMy0xLTEtMzE4MjQ_41a8969f-0388-4828-9773-b5d82135599f"
      unitRef="usd">1874325000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMS0xLTEtMzE4MjQ_0241a026-4d20-46c6-9014-73b7d92d3add"
      unitRef="usdPerShare">-1.74</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMS0xLTEtMzE4MjQ_fc77b9a6-fe40-4feb-9f7f-300377e5b84c"
      unitRef="usdPerShare">-1.74</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMy0xLTEtMzE4MjQ_434d42e4-2fe1-49d7-9ca8-6e4f5949d3b5"
      unitRef="usdPerShare">-1.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMTktMy0xLTEtMzE4MjQ_62d1c88a-a39b-4bce-abd2-5308133c93fd"
      unitRef="usdPerShare">-1.31</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMS0xLTEtMzE4MjQ_1d9f1099-df74-47c8-a64a-9cc41f6a4657"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMS0xLTEtMzE4MjQ_e8973637-a890-4c6e-beb1-b55b5a9ad947"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMy0xLTEtMzE4MjQ_38064d6e-69a9-4da5-bae7-cf5c88eb0e1b"
      unitRef="usdPerShare">28.26</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjAtMy0xLTEtMzE4MjQ_ab5fe4bb-4d9a-4945-8055-62c60b30298c"
      unitRef="usdPerShare">28.26</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMS0xLTEtMzE4MjQ_5e4db68c-3b06-4193-8a56-77790eac3ea0"
      unitRef="usdPerShare">-1.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMS0xLTEtMzE4MjQ_ce9d8063-b496-4198-8aef-83f3ae19b689"
      unitRef="usdPerShare">-1.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMy0xLTEtMzE4MjQ_bb9e1a31-6c6c-4873-b71e-9c850dcc277f"
      unitRef="usdPerShare">26.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjItMy0xLTEtMzE4MjQ_f21ea2fe-1c69-42a9-a522-0e8d99913ccf"
      unitRef="usdPerShare">26.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMS0xLTEtMzE4MjQ_0a967ef8-8643-4e3c-9dc3-3a9f98360e02"
      unitRef="shares">54555467</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMS0xLTEtMzE4MjQ_21104ec4-4fe9-49dc-8047-510d4a6d35af"
      unitRef="shares">54555467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMy0xLTEtMzE4MjQ_0aa0b955-b295-4891-9441-b007f5c97f06"
      unitRef="shares">69543510</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8xOS9mcmFnOmJmNmQxMjFmZDAyNDRjNTVhNDNiODBhZTM3OGQzZTM3L3RhYmxlOjY3MGMyZjMzODUzNTQyM2Q5Zjc5ZDM0NWFmNDQwZGM1L3RhYmxlcmFuZ2U6NjcwYzJmMzM4NTM1NDIzZDlmNzlkMzQ1YWY0NDBkYzVfMjQtMy0xLTEtMzE4MjQ_eaf0a060-e717-45fe-971a-2d5c5f5a0387"
      unitRef="shares">69543510</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfMi0xLTEtMS0zMTgyNA_3d64cbfd-0fcb-46bc-80f2-a08d8f9d9b31"
      unitRef="usd">-94774000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfMi0zLTEtMS0zMTgyNA_232458e1-e8b3-4713-924e-f6dd20e1f79c"
      unitRef="usd">1874325000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNC0xLTEtMS0zMTgyNA_f97d6d3d-9322-4e97-a9f5-0a2916fda876"
      unitRef="usd">-6547000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNC0zLTEtMS0zMTgyNA_8a5f4225-652c-48ac-9ee3-09d8e2bfc9a1"
      unitRef="usd">-108000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNS0xLTEtMS0zMTgyNA_7ba0a35f-8601-4734-91f5-f3c338203d6f"
      unitRef="usd">-101321000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yMi9mcmFnOmY1MzBiOTY1YzM1ZTRiYjE4MjAxMWNlMzIyNzk3N2YyL3RhYmxlOmUxNWU4MTc3NmZlMjRiYmFiZWY5ZTQ0N2RkMWJjZDNiL3RhYmxlcmFuZ2U6ZTE1ZTgxNzc2ZmUyNGJiYWJlZjllNDQ3ZGQxYmNkM2JfNS0zLTEtMS0zMTgyNA_13c077fb-5895-4eab-a680-f8fc9661ba54"
      unitRef="usd">1874217000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ie6cc362c4f604b6698f86e13bb3b5e3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xLTEtMS0zMTgyNA_d9f76105-e00b-4aa4-8495-e68e2bbd7eea"
      unitRef="shares">70550631</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie6cc362c4f604b6698f86e13bb3b5e3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0zLTEtMS0zMTgyNA_ca986fec-a424-4aeb-8e21-926f8d5c97ee"
      unitRef="usd">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cbd80b1c38d4e15abafa707e5b10913_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi01LTEtMS0zMTgyNA_ab51b06a-2d96-414c-86d7-76a09116beae"
      unitRef="usd">2334348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48e46f8b9b7c4fa794ef1e57c63f60ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi03LTEtMS0zMTgyNA_2c470995-affc-463e-b4e7-ec6fbfc23fbc"
      unitRef="usd">-1198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia915565fa9bf49e8a6089229571dfeb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi05LTEtMS0zMTgyNA_6e0e3539-85a7-44f9-bef6-26e740164974"
      unitRef="usd">-238760000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i020aaaa8244f4450abf7a489bae1b308_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xMS0xLTEtMzQ0NzI_2d979635-c3f4-4f1a-a52f-1e577b6f4637"
      unitRef="shares">16216411000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i020aaaa8244f4450abf7a489bae1b308_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xMy0xLTEtMzQ0Nzk_ceee0e74-5190-4886-ba9b-75ae7ef079ac"
      unitRef="usd">802486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfMi0xMS0xLTEtMzE4MjQ_168d53c9-119a-4a2c-b0ac-f17b46fde7a1"
      unitRef="usd">1291975000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7cb58067c996499e8ddfaee3546da6b3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNC0xLTEtMS0zMTgyNA_a9ee233f-0327-424a-934e-fd648a04810f"
      unitRef="shares">442646</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia723c5f1bdd7498dab4b5253a5239e6a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNC01LTEtMS0zMTgyNA_6a6a387c-e89a-4567-911e-3fbdb5211d66"
      unitRef="usd">1289000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNC0xMS0xLTEtMzE4MjQ_8aa48c9f-c7df-4814-a265-b1286e028441"
      unitRef="usd">1289000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia723c5f1bdd7498dab4b5253a5239e6a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNS01LTEtMS0zMTgyNA_01e985e4-586e-4db5-9323-6587839cb69c"
      unitRef="usd">15510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNS0xMS0xLTEtMzE4MjQ_bfc2d1ae-649f-4acd-9fa5-c2e4e172ee82"
      unitRef="usd">15510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iedff87c239d041ee903730df5ff0e42d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNi03LTEtMS0zMTgyNA_d9a20c17-1773-4b93-a25d-6a2d30fc96b1"
      unitRef="usd">-6547000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNi0xMS0xLTEtMzE4MjQ_6eb43c66-b065-439f-9713-5f5fc0715042"
      unitRef="usd">-6547000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="idabd827068424d0c94fda806b5666e9a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNy05LTEtMS0zMTgyNA_5229dd44-01fd-4b27-8578-b93f9ea8dfda"
      unitRef="usd">-94774000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfNy0xMS0xLTEtMzE4MjQ_01841355-e74b-4081-9cc9-d25fb9582a63"
      unitRef="usd">-94774000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib098b853fd0d4618a37120ad076e9c33_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xLTEtMS0zMTgyNA_84417e02-19eb-481d-b343-df68e35b4d79"
      unitRef="shares">70993277</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib098b853fd0d4618a37120ad076e9c33_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0zLTEtMS0zMTgyNA_c49bf259-88f8-4c32-a61f-98cecd9e8796"
      unitRef="usd">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icba6574b9a85494dab7e9c14215a1307_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS01LTEtMS0zMTgyNA_0e3e8060-23a9-44a9-b7a5-eff10a117bef"
      unitRef="usd">2351147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa8b31b9ebd44400b5d964739f3458f3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS03LTEtMS0zMTgyNA_9b20e5d2-bfc9-4f94-85c9-28144aa02b0f"
      unitRef="usd">-7745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97bac5a737ae4720be910bf41fbb0e01_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS05LTEtMS0zMTgyNA_a5ad190f-082a-4599-be59-79b3a9e2e563"
      unitRef="usd">-333534000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if6c10b102b3741ac813dad0356a92d49_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xMS0xLTEtMzQ1MTM_fe6bd396-348c-4393-918b-d8006242bdeb"
      unitRef="shares">16216411000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if6c10b102b3741ac813dad0356a92d49_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xMy0xLTEtMzQ1MjA_0e291215-365a-4feb-b748-143986472edf"
      unitRef="usd">802486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjMyY2UyNmQ0NGVkNDQ2NjE5YzY0NWU4N2VlYzNhMjA2L3RhYmxlcmFuZ2U6MzJjZTI2ZDQ0ZWQ0NDY2MTljNjQ1ZTg3ZWVjM2EyMDZfOS0xMS0xLTEtMzE4MjQ_11eb5a68-e11f-4d6e-bdd2-7d77c49fd0e5"
      unitRef="usd">1207453000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ic3fa642d4aed4cbc87a473f75a555d65_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi0xLTEtMS0zMTgyNA_060cf544-5c7f-4662-a58a-f902ec961ef2"
      unitRef="shares">69293920</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic3fa642d4aed4cbc87a473f75a555d65_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi0zLTEtMS0zMTgyNA_bf8ad4b0-60d5-4a70-b1c2-6f98a465142c"
      unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3315546551a7412ba1760a313ef1c110_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi01LTEtMS0zMTgyNA_b4e05a5d-126e-4825-8e1a-0bb7c4bc81cb"
      unitRef="usd">2242801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id72df7c6a122499cb275a14c404f6193_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi03LTEtMS0zMTgyNA_53578bbc-6b6a-48a8-8fb7-426e705e21a5"
      unitRef="usd">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3ef75081e0946589cf01741b601dbb9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi05LTEtMS0zMTgyNA_1cd5da15-f04a-4251-957a-e1ec5444cad5"
      unitRef="usd">-1843475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id99b7f6ad84a4d639bf1a58feafe6ab6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMi0xMS0xLTEtMzE4MjQ_c868f0ea-c305-4021-838a-6bff13deb5c6"
      unitRef="usd">399500000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i339ff47008914dcb996ae4ba141c02f0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy0xLTEtMS0zMTgyNA_797d589a-f609-4e11-a905-5ae799772e0d"
      unitRef="shares">518285</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i339ff47008914dcb996ae4ba141c02f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy0zLTEtMS0zMTgyNA_f4cfe42f-e126-4291-8cdb-d9d1ca5801a9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if03dffb153674380907acf14bba35d94_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy01LTEtMS0zMTgyNA_f934e575-74c4-4090-a601-df454302770f"
      unitRef="usd">7346000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfMy0xMS0xLTEtMzE4MjQ_af98b0a2-734a-4bb8-8937-b85b6ff2f5b7"
      unitRef="usd">7347000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if03dffb153674380907acf14bba35d94_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNC01LTEtMS0zMTgyNA_c41b584a-e8fc-4b50-bbdc-e1a66448f56a"
      unitRef="usd">14854000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNC0xMS0xLTEtMzE4MjQ_bc9f42de-66a9-42f1-b5c4-155163a3e7cc"
      unitRef="usd">14854000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i72e1016b843348d4859494db7ba331a1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNS03LTEtMS0zMTgyNA_dda99467-5b19-4daf-ab68-14ccec3678d4"
      unitRef="usd">-108000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNS0xMS0xLTEtMzE4MjQ_e9cbcaa4-6183-4755-bd46-603eb6143f8c"
      unitRef="usd">-108000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia8d6c97c0efd4da4aac22b43597a001a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNy05LTEtMS0zMTgyNA_ee155b2d-8880-4137-9076-242aac88ce0a"
      unitRef="usd">1874325000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfNy0xMS0xLTEtMzE4MjQ_306d9406-3d10-4d73-9f9a-650fc338e3a0"
      unitRef="usd">1874325000</us-gaap:NetIncomeLoss>
    <agio:StockholdersEquityDispositionOfBusiness
      contextRef="if03dffb153674380907acf14bba35d94_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOC01LTEtMS0zMTgyNA_e96c00d4-d027-4f1d-babb-da5f4769a969"
      unitRef="usd">-712000</agio:StockholdersEquityDispositionOfBusiness>
    <agio:StockholdersEquityDispositionOfBusiness
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOC0xMS0xLTEtMzE4MjQ_6c4d8516-31ab-4edb-a334-ccb667a51c0f"
      unitRef="usd">-712000</agio:StockholdersEquityDispositionOfBusiness>
    <us-gaap:SharesOutstanding
      contextRef="i25af98b853e641e0826021863429c9c3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS0xLTEtMS0zMTgyNA_a2e77d02-d6d9-4e67-afe1-185045713601"
      unitRef="shares">69812205</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i25af98b853e641e0826021863429c9c3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS0zLTEtMS0zMTgyNA_4f6fa828-1964-46ea-a559-6b6778d96e52"
      unitRef="usd">70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida08a64c245c4eb79187d42287aa92d9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS01LTEtMS0zMTgyNA_27bb8371-11c3-4ae1-950b-e8c6bab89953"
      unitRef="usd">2265713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f84d4c481cd4ba7be68a72191bcf918_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS03LTEtMS0zMTgyNA_1bc728df-26c2-46a7-962e-7b281c09d8dd"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e2f4983539c43e795b959c6ddd43062_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS05LTEtMS0zMTgyNA_02ead992-ad20-4128-b780-4d32c7bfa11b"
      unitRef="usd">30850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70b18b5af79b4bf5aca45b588737fa36_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yNS9mcmFnOmY4NGEzMTk4YzdjOTQ4ZTQ4OGJlOWE3YTM2ZjIzYTA4L3RhYmxlOjgzMDZlZWY4OWUzNDRjMTQ4ZmI0M2MwNDY3NDBlMjYxL3RhYmxlcmFuZ2U6ODMwNmVlZjg5ZTM0NGMxNDhmYjQzYzA0Njc0MGUyNjFfOS0xMS0xLTEtMzE4MjQ_ba23e4c4-0126-4afe-814c-8d6833e78725"
      unitRef="usd">2296630000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMy0xLTEtMS0zMTgyNA_b2d516bb-c554-428c-adfa-7ed9100d7b61"
      unitRef="usd">-94774000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMy0zLTEtMS0zMTgyNA_a080bda2-766a-4604-8dd8-263cc3d610ff"
      unitRef="usd">1874325000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNC0xLTEtMS0zMTgyNA_763e5861-575e-414f-b73e-46767a6eb1eb"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNC0zLTEtMS0zMTgyNA_38f1a7d2-5aff-4f42-a814-0a76bc272b07"
      unitRef="usd">1965202000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNS0xLTEtMS0zMTgyNA_b5ea93dc-f964-42ee-ad75-dbe5831055a6"
      unitRef="usd">-94774000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNS0zLTEtMS0zMTgyNA_f29a2286-50a7-42f6-ba4a-c01207a9fd63"
      unitRef="usd">-90877000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNy0xLTEtMS0zMTgyNA_5cd4c65d-df24-4871-81bc-6b0a92b7cf0e"
      unitRef="usd">2478000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNy0zLTEtMS0zMTgyNA_37c4b4a4-168f-4132-8f5a-c6aec4e09765"
      unitRef="usd">2479000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOC0xLTEtMS0zMTgyNA_271acf7d-378d-414c-b663-1729d04528e1"
      unitRef="usd">15510000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOC0zLTEtMS0zMTgyNA_97d4ff25-5996-4013-958f-e4eb4572049c"
      unitRef="usd">14854000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOS0xLTEtMS0zMTgyNA_b34dea66-285b-492e-8cb9-3da5e47c3ec3"
      unitRef="usd">-1150000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfOS0zLTEtMS0zMTgyNA_86548893-a470-478e-bc80-61dd9e16b8a1"
      unitRef="usd">-1664000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTEtMS0xLTEtMzE4MjQ_7ee41d1c-5a5d-41d1-9884-dc2ad9a9d150"
      unitRef="usd">2436000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTEtMy0xLTEtMzE4MjQ_4105b3d0-a534-4906-94bf-8a90b1ec78e1"
      unitRef="usd">2417000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTgtMS0xLTEtMzE4MjQ_27de165a-846d-489f-b46d-18d45dde38da"
      unitRef="usd">540000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMTgtMy0xLTEtMzE4MjQ_599839dd-5e1b-449e-a636-3325bcf16ec0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjItMS0xLTEtMzE4MjQ_eb894c2c-7a0e-43a4-bfa4-3a0523564465"
      unitRef="usd">2485000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjItMy0xLTEtMzE4MjQ_6b001bbd-24cd-4fc8-8e02-9ff84cc905c0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMS0xLTEtMzU3MTU_7b1ec498-fb0c-4a35-ac50-53e53b60a41b"
      unitRef="usd">987000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMy0xLTEtMzU3MjE_00c2c653-da6f-4901-b01f-dab1acafa8d3"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMS0xLTEtMzE4MjQ_d4748926-86c3-4e62-924e-b170f2c42e99"
      unitRef="usd">3391000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjQtMy0xLTEtMzE4MjQ_be1104bf-a84b-4a4d-9bab-95ec3c7373eb"
      unitRef="usd">3621000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjUtMS0xLTEtMzE4MjQ_bba95098-e765-435b-9679-3726b387994b"
      unitRef="usd">-5007000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjUtMy0xLTEtMzE4MjQ_64dd4b35-c986-48a8-9730-525da2245d35"
      unitRef="usd">-2941000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjYtMS0xLTEtMzE4MjQ_c8a94bfa-b36d-4a5b-acec-0bd64ebab2a0"
      unitRef="usd">-12220000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjYtMy0xLTEtMzE4MjQ_b570f57b-3e5c-4868-97fb-3f360aa9585c"
      unitRef="usd">-12697000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjktMS0xLTEtMzU3NTg_3f9dabd2-65bd-4186-ab00-6acd7a7e06a1"
      unitRef="usd">2500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjktMy0xLTEtMzU3NjQ_4200f288-30e3-4368-925f-8d00258aab72"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjgtMS0xLTEtMzE4MjQ_6856698e-c032-4122-93db-fb92e51ae6cc"
      unitRef="usd">-2405000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMjgtMy0xLTEtMzE4MjQ_5d572b29-980a-455d-810e-b6b97c1b8424"
      unitRef="usd">-1504000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzAtMS0xLTEtMzE4MjQ_3b90bc75-c73a-482f-a6a1-661928b4b9db"
      unitRef="usd">-97735000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzAtMy0xLTEtMzE4MjQ_8840ac64-d8e8-4f7d-b778-ae25734e8437"
      unitRef="usd">-90226000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzEtMS0xLTEtMzE4MjQ_de99894c-f5f2-4632-ae23-a8045712254f"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzEtMy0xLTEtMzE4MjQ_e6fce83f-5a7b-46a2-b664-4d541c12fc89"
      unitRef="usd">-30523000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzItMS0xLTEtMzE4MjQ_f3f6cec3-fa3d-4611-aa9f-dcb11a6c9b98"
      unitRef="usd">-97735000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzItMy0xLTEtMzE4MjQ_c26987b7-f74d-4295-934b-5131e9c56dcf"
      unitRef="usd">-120749000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzQtMS0xLTEtMzE4MjQ_68b9131f-f159-4dbd-8ecf-77847cd6fcce"
      unitRef="usd">355916000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzQtMy0xLTEtMzE4MjQ_0e7de1c5-7776-485c-908f-b23eed390cd7"
      unitRef="usd">61863000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzUtMS0xLTEtMzE4MjQ_acd5ca3a-ab40-4374-b994-084cec87de5a"
      unitRef="usd">332147000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzUtMy0xLTEtMzE4MjQ_1c943a6d-c711-427d-979c-c09dce5ef85f"
      unitRef="usd">134016000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzYtMS0xLTEtMzE4MjQ_8480976a-27d6-42e5-9960-d91be46a5393"
      unitRef="usd">2804000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzYtMy0xLTEtMzE4MjQ_e6f211aa-890b-4c21-9027-cfbdf50d2df8"
      unitRef="usd">1012000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzctMS0xLTEtMzE4MjQ_1457f2e3-9ef6-44f3-a85b-32d45bfc3b4e"
      unitRef="usd">-26573000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzctMy0xLTEtMzE4MjQ_b6a55f68-a44d-44fe-ac41-96e9d74980d7"
      unitRef="usd">71141000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzgtMS0xLTEtMzE4MjQ_c7a94860-1cf9-464a-aeb8-728781bfc747"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzgtMy0xLTEtMzE4MjQ_51b71b37-324f-4478-8072-24b638f4c114"
      unitRef="usd">1802936000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzktMS0xLTEtMzE4MjQ_3165259a-cea1-4acc-bbd4-2b963d39024d"
      unitRef="usd">-26573000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfMzktMy0xLTEtMzE4MjQ_f2691f0d-34b6-4787-9857-d86c8cf42b82"
      unitRef="usd">1874077000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDEtMS0xLTEtMzE4MjQ_5a63de8b-c9d6-48b5-b9f9-8c55c7205ecb"
      unitRef="usd">81000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDEtMy0xLTEtMzE4MjQ_d0daf0fc-6bb9-462c-9139-5a898d59fd41"
      unitRef="usd">86000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDQtMS0xLTEtMzE4MjQ_51230fb1-13a1-411c-b4ab-a6f8e85336c0"
      unitRef="usd">1289000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDQtMy0xLTEtMzE4MjQ_f3e6f393-c5cf-4ad2-9c78-3f561f8bf29e"
      unitRef="usd">7347000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDUtMS0xLTEtMzE4MjQ_a85150c4-d0b1-4c44-9cc0-592473c3ac5d"
      unitRef="usd">1208000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDUtMy0xLTEtMzE4MjQ_cc0fabbd-cbc8-4c92-952f-654dbf4c9dbe"
      unitRef="usd">7261000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDYtMS0xLTEtMzE4MjQ_3911d3f6-abbf-4569-9855-6b8d2cd27009"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDYtMy0xLTEtMzE4MjQ_343ce066-45db-41ef-89d1-eaa380464663"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDctMS0xLTEtMzE4MjQ_0183d318-81f6-4557-9958-48018093811c"
      unitRef="usd">1208000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDctMy0xLTEtMzE4MjQ_3fed14df-c5cc-40b8-8545-1f0bcfbcfed7"
      unitRef="usd">7261000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDgtMS0xLTEtMzE4MjQ_b0c0c20d-b484-4814-abe0-a43b48df64ef"
      unitRef="usd">-123100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDgtMy0xLTEtMzE4MjQ_1a748a91-5920-41c6-b04e-045c401bbc93"
      unitRef="usd">1760589000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDktMS0xLTEtMzE4MjQ_5ffc83c5-9bd2-4fa1-884a-b1ef6d224fa3"
      unitRef="usd">203126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id99b7f6ad84a4d639bf1a58feafe6ab6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNDktMy0xLTEtMzE4MjQ_c271731c-30df-4373-a0b5-ee5d3ee9314d"
      unitRef="usd">127436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTAtMS0xLTEtMzE4MjQ_2beacb4b-d553-44c5-8228-543f855b63b4"
      unitRef="usd">80026000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i70b18b5af79b4bf5aca45b588737fa36_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTAtMy0xLTEtMzE4MjQ_6abb075e-4fb1-4072-9279-6d6ec573201d"
      unitRef="usd">1888025000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTItMS0xLTEtMzE4MjQ_ff7388ad-e499-4303-a90d-cb3f8a2d8c5f"
      unitRef="usd">1536000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNTItMy0xLTEtMzE4MjQ_0967ad8d-fe23-495e-9046-902d7c07b78e"
      unitRef="usd">6000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNjAtMS0xLTEtMzgzMjY_a2dd34b2-bc35-4487-92e7-fa8f44085e4f"
      unitRef="usd">1842000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8yOC9mcmFnOjQ2N2Q3ODExMzQxYTQwZmE4YzFmNzBkNDI1NDc5YTFhL3RhYmxlOjM3ZjU2NWQzZDQxNTRlOGE4ZmQwNjI2NGJjOTUyZmE1L3RhYmxlcmFuZ2U6MzdmNTY1ZDNkNDE1NGU4YThmZDA2MjY0YmM5NTJmYTVfNjAtMy0xLTEtMzgzNDE_f917debb-69e0-4d3e-8aef-c81c32ac1837"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA2MQ_2c3d8a37-64fc-41f9-abbd-dd643161fff7">Overview and Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;References to Agios&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our,&#x201d; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#x201c;our Board of Directors&#x201d; refers to the board of directors of Agios Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company committed to transforming patients&#x2019; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for genetically defined diseases, or GDDs. We take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect, while cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for GDDs. We are located in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lead product candidate in our GDD portfolio, PYRUKYND&#xae; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. On February 17, 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#xae; for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States. In June 2021, we submitted a marketing authorization application, or MAA, to the European Medicines Agency, or EMA, for the treatment of adults with PK deficiency in the European Union. The MAA has passed validation, and the regulatory review process is ongoing. In addition, we are currently evaluating PYRUKYND&#xae; for the treatment of thalassemia and sickle cell disease, or SCD, in clinical trials. We are also developing AG-946, a novel, next-generation PKR activator, for the potential treatment of hemolytic anemias and other indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the aforementioned development programs, we foster a productive research engine and are seeking to advance multiple novel, investigational therapies in clinical and preclinical development in our focus area of GDDs, based on our scientific leadership in the field of cellular metabolism and adjacent areas of biology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, product liability claims and government investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of our Oncology Business to Servier&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#xae;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#x2019;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#xae; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#x2019;s IDHIFA&#xae; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#xae; development program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recorded income from royalties of approximately $2.7 million on U.S. net sales of TIBSOVO&#xae; by Servier in the royalty income from gain on sale of oncology business line item within the condensed consolidated statements of operations, for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, comprehensive (loss) income and stockholders' equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2022, our results of operations and stockholders' equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2021 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, we completed the sale of our oncology business to Servier, and received approximately $1.8&#160;billion in cash at closing. In connection with the sale, on March 25, 2021, we announced that our Board of Directors authorized the repurchase of up to $1.2&#160;billion of our outstanding shares of common stock, or the Repurchase Program, using the proceeds from the sale of our oncology business to Servier. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with Bristol-Myers Squibb Company, or BMS, to repurchase 7.1&#160;million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $344.5&#160;million, or $48.38 per share. This repurchase was completed on April 5, 2021. Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan pursuant to which we could repurchase up to $600.0&#160;million of shares of our common stock. On October 5, 2021, we terminated our Rule 10b5-1 share repurchase program and on October 13, 2021 we entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization. As of December 31, 2021 and March 31 2022, we repurchased approximately 9.1&#160;million shares of common stock for $458.0&#160;million, or $50.35 per share, under the Rule 10b5-1 repurchase plan. As of March 31, 2022, we have not repurchased any shares under the Rule 10b-18 repurchase plan. In total, as of December 31, 2021, we repurchased 16.2&#160;million shares of common stock for $802.5&#160;million, or $49.49 per share, under the Repurchase Program. We have paused our share repurchases for the foreseeable future.&lt;/span&gt;&lt;/div&gt;As of March 31, 2022, we had cash, cash equivalents and marketable securities of $1.2 billion. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="idf16b64ad3af4100843dc0cb6c96f297_D20210331-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfODY4_e5e58065-9022-461f-b312-f941e2dd4117"
      unitRef="usd">1800000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="ia102effd057548618be0c7faa2c14a71_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfOTQ0_4df1a40b-c2b0-4b59-bf7d-c3779f856134"
      unitRef="usd">200000000</us-gaap:GainContingencyUnrecordedAmount>
    <agio:GainContingencyRoyaltyPercentageOfNetSales
      contextRef="iffde9483458d4f4480d7cedd42c1d1e0_D20210331-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTQzNw_f7a39a13-203d-4fbc-99a8-0e5f02f57b41"
      unitRef="number">0.05</agio:GainContingencyRoyaltyPercentageOfNetSales>
    <agio:GainContingencyRoyaltyPercentageOfNetSales
      contextRef="i091236316b914dbcab5fb5da12dce5a3_D20210331-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTU1MA_4927a16e-8140-4ccb-ab2f-250b5d362fea"
      unitRef="number">0.15</agio:GainContingencyRoyaltyPercentageOfNetSales>
    <agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication
      contextRef="i75182c507fc84a0aa16c99db2a260ac3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTc3Nw_1726241b-9b67-49fa-a57e-980fc95d56fb"
      unitRef="usd">25000000</agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication>
    <agio:ContingentGainOnDispositionOfBusinessRecognized
      contextRef="icae28c36de4446c380e38079965eb99e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTY0OTI2NzQ3NTA2MQ_c30400f3-7f10-4fbf-babe-22f6ec2bf291"
      unitRef="usd">2700000</agio:ContingentGainOnDispositionOfBusinessRecognized>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA2NA_449f548b-0f70-40ce-b3d0-a594ccd1ac2d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, comprehensive (loss) income and stockholders' equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of March&#160;31, 2022, our results of operations and stockholders' equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2021 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA3Ng_8bb50db0-b420-4a52-afb0-c263626f7119">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfNjA3Nw_ab4189cf-c5a0-4e1e-a785-fb82a0a24b47">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and any variant strains of the virus and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="idf16b64ad3af4100843dc0cb6c96f297_D20210331-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4NzExNg_e5e58065-9022-461f-b312-f941e2dd4117"
      unitRef="usd">1800000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4NzEwMA_40861fa3-6ce9-4af9-a2dd-e2cd99573259"
      unitRef="usd">1200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ief104d7641164b449e022699db588dd0_D20210405-20210405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE0Mw_40ba7756-ec21-425a-b9ac-a04ef3486eab"
      unitRef="shares">7100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ief104d7641164b449e022699db588dd0_D20210405-20210405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE1Ng_fa993b9c-0159-48d7-9980-8ac49d3c9c2b"
      unitRef="usd">344500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ief104d7641164b449e022699db588dd0_D20210405-20210405"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE3Mg_6ed72c90-839e-4bee-a50d-0fa06058bd9d"
      unitRef="usdPerShare">48.38</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6391c1de417d466184f6c9a28dad5e87_I20210402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE4MA_20597e01-5ad5-49bd-b083-fe4453d70115"
      unitRef="usd">600000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODE5NA_08bd6c00-5382-48b9-96f2-9497f6da2dfe"
      unitRef="shares">9100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODIwNw_94909367-43c9-4595-b2ba-f3293c052b84"
      unitRef="usd">458000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i3a9168a03ddb448bb77713c08747ac62_D20211231-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODIyMw_fdd80240-864f-4ffd-93bf-5743279a7572"
      unitRef="usdPerShare">50.35</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODI1NQ_03bdfe9b-b3f5-43d7-81bb-224514b0cbf8"
      unitRef="shares">16200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODIzMQ_aa5532a7-8270-4ba0-8be7-3f7904161923"
      unitRef="usd">802500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ida0561a73598401ea9c42184869bd3ed_D20211231-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMjE5OTAyMzI4ODI0Nw_cd28b6b9-a04e-45e1-98d0-4ad789497754"
      unitRef="usdPerShare">49.49</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNC9mcmFnOjhlMzM0ZWQxZTJkMjQyY2Y5Zjk2NTZiNjgwZTk5NTM3L3RleHRyZWdpb246OGUzMzRlZDFlMmQyNDJjZjlmOTY1NmI2ODBlOTk1MzdfMTY0OTI2NzQ3NTE2NQ_c8c1dd16-11ef-40cf-8038-9b55be549292"
      unitRef="usd">1200000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfMjg3Nw_046e2257-2777-4ce7-88c4-6446f73c6bbb">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#x2019;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;PYRUKYND&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, by the FDA on February 17, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the treatment of hemolytic anemia in adults with PK deficiency in the United States, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;we began to capitalize inventories of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;PYRUKYND&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standards Codification 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate product revenue from sales of PYRUKYND&#xae; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell PYRUKYND&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of PYRUKYND&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cost of sales consists primarily of manufacturing costs of PYRUKYND&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#xae; r&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ecorded during the three months ended March 31, 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzNg_c2345397-a924-4b66-8838-53044a909d13">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#x2019;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzNw_cc6f0401-028a-4497-bd9d-8cd6835efeeb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;PYRUKYND&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, by the FDA on February 17, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the treatment of hemolytic anemia in adults with PK deficiency in the United States, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;we began to capitalize inventories of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;PYRUKYND&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzOA_0a5e09dc-6cf8-4e5c-9cc7-d0f71131e48b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standards Codification 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate product revenue from sales of PYRUKYND&#xae; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell PYRUKYND&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of PYRUKYND&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfNjU5NzA2OTgxMjgzOQ_04ee1505-1f16-4600-badc-a8ee8dd73da6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cost of sales consists primarily of manufacturing costs of PYRUKYND&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#xae; r&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ecorded during the three months ended March 31, 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV8zNy9mcmFnOmU5NThjMDZhNTVhZTRhMmZhNmMyNGVhMjhkNjBkMDIwL3RleHRyZWdpb246ZTk1OGMwNmE1NWFlNGEyZmE2YzI0ZWEyOGQ2MGQwMjBfMjg3Mw_ed14ab0b-e36a-4ce5-a741-d6fd601e27f1">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTgyMw_033f916b-d55f-4616-b186-b0e8c98268d0">Fair Value Measurements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and marketable securities at fair value. ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value and by level on a recurring basis as of March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the valuation methods during the three months ended March 31, 2022, and we had no financial assets or liabilities that were classified as Level 3 at any point during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTgxOQ_d66f2469-4874-4b90-b26a-e8115dc6cb10">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and marketable securities at fair value. ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTgyMQ_9dbca96c-a864-4d85-80b5-482c314c01a4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value and by level on a recurring basis as of March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5203cb569ff49ca98a0359fff1bd001_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS0xLTEtMS0zMTgyNA_d350e41a-8082-422a-8f8f-24975e4ad4b7"
      unitRef="usd">8092000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if96cc6c457fc41639d4fc3f4ed2f934c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS0zLTEtMS0zMTgyNA_3b550aae-16ec-49c2-b597-3ed4300c0fc1"
      unitRef="usd">57989000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88992bda51914909b6dd871d292700b7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS01LTEtMS0zMTgyNA_14a68414-57d8-42a6-901e-fd15f0325cdb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia69dec3d703147e0a24827abbbc23547_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMS03LTEtMS0zMTgyNA_0aa89dcd-c629-4e21-8512-22944f026b3f"
      unitRef="usd">66081000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4126d05954e4466c8ed0d02bb4506ffb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi0xLTEtMS0zMTgyNA_8d59aab8-08b2-4291-9eac-3794fe6a51b7"
      unitRef="usd">8092000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi0zLTEtMS0zMTgyNA_4d66c5d9-e86d-491e-ac0c-0696d64f14d9"
      unitRef="usd">57989000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi01LTEtMS0zMTgyNA_125b7091-980e-4eee-9995-a2f5462125ce"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0bcdc9702194332ba58fb885ff2771d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMi03LTEtMS0zMTgyNA_4c27c81d-d8fb-45f3-bced-46700055b339"
      unitRef="usd">66081000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a87ede4a0944e6aac0235cba36b26d2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi0xLTEtMS0zMTgyNA_b32198f1-2f9e-4588-95b8-e48a1f47e246"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8ca3b35d04643e0ad5bb05e77e88126_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi0zLTEtMS0zMTgyNA_282355f7-d2c6-4558-b8b3-21ae8be8fb30"
      unitRef="usd">272760000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7012a29f126a40258af0e6ed5765dbff_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi01LTEtMS0zMTgyNA_d6db9b69-28f5-4b93-b9ca-b769fa26dab5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie228033d9a0b4b799dd10eaf894a5565_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNi03LTEtMS0zMTgyNA_955d15a7-4727-43f9-8770-f57ff4b886bc"
      unitRef="usd">272760000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7413f9c5b84645e38c9f817ef9fc6d59_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy0xLTEtMS0zMTgyNA_997f2a27-c6f7-4dae-b4ac-3eb0a2169796"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46b75ada5f8f43bea21d6e34291436e7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy0zLTEtMS0zMTgyNA_71ef2e69-394d-487f-9879-8d6e6943d4c7"
      unitRef="usd">170626000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91bc918915e74396b7fef2d671257ed8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy01LTEtMS0zMTgyNA_054b6e36-2658-4bb4-870a-8bb148441c06"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48bb9c2460444fceb9a62eea46ed198e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfNy03LTEtMS0zMTgyNA_ac12c1bf-3f25-474d-ae6c-fa6dad88d00c"
      unitRef="usd">170626000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ffcd4120185407dba6ff4635e5381d6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC0xLTEtMS0zMTgyNA_538f99b3-b10e-4108-a6f2-af0bf9718bb8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9dbd1b26e91468d9424a22a13ad1978_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC0zLTEtMS0zMTgyNA_12729ff4-6101-4d8d-bcef-7897d8df2bab"
      unitRef="usd">655953000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4c15c9efd3d4ae6b10bdf6ef9f35bb2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC01LTEtMS0zMTgyNA_a906ec85-6a05-4c81-9dd2-8061493fdc44"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec10babe1b934aab9dcfd367e69adf4f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOC03LTEtMS0zMTgyNA_470742bd-c871-4dfa-94bb-dbaf617c53fc"
      unitRef="usd">655953000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4126d05954e4466c8ed0d02bb4506ffb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS0xLTEtMS0zMTgyNA_a4916a94-5d07-497c-aee1-1808b3f7de39"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS0zLTEtMS0zMTgyNA_cdd0318d-87da-4781-b486-8fe0367c9e82"
      unitRef="usd">1099339000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS01LTEtMS0zMTgyNA_67eb2f88-2c78-4bc4-9516-bb4cce7bd5dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0bcdc9702194332ba58fb885ff2771d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfOS03LTEtMS0zMTgyNA_fd4b2123-72d6-47f8-a842-f79bb004803d"
      unitRef="usd">1099339000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i4126d05954e4466c8ed0d02bb4506ffb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtMS0xLTEtMzE4MjQ_57ea873f-010e-4e3d-a866-73d24e683408"
      unitRef="usd">8092000000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="icb4f7a9e817f4d0f9f52fa6e4b3006ea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtMy0xLTEtMzE4MjQ_714639e4-66e1-4314-b60c-7a7875e8c4f2"
      unitRef="usd">1157328000000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtNS0xLTEtMzE4MjQ_65ffbce7-dc50-4f1a-a43e-92723607efa7"
      unitRef="usd">0</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="ie0bcdc9702194332ba58fb885ff2771d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RhYmxlOjNhNzVmZWExOTFhYjRmOTE4MGZlMjliMWVhZDVhMmYyL3RhYmxlcmFuZ2U6M2E3NWZlYTE5MWFiNGY5MTgwZmUyOWIxZWFkNWEyZjJfMTAtNy0xLTEtMzE4MjQ_81f1ec9c-1144-4f31-8bc9-135e56a8f1fd"
      unitRef="usd">1165420000000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i0c0d38b2a5b74f3cac9cdf9123533489_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80My9mcmFnOjNlOWQ2ZTA5MTA3YzQzMjM5OTZiNGJkZDE4ZGRhMjgzL3RleHRyZWdpb246M2U5ZDZlMDkxMDdjNDMyMzk5NmI0YmRkMThkZGEyODNfMTcyNQ_2c878bac-450d-422b-ac07-daee02f88e28"
      unitRef="usd">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMjI2NQ_f8014410-1330-410c-88ec-3cef86a07d6d">Marketable Securities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive loss in the condensed consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive (loss) income, until realized. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the condensed consolidated balance sheets with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three months ended March 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at March&#160;31, 2022 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2021 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, we held 307 and 294 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of March&#160;31, 2022 and December&#160;31, 2021 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at March&#160;31, 2022 and December&#160;31, 2021 was $1,066.8 million and $950.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of March&#160;31, 2022 and December&#160;31, 2021. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMjI2Ng_224f985f-5f98-4041-96e5-57a5efa0e847">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive loss in the condensed consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive (loss) income, until realized. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the condensed consolidated balance sheets with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfOTI0_563b3331-c9c5-4430-a018-bf018548f02a"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfOTI0_c76f4434-eb3d-4a77-9d0c-7aa436bdd444"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMjI2OA_2c1ccb4d-0286-468b-954a-aa2db91dbfc9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at March&#160;31, 2022 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2021 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy0xLTEtMS0zMTgyNA_2ecf1f0c-ea95-4c2e-a5d8-deb37ebedbcc"
      unitRef="usd">243892000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy0zLTEtMS0zMTgyNA_81001bdd-e697-44dd-97d4-8630f03327d6"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy01LTEtMS0zMTgyNA_46308aea-30ce-4f50-b030-8ed5b4c56f25"
      unitRef="usd">352000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1163f342e67f4b2b8954b9a8000defec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMy03LTEtMS0zMTgyNA_2bf2d596-8c80-4fda-acba-1b3287bfc59b"
      unitRef="usd">243554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie75239587a9d477198559b60a4c19637_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC0xLTEtMS0zMTgyNA_4ffd7a22-12db-4c67-bb17-8adf209e8c8e"
      unitRef="usd">24753000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie75239587a9d477198559b60a4c19637_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC0zLTEtMS0zMTgyNA_4579ced6-7019-43a2-be18-8b8e06a5e74a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie75239587a9d477198559b60a4c19637_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC01LTEtMS0zMTgyNA_03a81a44-4376-4c1b-839d-51ca14732b73"
      unitRef="usd">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie75239587a9d477198559b60a4c19637_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNC03LTEtMS0zMTgyNA_fdb30c6d-550c-48b9-9c81-c441ca2aa39c"
      unitRef="usd">24589000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS0xLTEtMS0zMTgyNA_c18599dd-5dc4-4fcc-bea6-0e9def16aece"
      unitRef="usd">577541000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS0zLTEtMS0zMTgyNA_7ab5997f-d91d-4b0c-9d91-d7e53aa47916"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS01LTEtMS0zMTgyNA_b6bc604b-3489-45fd-b075-ee65bd7c0d0d"
      unitRef="usd">2182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i784f84d08b5046fdb42b2d6c383708d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNS03LTEtMS0zMTgyNA_5e5c9bcb-e289-4b2c-a918-39bc4e48298e"
      unitRef="usd">575360000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi0xLTEtMS0zMTgyNA_b9e37683-f588-49db-8e2a-12b8ab3cd518"
      unitRef="usd">846186000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi0zLTEtMS0zMTgyNA_79464ec4-5a0f-4865-8282-b4de139df009"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi01LTEtMS0zMTgyNA_298d54e4-d415-4b33-9fb4-096d94041dea"
      unitRef="usd">2698000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44b2447db00040c2874fb5c5e278e3b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfNi03LTEtMS0zMTgyNA_72c795ae-09ca-4402-999e-345a43ea15b0"
      unitRef="usd">843503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtMS0xLTEtMzE4MjQ_c6c83560-f0b7-4947-9228-6edc242ed96c"
      unitRef="usd">29695000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtMy0xLTEtMzE4MjQ_89001eb5-4789-4839-b2e2-0a81874a18b8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtNS0xLTEtMzE4MjQ_55b58257-99a8-42b9-a960-41115fa077ee"
      unitRef="usd">489000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9cef39867a74079819ffe0340b554c5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTEtNy0xLTEtMzE4MjQ_4f0d17c2-f120-427c-899e-20c0bfee8669"
      unitRef="usd">29206000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i488b85c653fd499fa66acffad102fa83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItMS0xLTEtMzE4MjQ_74826d80-7635-47f5-a94f-666b31f3d8c8"
      unitRef="usd">149378000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i488b85c653fd499fa66acffad102fa83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItMy0xLTEtMzE4MjQ_d793a738-3526-4266-8dda-bbb6cfd2f102"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i488b85c653fd499fa66acffad102fa83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItNS0xLTEtMzE4MjQ_84de95ac-6848-408c-9728-cb6529aa558e"
      unitRef="usd">3341000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i488b85c653fd499fa66acffad102fa83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTItNy0xLTEtMzE4MjQ_e1e7d496-1156-44d0-8511-988ee10037d1"
      unitRef="usd">146037000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtMS0xLTEtMzE4MjQ_36120b51-f888-43ab-b146-46ec0f4921dc"
      unitRef="usd">81825000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtMy0xLTEtMzE4MjQ_4cca41ea-2c55-401e-b3f1-1726327fb342"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtNS0xLTEtMzE4MjQ_7e63885a-3e83-44b9-85ba-3140b71e9017"
      unitRef="usd">1232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05325d5c1172404596cff3bf376d9b1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTMtNy0xLTEtMzE4MjQ_3ea75626-3a8e-42a8-a779-06920289a97d"
      unitRef="usd">80593000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtMS0xLTEtMzE4MjQ_be72f08e-ca60-4bbc-bc30-17483d35d868"
      unitRef="usd">260898000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtMy0xLTEtMzE4MjQ_0015a211-23c8-46b2-ac7f-d06ac501fa5e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtNS0xLTEtMzE4MjQ_e7ef77bc-8a09-4e5f-a194-12c8332a3b95"
      unitRef="usd">5062000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa1cfedca62f472d82be8d85973de1d7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTQtNy0xLTEtMzE4MjQ_dc4db79c-3615-4e3b-88fa-0207b12606a2"
      unitRef="usd">255836000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtMS0xLTEtMzE4MjQ_34b9bced-dde8-4285-b8a6-1e9d802a4746"
      unitRef="usd">1107084000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtMy0xLTEtMzE4MjQ_0597263b-af4f-42e4-bdb3-de7e6913d232"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtNS0xLTEtMzE4MjQ_8cfab3f3-8952-4cda-a1f9-6f9f176287f8"
      unitRef="usd">7760000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOjdkOWQxMDdiMjgxNDQwMDY4MjlmOTU1NDYwMzIwY2I2L3RhYmxlcmFuZ2U6N2Q5ZDEwN2IyODE0NDAwNjgyOWY5NTU0NjAzMjBjYjZfMTUtNy0xLTEtMzE4MjQ_15a9578b-017b-4fd8-aac7-e13f892e3f5e"
      unitRef="usd">1099339000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi0xLTEtMS0zMTgyNA_2f170a16-1a0c-4939-ad30-0ba379615e04"
      unitRef="usd">269109000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi0zLTEtMS0zMTgyNA_4a2461b6-4b94-4f42-aa3c-0c9c8b7b7a66"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi01LTEtMS0zMTgyNA_b63568cd-3a2d-4dbc-8f5f-2c0de8a637ae"
      unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf964a81be38414aa97c9c309c1c2c82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMi03LTEtMS0zMTgyNA_3a4b4027-7451-447d-8792-faa00beab0b9"
      unitRef="usd">269073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy0xLTEtMS0zMTgyNA_0076430d-4fe4-457c-87a0-60b7b04d92bb"
      unitRef="usd">17764000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy0zLTEtMS0zMTgyNA_3aa0482b-ac2c-4b11-86a5-8724479313b3"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy01LTEtMS0zMTgyNA_7f8fa5cd-25da-4982-8739-a14fe9ad5a63"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieac319395ad2486b9899656e63bb1ef3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMy03LTEtMS0zMTgyNA_fe65bc1f-99d5-4fdb-a524-90d2ef714763"
      unitRef="usd">17755000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC0xLTEtMS0zMTgyNA_e7d418e4-e571-479d-9b3b-0962175e04b4"
      unitRef="usd">530490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC0zLTEtMS0zMTgyNA_cfa9fc37-946d-4a2a-867b-3a67ae31838f"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC01LTEtMS0zMTgyNA_6d063576-5380-45e4-b127-27eec9c2dd37"
      unitRef="usd">429000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79dd4f0c88284fe4badccb9475c4f971_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNC03LTEtMS0zMTgyNA_231efc9c-b4df-480e-8cca-126c8aa92b1b"
      unitRef="usd">530064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idca711242fee4c6ab4d75442d9612253_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS0xLTEtMS0zMTgyNA_74b7bd60-d80f-4f74-ae74-fa757b8a7c48"
      unitRef="usd">817363000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idca711242fee4c6ab4d75442d9612253_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS0zLTEtMS0zMTgyNA_7c4a5f23-002a-4e03-b62a-f21c1731606f"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idca711242fee4c6ab4d75442d9612253_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS01LTEtMS0zMTgyNA_a232245b-fe82-45ab-8dab-bcddc7e69828"
      unitRef="usd">475000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idca711242fee4c6ab4d75442d9612253_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfNS03LTEtMS0zMTgyNA_0fdfb71c-fad8-43cd-ba36-9f6ad78b3136"
      unitRef="usd">816892000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS0xLTEtMS0zMTgyNA_439d1047-bb5d-43cd-b294-af12c78496f4"
      unitRef="usd">40607000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS0zLTEtMS0zMTgyNA_2a2284ec-2297-4cfb-83fd-e30b06e7d97c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS01LTEtMS0zMTgyNA_ff9f0104-7bd6-4f83-bf5e-a9bc5dcf474e"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i756a2ef1edac4f07b53d1470ef869070_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfOS03LTEtMS0zMTgyNA_041bf45e-2de4-43ef-81f4-a1d81c14a228"
      unitRef="usd">40584000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i855087ce662749b2b547077eb45a8a38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtMS0xLTEtMzE4MjQ_0ebb081c-40cf-45b5-af25-04d35d77eb0e"
      unitRef="usd">148820000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i855087ce662749b2b547077eb45a8a38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtMy0xLTEtMzE4MjQ_0bfdcbd5-6a76-4d33-9646-2680d2d29744"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i855087ce662749b2b547077eb45a8a38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtNS0xLTEtMzE4MjQ_c701848b-6540-40dd-b462-b80d908d02e2"
      unitRef="usd">470000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i855087ce662749b2b547077eb45a8a38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTAtNy0xLTEtMzE4MjQ_5824a61f-274b-4246-8be3-4c2b185d7e13"
      unitRef="usd">148350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtMS0xLTEtMzE4MjQ_7f139912-78d7-4547-8779-ef7af4fa132a"
      unitRef="usd">77675000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtMy0xLTEtMzE4MjQ_df6e02b1-ed3b-4c86-bba7-70072fb0e9ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtNS0xLTEtMzE4MjQ_c2868201-5781-4d89-9593-d62c46d6b01b"
      unitRef="usd">234000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0577f8cd46849f2a8b97982550aea04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTEtNy0xLTEtMzE4MjQ_09053cff-d731-4b8f-9af3-030c98363b44"
      unitRef="usd">77441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2be1907947514eb7b13e3dc095194484_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItMS0xLTEtMzE4MjQ_1260dc40-3948-4fca-87d4-55fc7212a277"
      unitRef="usd">267102000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2be1907947514eb7b13e3dc095194484_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItMy0xLTEtMzE4MjQ_a06dde66-9779-4cc4-be95-aaa893ade93c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2be1907947514eb7b13e3dc095194484_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItNS0xLTEtMzE4MjQ_96d69f48-48fc-4b58-b476-39f1b0164500"
      unitRef="usd">727000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2be1907947514eb7b13e3dc095194484_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTItNy0xLTEtMzE4MjQ_e484f4a7-b4cf-4840-8e77-5c10df9dd0ea"
      unitRef="usd">266375000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtMS0xLTEtMzE4MjQ_1cd1c776-8418-4e17-ae88-aae5becfa003"
      unitRef="usd">1084465000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtMy0xLTEtMzE4MjQ_9a4802c9-0b13-4b13-b7c1-bd3e1836c217"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtNS0xLTEtMzE4MjQ_3db225dc-7896-4f5c-8805-dabb51e3d928"
      unitRef="usd">1202000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RhYmxlOmY0YjFhYzdkMzAxODRiNmFhMjI2NTM4NDJjZjFiOTI0L3RhYmxlcmFuZ2U6ZjRiMWFjN2QzMDE4NGI2YWEyMjY1Mzg0MmNmMWI5MjRfMTMtNy0xLTEtMzE4MjQ_7a341953-faf1-4211-9eef-3ebdb8d5b792"
      unitRef="usd">1083267000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTUyOQ_217d62e8-fe48-448f-9771-d6c1c36aa178"
      unitRef="security">307</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTUzNg_84c235a1-9272-4afc-b9af-cc13d71db4c7"
      unitRef="security">294</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTY0Mg_3afcfa02-fcf2-4e34-a573-d1f6142124df"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTY0Mg_705ce8c8-fc73-49d0-973e-c4e21ea96671"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTgyMQ_23119b7d-5b41-4825-a9bf-4a9b60b9da5e"
      unitRef="usd">1066800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTgyOA_ef5e8d3d-7c11-4537-a40c-b36f0d577a31"
      unitRef="usd">950500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTg1Nw_0b01d3ba-d3a3-4c70-b483-7484812ea7ed"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80Ni9mcmFnOmYxMmM3NDE0ZmM0YzQ3NzhhNzYwZTY2MTQwMmMyZDczL3RleHRyZWdpb246ZjEyYzc0MTRmYzRjNDc3OGE3NjBlNjYxNDAyYzJkNzNfMTg1Nw_caad5671-dc81-4fb5-b4b6-970be171df96"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90ZXh0cmVnaW9uOmQ4MGVkYjA1YmM1ZDQ0ZWU5YjY3MjIwYzhkMmRkMjJhXzY1OTcwNjk3NjY4NTI_4765d616-ee52-42dd-8c68-b8e905f6efb4">Inventory&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of commercial supply of PYRUKYND&#xae;, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90ZXh0cmVnaW9uOmQ4MGVkYjA1YmM1ZDQ0ZWU5YjY3MjIwYzhkMmRkMjJhXzY1OTcwNjk3NjY4NTM_8a400285-68de-4c77-9f68-2a2d5815ba82">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of commercial supply of PYRUKYND&#xae;, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzEtMS0xLTEtMzMyNDk_21342076-883f-4283-970e-085605a0684a"
      unitRef="usd">0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzEtMy0xLTEtMzMyNzg_a7a0e281-53b9-4322-8070-55d8833d425a"
      unitRef="usd">0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzItMS0xLTEtMzMyNTY_3a3acb54-c096-40bc-b6fe-3b5a43daf16e"
      unitRef="usd">2185000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzItMy0xLTEtMzMyODU_5273ae1f-4ce3-42b6-98c2-7cc3e9b79cea"
      unitRef="usd">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzMtMS0xLTEtMzMyNjM_e8f4a8b4-f37e-4c89-a928-be395625fc61"
      unitRef="usd">300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzMtMy0xLTEtMzMyOTI_d3f26751-3ea4-4c45-a32c-f5fa3f7d9da3"
      unitRef="usd">0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzQtMS0xLTEtMzMyNzA_fd6c30a1-7a1a-4539-aa76-d46ce38bddf3"
      unitRef="usd">2485000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NjEvZnJhZzpkODBlZGIwNWJjNWQ0NGVlOWI2NzIyMGM4ZDJkZDIyYS90YWJsZTo3OTI2MmJlYzIzZGQ0NWU1YTc1Y2VhZDEzYjdhNGM2Mi90YWJsZXJhbmdlOjc5MjYyYmVjMjNkZDQ1ZTVhNzVjZWFkMTNiN2E0YzYyXzQtMy0xLTEtMzMyOTk_4ba44240-8532-465c-aa2c-bbf4390cbdd4"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTAzNw_55b17ef9-e776-4620-af0d-6500eeeab2d1">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of six years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense and other information related to leases were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not entered into any material short-term leases or financing leases as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arriving at the operating lease liabilities as of March&#160;31, 2022 and December&#160;31, 2021, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 5.9 years and 6.2 years, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provided our landlord a standby letter of credit of $2.9 million as security for our leases. We are not required to maintain any cash collateral for the standby letter of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we entered into a long-term sublease agreement for 13,000 square feet of the office space at 38 Sidney Street Cambridge, Massachusetts. The term of the lease runs until December 2024. We recorded operating sublease income of $0.4&#160;million for the three months ended March 31, 2022 in other income, net in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the future minimum lease payments to be received under the long-term sublease agreement were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTcy_ca19be1a-fc43-4957-94c2-e00b566ebbe2">P6Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTAzMw_4cc79f4c-8fd2-479c-b587-62f8cc4f7fc6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense and other information related to leases were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMi0xLTEtMS0zMTgyNA_4567b280-a666-4723-b4bd-6e4c7258ce7d"
      unitRef="usd">3800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMi0zLTEtMS0zMTgyNA_e7b192de-a4a6-49b7-8133-012ad37645ff"
      unitRef="usd">3800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMy0xLTEtMS0zMTgyNA_fc01ee73-f525-4e8f-a05a-ac6379bd39cb"
      unitRef="usd">3800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjEzNzFiODg5MzNjMjQ3ZmM5NzEyN2Q4ZDAyMjhiOWNlL3RhYmxlcmFuZ2U6MTM3MWI4ODkzM2MyNDdmYzk3MTI3ZDhkMDIyOGI5Y2VfMy0zLTEtMS0zMTgyNA_66c25004-eb66-4e27-902f-8bbdf89a265c"
      unitRef="usd">3600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQyMg_829fc209-b3f3-4daf-8058-c3ed8024d052"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQyMg_9b7de839-de2a-4ee2-89da-31d1c64eba41"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQ5MQ_014c6079-db66-4372-a345-c29f23bd6f02">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzQ5OQ_4aa99f8c-8034-44d3-9317-82550ed24cd9">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTAzNQ_c162a271-85b0-457e-af00-934a5357630f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfMS0xLTEtMS0zMTgyNA_9c17392a-ec37-475a-bb29-5f492f043206"
      unitRef="usd">11784000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfMi0xLTEtMS0zMTgyNA_9e1e9a26-6fbb-43c5-8548-3e2a7f7c8e0b"
      unitRef="usd">18126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfMy0xLTEtMS0zMTgyNA_4fcce850-0efe-4d59-ac8a-13705b5b7d6f"
      unitRef="usd">18660000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNC0xLTEtMS0zMTgyNA_0560ded2-fd6c-4eee-b7b7-3b66883be430"
      unitRef="usd">19507000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNS0xLTEtMS0zMTgyNA_03a97acc-5800-4dcd-b910-15ae481bd4f8"
      unitRef="usd">20151000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNi0xLTEtMS0zNTUyMg_e3cd5dbd-2f55-4dbe-bdb3-46a8d3c59bb7"
      unitRef="usd">20755000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNi0xLTEtMS0zMTgyNA_43ea3aa5-7424-4fc7-8c94-a754623d2a65"
      unitRef="usd">3479000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfNy0xLTEtMS0zMTgyNA_3f67a52a-ef9d-40cf-be3c-d0f778395f5b"
      unitRef="usd">112462000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfOC0xLTEtMS0zMTgyNA_21df0939-e33a-46a7-8f8b-726194818802"
      unitRef="usd">18380000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOmE0N2Y3Nzc5NTc2YTQ5YWI4ZGQyNGUyNzEzMmUwMzIwL3RhYmxlcmFuZ2U6YTQ3Zjc3Nzk1NzZhNDlhYjhkZDI0ZTI3MTMyZTAzMjBfOS0xLTEtMS0zMTgyNA_851bd224-9b13-4d4f-8376-ff5a485e6c71"
      unitRef="usd">94082000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMTY0OTI2NzQ0MzkyOA_544f2b03-a5c7-415f-a989-f4c14b02dc00"
      unitRef="usd">2900000</us-gaap:OtherAssetsNoncurrent>
    <agio:LesseeOperatingSubleaseAreaOfPremisesSubleased
      contextRef="i15c7600459e34951a4cec3ff06faf28f_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfNjU5NzA2OTc2ODI1OQ_dcf69fcb-3aed-4e21-97b7-2931361c4b82"
      unitRef="sqft">13000</agio:LesseeOperatingSubleaseAreaOfPremisesSubleased>
    <us-gaap:SubleaseIncome
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfMjE5OTAyMzI1NzExNw_dc4a0a9f-92e3-449b-aac6-4263cccb1be4"
      unitRef="usd">400000</us-gaap:SubleaseIncome>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RleHRyZWdpb246ODQwN2E5YzYwNDg3NGIxZWFhYWU5Njg2M2MzYTZlOWJfNjU5NzA2OTc2ODI2OA_1b6e633c-6ab0-461d-9fb6-7ec774d42830">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the future minimum lease payments to be received under the long-term sublease agreement were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfMS0xLTEtMS0zNjg4Mw_c3b06c77-d33f-403a-a6ea-afe4e8c6feb9"
      unitRef="usd">842000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfMi0xLTEtMS0zNjg4Mw_f717025b-25fd-401d-8f0d-b2b8da5ad01c"
      unitRef="usd">1152000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfMy0xLTEtMS0zNjg4Mw_49c47cf2-e9cd-472f-aebc-0cb336d03581"
      unitRef="usd">1186000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80OS9mcmFnOjg0MDdhOWM2MDQ4NzRiMWVhYWFlOTY4NjNjM2E2ZTliL3RhYmxlOjYxYmM3YzNjZDg2ZjQ3ZDViOWZmOTdmNTJmNWY3ZmI5L3RhYmxlcmFuZ2U6NjFiYzdjM2NkODZmNDdkNWI5ZmY5N2Y1MmY1ZjdmYjlfNC0xLTEtMS0zODQ0NQ_63696a92-13fe-4d36-aa95-13d981932930"
      unitRef="usd">3180000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RleHRyZWdpb246ZmFjMzcxMzFjZDMzNGI1OWJhZjZmMTg5YWQ2MWNkZjRfNzE_a1c52ba2-a783-43b2-9153-ec6f3d243faf">Accrued Expenses&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RleHRyZWdpb246ZmFjMzcxMzFjZDMzNGI1OWJhZjZmMTg5YWQ2MWNkZjRfNjk_3cb50c25-cd12-42dd-92ed-505b461b7271">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMS0xLTEtMS0zMTgyNA_948151aa-e6e4-4da6-8653-ef20e2669c53"
      unitRef="usd">5387000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMS0zLTEtMS0zMTgyNA_07b54a4a-7053-4a16-84bc-26013cfa0bd9"
      unitRef="usd">19818000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMi0xLTEtMS0zMTgyNA_655a1627-defa-404d-a390-c70047c345b4"
      unitRef="usd">8626000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMi0zLTEtMS0zMTgyNA_c7e8fbc6-6eaa-4224-87ff-9ddbaeeac660"
      unitRef="usd">5980000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMy0xLTEtMS0zMTgyNA_2ae2a4df-5e63-4637-98f5-7b2b634a4753"
      unitRef="usd">1952000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfMy0zLTEtMS0zMTgyNA_9f43d3d1-c314-4d2e-920c-2a2dd4d61cc6"
      unitRef="usd">2335000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNC0xLTEtMS0zMTgyNA_95b04af2-cd88-4640-a5c7-7c5283f40e32"
      unitRef="usd">3782000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNC0zLTEtMS0zMTgyNA_826af638-3181-4da9-b9e4-ff302bb3d63f"
      unitRef="usd">3834000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNS0xLTEtMS0zMTgyNA_b05af587-99a8-4041-b475-1d6265f169f3"
      unitRef="usd">19747000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81Mi9mcmFnOmZhYzM3MTMxY2QzMzRiNTliYWY2ZjE4OWFkNjFjZGY0L3RhYmxlOjg4NGNjZjFlNmU3NjQ0ODZiNmQ3NjE1M2Q3N2Q1MzdlL3RhYmxlcmFuZ2U6ODg0Y2NmMWU2ZTc2NDQ4NmI2ZDc2MTUzZDc3ZDUzN2VfNS0zLTEtMS0zMTgyNA_28268d1b-ed94-4bc2-8dde-ad23a42ae954"
      unitRef="usd">31967000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTA_11bfa12e-31e3-4708-baee-6dec88dff18c">Product RevenueWe sell PYRUKYND&#xae;, our wholly owned product, to the Customers. The Customers subsequently resell PYRUKYND&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#xae;.&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of PYRUKYND&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets during the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTE_c2e7458f-4b36-4a8d-bd84-a077fc836e69">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ad81482e39040cfa13a399adf4f783f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTozNzJlNGEyOGQ0NDA0OTg5YTMwNmY0ZWQ3MzRhMmZlZi90YWJsZXJhbmdlOjM3MmU0YTI4ZDQ0MDQ5ODlhMzA2ZjRlZDczNGEyZmVmXzItMS0xLTEtMzM3MDM_33a583f2-a477-4dec-a7d9-017f3554372f"
      unitRef="usd">832000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if275c08a4b1a44d1a150f50c7c881130_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTozNzJlNGEyOGQ0NDA0OTg5YTMwNmY0ZWQ3MzRhMmZlZi90YWJsZXJhbmdlOjM3MmU0YTI4ZDQ0MDQ5ODlhMzA2ZjRlZDczNGEyZmVmXzItMy0xLTEtMzM3MTM_ae22ef86-9178-488a-b06d-24ec4fb1753b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTI_11a692a0-4580-4576-9855-838fcfc29dd6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <agio:ContractWithCustomerContractualAdjustmentReserve
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtMS0xLTEtMzM4MTc_ae8d1f8f-020a-4804-9a10-c0d7324f45c7"
      unitRef="usd">0</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtMy0xLTEtMzM4MTc_5bd6c452-fadf-478a-bcfb-f30e59f4a61b"
      unitRef="usd">0</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtNS0xLTEtMzM4MTc_68a7ee8e-2ba9-44cf-8a80-b55fbe89222c"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzEtNy0xLTEtMzM4MTc_f76354ef-e2ea-4783-b337-a8de21ba9e01"
      unitRef="usd">0</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:CurrentYearProvisionForContractualAdjustments
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItMS0xLTEtMzM4MTc_4493691f-c943-4a33-8419-b0797bd626de"
      unitRef="usd">37000</agio:CurrentYearProvisionForContractualAdjustments>
    <agio:CurrentYearProvisionsForRebateReserve
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItMy0xLTEtMzM4MTc_7583e9d3-b34e-4081-a233-134c4c4df349"
      unitRef="usd">56000</agio:CurrentYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInCurrentYear
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItNS0xLTEtMzM4MTc_f4165054-293b-4991-9252-51e42af7db33"
      unitRef="usd">9000</agio:ProvisionForRightToRecoverProductInCurrentYear>
    <agio:ContractWithCustomerCurrentYearReserveProvisions
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzItNy0xLTEtMzM4MTc_1904c3bd-98c0-4f6a-957a-c0cabb61ff20"
      unitRef="usd">102000</agio:ContractWithCustomerCurrentYearReserveProvisions>
    <agio:PriorYearProvisionForContractualAdjustments
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtMS0xLTEtMzM4MTc_e8252e69-f3f8-4057-b935-cc20a2b6d44c"
      unitRef="usd">0</agio:PriorYearProvisionForContractualAdjustments>
    <agio:PriorYearProvisionsForRebateReserve
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtMy0xLTEtMzM4MTc_3cc5e382-3d07-43ac-a814-2890c916bcb9"
      unitRef="usd">0</agio:PriorYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInPriorYears
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtNS0xLTEtMzM4MTc_59b1020e-eb34-4a60-9c46-c2050f0a68e3"
      unitRef="usd">0</agio:ProvisionForRightToRecoverProductInPriorYears>
    <agio:ContractWithCustomerPriorYearsReserveProvisions
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzMtNy0xLTEtMzM4MTc_29ab8ef7-4553-4f45-b01c-494ab1ef906b"
      unitRef="usd">0</agio:ContractWithCustomerPriorYearsReserveProvisions>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtMS0xLTEtMzM4MTc_17c1e284-1af8-4800-9892-f3a063eb1bc2"
      unitRef="usd">11000</agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtMy0xLTEtMzM4MTc_d0562ef6-eec3-4528-aece-852390d361c4"
      unitRef="usd">0</agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear>
    <agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtNS0xLTEtMzM4MTc_5f7a0cc4-7354-4aaf-8e06-53ba659abacc"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries>
    <agio:ContractWithCustomerCurrentYearReserveRecoveries
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzQtNy0xLTEtMzM4MTc_ff1288f3-9646-4a8e-885a-28455563d441"
      unitRef="usd">11000</agio:ContractWithCustomerCurrentYearReserveRecoveries>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtMS0xLTEtMzM4MTc_878dc9a2-4004-4b2b-9357-9e351f28b141"
      unitRef="usd">0</agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtMy0xLTEtMzM4MTc_79771181-349c-4260-9573-c6ce7b050b1f"
      unitRef="usd">0</agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears>
    <agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtNS0xLTEtMzM4MTc_30ba5430-b82d-4ca0-93ca-baee13895ed5"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries>
    <agio:ContractWithCustomerPriorYearsReserveRecoveries
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzUtNy0xLTEtMzM4MTc_8229b6c7-5b21-4710-a249-43b95bcfcabe"
      unitRef="usd">0</agio:ContractWithCustomerPriorYearsReserveRecoveries>
    <agio:ContractWithCustomerContractualAdjustmentReserve
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtMS0xLTEtMzM4MTc_f64d5d29-f3ca-427a-8705-cd6d7116d18b"
      unitRef="usd">26000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtMy0xLTEtMzM4MTc_367fc71e-4b91-41a6-a523-1fa17280534a"
      unitRef="usd">56000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtNS0xLTEtMzM4MTc_edfa1451-e214-4780-803b-878c5f2ff6a1"
      unitRef="usd">9000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTo5NGRkNzk4M2QxMjg0NGQ4OWQxN2U2M2NiOGIzODNkMi90YWJsZXJhbmdlOjk0ZGQ3OTgzZDEyODQ0ZDg5ZDE3ZTYzY2I4YjM4M2QyXzYtNy0xLTEtMzM4MTc_2b0c5eec-450b-41d1-b5da-5ef5cbda8936"
      unitRef="usd">91000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTM_ab8c6838-b184-406e-9559-e5d116ae1818">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzEtMS0xLTEtMzM4ODM_d5f0ab03-c19b-418c-ba07-532cd204812a"
      unitRef="usd">17000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzEtMy0xLTEtMzM4ODM_f388e8ee-ecc4-4646-8145-140329578ddd"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <agio:ContractWithCustomerAllowanceAndReservesLiability
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzItMS0xLTEtMzM4ODM_cb9e6686-d553-4cc9-8829-a3f0fceac10c"
      unitRef="usd">74000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerAllowanceAndReservesLiability
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzItMy0xLTEtMzM4ODM_14680efd-6775-429f-b541-d61401769d98"
      unitRef="usd">0</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzMtMS0xLTEtMzM4ODM_b733a89f-41cd-4930-b3a3-5d84840799ec"
      unitRef="usd">91000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpkMjBiNDVjMDQ3MGU0MDMzOTFmMGU4MmRiNmIyNDM4My90YWJsZXJhbmdlOmQyMGI0NWMwNDcwZTQwMzM5MWYwZTgyZGI2YjI0MzgzXzMtMy0xLTEtMzM4ODM_8dfb2358-d20f-4ef6-82c3-23f2bd19d30d"
      unitRef="usd">0</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90ZXh0cmVnaW9uOjU1ZGNmNjE3ZWZlODRlZTE4YmY2NWZkYmI3OTA4ZmRiXzY1OTcwNjk3NzIwMTQ_c0e97e4b-8479-48e2-b5d1-850573552ca4">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets during the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.</agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItMS0xLTEtMzM5NDc_bcd9c9d0-46a2-4cf5-bb30-71ea9eab0f3a"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItMy0xLTEtMzM5NDc_95e6d006-1b25-4349-b873-d7c1155175ec"
      unitRef="usd">934000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItNS0xLTEtMzM5NDc_6c9709f9-5a08-481f-a2bf-5d7fbc846ac4"
      unitRef="usd">394000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV80NzEvZnJhZzo1NWRjZjYxN2VmZTg0ZWUxOGJmNjVmZGJiNzkwOGZkYi90YWJsZTpjNTc0MDliYTM4MWE0OGQ0ODYyN2Y5MjJlYTgyZmE4Mi90YWJsZXJhbmdlOmM1NzQwOWJhMzgxYTQ4ZDQ4NjI3ZjkyMmVhODJmYTgyXzItNy0xLTEtMzM5NDc_97a274ee-efd0-435e-bed2-308930c6ca0d"
      unitRef="usd">540000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzNw_62a3b9e7-aa3f-4d3b-8570-cc6d49362da3">Share-Based Payments&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based share units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of March&#160;31, 2022, the total number of shares reserved under the 2007 Plan and the 2013 Plan was 13,027,919, and we had 6,142,929 shares available for future issuance under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock option activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,494,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there was approximately $44.0 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents RSU activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there was approximately $43.4 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based stock units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents PSU activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#x2019;s best estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $13.0 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Market-based stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of March&#160;31, 2022, there was no remaining unrecognized compensation expense related to MSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 48,156 and 59,401 shares of common stock during the three months ended March 31, 2022 and 2021, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 1,854,545 shares of our common stock. As of March&#160;31, 2022, we had 1,346,491 shares of common stock available for future issuance under the 2013 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i70609af01f924e08961eae93134c2934_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTQ2_70cdcfe4-c99b-4d18-9193-31acc676a69d"
      unitRef="shares">13027919</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia272dc6363a84ac2ad2bd1fac38e1aab_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTYx_879ad419-9d36-4420-b9d1-138fe6d5ae1e"
      unitRef="shares">6142929</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzOA_b360dae3-7fcc-4e70-b489-e519fea9a92d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock option activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,494,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMS0xLTEtMS0zMTgyNA_739aeb3b-0691-477b-8e0a-78e1f94ea25d"
      unitRef="shares">4798826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5c86e4fe16a543c093349fd84ce7ee87_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMS0zLTEtMS0zMTgyNA_9a72de22-c6be-4743-be3c-98e4a5bd1f74"
      unitRef="usdPerShare">58.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMi0xLTEtMS0zMTgyNA_e10ab490-c6b1-4f5b-8efd-422341b221df"
      unitRef="shares">647713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMi0zLTEtMS0zMTgyNA_2ff5d277-341f-4c25-82e4-cd47d75af9b9"
      unitRef="usdPerShare">32.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMy0xLTEtMS0zMTgyNA_f290d296-cbe6-4f62-89bf-c692a5f5f8e3"
      unitRef="shares">3250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfMy0zLTEtMS0zMTgyNA_cfcbef49-eff1-4fe2-b2f2-952c8e5a5116"
      unitRef="usdPerShare">4.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNC0xLTEtMS0zMTgyNA_dfb3e78f-4a2e-418c-8106-76d21f518088"
      unitRef="shares">168145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNC0zLTEtMS0zMTgyNA_fdaed655-ee62-4340-9a72-06a514f172df"
      unitRef="usdPerShare">68.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNS0xLTEtMS0zMTgyNA_996be199-92b8-4a89-a3f2-36eec0493090"
      unitRef="shares">5275144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNS0zLTEtMS0zMTgyNA_43d8d2ed-e76f-4e3d-a9e4-549915d6b808"
      unitRef="usdPerShare">55.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNi0xLTEtMS0zMTgyNA_34b68264-e4e0-4c61-b5dd-92037356c086"
      unitRef="shares">3494909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNi0zLTEtMS0zMTgyNA_fffa748c-492f-4827-ba16-6170a959d3c8"
      unitRef="usdPerShare">59.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNy0xLTEtMS0zMTgyNA_f28aa7ea-f67a-4a0c-991f-8043610d81e7"
      unitRef="shares">5275144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i44baacb616534e10bf3e92b51f3ca635_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOjgzY2UyYzNjYzgyYjQ0ZDZiYzdhZDEwZDAyMTEwMDM2L3RhYmxlcmFuZ2U6ODNjZTJjM2NjODJiNDRkNmJjN2FkMTBkMDIxMTAwMzZfNy0zLTEtMS0zMTgyNA_4e1f0a55-f1f4-41d8-a587-05834390875a"
      unitRef="usdPerShare">55.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia272dc6363a84ac2ad2bd1fac38e1aab_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMzMy_85ee516d-7387-4560-9fea-111c67d71aaa"
      unitRef="usd">44000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i83ae90ff305f4fc99f69ae4834a3f97a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfNDk2_d9ce865c-bc40-421b-8994-707dec7f5f97">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzOQ_9dae4146-be97-473c-8892-7963c715eaf5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents RSU activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifa54a29f6a2c403383d89cfeec3aaf59_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMS0xLTEtMS0zMTgyNA_8085824d-5b46-47ae-959f-8c85cb676735"
      unitRef="shares">1002924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifa54a29f6a2c403383d89cfeec3aaf59_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMS0zLTEtMS0zMTgyNA_427c08e7-fea6-446a-9cc4-83f8ce356b93"
      unitRef="usdPerShare">51.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMi0xLTEtMS0zMTgyNA_d8f9e97d-9195-4ef1-b319-7125ed61cd4d"
      unitRef="shares">634232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMi0zLTEtMS0zMTgyNA_8f8e9335-5dde-4cea-a80e-59c2fdba3524"
      unitRef="usdPerShare">32.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMy0xLTEtMS0zMTgyNA_b630645c-9015-4849-8a45-61ef3d30f65b"
      unitRef="shares">337463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfMy0zLTEtMS0zMTgyNA_a80f60c9-1c2c-4131-9f94-c7a7432f2621"
      unitRef="usdPerShare">53.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNC0xLTEtMS0zMTgyNA_b2d30d40-ee34-42b8-9ac4-e4d661d715fa"
      unitRef="shares">16156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNC0zLTEtMS0zMTgyNA_1ffb92c9-28a2-4136-acd3-1671b3164287"
      unitRef="usdPerShare">46.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNS0xLTEtMS0zMTgyNA_9e037dd6-996a-4fe1-9118-422244aca2eb"
      unitRef="shares">1283537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVmNTM1NDgzYTE4OTRiNmE5MjJiMjg4YmJiNGY5YmJlL3RhYmxlcmFuZ2U6ZWY1MzU0ODNhMTg5NGI2YTkyMmIyODhiYmI0ZjliYmVfNS0zLTEtMS0zMTgyNA_25985302-655f-4bd6-998c-705c36839186"
      unitRef="usdPerShare">41.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i1a58c0f62a674dfb89c5c3a8466ead8a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfNjEz_e31874dc-9f2e-4514-83fc-a2c03a30da58"
      unitRef="usd">43400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfNzUz_7f04d851-b184-489c-89bb-0a266a6a43cc">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjY0MA_d1f35ae4-472f-43b7-80d3-2238ac70d924">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents PSU activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i92b16706b28640548b80c7b1f2d3e403_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMS0xLTEtMS0zMTgyNA_d4228333-5403-41da-824c-7a8f13500453"
      unitRef="shares">234059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i92b16706b28640548b80c7b1f2d3e403_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMS0zLTEtMS0zMTgyNA_d3f90276-60ae-4216-98e4-2fba6a2cdbae"
      unitRef="usdPerShare">54.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMi0xLTEtMS0zMTgyNA_70cda43b-4619-4db3-8850-a4630d2ec4b7"
      unitRef="shares">108500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMi0zLTEtMS0zMTgyNA_2c3c0fd9-4dcd-4f13-afdf-1fed7b54b2b8"
      unitRef="usdPerShare">32.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMy0xLTEtMS0zMTgyNA_360e3fef-633d-4fec-9fdf-d60ee1380d51"
      unitRef="shares">53777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfMy0zLTEtMS0zMTgyNA_a1bb0cdf-49c6-45e6-a625-a08bdc5638fd"
      unitRef="usdPerShare">54.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNC0xLTEtMS0zMTgyNA_1b11ea95-97fa-4620-86f7-1419fd3405d1"
      unitRef="shares">5168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNC0zLTEtMS0zMTgyNA_465bf7c0-29bb-41cf-a937-49a177ac3b6e"
      unitRef="usdPerShare">61.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i65d1a1a869b64af6af400f631a1e6c4d_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNS0xLTEtMS0zMTgyNA_d0932528-5e9a-4bc6-8ae1-8c9a75c20e0e"
      unitRef="shares">283614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i65d1a1a869b64af6af400f631a1e6c4d_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmIwZmNkZDU4NzNkZjQyMTBiY2RlYjUzYmI3NmQ5MTUxL3RhYmxlcmFuZ2U6YjBmY2RkNTg3M2RmNDIxMGJjZGViNTNiYjc2ZDkxNTFfNS0zLTEtMS0zMTgyNA_1f33d7d0-00ef-4842-a214-d831dd08627b"
      unitRef="usdPerShare">45.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i8e402691929e44468cadbcc8453e6514_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTA1NQ_8585cbdc-98d2-4be3-9e12-9b1f3ee51d3b"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <agio:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount
      contextRef="i65d1a1a869b64af6af400f631a1e6c4d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTE5Nw_c5ade234-0db2-4005-ba8e-d8982c2654b1"
      unitRef="usd">13000000</agio:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjY0Mg_d3edf4ab-e86f-4800-81bd-c86d67ee833d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents market-based stock unit, or MSU, activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib271baa482c94d97ac48840b7d361a47_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMS0xLTEtMS0zMTgyNA_a499572e-19b1-4f9c-902e-f908b975221c"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib271baa482c94d97ac48840b7d361a47_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMS0zLTEtMS0zMTgyNA_aebc66f2-75b4-40dc-b19d-a3ec569115b4"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3f547c547c3d455d9028f77bd9be80d6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMi0xLTEtMS0zMTgyNA_8e75aa0b-23e6-44dd-931e-efcbbc0b8823"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3f547c547c3d455d9028f77bd9be80d6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfMi0zLTEtMS0zMTgyNA_c726da41-7bfd-45b4-9bd7-62142bf62fff"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3f510a7bc35c4acc904d0706efb5488c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfNS0xLTEtMS0zMTgyNA_406a031b-9266-4cf6-854e-b40577da4542"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3f510a7bc35c4acc904d0706efb5488c_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmFkNTEzNDhmZDJiMzRhZDQ5ZjU1MWU2MDQyNGYyMDZkL3RhYmxlcmFuZ2U6YWQ1MTM0OGZkMmIzNGFkNDlmNTUxZTYwNDI0ZjIwNmRfNS0zLTEtMS0zMTgyNA_38390fe6-58e1-4ae6-9d5c-8f36d9e62722"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i3f510a7bc35c4acc904d0706efb5488c_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMTc0NQ_673720a9-1894-4fbe-afcc-0e1b91cec7a9"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6c09eceb9aa140f8b2fa149e6232b87f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjAwOQ_041411e2-89fe-46ed-bfb3-0224f6a50ae1"
      unitRef="shares">48156</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i46afd29a81bf441a99b55105d1a18809_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjAxNg_5833f9d0-2713-414f-b4da-c164b8565db2"
      unitRef="shares">59401</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i6c09eceb9aa140f8b2fa149e6232b87f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjIwMQ_e7e12aea-c685-42fe-b161-37aaa1df1a3f"
      unitRef="shares">1854545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3ddbb4db5e1644ccaa03be39b46f2cb4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjI0OQ_d5a98ca2-8320-4907-ad57-d34d3673430f"
      unitRef="shares">1346491</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzNQ_bd65d64a-12e1-4396-b57a-d15463a0c1c1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3842af82e752402aa7a5fbeedccf54b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMi0xLTEtMS0zMTgyNA_482fd66c-c068-42dc-9a0f-f085f1296ff4"
      unitRef="usd">6201000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a9a1d0006454af4aeab6df1c2911d6e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMi0zLTEtMS0zMTgyNA_a6e3b937-1a3d-4fb4-a01d-0a7ac763b017"
      unitRef="usd">8396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMy0xLTEtMS0zMTgyNA_e66fad00-bfd7-4692-8990-791052c99d26"
      unitRef="usd">6165000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26c67bf64fdf4dcc9d2de216530f51c1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfMy0zLTEtMS0zMTgyNA_71290dbd-173e-45a7-9737-f01faed158f4"
      unitRef="usd">6205000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i32fbc5ef6e974995b656897e8b88a2a8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNC0xLTEtMS0zMTgyNA_f53f425f-c67c-4c41-affe-c011cfc99058"
      unitRef="usd">2919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88173f3394c14c71afab60eef3d941af_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNC0zLTEtMS0zMTgyNA_7577d4e0-6c70-4aac-ae6a-3b086b4f02cb"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i328200bab58e48e9be32dfe062e76e09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNS0xLTEtMS0zMTgyNA_8a959e2d-97b3-432c-9fc9-c5801bcce582"
      unitRef="usd">225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i538c902f308341ad8db797be144a4c17_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNS0zLTEtMS0zMTgyNA_7ec62eae-d52e-4030-ba87-89fd68c32426"
      unitRef="usd">253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib15521d93cb44d6183b8ea908841d562_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNi0xLTEtMS0zMTgyNA_616e75e2-2896-423a-8ede-23a29ece2f04"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefcb67b5c5064fd198f05934740baab6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNi0zLTEtMS0zMTgyNA_80ad2a9d-5ba4-46e7-a072-1fada51dd635"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNy0xLTEtMS0zMTgyNA_b8c0308b-421b-41e4-9173-5efaeb256cc5"
      unitRef="usd">15510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmUxY2E3YTJiYzMwNDQ2ZGNiMDg3NGQ4N2IyYjgwMDYzL3RhYmxlcmFuZ2U6ZTFjYTdhMmJjMzA0NDZkY2IwODc0ZDg3YjJiODAwNjNfNy0zLTEtMS0zMTgyNA_56371e2e-899c-40f7-ac6e-6fb0768bc780"
      unitRef="usd">14854000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RleHRyZWdpb246ZTE5ODlhMDUxNzM5NDBmZThlN2M4YzU0NzMzOGEyYmFfMjYzNA_4e7c6ac0-4b5d-427b-90bf-859cea22bbf1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20bb451b5406436aa3044e6572769236_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMi0xLTEtMS0zMTgyNA_d1674c9a-d242-48ed-a878-90ffe8dff8e0"
      unitRef="usd">6656000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iabd284c57e7c4c53b396b12930ced078_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMi0zLTEtMS0zMTgyNA_b5b3217a-f559-47c7-b7d1-343dcebb5308"
      unitRef="usd">6973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba1d1e1128ab469a92b7cd44c6db0d2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMy0xLTEtMS0zMTgyNA_7d3f5452-77cb-4e3d-934f-9da533e775c4"
      unitRef="usd">8854000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibce6cd786d794f4ba84de03a86627fd4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfMy0zLTEtMS0zMTgyNA_5c93d820-4f0a-4015-a2e4-02cd27e4137d"
      unitRef="usd">7881000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfNC0xLTEtMS0zMTgyNA_05f41a23-0b38-4465-b475-bb178b33911b"
      unitRef="usd">15510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81NS9mcmFnOmUxOTg5YTA1MTczOTQwZmU4ZTdjOGM1NDczMzhhMmJhL3RhYmxlOmVjNmUxM2RkNmVjYzRmN2E5ZTdhOTY3YmI0ZjUxYjc4L3RhYmxlcmFuZ2U6ZWM2ZTEzZGQ2ZWNjNGY3YTllN2E5NjdiYjRmNTFiNzhfNC0zLTEtMS0zMTgyNA_f7153fb7-b9ad-4ec8-be13-c032c15f9555"
      unitRef="usd">14854000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RleHRyZWdpb246YmY4ZTRkNzM0NzdlNGMxY2IzNWYyYWYxNmFmMTBlYmZfMTgzOA_e71de198-4b64-4762-b68f-003cfdf3249c">Loss per Share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2022 are not considered to be common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss for continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income from discontinued operations per share. Basic and diluted net loss per share was the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,181,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,571,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,452,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RleHRyZWdpb246YmY4ZTRkNzM0NzdlNGMxY2IzNWYyYWYxNmFmMTBlYmZfMTgzOQ_8bc31fd9-870e-4887-bdac-ea5aa40b62aa">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of March&#160;31, 2022 are not considered to be common stock equivalents.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RleHRyZWdpb246YmY4ZTRkNzM0NzdlNGMxY2IzNWYyYWYxNmFmMTBlYmZfMTg0MQ_17c6f97e-dcf0-4281-81f5-7495827e6f21">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,181,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,571,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,452,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3a8f36b78766499982b48169e8709eec_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMi0xLTEtMS0zMTgyNA_10b0fca0-8a8f-4f99-b3ff-1d45a8ebc936"
      unitRef="shares">5275144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d7ca6a9e8334a34861d3a8cc12a5faa_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMi0zLTEtMS0zMTgyNA_a92d514e-c304-4326-8304-da93bc2e4c56"
      unitRef="shares">6181953</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9f5a58c7510e4e6e8d4cb2499cc30bc7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMy0xLTEtMS0zMTgyNA_420224af-7166-486b-a3e5-5314ff362e2c"
      unitRef="shares">1283537</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2bfd973f33e846f5b7d28e08e0c6e96b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfMy0zLTEtMS0zMTgyNA_aa88e8a5-b4b7-4557-a1ae-0059f66fd92d"
      unitRef="shares">1263094</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia3df74c825b14d068c62180063fd7587_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNC0xLTEtMS0zMTgyNA_06a2cf00-6bb1-4ba5-8577-8bea896fa2ab"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iab52b0c782a64d07b43279f5e7626420_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNC0zLTEtMS0zMTgyNA_d0d42eb2-a62d-49da-9842-096b25d1de4a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i73a401f6a1c148b28af205ff7abe39ac_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNS0xLTEtMS0zMTgyNA_81e4bd8b-93a4-4b6f-9ab2-4f0054ad8316"
      unitRef="shares">12472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibdafde84e3d3486fbcdf4313d51d80e9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNS0zLTEtMS0zMTgyNA_a887b321-8cc8-4db5-94a9-4ed507f5eb02"
      unitRef="shares">7384</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNi0xLTEtMS0zMTgyNA_1892c6f6-a211-40f1-afbf-da26cffe20c5"
      unitRef="shares">6571153</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV81OC9mcmFnOmJmOGU0ZDczNDc3ZTRjMWNiMzVmMmFmMTZhZjEwZWJmL3RhYmxlOmQ3MjE0YzA4YTE3MzRmYTNhODQyZGEyMzhmYzQ2ODllL3RhYmxlcmFuZ2U6ZDcyMTRjMDhhMTczNGZhM2E4NDJkYTIzOGZjNDY4OWVfNi0zLTEtMS0zMTgyNA_50100873-d1da-4826-9374-ec2d8b7d080b"
      unitRef="shares">7452431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfNDY3_2e3d3474-93f2-4204-9b13-fe1411203bb3">Income TaxesWe recorded no provision for income taxes for the three months ended March&#160;31, 2022 and $12.9&#160;million income tax provision for the three months ended March&#160;31, 2021. The tax provision for the three months ended March&#160;31, 2021 has been recorded within discontinued operations as it relates to the income tax impact on the sale of its oncology business to Servier. There is no income tax expense recorded in continuing operations for the three months ended March&#160;31, 2022 and 2021, respectively.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfNjU5NzA2OTc2NzYzNQ_71ccd94f-e5bd-4923-bcbc-26406d0c5c07"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfMjc0ODc3OTA3MDA5Mg_3a5ced50-e247-4e5a-b34b-8f9e76152848"
      unitRef="usd">12900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i58b6efd93e554cb6b5cf258ce3e25526_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfMzQ2_c215b643-2152-4bd1-939f-252f7adb5aa1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEwNjVmYzcxNzg3YjRjNWJiMGZiNjg5OTk1MjEyOTAxL3NlYzphMDY1ZmM3MTc4N2I0YzViYjBmYjY4OTk5NTIxMjkwMV82MS9mcmFnOjYyYzcyZmQ4ZjI4NzRlN2FiMmQ3ODAxMTkxZjc0OGM2L3RleHRyZWdpb246NjJjNzJmZDhmMjg3NGU3YWIyZDc4MDExOTFmNzQ4YzZfMzQ2_f9cd7ea2-216e-444b-aa0f-eb06baa938b6"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M4\U<JV/R)BIIK5K.IQ'6= #*&I";Z:8@::-!-JFP' #<)E8:\G5H8\1O(^T
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M#4(^7DULO!QM%/.1LRC,.75&;F!E"_AG*1AT'C$[BB=TG+[G.G# (V@P:9Y
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M/]$B@?AI =XOK0WY!QU0/NA?_!=02P,$%     @ V$VE5&VA_3UW!0  P0T
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MR -ONG5M]4EEXG+\#9X\E%-:B1I-!76>=@H.76*O\*%>HPP?CT&G@]3N^JI
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MM2,"LX(7&WE#(!?3MS\M KG:LUVO;L6.I//1=(F,XYRXD4[9UHM2RY;=16N
M"D-;J84,PB(BVS#GHM5^*ZUYL26$9VP0RI2Z1?5@( (.EE*7K9:1K3#.2P_B
M$-)["LF;I[:UDDNE55 ,HH]''EJ7G7%T,&\-P-J)DER,"S:7Q,KHEES)V*<
M'H%6V:ABCP=2JJH6-FZD;DFL6^FD"=2A'C-I312$A:2,;M%5?<JHA9L.&*0.
MFYH=4  NP>XK(F(F&6J--NI/H1C>W..@>/7.H$-HS6&^CC3BSUA\? !2:3U<
M.1*3X:+[7DN_$8U454REK&W+SCY,3PWIUD4(8DV^@/U!^5Q\IU1DC!A$$0AK
M1&C2[-#)L*  G=]8%]YPX>U#AB<K95#2=XD1(42K*#=]KQ@*Q"V=4S=\$/7W
M"X7Q2$E,Q%LJJ5XB%]TJOEN@WC1:4:JW;6SR5+U!0 YW%F.4$$$(X"7Z"=N$
M:6(;L^'Q'Q'2)7(LX)*R%8Q#5LC'NIYB8=)R<H>$\V&19AG774/Q5M.[H;A\
M(JR,NX/R)2<4(>#^4'5;,R?8811FK4(JZ2>[2$(]BR&0A-Z.E89N Y*#I![\
M"I95<BF37,'UQR7+]1DV:!PXC@+]W(<;$W DQN/L>#'EV42,%]FXF/-XRN/Y
M/.?Q3(Q/LEE^S&/>S,:S,8]Y(3N>S9AN>_.3;'I\(K[]8OALO<BF\P+%Q"7J
M@W@%NY-%_OH1?^X7^LDTRQ<%5WGC[(UBOG #U A26U<AT3Y@O-Q!.K!CP! U
M4ZE(HJ,"R>U(RV!Y*ENGPBY"'O5T[1OZ#YWK9ZM<:@\,8>Q!3*:2:8P' 3</
MAP!9!Z?K.0<B<R[;-5X9AW*_3U&AK5DG6OIV^: 11@/C29;G.5Y3+?NWXG?D
MOG>G2RO=4N#E9"&^J,K03N!NY'/7LEXZ5:TI0]EZCP+#=1)"US;WY1_Z#NQ:
MPX4:E#Y0E2LDHN.H!-R,?I^NWF.PU-:1D4?Y<-KCO<<GQ%Y:IUY*L9<^Z Y\
M.71=FC5E8$#H;RT+"<,7-4;>:E7%W@W00W==')HE#CQ'5%:U:@,:;%^GR?E&
M[I(:Y&,9XR0PK^H8&]%Y*4>_3</%M.@X"'H5'06S\6(NOD:*HZMCEHNGWE.C
M.P_1FMPZ/K?Q4& "IC=IO]J_Z"_30_9P//T< #YKA7QK6D$T'Q[/!L*E)W::
M!-O$9RUZ*Q[)<;C!KQ)R? #[*VO#?L(&^M\Y%_\#4$L#!!0    ( -A-I53B
MX\?ZA@(  'P%   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*54RV[;
M,!#\E8700PL(D4SY(1NV 3M)T1P*&$D?AZ('6EI90BA2):DX^?LN*4MU'_&E
M%Y%<[@QGEQHNCTH_FA+1PG,MI%D%I;7-(HI,5F+-S95J4-).H73-+2WU(3*-
M1IY[4"TB%L?3J.:5#-9+']OI]5*U5E02=QI,6]=<OVQ1J.,J& 5]X+XZE-8%
MHO6RX0=\0/NYV6E:10-+7M4H3:4D:"Q6P6:TV(Y=OD_X4N'1G,W!5;)7ZM$M
M[O)5$#M!*#"SCH'3\(37*(0C(AD_3IS!<*0#GL][]O>^=JIESPU>*_&URFVY
M"M( <BQX*^R].G[ 4ST3QY<I8?P7CEUND@20M<:J^@0F!74ENY$_G_IP!DCC
M5P#L!&!>=W>05WG#+5\OM3J"=MG$YB:^5(\F<95TE_)@->U6A+/K39;I%G.X
M?:9K-FB6D256MQ=E)X9MQ\!>84C@HY*V-' K<\Q_QT>D9I#$>DE;=I'P(]=7
MD(Q"8#%C%_B2H<3$\R6O\.WX"]\+-,!E#KY>+@Q\V^R-U?13?+]PQ'@X8NR/
M&/]'%R\R..\M3,,S7 5D+H/Z"8._:*$/8!_(%-G#6 JI FR)4"A!/JOD80%O
M[R2%5&NH;O,.J*U9Z?MZ@QG6>]1^T5-FJG:<W'OE#4S"))W1.)J'Z2@=LIPT
MS^-ZF>,3F;HABUJ"&VL@#:=L2MAY&@^01JL"C3,Q%U @B1Z%\PD#%B;)9,A2
M))X$A;.4T3=-QO!)60+P/ROVDF9CIXWDSZ<S^-?]16>.J%$?O.]=NUII.W,,
MT>%IV72.^I7>O4O4MT,E#0@L"!I?S28!Z,[KW<*JQOMKKRRYU4]+>AY1NP3:
M+Y2R_<(=,#RXZY]02P,$%     @ V$VE5,F\C>CW!P  P!4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULQ5CO;QLW$OU7"+4H$D"Q+%F)$]<V8"MW
MUZ#(P7#3!D5Q'ZC=D9:777)#<J6H?WW?D-P?DF5?>KCB/EC>79+#F<<W;V;W
M<FOL)U<0>?&E*K6[&A7>UQ>3B<L*JJ0[,35IC*R,K:3'K5U/7&U)YF%154YF
MIZ>O)I54>G1]&9[=V>M+T_A2:;JSPC55)>WNEDJSO1I-1^V#>[4N/#^87%_6
M<DT_D?^YOK.XFW16<E61=LIH86EU-;J97MS.>7Z8\(NBK1M<"XYD:<PGOGF7
M7XU.V2$J*?-L0>+?AA94EFP(;GQ.-D?=EKQP>-U:_WN(';$LI:.%*3^JW!=7
MH]<CD=-*-J6_-]L?*,7SDNUEIG3A5VSCW/GY2&2-\Z9*B^%!I73\+[\D' 8+
M7I\^LF"6%LR"WW&CX.5;Z>7UI35;87DVK/%%"#6LAG-*\Z'\Y"U&%=;YZSMK
M\B;SXIXVI!NZG'@8Y:%)E@S<1@.S1PR<B?=&^\*)O^F<\OWU$SC3>31K/;J=
M/6GPO;0GXFPZ%K/3V>P)>V==A&?!WMDC]E)D8F5-)1;PU8()0-D78A'P)2M^
MNUFZ\/Q?3VPX[S:<APWG_SVD3QK@/+QPM<SH:H1$<V0W-#JT^I$$J%V*NU_O
M?_[QUW^^_>Z;Z?G\^[$PC17;PI3E3IBMIES4<=U8>"-\05W,[D1\&-XB+9>.
M/C>D/=;RM@^LLXFZD,B%3)$3QHI<.:B#(UQ8I!D6\A3I%:Q@@W?(NCQ7(?TP
M@-G>JF43TW%MB2J>MW\6;BRV)/ <QZ(T5DEKI5X/IQ8D2U]DTA)'MU$YNR\U
M8I4[@TM?2-^.".B66)L-6<T67E28)SUPP?\)AFJK-K@O=R\TK8U78<S2$O_A
M289HU[C)/L4-$$%FFLX1H%0C[!;:NK%8 #3,Z@"YB'5--JBHSC!E6:JU]%':
MRK!KLN)D><2"4#@AS'<K%9W'LLAK# ![L];J=XQL"])[YXR=/+39B8RI#WV!
MZ>!LRXMMH;)"F"QK&$4OI*@-@ ?XPD-^09Q=K3+)C&IJN)M3"1VUNT-"G8B6
MHLFSL=#$]@GG)!T.HD0%<!>  B>_IQH".0\?..F?O6/W3>,0HGL>-(!_ID>-
MBV_%Z[,9?K_[YO5L.OL>R1&RQ853_T5:)9< $TGOF"01[I1 +@I"@B&@CO#A
M*H-IV2E@P?'Q/G$47,FP,4Q#*[23L:ZDIQ%&I;.RR3&7',!C$C'>F]:3;,\3
M=C(NLZW?[ "68K*"IK<'[5!BHKM9TJ]&EDBM?P/ZD!?C <5[]EKRC=61N0:A
M6"'Y")A_*4EX.[-:X83RP&@5N=/NDFC.FC)(SV/I-VYSK]]+Z2@*J8IQC@:F
M*[T^I#IOD X"JK$8Q'C3QR@@>6O2 (^IV*9WKU_!U2Y!Q^DH>#?,K6K/'@['
MV=-C>-"7NE298C'#07!B/D E+-VC"I[AC@/@@T5(77;&M4A]9?)PV:9[O4_H
M_3S>T\Z@B!@CY%VB(F]KT0=H&95Q+*!JLM6H7F695BIKR9Z192T8UH#%0.&8
MCRNB0ZFS%*J0CNG0$CL?2)A+'&6P'] T,U6ETA'BW$-=:0^;'WS&)!54[;BN
M^YAA3N"H$#/.*4**#.F&HDX'"1T0HC!]7>JT>:!]T=>&4>@614MX&-#@R;D*
M"<*BO22_)>CKMHC:L N<:B>V5AD]OF= &*D0<N0AG&VY_W38H6 X>B ,"?K&
MA2PJ EL1(!YM9 D2503QS,>A4<VC7H.87#^9E+5Q3K$.H3O'L0Q9CYV7<JE*
MY7<OMJ&5Q?HVLGYCP*,UE>A$OW19,-2K1'<GJP'GDY"VQ#]*^/& 0DH?9M-!
MKIR(?_1R=Q_E;O@H*6"KQN(]Y8KQ'8L/5BW"!3L?'ZM!O8]JO.TC_O\A'?24
M<3Y*A4YYC@+^O\4:;S\#! &.+)WI$0HULJF6W&JLNN:O$SYLE5E5!^NY;=;0
M YP39$NL99U*(+(09K<*RF#8?B]]T(]2);1$HW.*,+7NB#MIO7C+/J^MK$Y
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MXHV8GL[VW!ZN1L4!+#S==1L^]O].[H*!2=LV?IT;SZ;3YP]LA8=?;_#/N#D
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M;/Q>&&^\J<,WNJ7QJ#OA$FTARAU/P/C*&-_>\ ;=1]OK/P!02P,$%     @
MV$VE5*C.CE-1"   =A@  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
MS5E;;]LZ$OXKA#=8-( JZVXY)PF0M.G9+M ]1MWV/"SV@99HFX@DZI"4'>^O
MWQE2DN74SJ7MPSZT%J69X5R^&<XPEULA[]6:,4T>RJ)25Z.UUO7%>*RR-2NI
M<D7-*OBR%+*D&I9R-5:U9#0W3&4Q#CPO&9>45Z/K2_-N)J\O1:,+7K&9)*HI
M2RIWMZP0VZN1/^I>?.:KM<87X^O+FJ[8G.FO]4S":MQ+R7G)*L5%121;7HUN
M_(O;".D-P3?.MFKP3-"2A1#WN/B87XT\5(@5+-,H@<+/AKUC18&"0(V_6IFC
M?DMD'#YWTC\8V\&6!57LG2C^Y+E>7XW2$<G9DC:%_BRV_V"M/3'*RT2AS/]D
M:VFC<$2R1FE1MLR@0<DK^TL?6C\,&%+O!$/0,@1&;[N1T?(]U?3Z4HHMD4@-
MTO#!F&JX03E>85#F6L)7#GSZ>KZFDKV]!;MR,J,[<+=6EV,-DO'[.&NEW%HI
MP0DI(?DD*KU6Y*[*67[(/P:->K6"3JW;X$F!GZAT2>@[)/""X EY86]F:.2%
M3YJY&)I);J2DU8J9YW_?+)26 )'_/+%9U&\6F<VBG_3IDU(P&R]433-V-8)T
M4TQNV.BH:/"1'Y*Y%MD]^5AE\ IP3F8%K6!)_ME4S% X1#22W HJ<R*6Y#V7
MD!A"*D)S46N01ZO<(1PYBIV5B0P*Y:Y%D3,DK6LI-@SH])J=WA>VDGL*?..2
M+\,E6;",EHRPY9*9M"1-#2F*+%DA%*]6J")NSRNN.2U(W2P*GL';)9/X&90E
MJ O/F2++=KL5!%0C)^_5,>H3,!!*@')():JW?S6TX$L.%C_Z:)=H(\LX-45#
M8E+#)PB ECS3/1/=@A^/?6A 864<\'G^%1YJ)DWI!(U:_"F,X8!N9NC0( %&
MM!YO:>TV1 O"RKH0.\9:(_JE81R^(7D769=\$ 547?07NL<$&JT"#QU$QR';
MUGD,99%E(_>:=/Y!5:V"K5(-Y'H79F_R'!" P@+AIMH-1;;"X+Q0&DQ!71\)
M-H"AVKS0<""@^B=-@8#@470@#SW4(PT44,@%%29;]R7& EH+#5"KFG(!^P.-
MB90B;?;EQQ4#X8<:;*DBD&Y>,'&F_M1&%OR[ICE)'#\*G&DP[433#>4%713,
M8'C9Z :@P95J$"\'^_6)-#\("J;5<A]E(\J4"RP,P_C9\X_K79\M>BT!+:4M
MW P+]R.G7)!_]:[XTQQO+'][LV$23FMR]\!DQA7$&>#/R!]#?VORGF7,L+:R
M?!(YDVGJI$%"SDB<NK%/?F\!ET039P+FA8$;A+W<G+P)G2#VSDGD3@- LEPR
M#N3CNX<:  Z?_20%=\;G)$G=)'BLP:$I)':"20SD$6X?NU[0;60\]CU]Z$33
MR)EZ4Z2?NJE/OD&FVRI)V$/-3,I#7F[@]8OVNWE,8S 'X4:\F,+ZP*'+8%!\
MSZ+(]>"T+XH.X@:8306)+585_R]LG8D2&C-ERQ0J5$$L)"MHJU=3;:S"AR!H
MR]9VS4$30*4U!1EZV00J/.0E?&U#3MN00RGCPAP>A^H&;D)VC&+!^7RT'#Z-
M4JB3OQJ<!EH$&B)&/E NR3=:-(Q\[5W2)M\QG/J.YV&*FL#Y!S@-(R<( \3I
M).[@\"8,)TZ4A.<D#MUINL<IXM/QXP3PF[B ^B.;/X*,[P1IZ,3A!':.?'?B
MG:Y4)U 3NM%/HL:>6;\8'7Z'CMGW9^%+03+[OP)) %#P8E,;(C=(>XCX7NK$
MGH<0@<SO(!*'SF0R.6]I!PB! I&D4+]\=QJ^ " (C\1'8$:Q.TGM2= Z\FA@
MJ5(".QGXON5ZC3[#@@TQAC.&#&#![2EJSIMBA^X?M"T@&ZJJ$0Q<L%#0=&$%
MAB@O3)0PYMF:LXUMIAO;P$'W!OS4=MA__UL:^)/?%'1^4"_AGX&'>N(T;C%>
MB=<AV%AGK/V^\T('HVJ9!/]+3F$;\#)V8\];9<_Q,S_\Z<K\TQI60I_2TD5/
MWC/]VO0JCW.9_NW3_*OSJW/O15D&K5(RC6TUC+T^R0R4@M_ZW^<3YY$@XPG,
M^(W)>(0?A@2]W $S;T%,S6#+R#LJ"T$4+YO"QK44.2L0O:HIVU;,= 8=L$FC
M>6%SR\XUA@$'DZ+)F7DCN;I_NT0O<M@"!PDB@=6!!A['&I"VXZR 6:MO-VQ@
M-@)U*# 87?.Y5[NMP@"S84:V7;*-\CZ?7Y1]MJ&V??DK4(XN=6W?>M=-)K9U
MG36P&U4_,*+:''SUB/K4_H>CZMU\-G,!K:8%;YL]!8))E.)9;M;QU(D\OP,;
MJ F>@#1H@Y,WLANWGLT0(PZ1;L;(VLXGQ<YYW/=;K;X,E_O9MZ92\XS7U-2-
M_5C8%7SH_&HA-6;S#N-2=]8WM4$)](2KE60K/ ;!&-])X\B)HWA@(/IX:.0I
MV+1#CN^$40+M\TD?O6KHL<8_>]0]2[#8V>:7Z%W-NCRTYV*;H9@62)J;6BL*
MGE.;=/!C+UK0%Y!@U.8['(94M25574!\,-S#>S#RYB-*%HV"0*OS]A#'RG8X
MPYW!7 BVPF_JA-/D5!,-[602&]+XF4XJP,&SKX\]_"U)#X :TR\(8A+$(?EC
M,/"W(_GC.OO%''7J.4>?$3]V8M_#APC1!).6^:*&Y>'P:L'DV??7'ELL0Q3\
MFQFVO;?)CX7L=4&",#"#<-0NAU):B-I4T[VEB9/$B?F=3D(R9] 65"N'K%@%
M6Q:&D>8E5$^\7#2W(AUO:CPS<5*8+'_8L<?N*L>#N^"2R96Y\<:VK:FTO1;N
MW_:7ZC?V+GE/;F_D(;]7'*)3L"6P>C#UC.R%6+?0HC8WRPNAM2C-XYI12%\D
M@.]+(72WP WZ/S5<_P]02P,$%     @ V$VE5-<<0Q[_!   A@P  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&ULG5==;]LV%/TK%QZP)]6V9#M.LR1
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MQ"R$F+VR@B]'WR%=\UP;*B4H#;71#SQ<?GI[P#M'YQV#P56TJPPBR*X'Z'L
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M!P(,6I[1S_#8&CJL:(/>&G6O<M[?5[;&UT;IFD:ZXN/*5:5I_5^4^=39L%6
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M"=)JU:7[+5_25W)-FC6W#0XHV3>P, L%B9'[NA(\DRI-CD\K')SH]34GW<H
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M=@[T?Z.4/1HN0?=*+OX#4$L#!!0    ( -A-I53_VX."U@,  #0)   9
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M6:-M4,#SA3%^OPD!#@^EZ;]02P,$%     @ V$VE5, ,1Q:. @  704  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULA51M3]LP$/XK5D (I$+2M(RJ
MM)4H'1J:F*H"0VC:!S>Y-!:.+[.=!O[]SDX;.@FZ+XGOY7GNSO;C48WZQ>0
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M#41*?"W'H^Y\8U[8AI6XBJCS+)JO&*T?:X3RR+<(OO' MPZ^^3??U$>".:S
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M.CJ=C@/079OK%E8UOK5LE*5&Y:<5_1E0.P,Z+Y6R^X6[8/C7+/\"4$L#!!0
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M:&5E=',O<VAE970R.2YX;6S-FEUOVS84AO\*X15#"V212(J4W3D&UF3I"C1
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MF)5JYU-K&%FY)[Z0!@>&6Q8XTD%9 )XOI30;PTZ-_D\B_0!02P,$%     @
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M')]S?7VSC39/MD)T\"*%LM.H<JZ^B&-;5"B9'>@:%?U9:2.9HZ59Q[8VR,H
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M<AUBDJ)MQ>U$\<9TLPU7V!O-L,"O%P@=@.LYY^IUHAMD_SU,_@%02P,$%
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M63'V37<^)W,OT$2002RU"Z+^]K"$+-.>%,>_E5.O?J8V/&T?O?]N@E?!K(B
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MYA9( EP/4/?7C,EC1S^@/AM<_ =02P,$%     @ V$VE5+Y0D8MO @  Z@4
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M&FPIMRSQ,09E'?"\D-+L#3OO_?.>_ -02P,$%     @ V$VE5(Z5/2EI @
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M_+"T71J5.V#WUU*:_<0)='T_^P502P,$%     @ V$VE5"&[[.:&!   O!,
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MUZ !-/@D'S&7"C&N+#&VTO26FX';=<DA8JIHG1UB<-CV$(/;3D3;7J1:0EY
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M,HNJJWF83B8G8>VWO%$?=[H-J/KW\?ZTSB!J'\$>.C4/_6K^6U%PH4PM;XR
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MJQ,A%4:<L#%RX\>*N31V2/'+M1T+03D!>[Z4TKQLG(-VT)S\#U!+ P04
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M/N[T6 W"'-#O-YRKT\(8J ;UV0]02P,$%     @ V$VE5'-F$HB, P  \@T
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MW,)AD=4%HYIH4=@>?24T=/QVF,*EC$IC ._70NC]Q&S07/.F_P-02P,$%
M  @ V$VE5$0^49SL @  U@@  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&ULS59-3^,P$/TK5L0!)"!?35M06ZDMK!9ID:H6=@^K/;C)-+%([&*[E/[[
M'3MI"%6HN"!Q2?PQ\_QFGC.3P5;()Y4!:/):Y%P-G4SK];7KJCB#@JI+L0:.
M.RLA"ZIQ*E-7K270Q#H5N1MX7M<M*./.:&#79G(T$!N=,PXS2=2F**C<32 7
MVZ'C._N%.4LS;1;<T6!-4UB ?ES/),[<&B5A!7#%!"<25D-G[%]/?<\X6(O?
M#+:J,28FE*403V9REPP=SS""'&)M("B^7F *>6Z0D,=S!>K49QK'YGB/_L,&
MC\$LJ8*IR/^P1&=#I^^0!%9TD^NYV/Z$*J#(X,4B5_9)MI6MYY!XH[0H*F=D
M4#!>ONEKE8B& ^*T.P250W#HT/G (:P<0AMHR<R&=4,U'0VDV!)IK!'-#&QN
MK#=&P[B1<:$E[C+TTZ-%1B5<3# 1"9G1'0JD%;D@MZ]X3Q0H,H><:MS3@MP^
M;YC>5;;C+96)(J<WH"G+U1GZ/"YNR.G)&3DAC).'3&P4Y8D:N!IIFL/<N*(T
M*2D%'U *R;W@.E/DEB>0O/=W,;PZQF ?XR0X"GA/Y24)_7,2>$'0PF?Z>7?_
M")VP3GEH\<*C*5_:-$Y%81)-[94>2TEY"D8#LMR1IETE39EV\O<70I([#87Z
M=X10IR;4L80Z'Q!Z$)KF!*]:_%0=%S=I07D7VH0L<;L6UQ2,EY$?1;XW<%^:
MZ6VQZO2C3FWUCG14DXZ.DIZ# BKCC. EP^_V!0O2VJ:HE>Z[([KU$=WO(52O
M)M3[(J%*W*@A0;<;=0]T:C&ZZH7M,O5KROVCE!=8H!E/STD*'"2R-W+1!"L9
M4UI24\,_H=A5?=K5]U#,]][JJ_=%FE7 S>^FW_QL2M%:K'K]OG^@FMOH$ 7(
MU#9.A50V7)>%M%ZMF_/8MJ2#]8EIVK;SO,&4'1_+9,JX(CFL$-*[[.%%DF43
M+2=:K&T?6@J-7<T.,_SQ &D,<'\EA-Y/S 'UK\SH/U!+ P04    " #83:54
M'RR]#4X#  !0#   &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6S-5]MN
MVS@0_15"3PVPC41=G<(VD#A9;(%V$<3;]J'8!T8>6T1X44DJ3O^^)*7(\B5"
M7@+DQ>)EYO#,'&HTGFZE>M 5@$%/G D]"RICZD]AJ,L*.-'GL@9A=]92<6+L
M5&U"72L@*^_$61A'41YR0D4PG_JU6S6?RL8P*N!6(=UP3M3O*V!R.PMP\+QP
M1S>5<0OA?%J3#2S!?*MOE9V%/<J*<A":2H$4K&?!)?ZTP+ES\!;?*6SU8(Q<
M*/=2/KC)Y]4LB!PC8% :!T'LXQ$6P)A#LCQ^=:!!?Z9S'(Z?T?_VP=M@[HF&
MA60_Z,I4LV 2H!6L2</,G=S^ UU F<,K)=/^%VT[VRA 9:.-Y)VS9<"I:)_D
MJ4O$P,'BG':(.X?XT"%]P2'I'!(?:,O,AW5-#)E/E=PBY:PMFAOXW'AO&PT5
M3L:E47:76C\S_R*U1C4HM*R( O01+23G-KU+(\L'=/-4LF8%*[16DJ,%867#
MB$^_7*-KRAIC]_ZUE\W#W/8P'Z[!$,KTF074;D5/0V/9NC/#LF-VU3*+7V"6
MH*]2F$JC&V$9[/N'-LH^U/@YU*MX%/ K4><HP7^A.(KC$WP6KW?'(W22/O.)
MQTM>P+L4AJY<"NTU1DLH&T4-!7V8<\GKQO0YOR%*4+$9YOKG%PN,/AO@^O\1
M6FE/*_6TTA=H_2<-8:AL;X'VMP!^-?21,!!&HP]4=(J>G9*TQ<X\MJL@C_,\
M*S#.DFGX.$SUL5V19G&:X-YNCWS6D\]&R;>W5M8N77HD&7F/E[\GC8J>5O&&
M&A5'N<_B(L-I>J#1L5V.)_ABH.4>^4E/?C)*_@ZT4;1TE:.EW@AJQL2ZZ($O
MWI-8.-J5V.@-Y>K ASK@>))D27&@UTG#/(DNTM."X<$W H\&8'/C&P91PD?W
MS7RM<CC>G1"_*^UV11HG;ZE=<B1)=*C:F,D^Z5T)Q^,U_(;73/X&Z C7C2HK
M*QNJ&1$GO\?[Y^RJ+<[>E6J[LHWSMU0M/_$BI45\J-RQ69%,#E^V<-";<5 ;
MW[)JRZT1INU=^M6^+;[TS>#!^I5KEWW/MX-I>VW;F6RHT(C!VD)&YX6EI-KV
MM9T86?L.\%X:VT_Z865;?E#.P.ZOI33/$W= _R=B_@=02P,$%     @ V$VE
M5!T?"C1B @  _ 4  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULK51-
MC]HP$/TK5M3#KM22D !M5R$2'ZW*826T=-M#U8-)!F*M8U/; ?;?=VR'E-WR
MT4,Y$(\];]Z\L6?2G51/N@0P9%]QH8=!:<SF+@QU7D)%=4=N0.#)2JJ*&C35
M.M0;!;1PH(J'<10-PHHR$62IVYNK+)6UX4S 7!%=5Q55SV/@<C<,NL%AXX&M
M2V,WPBS=T#4LP#QNY@JML(U2L J$9E(0!:MA,.K>3?K6WSE\8[#31VMBE2RE
M?++&K!@&D4T(..3&1J#XV<($.+>!,(U?3<R@I;3 X_4A^F>G';4LJ8:)Y-]9
M8<IA\"$@!:QHS<V#W'V!1H]+,)=<NW^R\[Z#)"!YK8VL&C!F4#'AOW3?U.$(
M@'%. ^(&$+\&],X D@:0.*$^,R=K2@W-4B5W1%EOC&87KC8.C6J8L+>X, I/
M&>),-A.YK(!\I7O0Y!T9%06SY:6<S(1_([;8-U,PE'%]BRZ/BRFY>7.;A@;I
M;9 P;ZC&GBH^0Y60>RE,J<DG44#Q$A]BVFWN\2'W<7PQX#U5'9)TWY(XBN,3
M^4S^'=Z]D$[2EC)Q\9*KI213IG,N=:V _!@MM5'X6G]>H.BU%#U'T3M#,5=R
MRUP#X=T0Y@F-NSL%N5185]PE!=)CJ9FHT<:&5^X6]:DK\WP#QV<[?IM%:;@]
M+N+?'MWX8V1_K>,++?U62_]_:&F$,+&^HJ1_5<DE#R\A/&JD"M3:S1>-.=3"
M^'?9[K8C;.0Z]]7^&$>;GT1_POBYB*]NS80F'%88,NJ\QZR4GS7>,'+CVG4I
M#3:_6Y8XGD%9!SQ?26D.AB5H!W[V&U!+ P04    " #83:54J3PF,BP#   ,
M$P  #0   'AL+W-T>6QE<RYX;6S=6&UOVC 0_BN1.TVM-#5 1DI60-J0*DU:
MITKMAWVK#'' DF-GCNF@OWZ^. DO]2'6#QM=(HA]C^^YQ[X+MAB69BW8_8(Q
M$ZQR(<L161A3? K#<K9@.2TO5<&D13*E<VIL5\_#LM",IB4XY2+L=3IQF%,N
MR7@HE_E-;LI@II;2C$B_-07N\34=D6[\D02.;J)2-B*/Y^]_+I6Y?A>XY]F'
ML[/.X\7UOOV\ BY(Z"7M'T%ZV>G@Q !BY/%QY(>X,>JK7>IZN&5J/#''P5&:
M#DBJB,,Z9>-AIN0F<Q%Q!AN9YBQXHF)$)E3PJ>;@E=&<B[4S]\ P4T+IP-B2
ML5*Z8"F?'=QU/:BFFB?G4NDJMHO@OJ?U\#V@Z8% +D0KL$><83PLJ#%,RQO;
MJ097QA=04+<?UH55.-=TW>WUR<:A>M@@4Z53IMLP7=*8QD/!,I"C^7P!3Z.*
M$$!C5&X;*:=S)6FEH?&H&Y9VQH2XAU?M1[;#O<JV<MJ!C,JV:07534?C.L"_
MS>:XMVE[K^(-"OZDS)>EG8ZL^E K[$ZSC*^J_BIK!6#L79R=%H58?Q9\+G/F
M)G]TP/&0-G[!0FG^;*-!J<RL@6D2/#%M^&S;\DO3XH&M3%-.JPS7W'N#FO_N
M.L^99)J*;=&V]D]YE5^M.+KZ5Y*K7Y5]P5Z-]?YYZB+[;T%D?/HBH^3T-=:G
MF%,7.3A)D6&]?V\=$G:."*TU@*/8B'R'0Y_8! VF2RX,EW5OP=.4R1<G!4MO
MZ-0>]7?X[?B4970IS$,+CLBF?<M2OLR3=M0=+$0]:M/^!M/KQNTYT,;B,F4K
MED[JKIY/JV9@&S9J?8'#/G)377X$\W&8'P$,BX,IP'R<%Q;G?YK/ )V/PS!M
M R\R0'T&J(_S\B&3ZL;B^'T2>_EGFB11%,?8BDXF7@43;-WB&#Y^-DP;>&!Q
M(-*?K36>;;Q"#M<!EM-#%8+-%*]$;*;X6@/B7S?P2!)_MK$XX(%E :L=B.^/
M S7E]XDBR"JF#7N#<21), 1JT5^C<8RL3@RW/S_86Q)%2>)' /,KB"(,@;<1
M1S %H %#HJC:!_?VH[#9I\+-_U_CWU!+ P04    " #83:54EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( -A-I51L
M(O@&!@0  $HA   /    >&PO=V]R:V)O;VLN>&ULQ9I;3]LP%(#_BI6G[8&U
MN< VM$YB;&Q(L%64\3J9Y)1:.'9E.^7RZW><MN",<+07-T^)G<3]<A*?SW;Z
MZ4Z;VVNM;]E]+96=) OGEH>CD2T74'/[3B]!X9&Y-C5W6#0W([LTP"N[ '"U
M'&7C\<&HYD(EGS]MVYJ:45C0#DHGM,)*7W$EX,X^'_=%MA)67 LIW,,D:?<E
M)*P62M3B$:I),DZ87>B[']J(1ZT<E[/2:"DG2;H^< 7&B?)%]<Q#7O)KV]8X
M?GW!$622'(RQP;DPUK5GM.US9%P!GKPN-4Z?".G ?.4.OAO=+(6Z\<W@78R"
MVVCCL-VN@WAH_B>,>CX7)7S595.#<NLX&I >4-F%6-J$*5[#)#G6*S!LRF_
MWQ3^RFFUOD&'9$&XS*'  ^:T:AEC\J@*E(6*X9[54E3(4;$O7')5 @L@,P(R
M&Q#R3Q9 Y@1D/@CDS./@I0%D04 6 T)V(KE/0.X/"9D'D <$Y,&0D$4 ^9Z
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MU+N^I]XIG]J8KCT_:WS^/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%
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ME:.8RE%0Y2BJ<A16.8JK' 56CB*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM
MD56@R"I19)4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR*A19%8JL"D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJS#_Y3UW9C57_^3;.YII8OZF,_:'[_33U!+ 0(4
M Q0    ( -A-I50'04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ V$VE5.Y#%1#O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ V$VE
M5)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #83:54P?^KE#P%  !I%0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ V$VE
M5-YTX"U+!@  (!H  !@              ("!@ T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( -A-I50E+(,1"P,  (8*   8
M      " @0$4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #83:54WR\IX!T%  #(%0  &               @(%"%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ V$VE5+3&*.S! @  & <  !@
M             ("!E1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( -A-I51*K&AQ2 4  /X5   8              " @8P?  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #83:54LOUXKE,'  #J
M'P  &               @($*)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ V$VE5%=\KZ3*$   M2T  !@              ("!DRP
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -A-I53+B)IJ
MF L  -P?   8              " @9,]  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #83:54;:']/7<%  #!#0  &0
M@(%A20  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -A-
MI50LM=UD'P<  +\2   9              " @0]/  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ V$VE5.B5WG=^ @  4@4  !D
M         ("!958  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #83:54_X>\PHP%  #S#   &0              @($:60  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -A-I53BX\?ZA@(  'P%
M   9              " @=U>  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ V$VE5,F\C>CW!P  P!4  !D              ("!FF$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #83:54J,Z.
M4U$(  !V&   &0              @('(:0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( -A-I537'$,>_P0  (8,   9
M  " @5!R  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MV$VE5)8=UCV8 @  2P8  !D              ("!AG<  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #83:54_ _IT)@3  #R/   &0
M            @(%5>@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( -A-I52:^:&]$P,  #$'   9              " @22.  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ V$VE5/_;@X+6 P
M- D  !D              ("!;I$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #83:54P Q'%HX"  !=!0  &0              @(%[
ME0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -A-I50L
M@,OQV ,  &,)   9              " @4"8  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ V$VE5!MCWZZ5 @  @ 4  !D
M     ("!3YP  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -A-I50GD,S.E 4  (TI   9              "
M@>NQ  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ V$VE
M5$N?U@\K @  F00  !D              ("!MK<  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #83:54*38@71L#  #Y"   &0
M        @($8N@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( -A-I51]H>],VP4   8A   9              " @6J]  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ V$VE5%O1$L=> @  , 8
M !D              ("!?,,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #83:54L'YMWA@#   #"0  &0              @($1Q@
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -A-I52[>[=Q
M>0(  /X%   9              " @6#)  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ V$VE5-.(<D73 @  ) @  !D
M ("!$,P  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #8
M3:54TQ*',2P"   @!0  &0              @($:SP  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -A-I53GK+@@G0(  !L'   9
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M970T,BYX;6Q02P$"% ,4    " #83:54(;OLYH8$  "\$P  &0
M    @(&-X   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M -A-I50>LGV%GP,  "H-   9              " @4KE  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ V$VE5'\NRH\[ P  = H  !D
M             ("!(.D  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #83:54'P!BA<,#  "T#P  &0              @(&2[   >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -A-I51S9A*(C ,
M /(-   9              " @8SP  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ V$VE5$0^49SL @  U@@  !D              ("!
M3_0  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #83:54
M'RR]#4X#  !0#   &0              @(%R]P  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -A-I50='PHT8@(  /P%   9
M      " @??Z  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ V$VE5*D\)C(L P  #!,   T              ( !D/T  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #83:54EXJ[',     3 @  "P
M@ 'G  $ 7W)E;',O+G)E;'-02P$"% ,4    " #83:54;"+X!@8$  !*(0
M#P              @ '0 0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MV$VE5#B#;R;$ 0  #1X  !H              ( ! P8! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ V$VE5("$^)W  0   !X  !,
M             ( !_P<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H
,.@#-#P  \ D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>118</ContextCount>
  <ElementCount>272</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OverviewandBasisofPresentation</Role>
      <ShortName>Overview and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Product Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenue</Role>
      <ShortName>Product Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://agios.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/MarketableSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Inventory</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Product Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueTables</Role>
      <ShortName>Product Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ProductRevenue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ShareBasedPayments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/LossperShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Overview and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OverviewandBasisofPresentationDetails</Role>
      <ShortName>Overview and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/OverviewandBasisofPresentation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryScheduleofInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Leases - Schedule of Lease Expense and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails</Role>
      <ShortName>Leases - Schedule of Lease Expense and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Leases - Future Minimum Lease Payments to be Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments to be Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Revenue-Related Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails</Role>
      <ShortName>Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Unvested RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails</Role>
      <ShortName>Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="agio-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="agio-20220331.htm">agio-20220331.htm</File>
    <File>agio-20220331.xsd</File>
    <File>agio-20220331_cal.xml</File>
    <File>agio-20220331_def.xml</File>
    <File>agio-20220331_lab.xml</File>
    <File>agio-20220331_pre.xml</File>
    <File>exhibit31-1x03x31x22.htm</File>
    <File>exhibit31-2x03x31x22.htm</File>
    <File>exhibit32-1x03x31x22.htm</File>
    <File>exhibit32-2x03x31x22.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="532">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "agio-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 118,
   "dts": {
    "calculationLink": {
     "local": [
      "agio-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "agio-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "agio-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "agio-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agio-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "agio-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 33,
   "keyStandard": 239,
   "memberCustom": 16,
   "memberStandard": 20,
   "nsprefix": "agio",
   "nsuri": "http://agios.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://agios.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Fair Value Measurements",
     "role": "http://agios.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Marketable Securities",
     "role": "http://agios.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Inventory",
     "role": "http://agios.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Leases",
     "role": "http://agios.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Accrued Expenses",
     "role": "http://agios.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Product Revenue",
     "role": "http://agios.com/role/ProductRevenue",
     "shortName": "Product Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Share-Based Payments",
     "role": "http://agios.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Loss per Share",
     "role": "http://agios.com/role/LossperShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Income Taxes",
     "role": "http://agios.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://agios.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://agios.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Inventory (Tables)",
     "role": "http://agios.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Leases (Tables)",
     "role": "http://agios.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://agios.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Product Revenue (Tables)",
     "role": "http://agios.com/role/ProductRevenueTables",
     "shortName": "Product Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://agios.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Loss per Share (Tables)",
     "role": "http://agios.com/role/LossperShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Overview and Basis of Presentation (Details)",
     "role": "http://agios.com/role/OverviewandBasisofPresentationDetails",
     "shortName": "Overview and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ie0bcdc9702194332ba58fb885ff2771d_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i0c0d38b2a5b74f3cac9cdf9123533489_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i0c0d38b2a5b74f3cac9cdf9123533489_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)",
     "role": "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "role": "http://agios.com/role/InventoryScheduleofInventoryDetails",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://agios.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Leases - Schedule of Lease Expense and Other Information (Details)",
     "role": "http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails",
     "shortName": "Leases - Schedule of Lease Expense and Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)",
     "role": "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Leases - Future Minimum Lease Payments to be Received (Details)",
     "role": "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails",
     "shortName": "Leases - Future Minimum Lease Payments to be Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "role": "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails",
     "shortName": "Product Revenue - Schedule of Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i5c86e4fe16a543c093349fd84ce7ee87_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
     "shortName": "Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i5c86e4fe16a543c093349fd84ce7ee87_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails",
     "shortName": "Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i44baacb616534e10bf3e92b51f3ca635_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i5c86e4fe16a543c093349fd84ce7ee87_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails",
     "shortName": "Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i5c86e4fe16a543c093349fd84ce7ee87_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i9dae1e2bf78b499980a14a35922f97fc_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i5c86e4fe16a543c093349fd84ce7ee87_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i5c86e4fe16a543c093349fd84ce7ee87_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ifa54a29f6a2c403383d89cfeec3aaf59_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails",
     "shortName": "Share-Based Payments - Summary of Unvested RSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ifa54a29f6a2c403383d89cfeec3aaf59_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i92b16706b28640548b80c7b1f2d3e403_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
     "shortName": "Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i92b16706b28640548b80c7b1f2d3e403_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
     "shortName": "Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i3842af82e752402aa7a5fbeedccf54b5_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
     "shortName": "Share-Based Payments - Expenses Related to Equity-Based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "i20bb451b5406436aa3044e6572769236_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited)",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3fa642d4aed4cbc87a473f75a555d65_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3fa642d4aed4cbc87a473f75a555d65_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Overview and Basis of Presentation",
     "role": "http://agios.com/role/OverviewandBasisofPresentation",
     "shortName": "Overview and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://agios.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20220331.htm",
      "contextRef": "ic3af38170eb44c6aaf9b584e5fd0d8b0_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "agio_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Costs, Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_AgiosOncologyBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agios Oncology Business",
        "label": "Agios Oncology Business [Member]",
        "terseLabel": "Agios Oncology Business"
       }
      }
     },
     "localname": "AgiosOncologyBusinessMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_Agreement2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement 2010",
        "label": "Agreement 2010 [Member]",
        "terseLabel": "2010 Agreement"
       }
      }
     },
     "localname": "Agreement2010Member",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Available For Sale Securities",
        "label": "Cash Equivalents And Available For Sale Securities",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ChangeInContractWithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Asset [Roll Forward]",
        "label": "Change In Contract With Customer, Asset [Roll Forward]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetRollForward",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ContingentGainOnDispositionOfBusinessRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Gain On Disposition Of Business Recognized",
        "label": "Contingent Gain On Disposition Of Business Recognized",
        "terseLabel": "Earn-out revenue for royalties"
       }
      }
     },
     "localname": "ContingentGainOnDispositionOfBusinessRecognized",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAllowanceAndReservesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Allowance And Reserves, Liability",
        "terseLabel": "Component of accrued expenses"
       }
      }
     },
     "localname": "ContractWithCustomerAllowanceAndReservesLiability",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities, Product Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAssetRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Asset, Revenue Recognized",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRevenueRecognized",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Current Year",
        "negatedLabel": "Contractual adjustments, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesCurrentYear",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Prior Year",
        "negatedTerseLabel": "Contractual adjustments, payments/returns relating to sales in the prior year"
       }
      }
     },
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesPriorYear",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractualAdjustmentReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contractual Adjustment Reserve",
        "periodEndLabel": "Contract adjustments, ending balance",
        "periodStartLabel": "Contract adjustments, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerContractualAdjustmentReserve",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerCurrentYearReserveProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Current Year Reserve Provisions",
        "totalLabel": "Total allowances and reserves, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerCurrentYearReserveProvisions",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerCurrentYearReserveRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Current Year Reserve Recoveries",
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerCurrentYearReserveRecoveries",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerPriorYearsReserveProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Prior Years Reserve Provisions",
        "totalLabel": "Total allowances and reserves, adjustments relating to prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPriorYearsReserveProvisions",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerPriorYearsReserveRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Prior Years Reserve Recoveries",
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPriorYearsReserveRecoveries",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Rebate Reserve",
        "periodEndLabel": "Government rebates, ending balance",
        "periodStartLabel": "Government rebates, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserve",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Current Year",
        "negatedLabel": "Government rebates, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserveRecoveriesInCurrentYear",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Prior Years",
        "negatedTerseLabel": "Government rebates, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserveRecoveriesInPriorYears",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Right To Recover Product, Current Year Recoveries",
        "negatedLabel": "Returns, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductCurrentYearRecoveries",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Right To Recover Product, Prior Year Recoveries",
        "negatedTerseLabel": "Returns, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductPriorYearRecoveries",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Right To Recover Product, Reserve",
        "periodEndLabel": "Returns, ending balance",
        "periodStartLabel": "Returns, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductReserve",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerTotalAllowancesAndReserves": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Total Allowances And Reserves",
        "totalLabel": "Total revenue-related reserves"
       }
      }
     },
     "localname": "ContractWithCustomerTotalAllowancesAndReserves",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractualAdjustmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Contractual Adjustments [Roll Forward]",
        "terseLabel": "Contractual Adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsRollForward",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_CurrentAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Asset",
        "label": "Current Asset [Member]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentAssetMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CurrentYearProvisionForContractualAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Current Year Provision For Contractual Adjustments",
        "terseLabel": "Contractual adjustments, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "CurrentYearProvisionForContractualAdjustments",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CurrentYearProvisionsForRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Current Year Provisions For Rebate Reserve",
        "terseLabel": "Government rebates, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "CurrentYearProvisionsForRebateReserve",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_EmployeePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Purchase Plan",
        "label": "Employee Purchase Plan [Member]",
        "terseLabel": "Employee stock purchase plan",
        "verboseLabel": "Employee stock purchase plan shares"
       }
      }
     },
     "localname": "EmployeePurchasePlanMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_EmployeeStockPurchasePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2013",
        "label": "Employee Stock Purchase Plan 2013 [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2013Member",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_GainContingencyRoyaltyPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Royalty Percentage Of Net Sales",
        "label": "Gain Contingency, Royalty Percentage Of Net Sales",
        "terseLabel": "Contingent royalty payment"
       }
      }
     },
     "localname": "GainContingencyRoyaltyPercentageOfNetSales",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "agio_GovernmentRebatesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Government Rebates [Roll Forward]",
        "terseLabel": "Government Rebates"
       }
      }
     },
     "localname": "GovernmentRebatesRollForward",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_LesseeOperatingSubleaseAreaOfPremisesSubleased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Sublease, Area Of Premises Subleased",
        "label": "Lessee, Operating Sublease, Area Of Premises Subleased",
        "terseLabel": "Area of premises subleased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseAreaOfPremisesSubleased",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase",
        "label": "March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase [Member]",
        "terseLabel": "BMS Repurchase"
       }
      }
     },
     "localname": "March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_March252021RepurchaseProgramRule10b51RepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase",
        "label": "March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase [Member]",
        "terseLabel": "Rule 10b5-1 repurchase plan"
       }
      }
     },
     "localname": "March252021RepurchaseProgramRule10b51RepurchaseMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_MarketBasedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market-Based Stock Units",
        "label": "Market-Based Stock Units [Member]",
        "terseLabel": "Market-Based Stock Units"
       }
      }
     },
     "localname": "MarketBasedStockUnitsMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_NonCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Current Assets",
        "label": "Non Current Assets [Member]",
        "terseLabel": "Non-current:"
       }
      }
     },
     "localname": "NonCurrentAssetsMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_OtherStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Stock Awards",
        "label": "Other Stock Awards [Member]",
        "terseLabel": "Other stock awards"
       }
      }
     },
     "localname": "OtherStockAwardsMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Unit",
        "label": "Performance Stock Unit [Member]",
        "terseLabel": "Performance-based stock units",
        "verboseLabel": "Performance-based stock units"
       }
      }
     },
     "localname": "PerformanceStockUnitMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application",
        "label": "Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application",
        "terseLabel": "Milestone payment for achievement of specified ex-U.S. commercial milestone event"
       }
      }
     },
     "localname": "PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PriorYearProvisionForContractualAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Prior Year Provision For Contractual Adjustments",
        "terseLabel": "Contractual adjustments, adjustments relating to prior year"
       }
      }
     },
     "localname": "PriorYearProvisionForContractualAdjustments",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PriorYearProvisionsForRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Prior Year Provisions For Rebate Reserve",
        "terseLabel": "Government rebates, adjustments relating to prior years"
       }
      }
     },
     "localname": "PriorYearProvisionsForRebateReserve",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProductReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Product Returns [Roll Forward]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ProductReturnsRollForward",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ProvisionForRightToRecoverProductInCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Provision For Right To Recover Product In Current Year",
        "terseLabel": "Returns, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "ProvisionForRightToRecoverProductInCurrentYear",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProvisionForRightToRecoverProductInPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Provision For Right To Recover Product In Prior Years",
        "terseLabel": "Returns, adjustments relating to prior years"
       }
      }
     },
     "localname": "ProvisionForRightToRecoverProductInPriorYears",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase Program",
        "label": "Repurchase Program [Member]",
        "terseLabel": "Repurchase Program"
       }
      }
     },
     "localname": "RepurchaseProgramMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]",
        "terseLabel": "Schedule of Revenue Related Reserves"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost not expected to be recognized"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_StockholdersEquityDispositionOfBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Disposition Of Business",
        "label": "Stockholders' Equity, Disposition Of Business",
        "negatedTerseLabel": "Disposition of oncology business"
       }
      }
     },
     "localname": "StockholdersEquityDispositionOfBusiness",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_TIBSOVOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TIBSOVO",
        "label": "TIBSOVO [Member]",
        "terseLabel": "TIBSOVO"
       }
      }
     },
     "localname": "TIBSOVOMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_TwoThousandAndThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Thirteen Stock Incentive Plan",
        "label": "Two Thousand And Thirteen Stock Incentive Plan [Member]",
        "terseLabel": "2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndThirteenStockIncentivePlanMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan",
        "label": "Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]",
        "terseLabel": "2007 Plan and 2013 Plan"
       }
      }
     },
     "localname": "TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_VorasidenibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vorasidenib",
        "label": "Vorasidenib [Member]",
        "terseLabel": "Vorasidenib"
       }
      }
     },
     "localname": "VorasidenibMember",
     "nsuri": "http://agios.com/20220331",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r170",
      "r262",
      "r265",
      "r419",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/OverviewandBasisofPresentationDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r170",
      "r262",
      "r265",
      "r419",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/OverviewandBasisofPresentationDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r171",
      "r172",
      "r262",
      "r266",
      "r447",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r262",
      "r266",
      "r447",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r54",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premium (accretion of discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r57"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r67",
      "r70",
      "r77",
      "r78",
      "r79",
      "r119",
      "r120",
      "r121",
      "r337",
      "r448",
      "r449",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r309",
      "r310",
      "r311",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r284",
      "r286",
      "r314",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r286",
      "r305",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r42",
      "r174",
      "r195"
     ],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total common stock equivalents (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r114",
      "r159",
      "r162",
      "r168",
      "r193",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r335",
      "r339",
      "r359",
      "r383",
      "r385",
      "r421",
      "r434"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r26",
      "r27",
      "r65",
      "r114",
      "r193",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r335",
      "r339",
      "r359",
      "r383",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r180",
      "r201"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r177",
      "r181",
      "r201",
      "r423"
     ],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0
      },
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r179",
      "r201"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r179",
      "r201"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r287",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Additions to property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r52",
      "r105"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r100",
      "r105",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r100",
      "r360"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by financing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r16",
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by investing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r16",
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r36",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r36",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized; 70,993,277 shares issued and 54,776,467 shares outstanding at March\u00a031, 2022, and 70,550,631 shares issued and 54,334,220 shares outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r73",
      "r75",
      "r76",
      "r85",
      "r428",
      "r442"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r242",
      "r244",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Contract assets, ending balance",
        "periodStartLabel": "Contract assets, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r242",
      "r244",
      "r263"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r242",
      "r243",
      "r263"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r274",
      "r281",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r90",
      "r419"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r182",
      "r201",
      "r206",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of debt securities in unrealized loss position for less than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r187",
      "r202",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value of debt securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r188",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities in significant unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r15",
      "r19",
      "r318",
      "r325",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for income taxes recorded in discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r86",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r132",
      "r134",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r347",
      "r348",
      "r429",
      "r443"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net (loss) income per share - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r86",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r134",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r347",
      "r348",
      "r429",
      "r443"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net (loss) income per share - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period to recognize compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense excluding options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r77",
      "r78",
      "r79",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r147",
      "r194",
      "r238",
      "r239",
      "r309",
      "r310",
      "r311",
      "r322",
      "r323",
      "r346",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r448",
      "r449",
      "r450",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r349",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r350",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r349",
      "r350",
      "r352",
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r232",
      "r274",
      "r275",
      "r280",
      "r281",
      "r350",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r274",
      "r275",
      "r280",
      "r281",
      "r350",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r350",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r232",
      "r234",
      "r235",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r354",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Fair value of assets (liabilities)"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r370",
      "r375"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on financing lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Financing lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r204",
      "r205",
      "r208",
      "r209",
      "r233",
      "r237",
      "r345",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.",
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Contingent milestone payment"
       }
      }
     },
     "localname": "GainContingencyUnrecordedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r103",
      "r338"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Royalty income from gain on sale of oncology business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r89",
      "r104",
      "r124",
      "r125",
      "r126",
      "r127",
      "r136",
      "r139",
      "r333"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss from continuing operations",
        "totalLabel": "Net loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r81",
      "r86",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r137",
      "r138",
      "r348",
      "r424",
      "r425",
      "r429",
      "r438"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Net loss from continuing operations per share - basic (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r81",
      "r86",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r137",
      "r138",
      "r139",
      "r348",
      "r429",
      "r438",
      "r441",
      "r443"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss from continuing operations per share - diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r15",
      "r19",
      "r334"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net income from discontinued operations, net of tax",
        "verboseLabel": "Less: Net income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r82",
      "r86",
      "r135",
      "r137",
      "r138",
      "r429",
      "r439",
      "r441",
      "r443"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Net income from discontinued operations per share - basic (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r135",
      "r137",
      "r138",
      "r341"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Net income from discontinued operations per share - diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r17",
      "r20",
      "r21",
      "r22",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r319",
      "r320",
      "r321",
      "r324",
      "r326",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r130",
      "r131",
      "r158",
      "r318",
      "r325",
      "r327",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes recorded in continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r102",
      "r416"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r102",
      "r375"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r44",
      "r212"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r25",
      "r63",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r64",
      "r112",
      "r146",
      "r210",
      "r211",
      "r213",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r46",
      "r212"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r45",
      "r212"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r93",
      "r157"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r420",
      "r432",
      "r469",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense and Other Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Undiscounted minimum rental commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesFutureMinimumLeasePaymentstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r114",
      "r163",
      "r193",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r336",
      "r339",
      "r340",
      "r359",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r114",
      "r193",
      "r359",
      "r385",
      "r422",
      "r436"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r114",
      "r193",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r336",
      "r339",
      "r340",
      "r359",
      "r383",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities - continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) provided by investing activities - continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r100",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r100",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities - continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r71",
      "r74",
      "r79",
      "r83",
      "r104",
      "r114",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r136",
      "r159",
      "r161",
      "r164",
      "r167",
      "r169",
      "r193",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r348",
      "r359",
      "r426",
      "r440"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r159",
      "r161",
      "r164",
      "r167",
      "r169"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r373",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r371",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r376",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Overview and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r57"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r72",
      "r75",
      "r77",
      "r78",
      "r80",
      "r84",
      "r238",
      "r361",
      "r366",
      "r367",
      "r427",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r91",
      "r103",
      "r214"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r94",
      "r97",
      "r178"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r287",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r35",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r35",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r26",
      "r50",
      "r51"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Cash proceeds"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r99",
      "r308"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Net proceeds from stock option exercises and employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r94",
      "r95",
      "r178"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r33",
      "r34",
      "r215",
      "r385",
      "r433",
      "r437"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r43",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r317",
      "r418",
      "r480"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r239",
      "r312",
      "r385",
      "r435",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r194",
      "r309",
      "r310",
      "r311",
      "r322",
      "r323",
      "r346",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r155",
      "r156",
      "r160",
      "r165",
      "r166",
      "r170",
      "r171",
      "r173",
      "r261",
      "r262",
      "r419"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r264",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue Allowance and Reserves"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Excluded from Calculation of Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r286",
      "r304",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocated Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r31",
      "r47",
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Performance-Based Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Unvested Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Market-Based Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r287",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r289",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested shares end of period (in shares)",
        "periodStartLabel": "Unvested shares beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Stock\u00a0Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested shares end of period (in usd per share)",
        "periodStartLabel": "Unvested shares beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Opportunity to purchase of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of stock options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r291",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Stock\u00a0Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of stock options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r285",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r77",
      "r78",
      "r79",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r147",
      "r194",
      "r238",
      "r239",
      "r309",
      "r310",
      "r311",
      "r322",
      "r323",
      "r346",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r448",
      "r449",
      "r450",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r147",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r35",
      "r36",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under 2013 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r36",
      "r238",
      "r239",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Common stock issued under stock incentive plan and ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r238",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued under stock incentive plan and ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r114",
      "r176",
      "r193",
      "r359",
      "r385"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r374",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r233",
      "r237",
      "r345",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Shares repurchased (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r60",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r60",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r36",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r60",
      "r240",
      "r241"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost (16,216,411 shares at March\u00a031, 2022 and December\u00a031, 2021)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r238",
      "r239",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Shares repurchased, aggregate purchase price"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r117",
      "r274",
      "r281",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r133",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r132",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net (loss) income per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r484": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r486": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r487": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r488": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r489": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r491": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r492": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r493": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r494": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001439222-22-000040-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001439222-22-000040-xbrl.zip
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M!UW/]VS\^S3[XNWCDW8+_NS>UGWX'+RSW5[;?QV]_H]J(KTE&N9=T-@1SW0
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MH037$JPX8@\V:ZDGW"HR_<A:JNO$U'4LR G*%PW7.6,AY)1HC8/R$29VT,
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M2EPR$073,.?/MA)=*DY<CZXWG5-Z25*?K+O.!!>(HS("*Y4Z&$ZYI30?M0H
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M-F,:'IKVR=AGX2'^US>7\>/OAU-P@H!5GN_$DW:GMU IPC<]>,%9;SDUSF)
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MC'%.N]@8/J394X\EH<CI*! /@B&M.$48"PK4E$2;JU=PL:@,G8G->.59@U.
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M^/GUY69FL6Y$.]=>:UA^#(MTI2<YNOE@./-<>J$PC@IA22SBREBD&6'(DR!
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MU;/JYT]'^YL?+FI'\,Y/^KQV\8'7H&\P3C 6!_0+\3%0ICT*VAK$<23(4N
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M&BH8$U@")S%$##9'NY D$BDZ3 ..R>F\8$6Q6N2"S<21,^714U, "*.*HI2
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M\G<.J-',!N=V8Q,^/%BL',16[-AF09%L.&ZT&MU>IRAP\,H*S[\D2]KL"P$
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MQ&&9Z[R79JO<(RV#0DI:6#4B7;2 =[3-&&\SOIQ]U<!> WN/#O:NDQO$=>1
M#9QQ"NB<58;'1*)07C(@=_$2*G=!2E #@'<*@&RQF(SG"ALP7FU*'G')(G(\
M*A2]3"YYRI(KQ62(64'J:8-[#>X]$MRSA@@A1;+&)6ZBMA)K0ZD1BH04G6EP
M;[UP3RS@GHPX,L$,TL(JQ'DRR,4D$951<4PD-XH#\6.ZK>1RLY^GAGQ/U9U_
M,2*<Z\_'%%OX/TU!GC@7V+JD+-?&V4@<P_JN_?D-%ES-GS_K:0G7?G_U"8P_
M9203R+.4&UL2FUN<)Y2)K'(R 2U20()DF\+_.+E&1O0CQ8.&"35,Z':@UWB^
M[AWT3N=![\LGD%;@0(HC00Q&7&N)'+!9I(2-*B:LC 7+3V/:YEHVB-<@WJ-&
MO.M4>O!:1IXBD59PYK%AC)L4-/>@-U&K!O#6!/ 6.I<3J8-@WB!"C$7<4H\<
MMAXEHAR7*415:JRUJ2%MHS:C;G+3";6Y<B.NO';D9"K_=^/*R ^YE]3)7<.,
M[ZW.<#B.H572]2=_ZN6XV%R0#Z:IUP(+O_7RW>O7-XJA/&>:-L.U<CW/BO).
M:"R5-T9R8Z(.(=D8F> R6.G8#TK0G>=BR4OQJBS.?$'3RO-2/MP_R0,;OOPG
M#GQG&$,34[FJW?F<JL?6Q$@92P@SJA"GW"+#<E.#(+FVF&N"T[/GG-.VY,O6
MR#6WYDNPY:X,CX5'WLC!NK&Z7M*BZ&_-*JWU*EWG]$M1YD4B+@3%C0[6<2>H
M8%909J*T5Z@(>B4T_J_MCN,MP+@QE:X$QHM14=)*R[3R*.IL*0FID"$D(I9<
M@'4F)$A9+"5M&BC>+"5OH+A9I6:5FE5J5JE9I75:I?LM1]^0S_4AGTM^>FTM
MU]XDY%5(""Q_CBR5 CE"M8R8:L[)^K'/^V[]]I#*6I0".9OK5.:ZQ+$W+$5)
M6_&?_//%Q84VK+7376XP30.N9I6:55HG']1V^#P>CDJ5W8/^K!I=+D3WJE>7
MH"O' P7X7LSAWMOXO^/.L#.*[^+@:\?'BC^\C;Y_V"MW*52B80TK8PWOEEQ6
MF$2C1>1( $= /#B1^R<R)(56FAGO9&F*+-J"+(=S-Z"PUJ#00'>S2LTJ-:O4
MK%*S2NNT2@_ILVK(Z@:1U2475\ZL#L1&)+E)B%L?D$E6($\CCT31&#5=0[;Z
ME(+X2B7MXMV:]<_-[7.?5I1><WC2K%*S2LTJ/9U5ND[J8PPI:>4I,P%S$J/!
M3#$<DD@)1T[#S1MCE]WGG ZPN87#9G6!W0B*MEP7)QA+L2<*$:48XLXP9*D(
M2%H:&,Z=8!UY]ERV!5_N 'OUW,A&N1L(;E:I6:5FE9I5>G@ZLP(G54-GUH/.
M+'F<)*PI\U(BAZ5 G)F$C"(,"2"K'BLB,*=KQ6>>4CP5J,#-?4L;ZSYO#CF:
M56I6J5FE9I6:55JG5;H.90[6!4T5EII3'K W/ 6KL71"2AG-58(0+Z#,P EF
M'+GAQBOCQJ=+I6 %I28$SA$F*2#NJ$):*(V<8<E$JP,LZ;/GAK>5XK>O@]:H
M<0.VS2HUJ[11J[0>7J1F2[RK+7')782)YH0)@:+B#G&L"3+>&Q2H2,X(3:UD
MZ[4G-I7PFBLWXLJ;!M'5A20KJ5^L)?G8&@SOVH$_FG07IK>)N5O!M&W&'GV]
M@GH.&^VT8'E3YI)HRQ2AV :LP&SUK.I7=Z4Z>DWKX;O:F/??+97)R[GO*F**
MB(DNY\8'Y!AG*"2I(Q..!V5*ZV%C6)NJY;.<FQW7K@9[[N.4]Y8CO7+9[SM&
MEW6#YJO7!%_AQ&PFW"Y;1#?#VJ;=\>KA=*G=,3<N46&0UDDC[AE%5I*$C/;1
M!Q.U,G(5[8X;&&U@M('1V^;0.2N%XLY8+;CAP3H%\$DX)<(2AM5M8+3Q):T,
M8Y<J,T06-988468-XAS^<<H*%%,BV!*B7$REQ;(@;7).]%$#M0W4-E![W^U-
MK7:,.# R ^=P.R>"D5PQDQ@7.EU"69OVI@\!NHOI*\91'$6@R"4/H)L,1UK
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M*>#_*,B02T1*A6R*!!$M,!>*,(E)Z=.G"6W357="N#7^W&.Q\)N/]8:UQ.\
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M:>$O$1C_2:;_C5/E 9TJK^LE>=VUO1% V<O)JC1XM3J\6J[.I;G&1DF+ *G
MV*)1(&,D1L$0%[FT@AF6<S;UK?*Y&F_*&NOVW7M3&MV^']U>CK:BA%B+M,$.
M<4\),I@JY),+2>! 0](Y5Q,3NAZZW42RSX54_53'5/V<V4HY=F^Y4_A]^=AP
MI7F%3STN]=X#KZ8'P4T^T'U!I5^B080+E6ADR,0$-(BG'. N'&(T<.&29XY'
MH$&R+=3:!Z8V\>V/T=O3H,<:H<=BF5.PDT22&EF>P[)XBLAZ#FQ+1A,4-QKG
M$RM%VN2<^NWKF"*SRJ*B&T*WKD"R5ID\N+FFY;JE")Z#@$V*X!W"WW+=+Z^L
MX5IB1'PRB$MND8U.(T6UT@38D^)J'0L6-JZD=2<]*]3WAO/<4ND7"X$1IXAC
M"DPDGH#S*(TT5A11[B33B7M"2B$PC6G;L%L?=35>IH?V,C7>I WU)C4XN#H<
M_+)<D8I(086QR$=+$+?>(^<"1]09R7*T(N6A\1P]=<S8#,]1@Q0K18H%QI2H
M-"3A@!A0) 2$22&CA4)!2Z]]XM1I6AB3XFVL5A4+N)Z.HL>1P_='IV=[?@4Y
M?+?/B]ZTNS_^D/DZ"*(%:)^F<E+U"^@[&-SMSV@W<!]\T)BS2EUC*1?^>M"!
M%3FQW<DZ-=O;-;8W^'R)" L+?#=JA[S)D63:">1,,DA[(;RB6$3OGCW7MVE@
MVX2WK[&ZKIRW-NJZ4G5=8*. H3;AY)%T+COMJ4>&,(.$U48'85+@!-3U-CFT
M]Q>>OG%%\3=NP)N? )!=GB=G\AB'H[[_TNJ?%&2+_\2![TP:?,?CDV[_-,;Z
MFI,Z>: %T]9KSGL?)*/QU7 XSOO!?GIW9 =Q^+X']L8K^$,/3*^<_%3^_#NL
M4GC1/\[-V@O#SC''0[BL.\X3_RXOY_Y)<SZTXOUEN5"#()3AY @B+/M%"?'(
M<>N0E4E'+1B3/K?];E.]7*BH.1)^-)!PIUF/#22L-R0L.D!9E(D9ACP( >(V
M4&2\TH@E(4G2+E$#=$2UV>T3H9OCXKN/DDOG>#^;5(0U9E,7' 1-O=A-"/%]
M8>,Y92*T( )[C@(&SL0]YX"-'B-A*%<,1,&+4.@2UAMQ,-0<):\!@MS747*#
M( ^!((NU83U.UCF0?><U((@!=B5H0E+PX!+\'EQA5U0V.0B;RZZ:'(2'9E%7
M!, F!^$.T6^YC@4SA 26) ((!-M2R-RA6 @DG0[4!ZHP-DT.PA/0]WO)06CT
M_=[U?8'M,,Y\Q%*"J@>'.(D):1,(BM8RC;GD4K)UU/?&FW0-OM-XC=: [US=
MYFOLN]4AWG*)"DPT"XQHI$DN42&$0L8(L/0T?((-K#GQC8>H\1!MBH>H08N5
MHL4B/THQ$!Y2/FOSB&,'N"&X0"1AYQ/\?RPE*1Z]-VAEB08/3)>.;.\PY@Z+
MA3CE$*7R0ZY=^A44I3=JVBRN5WYF1L'\OY>S%7H;AZ-!QX]BR!]L]\+9/\Q=
M^1K>O ^PZ0<Y^'4G5O^=ABR\_*>2A[=V%%^F%'U32'&%8+I<X,)ACSW% 3FN
M.1 NPI%U$2/+&?PE),EC:;O&VB"!Z]YVK>G5^!AY5P,W&PPWBS7DK>+:&I(/
M_S'BQ$OD,(\(<^$Y)L[Y7).9M)7$;;&R\,DUXV^;EN_WXB)>UK*CEHN'G5ZO
MA$2EUN@HMDZ*QCVQY+_KX*/7,O(4B;2",X\-8]RDD'NFJ!BU^O0JPR+LN'<)
MBPW*K0[EE@MGB)2\9EX@XP)%/%F"M.86.1*3#)3"7W+E>0RDBJY3IXPF<W#%
MNAZ,<2I)"]IM>9#,N$2LT"G:%*5ULN@Z;G1]DW1]J6^U(HH1CQ@.*3?!8LAB
M)U",(K 8#2.Y2 ZAJLUO7RKL_M(.'[/7Z5(^$^'OES*9.[3['K *R/DS]7_O
MZ.4?#<!S[JP%(Y=(P7@DV"46#76").:M9*( _!4CKQJ ?WB /]A>(G/415AA
M[E 0@B'.@=9I2C4"\IZT$$XRQY\]U[B-;\_E'H>7K$'(!B&G"*FP(]H)FY0!
M)4K">LN%$UHKIL ,JBCP77L!&X1<*4(N4&"P9!Q6(H*EFQ-\<JE<0Y5!,LCH
MA6)@X90$'ZTU@*38")!<13#;EEA[@GQ^\;=WXY.3;LS%:&RWA.5W^\/Q(&9>
M#.N&"FV>JZ,+C'D6XC8:P(.KA;U9P;AK3.2-BKJMZ_V+Q/U2>HS#?T/GZ_-_
MP3^3Y]3KP^%.OYWTAYT\O[\.8M?F=/#?OG7"Z&B"S7/?JF3Z5SS[BG4PCO'H
MXJ_,"65.-H^#^]]B:!Z3F I/F8KY?X\&D\&<V,.(W"#:+\@F&.NOMOO-G@Z?
M_7+FE8X[/30_?XNO?N$+IG1G+U@I/^Q _2J<^M=Q3O#/5\&8[-J,I74TR+OX
M_^E8+$7RBBBM'%!@ /SDI#;&"$JHP>23>O;\(,MN!HF<(5?%;=B-?9EJ4UK^
MM[S3.:(Y+V]V< @B5U2?GL7YJ4H5/9^I:<$*F*"N/1G&7R<__#:I9M3IE=<L
M7_JMOGVMVUF@%S>._+SJXUK6C=E26&5QK[>T^L&U)FP535C8>*O/%(=OR@L_
MQEODPL\NNRW!6Y)=_/%EM[W\,\'8W0SV:@-:968?,>O!$<XW ;9AP&63;XWZ
M%S2=SC%=UGMXW=&P=6)/B\CG*^"/@YSD%__)A4N6@^%OG>:S^6;BXS0&[R!C
M\:0#)/5E%B201R"IN?K->#"(X??Q:*\_^A!'KVTG- ;@Z@S 5TLNLI04T]H&
M%+DQB#/,D#4XIVNSI"T-VHL<1-86:]4L947YB0U8/5*PNH- MJN"58-'U\.C
M!8<4-E+9H -*D3+$C8C(8"YSB_"@/%9.:3"SU@F+'EM-U6; S8!O& >Y ;9/
M"2 8V7]B-FLZ5X\0N&K,TP8S@O->\=$P@I6;+[#]]X_C09:DO/'OQ2;\?'7$
MX//\6?[A=_C\$]@B@7%'D?-,(,YSGR(:%0B63IQC+2(OAHKF=(U"M584EMG
MTB.%I94;*C^"I:;8R\T1Z72&2'#]IV2("M$Y)$W$B <6D;8Q(:^)9]1ZHMGJ
M&DRO.GSTPM/*BPX1G__+#7Y9.#YYF+/'<L=?LSG>\5<XC7P78W%E'\-H3O,Q
M-UCKL;B^7_1[(3NQ0_ZIG/':$?Q25P6PW=:[$?RA-';9NO#%G]SIKKSX=#>/
MMD#)#T_I ,::(^'U/D5MCH0?2N^6(GN*WFW_^6K_7>OUO[??[FZ_>/G^X-6+
M[?^\:[=>[;VX&)RN<IS]$.]R$PA>ZZWG_-?\Z7W/CD,'WNCGY=%?$2CYLXO7
MM=Y%) SODI7^/!Z..NGT@9::;+5J/KPW/H9;^!78Y6<I[_[@T/8ZWPL^S*0(
M?MGNA=>#.,RQ</G7_305JYE4[4Q#Y Y@3+]W^_[+P]+A[WM3.GS4W?V^BS_^
M_>:?CP=_?=G]_.;T _T@/G[^0O<.RK.^?2S?W65 ;;OQWV]//_X=3ASE<O_/
M]]]WO[_M?MSYH[M[_.9T;^>OSQ\_=X_W@>[N';^B^SN_=\LXOX=,;>GNFT_4
MLZ M4TCRY!$GR:!2MSD$R1F1!-BG>M::%I/<SO9$HM'E,%$92.386A.%\F"/
M"TZ(\5P^:T6P,4ZRC@[&L!7N R_]V@&YRI$$O]MA9YCWE_DUFM#D6E86L!D^
MJP=0+J[6Z<>#.#OH*"7A*@83F>)>2^M ["*/BJF0=.#/KJYI\IX5[9KP QH6
M!['G*ZC=/NST+P;1M7K/2_GGP1$81H='_?&H-3H""7HSM@, _>YIZVT\Z0]&
MN;7M'V#Q5AL\P>A->[+C:P"0W[[%=OF)_-:J_S(>3O^2!;/^:W\\.//G80=>
MQ@YRY L([##'S[3A%Q_!#/MV!!-=$L]J<&L-<B@-7-?JPU\'WSK#V(:_P7I,
MEZ+U^LB"7>[CN)AJ<#.PW;?*HSJC8;[1;#\<CMVP$SIVT(EPW=E!MG[OVT%)
M?-N!!_I1?S"<#+L\L"Q^'IJ;7!<FU^5?+AG+9@C+-95B@D%7H1,/*^A_@]T*
M4F5;KM,_.;,^K=J:S?\][HRRA.0USN';V=>3C=P30,B\OQ7W@_JMU05K%"2A
MTIW6T.</.PEVXVZTP*B'1YV3'/.5Y21U8K?(B8_=[CB+_'$<60?".#RN8L#"
M9YN95AZ>+4($(^SV#T_;K6^=T5&YR6$?AIGO 9>44//0206-1ITLT>W6\-AV
MNZWC?C?Z,=@9QS%T/$S!,'NK6H>Q%\N;@E:'F.#O(0>SY_HO()MPP9\[.\.M
M%LS0R'[)4S0\'<*&/IP,I&5/3@9]ZX_RO(083^ ^Q7(8CO(+U+>"!86QP W#
M &:G#+L4L@<)J<+AOMH)E:CBY[_&;KYJ %M:7@AX^. PCFJ-K,8YF?C6,,*;
ME:\.86%&\;"H;OYV=*<PU:6:38FZS^FJ@[ZSKM/MC$[A=PL8-BY  X)3A_+/
MYN=;!^;MR$X&'(>@S>',L&*IA@.+<=2!F87I'76^5HL H-*K1C6LEFHRVBQ(
MV4U9!GD4;7=TY+/PP<!2!78%%4X :GL94DH*;K\+PG,XKK:7R<S!;$:8I_Y)
M/2E9\ :MD_ZH+/UD_CKU0D_7,3\,R%=!.Y##%_;8#3KA$%!SUPZ'L)+C81Q=
MYH>Y4&VO[KAZZ'TM%F7,<Q[&/A<C[H6"_WE"LD# 9+7R#I= %?OMUNL/;]__
MSX>]'=C=%/^M]1,@ 4PLK/3/[58G+U%5L]@"TA<=A9TH"T] H].3*ICS> SJ
M,&J=G [&7_-SO@ _SAL5?.'U_\#FUOM^>EPO5)'2V2)FK2YQHG#CHPA:?)H%
MS_;B<<?"@N[#%AS= ';FTQ91[5:F[D7X6^^WWFW!]MP/90 [@_%A:SL 8G6*
MEH"<E:?_L;/=KG3X*\C#PHM.AG/I($H :P#1GPCZV7=L_?3Z?WXN*IN1T)].
ML.]]+UMKE=4)[_&JU_IK#$J=?>^@3S%OQ#7@VA;L>5]BE48S'AWU![4)DL<-
M6]'L97:WX67J/?CE.(?;PM+L3O5Y^S /H%SY<A>N//?UYE_E]?^<,_#IC>$-
M^KVM5I8F>#  13[H'F8+>X9F%6#EKPWB(2 \2,@I_%BH>6E&.QQF">KW#OOP
M>F4:;!TS7&8A*VL)?NJ- %@CW'A<X<M55@KPK9L'E!>IXE7^2X8IV&PFP%PF
MX]V+G78I+0FJ4C:]T0!$;X86\'-_@C7YV=M_(L,EO%H%U.U6+VMVWDDJP8)Y
M>SO3B/:UI;H,MK Y&%6H%_@Q ]+<JD_$U\*D%;L9_I:WY&KVRY2!W!P.[/&P
M"$CJPW8\@*6HL2QOK]G*LP/8DF/O,&^4A4G .@YC_%+VP3X\[FMNG FX!%O6
M"0A%O9)UPMIAF?(S>\B\?.0; C6?_CX_NAI!4]^/AX6VY"7.FT^[Y7(CSFPT
MY ONB!@]8BFIM1& \3,PB[R*@\[PR[ PBDIP*K):KU:>9% ?&/*@L*"JEA^L
M IASO?X(>.IQI^*S;6!L/@Y&MM,K78:J,Y5*4(#'%+'*E&:RW%/YJGC'=.VK
M?0?><YQ ^W,N9$&=G"=YFI>H%M%JFSLC3/D5<OMM^'5<0,GEP4SR)H_SP.K?
MYV"TVK4 G&IY[/C)%P:Q<^S&@V%1H/*T/!F3Q[?K_22?58%)F?4@_ZEG#_/W
M#[M $+NMPT'_VZAZP[K+$GPV2<4 Z/MJP42M>639-2KUS19#%<#:+JL!NU:]
M.YUYH]B#0?G:>LC& [#TJM$XO$5L?>WG!<CWSAPO!\)FWT+6G)+TY(J+OBAZ
MM\)&4)UAO=-T!@%E\G@*Z@[FEX^3+@N#X>+-OL337+YEF*DJC'<&S_#D&@+:
M4X[4[4Q>UW=MY[AZW&'FH;U:[^>0XP[ >G/LWG>V.LW),K??\Y69]/MXF#E(
M(?#OBET\V RC_U)( O:Y6Y" D?:,NF7![\9192NUAG/3T9],AUN>CF7/R'_^
M\Z+B)]4%Q<R"9PWB2>7'+-SP_(9H%2V;2[.N$? J8VK/T+)U\.KW=_O_W:]8
M5KM</P$N$ M[&)=MB"&H[P ,3E"SCFMGLD05+MH"/THF*TIXYLE30)UL[06S
M;$X'F]+2#';_=([A 0"F__<ZY=42D4YR&YA-G&"L.0L>>R>]D8D:50>^,'9!
MX(N^K /W3J=H?0;[_321\:O6]C=/S/^_O_.!?XHB"HVER''V%'%)$G*,4)0,
M)Y&&P E1^2SGHB8> ,+=2I[K4O"CRAO:[0_+]CY'#^H]/9,E0(GC:I\I[&E>
MLJXC2Y9@&E,*6"C!M23:1>Q5LI9ZPJTB%]0ID8LB]"<,J^H06DRR][U!/G<&
M[=P^SHF05Q,?^=3$Y^ -_L1!G2W'#GGJ,.).&.22"L@SI4S20I)\CDG/*4->
MB<_Q6?$!K$MYC^_TB[O\+^!NQ9-0T%RUYZ$LVZD 3@5V>[!]A.Q16+3 ]V;N
M!. 1"1"B2.<?.]N516U[,V<#$)GBY0,)!M@^SJ[XN<?5[M1A)H2M;!.VLGSG
MW-C#":DK=A+(]M?L6CEC4DY\LM5#_QR ?=&B0.TZL.553RQN/1A-9]CWG>(V
M!($].@T P+&X+4A^'5H<-T4K?@+%F3H70"'RD^JCA]*_:CC.A+A^\XH)ST]>
M3<WA1J%C#WM@M66O)F#G_+3">/),P?8V8:CU_7YNYRGXE@WW,A6#_JGM5LSS
M0NT%M7%QL*# H+O1<,VXT($GSC4.RD= '5#@0"+^P69 )XH,7+F_J,5OJT&]
M!B*?/:F'L"/LQ5%F0\.ISB+ZQ)1V]^#-][UOGY*RS%C"8%99R"6 /#+&:H2C
M2)@FH1PGI9S'@M+^?WF)BR>O!^*0:4LQ=L_0DIF:Y4T@3@HSSI.?R6D$?%Z^
M'_\!@C/,C7A.)SO"C44*&T*99$ R#.'!>>M$<B)80H./PK)&I%8N4N_)[O8G
M;JBR1$:D"8>=P'N'K*,)48%A^IFD*5H@$E>6J7FTFDI4Z@R&HWGS?,*<YZ^^
M1+JVINR^.!&MKP&S$.D^FMUXXM(M4;45__U]T &CN-O:/<WG(._@FVZV*[S:
M^?>K/[9K!9CZ6/.7BV,D^I@-9'LM=J,$T=0+K)+7W&(+L^N-"8Y:*K'U[ )V
M(\Y(\.O^H J!>3TQIW<[,,.C?B^^KDC7VS*X'//W1W_P!]C4O<,LUM^RBWY[
MMI\V).A\X?<,\)0H*BDG#ADG%>(F662%BLAHG+P10<CD@ :)K1_QH)G3XWBR
M3%-R7,XQ:]=1)DASSI=\^' XB)6#J9",%[&;/>"M%_W!27\PY_Q/\*W^M\GY
M8]&?B4Z4 \;:PS9EZ^=Z5>=Z@.>GU6[2,TIPCHMXP0OSRT)4S]..KE9-[:PU
M&$L3*'W50.ES0_)^&&*W$)+'/;!.^%](E'.<A&;140>6 $F!NI N5-4'\S,2
M6AU]3#P$V3G7/XX51:E(:Z<B,#=WD7D;J?9,AL@YEYYI'.%_RA@IHC,F_BAE
M]2P#F/+746:S^[V=SG""CC,?&9" _F$/IN"*57>>WC[_ >\?O*)[W]^PO8,2
M-^L9!NE(#*E$<+:A$G+6141IDM%3EZ@!&XINJ:4MOS79[>'_?V1,@2D_V9[K
M779B&<T+WF'>J7/$T<21O.38SD+<ZHSB\?R&[:=!^&>##J=!TN5>T^[Q<R$*
M@"RQ=0R2=33,U??A2V<<[W1K*7[W#N/ 2T#Q?MJNRI:!K+^&5_&GU;]/.;I[
M#\PR(*.":X=P4B"EV -_8 $#/35@HP5B/0V+T=IK>_ASS9.O::#YR9E \XT_
MYCJX6'6=[99 BN%1S/ZZ\O9%,ZO-?**>[9NI?_8:#N(1?"=;LS]E _OG"0Z5
ML_5\:'S4[^;3W?]7:@H"3ET9,\HMJE.[B05]I1&6<X<$1LWP!L\J,0SC2;9.
M=4XW_?6BYZ=IEM+<2(H+U\78R^)V8@=5;$EE9,'\N"*,=EBYB7M F[KGWZ<X
M=FN S@%.=1!JMOM*5$"L8AN VN4XTU8.ICUSHE*=2M;GBS $(!^]O*/G0(D<
MNU4._>>_T(LY[BO[V4?]5K*='%%?QE-%SDS'.&$-EXE5_@8H6XE9.R,\JY>/
M6RU[M="S=X-UM5.IJV*]9A]V>A4EJMSE)6VH"E:%ZX8Y5JG.:;M$8L]=Z6+.
MUB'<D]&C,OJZC<UP%N^V(*+GS_$UYF%0QCU=>P"I:7#;UZG/=O(4&*"+)=S$
MEY>I'W,:<U9$KYQ,[\"-LC?VK$#D0XMR=MP[G<SJN([$*0K0SZQFE(.=ZS>N
MWNY*X%8M69F"<Q].6M_@4Q"U3C[=*30I2^=$M<];D2H:*?1A.?/D3'3(=N<K
MJ@_/G+,4_E;%&N:8]2J&)X9)#=424P,JYW-46Q7!7K[QY_;VZTO?=3(MYPK.
M\*@_[H:\)H,<-YR]-/W>YW&OLBRFH?AS*/8#2<R27XMQCE.']9[&)]2A6]O5
M@EV0:?,_2S(!W[Q@5<IY5UZ:U.G"5=/1OLOH5/F4\G F75[!N#X^[I1(]#)]
MY=*7.1)C%FI</8'R<[GG1F[Q^\4A?74HF<)]EO!)^=X)GDW_4&\CWP""<PC<
MM]Y"AM%6:[O;K41ODF@RWQI@;HN+.5RO-PG:]_/)EY>*]55WSNJF):<%MH@B
M(S.]678CSB<.WJVM\3J[7JL&Q6 SYWCF'#-:99U.-]4=X-.#SDGE-G]J5@?;
M._RDG1,X.(P<SRV#K:#()OC54\DDE4D18AZKU;$H%H\A]?+%)'3GN *23J\^
M@YCPE)D*#Z:O7S&;"4_-0-0!3/&C";LX/U1NN)@T$,_Q9N1-*9??KT.",TY,
M"5B5GE"/[(SI]Z# \7X8]]-+6,3L$!P^15CX]LDZ3K3Q"7EA 18BB<@J+5!R
MFEIL*7=</598>%^%0L2)!#P"5#@H"8QYQYZF2O:OR5NFV=+C8F4<YZ3.Z12U
M6Y_'X7#&4 %6QL<G-4AD%GEL@7&7G,?:7,GD-)/OXRG?R0E'F=A/XL5+GF-E
M>68;^FOLC6O".8FFKT/V*]/L;",E/W6EU_<MU\[=NB3 V=XD@:HV^K_%2:I4
M1= N?,'C.#KJAXQUY5Y_%Z_!PG<R[SW*D0B#<BI;Y8J6$/H2Q]MK?04JUQ_7
M^>?+<_8MXW2W$[]6Z1LY7Z7?RP=9[3,F'[QMY4BHL/5HXL#(/!]6*;_<W-A=
ME90/Z&L'@U)K*[]OO&@%IBTGZNX3A:26-<M?.'=5:H-]W.U.HMU 7*H1YF^_
MV/_OJQU$3 O4(,1CP.]RF%TEO&>N6^5NU;]-]B&8UUF4]<5NBYGD9M&N,RAF
M0=FS-(R\UPR^UB.W^9P]VZO9<78VE:U]8<X*/&%8"T,\/NGV3V-$$UFLI;I=
MOUK)G<@+7IO4<W>IESJO[Q'H:\F!KL_SYP=>Q>Z5URYISH *\ZZ.J8J!K@X.
M"Z6'FY2DD>ETEQ<%,R$+70Y[S,F<G=YPLG-_[0S&\W9(+8>@Y76"4$FDJ;+Q
M)@N7;;S, *8/.1-L6,(=X7O]?.ED'7LE@[B;I_6P9+VT8?.M\U]*685LT4S_
MX@$T^\>39.8JM+'2ML)BCG-TYIRZI07J,GWW^B#EK)-LP:@NYG291##6*X.V
M=A7ET+C94SK39:P9%9AB?C2NLIN*6.9[5*GTTW"H^3O\@-NLZ_YRS4WT/QT
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M#N B2W$2W'M55&\TQ2GU<20-?UE+X6ECO'*1CNWT5][=*IYK*IYKYQ#S&(G
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MNJX=V^^QYF+LUEK Z2W;;E_4ON>F':%FA[7A<:P-^S"2$1J<PLK$XFF#,S>
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M8G/)>'-)M;E/N+E>R01;RE%T+"!NE4(F%'$KEC/I0N"Y(L<-3HUY+P>L+<@
M>R5:1R"3G1TEQF1_V8VJ9!:Q=W)HY(=EFGBXF_')+:.__'$,9^VXG6X_>/H"
M\ UBNMTJ0'(W?^<M6_O;&X?4$^\=#PA3+1&7VB$CN$76TN ,"2YY,VL_"2<(
MH\K$$"EW"FM,E-*16.R-T#$MA?UT8U?=K+;?X#PO=(C6H%!62H4F];+"D8^E
MQ@0_>M3H%*P\S8*YM.WI(+X?__+[N%UFJUN,J+CI]VG6$*?S&1+9CU!>_OV\
M%8;'[XU9$Y)D/6V4V#%Z<7F5K!4JW,S17'F-FS6%U:V7\1JY]=K/'DOPFN0/
M>^S/KPG&J\&NU&#%[9>O/_87:4GW3")ZFE@*?:=0BG]L99NC=P:/"(/_O4-C
M[I_,S8/V'OLO,[LY_WPQNXU./MX%M>&?KO_;^H?>8'B/&=ZA&_9*+<:53Z)8
MC:S#WEZ8Y\TMQXP;X^VM1S[ +5:B.,6=6HA'9F&N<IKEA[-^'[;J_1T(XQ'+
M< =:JIY>/?WVI_^"0V_J=%]]\R[??#O]_[ZN_;56V^T7(5OWR1>_:]>1%0ZM
MOFF*KR9"FA#)$N,T2I6XHTX;P9VQ&@888HK^E@AI]JL:(-.5/R::>%;"_\B.
M_;L%2K/5=%V- J7#M^V]G1P+UFJ<'/UH;L)W-O=YXZ3=V=[]2IJ;^^>-RZWS
M?;I%9P.EFW1''&S"W.C6Q3:\L[FY ?,\NMC>VX?Q?<7-DXW+QLD?)_LG!ZDQ
MW]601I](PAY%:W)19!J1%4'#\CJFHHO!^=QNE;.Z?GP6]_*U2ZK J@*KQX#5
M503#YS[8A5>F8C::_X@ 7''7_JA ZGX@-5OU4,/V$Q<"BM(HQ#G\9E3@2$N&
M$^PA54&^6R>\PJ<*GUYR;O]8(8#*;JP*H!X(4+-5%SD D;;1(H9]1#P)C!QF
M&.D81(YHEXF*=^M,S&M0<Y[T"IPJ<'JMRM/CJCU6V'0G;)JM]DA=HD$8B;37
MN2A!L,AZ9Q%QC&KEDA?&E1:>$,ND0;V=UIF?<UIDMXAVK-IFWB%37PG*C-#*
MFL"5(D8+(.$<I.N)D4Q5?JAE1ZGF? ]-GE)0EE)$:'"(>ZF0<T0A;4.BV$0
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M!U44<9L\<L8FY#UA09'@N,^1OF;>43>;A%^O]>/@-,+%[[%]42^D!: *@"[
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MUS>0)""3G$0J>J7 MJ":X;GZ!LNH#ORD_D&F_70&^Q\G9WXEN)Z.""6K2Z[
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MQ.IZH!$'@RK7J5^F0XSA<F#;-T!EK06B"+X_2*T2I>&V0EG(%W+?@Z,NC":
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M5FCXS&A8.*\V)A&8&]TP#@NOL'!16#BC&28EF> QH4BCS9HA0XXQA:P.D1+
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M2D8"[!2I5W<RT$C[KZV?+T0DU 6\$>2["?)\8D)&69)D(4DC[NJ#PHZ="$E
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M3"X!G8ZS6)(D#@31)C)@XD6&)FKK-5M5.OJJT/<ICIT>W-9;\XHU8-N [9J
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M)$5H0/"N('@Q"X*IL)$)@HA0Q03AL'T1E<0A,;&F5 @:"Q=P$*XJC+0!P 8
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M;(#! 8O;\,V"W>;E'Z3P5)H[KALP%9G141B%,N%2,VDP&R:3.DPLE5+=>MW
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M$8#U1FF"]<T8YU)+9A7&);$D;(LP?@EIDTWV^]H 5Y/]OAJU^'Z0WL1$O0!
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MAG!4D5)E8A(QRIG*(@82LXZX<8,65'KFH;'V>JAYJBM?6H.?/75@W9R@3?;
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M:)QI?((!@5.Y<@9Q>7):%%]_XPPH?/9N<?Z)BC'6-<9N?!BZJ )XR?\WJHW
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ME$>_S[RQ#*NNQZ/;,A3=AY_[0&L,-UG4HGXOFUED)HYM8<V@S=#!"/6)U[Y
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MZV@F_%DGO*]0)RJ-7S1:R[^1@+0T5AUOR,CJH1V7L253(OU*C&M$%54PS))
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MA7[F6FH+XS"V]CM2*>1]+&Z%(??5T$R1J=?'!]1U[.IM20N?,"KO]0F>^'S
MV?ZP6Z0Q.B ;UE\] IW3^K-^]W*O$OA3E0M,LQG WE[1,CI9PCT?+L99D8Z-
M=DZ3KRG:!2VNG1D?Z=LL?J?;0>OD-_.?:0("JG$_[! ?>Z6Z[O:COW&X**L
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M*I<D=K%0'^3Z"(AZ+(.3PYTW1WM_[1R]]22ZQ1]H[Y15#7QA[D'^HS^^+DX
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M5'QCV?=(RKX;ZSU2#9:R#SE%9S_=NAS\D-5@?>9VY2_?G@:ZSTYPV[&+OU[
M\[=[?GM[;-%7;RIJZYT4UR:"\PF_V]K;'T?PL'6:9'!GUZ;\@$5J_'JWKHLW
M_(P2].P+E:"Y:CQ=)/F5E9P= B9ZJ;SM<SR83-%J#5:GY<@\P0KLJN!=_9&6
M$:[A"J]8&O1^)5K_D?M),@'UW]3#/^ED]._?[%&5^_Q)N!;^_RY*5\:Z,B<3
MT!F?3I(Y/.R/27:3K*N__#4L[:?YB;^ [7<??,/Y_*N](5O9F9D6+(X_DFK
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MG!;+!Q^$YP$#=SF<+3!SB-YK?X7</L@U/#A+7_2OVO"&)@B0&KE)B9475<G
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M34V58/+Q2<TXFH!9N)>NM\RMIEV]2$HUBOYSWRE*.(>2 >?<^\OW;^$_6)'
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MYR,&5RY>U"YSFZ^#;>^(F.4?\25&5H',GO@:!.+$9!RN!">\0Q@7&&$/L8C
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M5G!?@G3SL_Q;!F+,1?(P9'XE\'6P@&?$79-=;!]$>C23ZP PH6?5>-<^(W?
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MA&!&%@!NAUF4WA/RQ[CRY=GD+2GRY'FI=':"L!#V09_]TG' GG&#>2"C>1!
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MFD[>("CE<""VB3[K&"7<+]8Y-"6,IVBX*-SS'.#*,4*!W\89![(,]\'G>6=
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MB"SBU:$D.0S?:S^4;G%C%LCU;FJPZK/C@U5&V$N#2[>/FR96S .@GU<1]92
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M2[:E"PX+_-'44[$! )MT_HI;(5V_*,^=->2U]H]U->GSI;KI;G&18@#A#PQ
MB+**5/^7A/OX9@W[DXYI^KYP-!#YN,0:YZ5^2'G9.=Z-SB<Z_-8+5$7Y3='O
M)>L8(J([%BY77'&8R"5Q0(0>6N22/4LD2K";T+W(/V'Y5MIJ'QJ8BHS \H3
M%!M"]6-W;\[6F4YRN1ZE^<J-QE/ZM($^,Q,E, _P752A,U_G:DF='J@U]&U)
MIYXXF7SJF<C$&<8#?F(_Y_L=^I5V*/N_DY]JK9Z\;EK/ND 31V)$Z]K_B3:Q
M6WA'SYX]QO;X\T^O3T^S7?LZ+!5P*WPL9VOVG2;=[+)<,H=ZJ1[DQNX10:2/
M[)5DI\15(W.%)>N5[I?7%UQ>LB0(T;ED=*C4)OU:"R7#=P$K3ZOCA?*$@.5)
MBZOR.XLB\?4>0Q0H)P!I\^AR-)09V:BELC$QX=.Z;$BNE<]+ZC?S"2D7[GV
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M**%E%^X93Q4:,-_#'>65B^SD#)^UZP6? /.JEJ!$,K9NW5<$WIMW$V=H4$W
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M7EMDU#0T%P I2*OZM?12$P)403O>5B+; XSJHL]KG^;]4'6)@A7&))B367,
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MXG'1U2Q?*V\BJ[Y)"X?<6OEM46J1$=E8KS[B)Q-H+M5UW9(B$!C6W;KF(ZZ
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MTW N<OXB',*1.>8^3UCW,,4^;8,MNI^VKV-?F?-8^7UMN3X]52U%*Q+\S,;
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MD?)M@IA(+!+E-!^F(DG*DLH)^V;W/[9IL<>=24)J+KKQ"0GRB.3\+H7Z5=L
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MIP])K#+G$I_9C[5;T9&2^:MAR4;RHMJ*+=LZ"ZNV+H6#VJQ>_Z7H=N9$%D/
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M<LR=E-Q]T(845K7B15MY]%TPNP+**&X,?0U\L8*4NR)0P@C(27(?M37&]O&
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M%?+KA(/H+!% 2^>L2):)/L>)FG5A2,JY%_..)>%^D9;13&JC-$0:!_)3G(?
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M92BJCAH#.%VL-UI%KOH$K?="&Y*/UH8S-[526^D<; ?7Y\?/>UKWK]*K:O&
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M]GG41/'KD6MCK=TD&M^4:(N%?/CYYV]?ZHH_.1<$0Z94"0RR$I* <?(52BA
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M3> L6!>RQ2#O+P*^Z\F=%P-;KI1D'H%P%^(>#^"-)[>4ZV0,8]GR-FY>]\7
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M;%KZ^*? GFYDW_5:= /F63$$5RSR2/M'JFW_72$&>V,A8$)"%76,?B4^+'G
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M[)N.,<\&M8_^TM8I%_':)')@W%O@6,N,2\)*PP*<![+MC4:I[KHG9X-.O^O
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MU(A[H4G?U?#LI_M\C^6>4'FJ!%+E&K_:%+30L)K$\>5<(86DC!BD<< A#D@
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MD";8^WMZ(RQ'P"GV\="#ZVC9_#<<3"A]4-^.FT9:(6?TWT>ZH;Z=,EY&_V,
M>@1"_F(":E:FE0^2T;4L/^3+Y9N\,#CF BO!6$I@S%4,,1-<+WEB#A/%L> B
MU+\6UF&/IUJ:VNIGBQ4T8!TBZ4Y2>GHD\$K4T!X$>QR!SP8I:*!:QO1;O(7V
MH8:^J/N^ @MMK#X91GCR >,%#=K8\21$T.J&W@&!].:FD#=-!'JSYU0%GF_W
M2U$8I3()$Q@0I2".,P4SE#"8$:F7A3'AJ5N)9:M6IR:6W?P1%VU3VW%N-Y?V
MSN3 :OH4KZ&RW;*N4VF 03:GG5CR'8UGT?+8T7?V9!R(MG.X>;*[6]UQE\A$
MJ4SIKA,X@3A+"&2<AS#@$B68R33-G)P+QH4_-96LI^IU]1:34-\D(*__]OMJ
MX9J7;N0W83+;%].<"3_C'L:V-H/MY'N*FQM'YZO?SP['Z#/FY^V>9]CK\#>W
MM_3P.Q@@7\XY4XBD:005CQ'$-"8P$S*$*,-AR!%#*;+*!>4%S>1&N=8?VL(+
MVDL&D,OZTFY@&ZV'!AZGG#V@#R<'\>@#[859[]4>^R,:O2KDQ>0=JAYY^4,O
M3>ZZ$?UJT&B:?=S9""!!%@F:13!2&=/K$\Y@1B,"199BE1$9!L))B-V:GYKR
M=G=A?J/%'W(-J\$65,N+]K-^[)MHU:I'+-<)@_$\]#R_0_$&>I/PM 4_Z'9-
M/^8&2G)J!>&9DIBZT',\2:G34_I)WE./ZTU:BX0(I=(H@B0)3'JD5$":J01R
M% DB,Y*&4>0B;8>;F9J$5?.3*G6\R1Q'[^J41XM5DWJXR25ZITUX*.I%M8GT
MW<0HU$YZR\9K?>&:$.E(5]AIVN4$#ZQ=>Z$<_E.*G.; JPH=:6I4M3EM[JZJ
MG+FZIWJ8M?(K>5](OJ@7W"MQ=9<7Z\4_Z\-2192,0TG-GBV!F*<,$JXG2Q(C
MK$+! I0X14^<:W!JBM*%6N=,ZX!UE(=S7%L*A4<&AY:,:@-RC\(K&PK=Q<.2
M%[\R<J[1<07%DH(]:;&]KW?MHOQ.?ES3=;V15Q=:_'@KY=HTU"0PI$NS)%SF
M9F@N7SS6^23H\I<B?[C?EET]O&RLJS#$5.G%'#(UN:F>\T0AADQ%&)(4\9B*
MC$69E;/1R+@G)WF-!: VH5N1^<AV3K\:'&.]%G:R.L'.'MYAP'<_]ZF_-";K
MO@LVC8)][ I/8W;(@9)0HS9_R8!F,NVT$82[>1RN]7AJBI,T*_\Y8AB+.*7Z
M7<HXQ#*-($N1A(2RB&1Z>!+2R<W+&<'4!AESS&-R]-7QM ?3V3Q)VR=J6RY.
MW.?>=2[#QT =,O! 4&-O<WEM ISW,M?,JHR C1'UKJ7OD: '@0-HN@N*9U#G
M'B0=UMD^#^JGF-?ZA7NG7\&K;XMRGK$T)E&FQ9"F$F+%$624AS"-TT 2$QF0
M.>TI=!\^-9TSV( !!SX;>(Y3Y">TV0E17S(&UAAK'IR%XY#!7C7A20.C?NZ'
M3-O]D@]><WER\JI>SGOU>RFKJIMSH1!*213J&4N00HPIA93$#*HP33@.<18&
MW.6;/='6U#[A-SN)R/N4 3Y%K=UW[8FP@3_SG?SC%5"8*ZBAUK5[9X"JM2GD
MVRGB/LQ^H 5A@V4GWVWOV7*3'S'\5&;R8[?TU!2Z*/Y&EP_R[>K^85W^*K_(
M95!71)^'F!(9AQ3J-9" F$D%:18RR!2B418QE>'425..MS4U3:FP@<!11$YP
M:2DB?A@:6D0T2E#!-'M2!N@,-(2!SS5:C_,'"T[\ZL2)]L;5B?.&[^F$Q2T]
M0H@/Y6"JQ.>ZR+F4HEFD+)>2M[$Q7"Z^F)V<<AX*HE<//( T-4$F3 8P"P(,
M:82)%(S24*M(4[[DDV6D\26 K#ZDIU55/HURD&G"ZNS=8R_OF-.2- [/([G%
M7F"&IPA>'TR>C/"]J('Q(H!]\/ D0MC+ R_99OY$OVUWNZ]86:%QVI4\^(0)
M?3[-_J,I*[G%"3ZW2+T?-YWD8X#MQ,/M/</&X4G##V\1GK[%[;T6<C%_O5HO
MUH\?[^ARN2F)$09(\##)H HDA1AE%&9QD$$9)92+2#(JK-8!1YX_M;E_#1%4
M&,_7R;!B\+0:>.!E8 5PH\3ZLS]C^(%/O93\SS?YEY_UG=57_@]L?H3UC]6G
M?>R9HWS.9PQJ/^%SE_5,+K_UB[U:B2K\^#9?ZOO+.@1OGL8\DRKF$(6B2K<L
M(,DD@S+D3"(:XX1F+H4^SC7H]&&/4,KCDVFCZSY<>;N5'=S_^B<2!NE?J]*L
MKI$49^FWFQ+X)'5@5?AUA\G7IUES3Q!O287??/#G&ATW_;LE!7O9WFWON\ M
M^:JN3MQIZJ6IQ[I:SPF2480B"B,L%<0T8Y"(F$"EI(RS)(P"Z12W=;JYJ<T?
M&J @-ZA[N" ?Y]5.0?RQ-;!^U.['+5T=J#/0@/7L?7R6%/^^Q\>;'-_S^*SY
M!_V.S]_5=_5L0J_JLA.2&?>Q6IH^2OY0U,KENIBV?>"$OH$.Z!DPL#LC*=@B
M'VBU[4J8Y\6W=?,CK\5=:=E?FCL_P8>CXV&'RG=R_5Y]HM_V7!YI@F7&.$PB
MH@=IH4)(XQ3#5+*4)4DDLI#T=WETPC*U$=PX/W9KCQ[)8S&" Z1;E[IL.@[>
M4>-L2G:=(H]YQ1M%W3C3Y^K8=3-@^EW_N[9[1%?*7ATPH%.E&YYG=*_L1=QI
M1\M^C^Q?"S O#D>-?LI?R/J<0HHY%5F"HQ1!Q4PZ(J)22()0P21(%46IXH%R
MV[:Q;'B2VS?NI?^L.+;<FQF N:'W:"K(!PK]M;B;,G\M=+_E_5S(\E[5SZKQ
MT8OYN5!RJ(:?T_T]LZ<=.%+=E IL]R)4FK&$TAAFB#&M2BC3TT?C=9K$@N)$
MT)@PIR1I%HU.;9[X2BJI@0E0]$F&;$6SG3#Y)F]@43I<GN])\5'O&T N%/G-
M-V;3\+AIQ1RHV,L>YG+O\$62WVBYFR<13P5'*4P(DQ C_1-1$8,JB%6 94*"
M:+ :R0; U&1)OXCI<"62*\KMYTM#$3G"O,FY0+*QX7GJ(W?9>[;RR!6(R59'
M[E)T27'D)\_I&6W7<4W[2)?R:B5^HVNS-?CX7EU]H8NE<4][DQ?F'[>;AG/&
MLY2%"8$\XR'$:<HA2?7L*^5)@B0-L7(K!M\3Q]3TKC6CW@6ZJRW8'.]KZ*79
MU;FK4B96J?O*C2F.X7X]^\U.+4?HC8%%\VE'&)A5%[165'MOYHAC"WX&-H9!
ME1?0]);'T,/+&/4;I=@3R[@!C9<1MA?[>.'C!BJB41Y+5=XD)'_]319\4<KR
M[>JZ*D#Y=VEBKJ2X^J('B!O9_OMUL>!R'O,DY4S$$"4L@IB3!&:IR*!B@60)
M43+)I-<B&E[A3TW+6W"7'Z2,_!K8:?QT.W?@H<&F@D9YIH3&IDC&A@23,;2F
M809:(D##Q.8J4'$Q8KF,0?IPW'(9?DV85KF,0;K'N5S&,"A\!?<ME_E7$W&L
M1^P/LI3%%UENUD/S,$[#"&,) R;TB!>2 &8T93 .@@@)JE@F[8N&.C<_M1'+
M]&^^:G(5T\:937XS?>Y45-2]'TX/.<.S.]8N\=^?[A)O\ -M &@MZ.S,#$JZ
M0ZW20<G_O@J8]J;"/>;QY%.?.=#1QN+ST8U63^DQ$KR^NU_FCU)6[N+7^@VZ
M->>+^G4(41 U>0RRA,0)BO0,+8U2B&-3"I5F$L9A(,,HDF&06.69L6UP:FK?
M0J[#1L!] QK<ZZL<=,>&:@MY]TS@P(*^X:Z""UJ\H,H]91"?SQ[1CTD'S?;,
MZ$@J?9993S+NP,Y)X;9YSGA2[6#5$W%VN6^8D+Z-AWS(&:*$)U!*'D.,,8<D
MD2DD$E'&0T9Q0IV.0"T;GIH\[X:DC17<YQBJ, 2]0Q^('@SV&R0NP96=4>/_
MGB<FP942UWA ?_$(A3D[?27K_[Y=77%>%?FYIH]5LO<,,:I"1:",$((XD<:!
M3/="2!"F4:2" #L=89YM<6H*U<(#]S4^Y^B ,P3;"9!7V@96GA8K^+%%^Y/9
M]]T0>7V&R#[^^7;D^/;"/]/JV+[V=B0<\*BWO+&?QKR3ZT,E+#?.&]L2EH?2
M)F\&ZE1Q&<LPAE2RT"1#T),EQA+=,3@2<1;&3,4N0N0'UM34:NO^M"WLZZ98
MGKK+3M;&[X2!M<]$))THZKOMGFY1WX/)X0>9J?GEVZN<>H(VJN;ZI7-7F#T_
MO9]ZOZ;%2C_7I*^OCK^VI65CC".5H=!T*-<S0X8@,7DB$\E2I4+!]8+619"/
MMC0UC37!9Y67P^DP0T<Z[033"TE#;QLV&*N0S+H6[^=!BN^>)<.K0!UO;53-
M.6OTKHR<OZ&?,GPJJK*OC]7BM$IB>\7UVK0P)^CE^C>YOLW%/ R(2I1B,(S-
MT;,,]/PMX:E>38:!4C0.>>A4-M>FT:GI1<5Z"0K9'CZ(&: W-T65J[9S(G'2
MZZ5_%]@)BV]B!]:8%FZ]@3YKLUNWF,V<JER#&K8_P7$AR:OV6#4\J@RY4+&K
M2$[W7EC%^W7CV+%9F&""4IS%J5Y"(CUM,6DRLS2)8)Q&,4U0'+/0J7+8T9:F
M)D/5%V%V@EM?E[_TK,:]1ZF=PG@A:F!9V:[/6I"#+,/.4C%,:>Z]UIZG.O<Q
MHX\6Z#YZ@X>)2ZL\C9>>^4C:B=(\B<(L1)1!A:B$F 0F+5Z$8!(J),(X"GGD
ME'''MN&I*<?^!.9B9V_K/N@Q>_'$[*@SF,[,I76'KO3Z^NPR\[))C 57PTUD
M3C7^?),9"TI.3FAL[N^;Y_OM2G_OU<ZN?$77M$TZ0&7&12P%)*E99;$TA92$
M&*8H"KA"&"MLY4UPKJ&I"5.3YKH#%ABT9Y,1N+%[6H)\<C;TQDQ/NGKD!S_-
MQ86)PH\\?.2,X:=-W$\=?N9ZGV5^/M3I33Y(GM^L%O\T.:G2,,,D%C!B$=,*
MH3@D.,8PRJ((X0!AY. &:M_NU 2C+7CMI6;//LNGE6) [@86CJ.>_74%P@8Z
MV&(?AMY+7?DOIOF_@0__20[Z%2S:?]P$RA,=M=&N&-'QVWO&.)N9X=NR?)#B
MU4.AU[1UC%BU^57]VTX4F59L(G"&])Q.J%0K=JC%.A,LAAEE**2*2(:<'*^<
M$4Q-NU_F=W?YJO'C7U2&@(>5, O0^E?Z;5E5DQKCVU_[/'Z\OG8,0G;N)[L%
MZJ#L#ZS^]0*U!@]J])L@WF;?O;ZDL6$3R.MQY[TW?W[#<)U1C!M)VY>DO6#8
MW@_JN5M?W-!54[!82W*9+Q>BCK]=B6O]*K=#[GO5U(ZFRX_Z-W5<[K:<UO8P
M'4G"%,I2F(HD@)A4;F,4P5@@%0<RDRG.G#;Y/0.<FK:^_R*++POYM5+-%[1<
M5!EXNI8YGA7X[E#+(X9G[*:A3R8ZIE4>8UOCJD[KFF?Z;F,@V%KXI!K@(!X9
M0W6 W_,0WR#'/489B.*]TY>AVAD^R>2GK_F<Q#C*LI1"E*H,8B5-#42!(5<X
MQ<B$-"BGDD:.[4]-X/6G@(=+,6D(MU/H 6D<6(![)9C4)CQ/?LD.=\^67M)@
MF&QVR0Y!ER27[#YFV+(";2*V3R8D8SLQ2L.(1YQG4$58SW2S&$&6A022D @<
M9@&FPLD+]S(X4Y.]<]GT=Y+IS_2TJ>1ZSE1]O*V)PY0P.-*?]C(Z3B^-H*H7
M=Y">S%9I0@>9TOJA^EF*)1R!-,D2"J?IZUM8X<Q3^RGV"[HTV5P^WDJY_M6\
M/WH6_"J_HXO5/$@)9X@PR%(J((XY@AGB#*HX(V$6A2)*G#9MCS<U-:5MD((*
M*FBQ@L\U6LL$(18,V^FC']X&UKZ^E#E+V'DVO,K3B>9&E9[S9N_*BL4=?1.(
M+_*BWD35TK2D9;E0B_KY5^+_/-2U!U_)DA>+:F=U'@O$. X9#,*8Z&E=A"$1
M@9[6,9D@E:1IYC:M<P4P-7G9!>V<"-R1?SN9&9+5@<5G%^^LRO)*BV:9 [;X
MP>?K?+G@C\-,K_I2Z#G7MR.(D9-\]Z-H/[MWS^?TU;RFVE)U8E3[$%\]K&_S
MHG+F4+&0::;,5"F.(,9*Z86K(A!AR9&*XHA*IR.:T\U-3<\V:.O#ZUGM1%T"
MND%<N5C7OW7TK3Y#O*VT^:)S8"';,MF$@C7>ZENP/L7*AA3/TG2RR9&%R,;\
M?=FQNJN?R/RBYV9U]/N-7/''WU>%Y.9^<75G4IC,,6<DD!3#3$F](*,,:Y5)
M0BC3B,9Q(K&*0Q>5.=/>U&1F W4-[A9+J;5F)4TBHSMK[VA;HNU4Q2-] \N*
M00HZ4&=@"Q;4:/WIBB4M7H7E7)NC*HLE ;O28GM;WW"+VN6LHUOO'];EFJZ$
M;G >,42H"6@7::B7: F2D$:IGL $*$P3FD9:>]R"+DXU-S5E:6()&J>\IT-O
M![9K",9)QD]KC'\>!Y:82RGL$99AP\R%P1DGFQ@Y1,/&W/U #:N[^DU7=FLH
MF>I:VSI*5YP_W#TLZ5J*7XJ\+(V>T:69)1FA>R%57LA/]-L\5F%,$DR@R@33
MDQJ!(*-! +,H)DHOI#@+4Y=)C1=44Q.H+4Q@<#IN&/GI*+M)T>CT#ZQK%B7C
M3*:.C5F@L@OL=-@,L,HVH(WS-]/RRK77^9@?9*/.VKR2N3NW\_OP'M%UUWE1
M^[==YVL36$"7O[5+J.:HL3YE;#"^62Q-_C7U3GY]53S<7-W?+YO-M7D:1S+!
M0D"1$0ZQS!BD01A#E68\U;]B++ /OO,&:VJ"_=ON A7H3@24WR[DE\JKT+BU
MEO>2+]2BJM@#?__SQS\#KD=KXX5.EYTEKHG>L5S@>N[KTY+_?#TX]"Y<;1-X
MK\#&*K#MT=:;8VL8T):!VC1SDS8.&.M Q[QGZ3^'&,-GZ<>10A!'[4^WL$;O
MM)^,>O37VGA!D=X9>A(SZ?_I_=92;^BBJ"*2WLEU%;/9*7B'1<@I$9"P.(&8
MBP1F68@@,N6X)8UY$ED-N.>;FMH@:I""+P9J5=W.8"W!C\MM-0''LZ03)-LM
M;OQ0-_#H5;'6A#*:#,X54/#C!NIQTIP7(.?Y\+JJ.-'<J$N%\V;OSO\M[NB[
MK7LEA'Y[RBI<Y7U1Y5=>F<+0"4D45PE,,H0A#L,$$FI<<!@1*4T23D*K#//G
M&IJ:9C3[D W861TPIBD%+6#73=PC_-INWU[.VC@;MST(Z[%E>YJ-"S=KCSQ\
MY&W:TR;N;]">N=Y3)IW*7<;XF9=-T<:JH=(XG\TIS@1.@P2F 39)1,T.+$\#
MR$,:)[$PN7;8?)VOZ=)B1>_8N)-\;" ,]S5\,FT VA:YK*M-%9LJKW3C6F0R
M""YK)_]U;M(=ZR_FT9AX8;:84QUEL1P?D/Z!=>A86IX*?14B4;;E=L'6@ '9
MOC!!CR?6O_\L/19$.*?J.?7,Y\W78V'MV:0]-L\8-C[OG?RV_O15+K_(WS2^
MVW*>2&D*$V$H.%80)VD,32Y\2#D1B#%.@\ I>VQ?(%.;;NK7]7AY4[]=8+=$
M'8/8@4<"YS"Z*G[N_<IC6ME+67R6"+D],).,C3M&6=^HN*//N[CH;9/4<I,9
M7H12I+$*8)*0#&)L(N,D4S"($AH%,DZ5<DJV?[RIJ:E< P]TMMX<\^V?H-52
MU[R0-;1R;4'.VD2T0Q>I/<+&4&5I=YM[KD*T1\P^47KVV!W]=.+WC[_D7V2Q
M,GKT,B_N\[92V4I<&?]-W>#V@+^I!(]"$04HP9"EB$ LPQ R@BGD/,J"@"H6
M$"=7IQX8IJ8L6P- N8'J)BU]>L).<P;F=V Q^OTCZ+#;Q5]M:K06=)R;P.?:
M"(]"=0&%7A6L#XY1I>T"HG8U[Y)']1/#0Y4=FT1:W<J.)I%67=Q1BFUMQ[E*
M2,2PI%!F+#;IO&.3SCN"* L#IB3'.'6:5UV$9FH":4[PN*G!>M^IP:I::SJ%
M<0$$HF,1R#<FN<GI97UI)ZRC]=#0>Y;'B^-NS'E2'+=K4:<\KC^]]<*L5^6]
M#-&H&NR%O%TU]O/0?KJ\7PW]2"*P.4DPR]*4P"S3$U*L)ZJ0DDQ +<VQY!RE
MH=O:UKKEJ>GM=M-I:7!VE[QN.FK/O9UF#L+HP/K88@8_MJA_TN*XN[&W33KH
M3P>=V?*J>?:MCZIOSJ3L:IG[ WH&0LN5?NS23%C%W6*U,"MVDPR_J9TW3\,P
M"HG@, R15BNE)XLT"QF, X2Q1"B6L5-"F3/M34VC/LJE?O+-#-S4N*OU''V"
MW#$>^@S?=@KED<6!=>F7#F]/L;:E,CV&0]NQXC<<^DR;XX9#VQ&P%PYM>5O/
M$B9[\;B!0E*%5"] B3!)JE(*:62*9.(L"GC*1!C)^7V5<.;CFA9K.V6Y*&1W
MM[7A/H@7\F:Q,H75 6ORN/5.V++/;(8R0EF80$EQ!'% %"0L2&&DJ,DP&,:*
MBH;9URLQ&J]M6T.ZUHF!*+43Y"G'B]?89GYCP\\:[K> RO-$A)\U<J\ BN>X
M[^IY+TSE7)-E38MQG76K*'3_5K%M+QZWES1'ME=?:2&>%EHQ(15_EXN;V_6F
MO&A;@N6Z6' Y)PR11"L%3#.L%3D*8LCT0A2JF :!I/K_4BL7YI%Q3VVVV&*%
MM*G%*QNTQFN1RUG[]RKPZ=)2R&.]&PX".*T>'T-6(:O*6G=M!AVCS49E][K6
MK::R?-86OIJ!CO4ST-J_J>C<,@ J"CQK]WA]YG]$& '[^./,>!UR</0:L?E^
M8^*V1LQ[U<7Y059A_:9N=KD'L]QFR@\S$3$<9I"CE$/,I%YX\"B"L91(*44D
MBB.7L>Y"/%,;PVJY>M&5*\?MV$L[R&[ &9'V$0>2S0#1&4.&*;GEB3^OHGXI
MIE'%VA.!NR+LZ[$7!D>_7=WK5<RO\HM<1HTG3\Q82@.,37'$&&),"<R"1,)4
M(H),<:PHMDI<9]'6U$2QPO:O?PH2]%=''_13A-H)G2>:!A:Q;BAT#70&*J@@
M&L#7R8*38<*A#[3W//'0QPT_&A!]XI:^9]XF74Y>/!ZJO!DCQ-*($4ADF$*<
MQ@&DF,=01AA'6 M')AV/N8\W-C6YV&!U/<<^P:?MT;4?E@8_K6Y@#E]:U(81
MSR?2)QH<^1#ZO.G[Y\X6]_2(E-Y?.&YGN.]RW6AI5HMF,?GZ&U\^F+W3>E5I
M)CSO\K4YB^+ZDB8>);]9F:1M31+IC* X56FD%W(BTDNZ)($$B11&$>41B3BC
MPJHFP.!(IR94=>;C&J')B+;=Q.+:&+#*UT VYC2A8-OK'>*!!^W\T\(XJ2Y]
MWH7D#&QL;3<@-^8V6Y&FFHON=VTR:&T&GW+PH@H!;,R>G4MC/G+_.P2/3^4]
M&"G2?"+O@UM<^QA]=#((?E  XT7,C\'CD_#Z41KL,?.XXKQXD,+$]^L;;Z]6
MXI59 N7W==!&N6[#U>:48,ZXR&" 608Q"A)(PT1!0?27QIADJ136TPCK9J<V
M)VB 5ZE8#/+*=4MLL5=3 Y=L(/8=8#&4#T+KP.-RRV@+&FC4H .[$MEM&*LG
M(75FZJ0JVC]M/(ESMO")7KG?W3-W/^=&PK3<5?7P3!)JMWCLXP^8UCO>@ 0M
MRD'"L<^3X3>[^O'FQDV9?M;LO3SHY^_H_3ZW*=3?KV]E80XI"GFK5XZ++_+M
M2J\BY:]Y6>[F8>_D8-]D]GHGU^^5*7B *)6$4 QC&DN($ST&DRC$$*N(TC3F
M#(5.7N8#8)S@,+TIA) ;&ZOU^\9(L-3V.=:N&*!CK17N.;MK:&E\__+M#-A5
MM]C8,0-4Z=?(<Q6+X7CVK;K><8XMUT,1?4#G!VO*4T;,#\87Z%-N%G5?3,JU
M7#SP=9-O;8YEG*4\0S!&H4GU@Q.8*1I5-8HRF@6<9]0^&* 7!A>M&"]0X(-<
M/Q3&.9#M1@Q<F(GQ9'<DBF'!XQBF'"F(HX1!0@,":1I13KE .(AL(PA&ZHSA
MHPLV72&?A!D,V0\62^$AF1UX2#R6@;2";W88&P- 8\&LS4<Z).479B'U1?WW
MGX;4A@GG/*0G'_J\B4AM[#V;B=3J(;U7;&:G0S]3R=+D-J7+-W*3I6N>QG$D
M@B2 ,B5,+[ZB$%(:Z!$@(IQ++/4@$#@NODXT-\%U5+4Y=]^!"Y1TS4%PAF/K
M=9 GYD;:T>PB!0:JQTU,-U)\KS].-3GV4L+"_ .K IN[^NG)L>P:* N0"C(]
M6>3*)-VC&60)#Z%25"B<RB 13KLX_W_+8W)9UI+IYRC9RS(\0#:2,7./3"+3
MB&->$;]91$QMC5?-?/5305?EHG95O\^+]1RQ4" N&*1"ZGD%01(2$7&89B3F
M 459B*V\LDXU,C4M:'&"+5!0([4OAG.4T-,ZX(NF@46@!T-.U6_.4="[\LW1
M!X]6]>:<:=V*-V>O[9WFK-E0?*.AO:S3J%6>')N\A&D@PB"((ICP5.CEA''&
MC&4*):=9)M)$,)+8U+BQ;]))!$:H;&,229KC%V"Z#_ -XMZ)(FU8)YQ2SC%,
M8Q1!'),,TI1IUA/"F*D<(3+LF%7.)^LCI>\<FW6[F9E?+@?6YQHL^-' _:GF
M<HNXDTBSKGB8*W-"-0-7ZW6Q8 _K*K/!.@?7U.\BT)Y"W]GESC4[=EHY2QH.
MY).SO;-G8N+\[BY??5SG_(\JVF@>I*&@E''(,AEK1<(,,A0C2$F"S F_GA Z
MU;'9;6!J^E/C Z4!. /_ _T9H0#<TZ:LZE]!$,8SA)#Y7Y.;"-"']6U>&#?'
MOX(4S;(LFH5IVO[KHBS-'HMQOXOQ+$V3&4XV_YAO<\P N@:_&1>F)D QF &S
MI3JK[M2/C6,T2Z+@\&.C",_"$!UY["O)JT"Q)T\.'+,<[[X8=J)Y27</?GI1
M]?3'NJ?;H,>*5H_IA8_8[S=C\&XCXR8!/F+B7E[?8]?U3B!!;VX*>4/K>M0?
MY!>Y>M!KX95\NY9WY9Q*EF&!4H@RA"#.!(&,A11RI4QZ7L0Q#ATS1)QL<&I*
M]A2O&>,;Q."SP0PJT,=]^OJ1;J<*/JD<>J%[&8M]$CI84>,[8\/I1L=.R6!%
MP8&<"W;W]1.<UW?WR_Q1RH^R^++@\G":G:<A$F55';7[[TV4Q'_)]38XXKKR
M?WB3%\VOS'7!/*(A#VD40A0SDV \R""C00@5#F04)@F3F=-YWKCPIR:&>SG=
M:J<3L\C9Q$(^#9V4==K4*L%;5:?6,;';R*^+G?!.]R486,;=@^@V(7./>H'<
MC9.K304J+T#'6'\CP//TD=?Q9&031AV=GJ=[=L>Z9T(Q<O[3U_]X6*P?WZ[*
M=5%M@Y>5;^RG6[IJ<M5M+-S)5/>+?O3Z%5W+3=J4.8UPA*5>#M1_(!Q#$A$$
M14AE0E"$0A;U3%?]S*:YR.QXCJ^_MWK:[$EL_5_U'+H9?9\M>:K/%RL-B!*$
M(9BD*37)T#&D>HD)LS1 $68TBI*T5[;N[^ZU&MZ%=_>EDBOQW^UULIO(30'J
M1*=W/;/XUL2 #C.@H@:L-3?;'+\;>@YD^*TH H8CL$VD-H%$OP/T^32R /LT
M[/M($3Q 5WK+'SP$MGX33@UM4;Y7.\&SC_6?G1S"J0E8I0DD*A,0\X1"EB81
MI&'*,Q4PSB*G5)AVS4YM:Z1"78VB)E=$$['@-G!:\FTWM/EG<>#!9T/@%O*L
M#I]_!)^;_PZ2%,^-*:^2;=GTJ*+J1L>N[#G>W2.H4B^M55[<F9BSZA3L=[VZ
M;G+(LIAQP60,A> <XC3AD/ XA0)A% 59BB2U2K-YIIVI24\':3,IJ\[=P8-&
M[)*;Y@2S<10(:N(?HS"*(58RU/). AB@F&%"HA2S<*Z'(9:/R&VWO>^:W=.*
M[I&Q@26\ [)V"  &YOF4QTYD.40F^B%MI!C$P^1YBDP\S\3)&,03MX\7;7C>
MAB=QA1:7]YL6_RK+4LJGL0.=B@U<5(,-@TA(/0@%0: '(9Q!'A 1A&D@*74J
MJ7&ZN:F-134\MWGO&4+MYKO^:!I8)&N@L]UJQ.5 *9_M>/$ZJSW3Y*BS63OS
M=V>QEG>YQP>]UG/B]>/K.UG<Z.?^4N1?U[=F?X"N'N>$*XH3IF>OH<00QS&&
MC&"M'EBQ2*L&QLC*T^I,.U-3C!HJ:+&"&BQHT-I'"IVB]K2$>"1L8.WHR953
MS) %$[W#ADX]>[3((0L#N\%#-I?W3$6P7.9?S?SD35Z\RA_86CTLFX5S^4%R
MN?AB(@C:J'E$(J)0(+0>A$++0Z@7MRRB,$I"SF46!K%"3ID)7%J?FFA\D"8C
M1.-*2!O4Q@>I@>V8K\"I(^SF(X/1.[#$M!C!%N0,;(RI_'5>%E+H99V)GQ@B
MQ4$?XOQF/'!",&X"A#[D[.5#Z/60'EMUG[[FGV[SAY*NQ-5*?+I=%&LI:]_U
MM[KYE:FK?JW?OF9ECQ(4L90%$*,X@3B,$I@EG$.1,8QP2DD6V*><=FM[:OH6
MHB!J=@$V:(&!Z["'XLB^Q2;4<)P.+&H:.&B15PFG6^P'.>ZS8>5(ML,FUG"D
MC[2QY4:^IPVO?JR=W 1S?.1X&V/];'VR6=;S$?XVT#;)-]HBCA_D'5VL]$/?
MJS>+DM/E?TE:S#,I8STNI#"-D@CB2")((Q)#%H=,"D251/S2S34[*%,;,6J0
M9E%HWMS+-^ L.Z3_YIQ_FI]GXZZ3N6?6U(6ZI@MALC0V]I@U2FT1,"8-N[?G
M1NO@^WZ6<)Y]3]"--IO]0L<G]@[?O,]+NORER!_N7RYI62[4@M>N1M\6Y3Q%
M0<PCF<* I"G$7 DME0F!,LDXEK$@(K%*.V39WM1$L84+*KS@*6#PV4!V#]T\
M2;B='GJD<6#1NXC!/F&;-KSXCMH\V>;809LV!!R(V;2ZK><^I9[^B<7RP4P"
MMZG2W^FWYE5N)&V.5,I5E!)(L=(+=ZTUD'&]A$]C)11#B8JH4[Z=<PU.36:Z
M>)^4-3"0P><:M*/0G"7=<AO2(Y5#[SQ>QJ+[1J,E-7[W%L\U.NYVHB4%>SN(
MMO?UKZ5=5V$HWZY,K1"])OV-%G_(*J52[2#=J=FP$B]EL=;-?BJH2=9RI2=C
MZ_)0W6C"4A5)%L P)!1JL4*0H2R$5#"1<D(I2QP3@PT#=&H"M[6I\V&ZU_,>
MI$_M=' */36P?G9,!(M576/';+EU.J^)SMD:"GXT5S2V@L984%O[TSCUR(?L
M%>^US <!.WH=]"$I/U1#?=#VW)UP7IJB I9U!_>NG] '7^'R6ECPJ+6]/3Z>
M/FTT'X^#1G2].@Y?T#?;7[DV;^[K.M=).0\CEC'".21Z4@$QC4@=$97@A#.B
M8AP+IZRONPTX30]&R/%:I42H2N%6 TZ3\\5Q@K#'HMW ?@DW@W^?&EK%R.MS
MC/3(B'?8;,\9\78:&3DCWF$3]S/B';G.4\6V]G?;VG!-79K%IH9$=1221'&4
MA#2&B5#&?Y-4&0P"R!0601RD$0KI?&7R:LF^M<(LH5A] UG]#70!#?DIU, ?
MM$[0#7B]MK]O-L=_+NJR8J"0R_IP99T#4P>RFLNN;R7@M7U5%JD+*U_9]JB%
M2\30O?2\)<@VO^_6XMP:L_'^.GVNY;=3+JQ,-D#G?/]%RAQ)<:Y79OO\YRU=
MYLC"V2IFKL_K-_O<+J:VRZ@ZW';..0M#,P_EIH@H3DS1D33+3!V"+(DSCK%2
M+MM=QYN:\(95V7/#Z@2O=C-3/VP-K/P'=_;&B;L_SX_7R>R)YD:=UIXW>W>"
M:W%'/^GX5$A:/A2/E9]7E8VDG"?5_\,)Y$*:+?* 0D8Q@:$42B8D40&B+IIQ
MH(VIB44+L4U7WV3%,GFPZA\=$V =HM5.,BXD:V"MV/#4)'NO ?H3A!/6>U6"
M0^V,*@$G#-W]]D]=VO.CU[>]5YU$1)7?"E)<,*$8U!^Y@IA) C-AHI8Y"02G
M+.;"*4_RP5:F]N&_S)<:<VZ<MK[()TG.*E?ESM\[.<R>WM3'A^AP#U@JQ*6\
M#KZ2')I2=UDY19E?83G8TKC2<LK8/7$Y>?$ SMV_K\2BK *-I'C]C>M+K^[,
MW^8HBU06I!*JB$N(,QS"C$04THR$*%!QE$EFMW=V$8[I;9R]U1#U\RPK)E[6
M"78*-!RQTW'C[IH!:CM ;<A(SMOG>!S/;_LHDNFX;)\CR\E;^^S#>IX1TO+V
MNLB_+(04+QY_+Z5XN]H@N.)ZX*N6=>:@NRY')D6GM![)).6ADI#$2L_.0AI
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M5\/FQS4MUF,0N]O<</2^D#>+U<I(&:-+,VI<S"=-TT1)',.P"@5AC.@I=Q3
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MI*1IB<H$6QV.GV]J:I3QV[]]^;>H,=:ZLO4 HF84X0>GP!3QVY<6H)?H8&:
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M-59Z3*^[@$. [=G3MFZP/7O6X?[MV?.77Q&O4%7+>+MZTL^M9:76:_4"5-O
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MFRU9ZO.B?XCYM^\Z^OJ'6BI_$^__%&LVWXC']9P=92.GE&.:(@D2(26 D.2
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M/6B#0X?%X\8;'^Q]/!H$'&YWKE'_O!;?Q7(S_R'JQ99Z\H-4*ZY9PJ@L)>$
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MXQ1*(&B2 "A9 A!5_049(W$I4$H3JV/?ZTV:VCJZ3MAAON9>'OK,C!#'[8G
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M8[V&]5W&Q'<0WT"+8X?L77:^)T#/X";7<+PS^ZQ:2"_EF"4)@8 04BH2R27
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M\^<B'IXE?,ZW-[(BST7'3P5V+M]B'\O^=4WT#LZ7ER>Z6LRD0#3.2@D@Y#F
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MYP.5P9J 5S4P7M% 'S@<517T\L!KJC?K:;R:N2_F[.40IRJX*(H\S8$L\A+
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MUN*[6&[F/T3S6[O3/,NG3N@+W%NNMZN/3(X:B?X@8:5N>/D-^[2T8=RP3#>
M3L(F'1_C&'FD-R<V;>)6^P5E64Z3,N6 49:JJ86$@+*<@APG10(%C#&%5C*
M?:U,;>[09@F1REC#[-!A',V8Z&IT O--;=]^QS$(NPQBX#?<IK>E<:-IAIP]
M"989O/CJ'9"WY'F^)8NZ1G>3=,[5Z/UAM]VMQ<?-9J>'\QE+8D9DK.9X3"0
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M8>M.ZK;OC!FC!WP3 M/Y29&&3_N7H DK[]A]%S4>^6-I1^2\4K2M#:/RLR-
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M@,M$ $CS1$U?XA24,4NPD'%1)E8Q[N9-3XU.:E'UU_DX=]7&DH?"1A9]8L9
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MYR>NWENZ6C9=;VY\6*S^L!4W''K$E+[](T%TO3=761I:!OTL)*$TST\;O)7
M^5G7!]3,S]_C]G[_NM_3/GQDGP59S/\E^,]DOJQ*<B2TH G/<C4-0@6 .92
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MU*0IQ.Q;PF<8QV_[5%^KAWJ5HFG_L]B(]0]1&;:I/N%4DHQE) ,"\0+ N&2
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M[V]C:@2OK 0-/QLNTH< -"#AZV$)S+;*P'V856VB2U'2,P!9\.?U0(U$E*>
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M!C5O?G((K?^_Y[BD)\Z^OLN?%TN2 W.NE,B!Z9A ">\@..,A!6LRHC'!X&
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M"RB!"I Y R$:6QNM!.O:I QV(&Z<5B;ML#2T/CJ V&WB+;*DA/? D3A001C
M0K*R:!+GR9E2VL2 ^\-F\'.QAN[VP3(^'""+-<Y.&M/]NIC'"PYS3K$4BV!C
MW8,]:=Q)XZ&FN"FB-::8IVZ5M0_KKFGM(;(;)E'55DT=6*HWGW/M$#3_^'/&
M57Y7^R6_*;^1&:Y"G+"L*KT"C'#U@K[S@)P7,!)+E-9'G]JD$IXDJX=(;A!X
M#2?\#I#T=KD@=M9?W\Z0+/P\U03<YWK@4%W$PFTLM0-(,"F#2BI"%0TD;:PN
M'G/"IVK&CO&G'J>JAP!N$!P-)OH.8+0]G,H/KH@0F36A=KT,@;Q *1*@CK'V
MRS6*<YF%>>KNR^$H>H*H'B*[04 TE. [P-"- .+&SLQXD%FZ ,+5Z@A![+A(
MNC8Z)6]1T?^>ZO1T9 KI+CD]1''#;&)'"[L#Q&SIGYCLO"PA )$70&FGP/'(
M0"BIZ;5!8J,LX_;]/81H Q[P[B7.#H*RGZ<8IK.-0T^;Z*: _]-B1D)?U0UU
M_?5*-"$')VOS3&MMW5*9 ">4@R+B9D>5G#_5\>EPF.Q*X;@!6/-2DR:*ZL *
MW>#K;J;$2Z<83QR\"ZS6 3M ;QBM+(%"!QU5D*TAUU4Y2AL,/ ZT8Q32 ;1>
MQ%B[_Z[>XM>:S[A,F[%@I69" K/9@,K9 DI)7^9"WS"I!/E4??X1&]Z#]'0#
MJ:.T?7<S/%[T?0!H>4YOO2>C24@L<Y8%L$)&7*F$$#1]&0LJ7C#'_&1;DZ,P
M]#!)XVY_[6 T@ (Z0-+MK-<E/Y==72:F1!ZU8T LN7J:6,"7&*"0R\E3#MFD
M-CO=TW2-FW1LA*D!5=$!L&YF,.[Q$EE*.E($HK00H!Q+X()BF^;$2OED=*,,
MY%-4C9N!; 2JP=30 :0>*K*ZQY-G1@8NZMEEL;23%UHFC%8-*SYK:05+NLW)
MW"[4C9N?; 2QP=72 =0>VMC)_#(N#82B:[, \A,Q"P4YF5([FD4?VGA6![I4
MS=*5C6!TI,@[2%D]LH'?2,0659LFZPC&:G(. R/Y)&(-$\9BLI1.M[GH]4W2
MNO'2V^4/AE5/!T;JP;W]9MI?9EV"IU#$^+J]6PO..0O:QT!22Y@:72O\!F'=
M>._ML#:D:CI V@V9T4X>..840%JDG;PD!4Y21!*%=C*H'#&U0=4-(KIQU4^2
M[=Q+Y!WL@T](Q$L?96$*=*YNH(X(04@+40H;&.8H;*N;SD<=SYS")V^'I8$4
MTH$A>GOYW@U+%S<(/8_&&@V..;*E2)ZGDQ3%BDA0T*)HDE"K\O"[Q(Q]K7P8
M/=^O"3]*Z!W@YD8;N OZM<]<%:+?R]K&W-300G$2#\O,*(9&MTELWJ5D[-/A
M)H@Y2MP=P.5%2IL#<IR]Q6GZ:?X2/T]I=[S!UB2%K(0*!8J)M "$,[04T$/=
MB^N6;&)J4W;P;=K&]:\;06I@E?0 LAC/S\YGM2'-IFRKMC-=YD]YOII^R75@
M[%G^>;%:/5[V_B+]Q_EJ?5%:^J9\P#\F'D5,2E5C'&F=<4$KSI&L68A%Z"2U
M?[*K[%''?T,S,ZZ3WPK&(RN] ]Q_6%)4?+[\>F-[\/5R8BH*/),%E!$20J$]
M(JK,?/"JF"?G!A\.V_NTC!L.-$+=D2+?'S1^"YIY_EB1_F$P[+S+:YS.<_H1
ME_/I_./JQG)ZE<LT3M>3*'TI06;(A42DL@X0(G,D-B^M3]%&;(.E;],V;MZ^
M$;8&5DD'!NJ^H"8^B%"O:$!2AJ)OF1&<<?1EYA*MST[S-KTT[M,R;EUR(Q =
M*?(.DE[?2N1,DLV%1VF FQH""4S@4U)0," C.860F^=-'Z2LF]/$DR13CU?.
M8& ;H5GGVXU./N7U-.+L-D.#=^Z\_:Z3M?%\@L53]O1DQ;#,F %=ZMC$2$CU
MS#,H&K%XB<SP-@FF4_3TO)T1)(F_66Y>FS:^Y=N\W,Q:F-!Z+:A=@E2OJRFF
M(M2AD<"=899I'I5OUKAC!_K&3M8.C**GT[:#**D#Y^PV5]N9'B_.UY\6R^E_
MY30I3D>G183 $AER% J"<@Y2$2EY@3JR-H[:TW2-G>4]*=2.4DJG$/MIM3HG
M3I3W.25NP89DR,?5"%XZ^C)'PQC+]+ V/1@>IVGL;.\(T#I &9W"ZN8THEQD
MY(P3$U;6D:DE@Q>&K#%'$I9DQNLVN=MO$#9V'G8$@!VJE@Y0=N- Y-$M7_@<
M*7XR8*O,%"*%UB4SR-':%)SEM():'WX>Y90US+\V1MO0ZND+<?=V?F^M]]Q8
M*+GV/-65%486.V5-@;807*M6U?B/$C5V%O9T"#M*'3TBZV+CCTAFU^9 \G"<
M%@@CDRQE 6UC])@\A?AM6L\\0M#8*=E3(^H -?2(IIN[?.2&28L>?"X!E+>T
M,H0W$#)+QK%L6*,N$D?/X!Q\9M9XN#I4(1V Z]8)ZY:;B>!.YZPS)*/KN;RC
M]<$P@#,J:*\EED97T1X@9B<H#3YFZV10.E;\SV, UY485XMR<9N%OCO\)*YO
MO:=!+G\OU@;*XV_+;:[>? 7$2*A!KA%BCI& PS,XES583[N=0=K;7*LFY0\2
M=/QY]L4#/]2*HHG6,KA,.[8/2 %MCK3.,"(D7CRJ$KGBC:>-;>@8-_L^A.[O
M'V(?+.<1=[#5<EU[5J;SN*9P-"^_3&-^\<>4[*<C!E"1 2X.027N211&0#9"
M)N2)!;Y3_S5ZP0V,T%=W\?$8!9V<SQR@S<6 HNT#&IMS\RT'JU>+,YS.)SZB
M$$I&4B<G#\T4\M4*)P%IZ30J95S:J8G#/OBX3\8X(!E&L_=A<J28.W"$+QCY
M)9^%O)SHDK $@5#J71&%Y(,%+3D4I;50J")G;5I:W2)C=(P<J];[+88/E'$'
M +FRJ^0NYI_HKZL)LYSI$G5M2)E!"19JFW8!O"BEC;-%JS;YG/NT=')0>_B>
M,Y"8.P#*N_PES\_S:Y+2@^.UKB8W9^DRQ31@L<ZM*,)NNT24*+TM127&L%'!
M[TX$=N+&'(B#>]6^PRNE?ZS]^$><G=>T5.VE2_]/]=I%8)X" J%K:[=Z*UO4
M(T):HBA=\876:)1M4H8'$#LN!IN 9C]@'JW!#D!ZU<#D8CK3=7MHEIE2!1DD
M)20QPB5@P0+$1PS%6I]9FP/=1TGJ9!\=QN@-(_@.$/1RL5J_*7];+-)-C_3]
M8I8FW%B.OI[>B%*G"N1-C1:YIR%Y%1*KJ8]&!R"/T32NT1I(Z??./ ;10 =8
M>D?J( +JB.=79'MGB\V0DPMAD>N:F&$E@]7TQV;8*8I(]MSER*7#(G*;\N<G
MR1K7*K5!U'!ZZ !4?\MSDM&,>'F1SJ;S:97/>OHE7['C-/-%<8BNSL_!2(+2
MPI-1-U)HKVH[P2:P^@9AXQ9AM@'6D+KH %K5\E:;>RFCB:#MWQ5FP'L?0$69
MP'./$(WD*&GA.-7F=L)=2L8ML&RWSQTL[0ZN\UU)Y?I._L0)*^B?!,HJ!ZI.
M0'4Y&,BJ!*&\\%*W268^0$PG5=\#^]<'"KL#O/P-I_-*]YMY;=?PIOQPOB+1
M$!]:52M).@T5[2H:\NHR1\B<\RQXUDFV*0)YC*).RKF'0<X@8N]@<ZHCO+==
M/;9+X*<Y/9L^F22+FH7(P;F@0;F,$.I.:X.V&$JQRK;I.OP819W49P\#GT'$
MW@%\-JUD[EC1BYVW3IW$J!(17* $5R<[HP"TBF("KVTPJ+7)#8?M/4I7)X78
M ^UAPZF@ T!=;\27"=7I_)SXNB[-FE@FE&%,@&;UI#N2:X>>![ <,1.3S)HV
M":-OT]9)/?90-FI0573@*]WFZ-5T%;=,Y73-TV5SJQ?K]7(:SM?U//3#XEW^
MO%AN8A7ZA?772306#;<6!!96#T@C8-8."G),FG9YVV@&[6 L=%+BW0*JIU)L
M!^:2F+H1NB3,,02MP.L<*7Z1'M Y 9ZBYV2T$SFT<?EOD=%)Q?<PR#I<P-W9
MNX<L^-N\_ %7T[B]_Q=CXBDE"=S5/I;6&_#!:"B>!60&2Q1C[:RW"-WM?(8]
M$XBUU%(')FHG]EY-9^>U&'_#8-"1*8L(L3;N53Y:<*IX(+Y+(*E:KMJTTMB;
MU-V ^%Q*;-IJJCLH/NTFW%YSR?'"HB30"%T=715JB[D"S#A=-.=6B3:GB@>3
MO!LTGTLAQ&DT]_P@>FLU&N=DXJ+6\ZI:V9L]N*0#[0ZN,.MRR(UZ11Y!]&XP
M?2[G":?27@= O>RZ>MD\8K/D)NAL+#X62%EY4$HE",R2@Y(=L]8F%7R;N/A!
M<G8#UW,Y<CA>XAV$)'>9N%@"DY)T*I[HYBYP4'5P\:8BDLL8/9?"1]4F4_P(
M0;M!Y[D<-PPA]0[ \_<\_?B)Z'[QA8SIQ_SK>;V&\J;<N\._71D,M9>\&! A
MT,HHRD'()H"(13JO%#+;)IK=B\S=@/9<#B/:::B#+>\1YF[NXK<Z2:@<=(C%
M@C0N;$<=.Y,C^9\J&EZ*Q-(F';<GH;M!\+D<6[34TO/KUG!KS$=U3+<N:MO6
M#=]\:>,^#OLQ/7QSYNWK7LS3 T-6KHK<BE0> X\0>:SM;X,";PCH.3/)"I+#
MWZA)RYZ$#GQ$D8LO7M$:*]R"\@K!,ZXV]7TLA40Q>9LZVOV/*$[1@'EPI'SC
M_&(/Z7>PX3XUJ.A&&#U=)/J\-N+)K_+VOU>R4Y&Y:L8A9BZW&4K/'0G "VZ,
MY9'S-BU5CJ>]DYM,)P#IB?7<,;)_FQ-;L]HR\7\N9M4]N5%G>#V):SE=T;=>
MT9?SCUNY7(WD"HGIE!A"8.A 91YJW7.$PC)SOJ#UHF'%50..1KZ+=6)D[K@P
M3@J3#I;+ R*X9B7P;%)@(%6H\@T4-6BO@ L68_*Y,-?J-L6C1'52)'\"TSV4
M9I[';)N;0<;]83YM@ZJGWM<XGMJ9U>%#J2?F,BE1R(C5S'?M<T2!>P:L;1:Y
MECXQY:)N5(.W$WD#]\[+,M%*# %*YHR8]8Q,-]-0A-&Y.*^X;7/1OJ?>></C
MXAN=]/:1>@?;Y!7U6XE4V[R8UR6\Z1!&;H@2,AB0NDZM(.L+7C.RSK8H5HPF
M!Z#-")$GR>H$40?H^S'H'"W\#I!TAX>+UF&9Y<AB0HB^3FQ"28Y"-@C6Q!2R
M""XU*C!XD)Q.D'.\NN\>UATM^PX =*/%]D6W.*NMH?5%B\E(7OMJ&T RT\0*
MA1PH,85&D>D]4L8%S@#J?;R=^0&R[@ L+U+:=.3&V5N<4B3]$C]/R:N_8$:)
MR 797LBZEN1SG\#5"H?L:T]+Y"A-FWWK2;+&S<X-#Z+A=- #H+X][/Z2,6NU
M=\B 6^))>4TQJE0&+'D 21D,EK>Q2CN3.&XNH0'0FNBF ]#=G4=^P87G&+0O
M&CQSQ$6,'A!%@,2TM:I(;DP;A#U,S[BW\(>'TP!2[P [M\9(7+" 7NF@N(2@
M$MG<VMN9N)+ 1(B!IR1U:7-T]0 QXUZ^'QXUQ\J[ \@\4#9CN5*2^0RX2>1B
MG1UH? #!=32&L61YXY*"G[ML9SQ(6'^8F#L RMV3J9_F]Y-G[Q:SV>O%\G=<
MI@G/ F- DE:P 50@A\])'0%I=45)R\*(5IT_]B*TD_C_0%S<OSG03$D=8/!^
MV9V).4?K241B8VW)<*-A">K,)9,X9Z;1L=V!Y8^M<-14\7=MV5%:.!A&GS=G
MS[1@ENN!=KZ[ IH$FS(M, _6VMJTJX[P<N3N"63.)XS"E5;'(W=I&7?G.RF<
MCM-#7WC:CI:\62RQ72V;;[[YO+FZ]>,?>1FGJYPF3FMEBB-A\9H/"06KT?<@
M-?F=7!E:5ZT\K7UI'3=_<'(\MM-C#]OHPQQNIC@_S" GX^Z342 QU\-0%B%P
MPP%M5ABYRZ*TN;B\-ZGC)B8ZP.E 6NP IB_2?YQON]NM/BP>22QO5F7 3=7)
M6>U6ME'UNTR27DW7^:)!^58R[W)<?)QOGK(1TJ1$HUAD"F*I?5@DJ\VE<Z+0
M/Z&K3:FX;3,!HS5GX^993KD(NL)(!VMFETK322('70I."U]Y5QO4%@C9)0B8
MK-5,A\3:W)[8A;IQNRJ>$KN#ZZH#_-V^**(RS[RVW$[)F]IBO9 ?[S/D;$*T
M7-L@V^2 ]K^FT^Q>XBD1=;CT1X1.+2-]( A\-5U]OABQ?:,O,C+/!=;T:TBR
M%B)HP.(U$)^^R!3H^]^LD=WGA>/V-SP%=IJ)?W](^2VDYOEC/=;]T#!MF#"9
MHE!"5'56N^/$!TN\]AZ5Q483M6L4SQR4-FS6YG#<M.$^6C@RS?/C/+5*&A95
M:%M. @I*D@G) )S@"$$%IXJ.RC::HW=@TK!=1\.1LX;[*&)0.)WN&CZN/KV>
M+7Y?-;YX?_\UK:_:?X.QX6^$7+WQJN!?9BV3S+320IT')"(#Y"6 4T*8PFR,
MKDVCEZ>H&L ?K\]\NUQ\F9+\?OCZ&VGAI_E5H_<7<3W]LKGG]U"CQBO9V.2C
M2(I\1Q[)4GL7(-39X"02+%P+#*7-,=LP]'=RQGLLZAYP]T^MW.Y"3&:D0U<4
M2,42T+\*?'(>,A,1#?,ZNC9#C3KJ!#$&#IZ,//=12@<-P8;K^\Y<L-8) R%F
M"KF938")>9"!.\QH,& ;.WG:AO[-SIT[0/(X8#AX%7S)R[ XW=04VI("-U9
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M/;;OM6X>$QG/S!J_RFN<SE;#&^7+![>TS0\2WY6)#CR*Z)0'J1TAQRD$C\9
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MKSK+W3AAWF;X@B.:F(=$P3(HAAQ0(P-N"[-1IHB\#90>IVGL 1I-\320*KH
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M>P7=<Q,ON7&E1!Z=KGVE#(7%V4$0+D(.,1N?+%K=J+[E2;K&S6&V0M: NN@
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MUA\6%T;SBL_M"@@Y.R]%K3NSM$5;2XO+L00HT9MD1=9W9Z+L8UZ>>/.(P?Y
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MIS+XJ#.9-[/'F\9QI->CX_=;G>9[3W9M*;YKBCJ3SM;5ZPBH@P1R(BCHEL5
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MEW#*B_"<ZDI )X"SXL$F0*>(?TKXG2!+4-9ZB<D:#NY!TX"]" E7DR0J#0$
MT0 MH3D7[$FY&[-,FZF;H]3*D7(>V9IGG#Y&NV%E<P5L;F[,FK7/!6_]K</;
MS3WGO'QQV$L.CEV-J#I!((HP6:;P&MQVQ;B5 2!PN!IJ28YD$J@<:N7&)$YB
M.>B1*)+>A7*I-JY"/2).:W1$2FE-*@4^.[8#8 @)I$7O7]ZER%5&DIV!DZXK
M#8EDE[>2O1WY*E1-]D1\BZ^*$L$B(I3T,R*N%>!&()$M&S>4W6LH0T/4SX=P
MA@0%^*](H YZ6P11OC40[77;W3 .%](AUX>W0D3[/)2:%&Q37KG-JU#4&TK
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M+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( -A-I53:Q#LPGQ\  !P\ 0 5
M          "  70\ @!A9VEO+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4
M" #83:54P+SL$EPQ   1/@( %0              @ %&7 ( 86=I;RTR,#(R
M,#,S,5]D968N>&UL4$L! A0#%     @ V$VE5)T@K?:>N   KM(' !4
M         ( !U8T" &%G:6\M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M -A-I51N0->T"&L  )$4!0 5              "  :9& P!A9VEO+3(P,C(P
M,S,Q7W!R92YX;6Q02P$"% ,4    " #83:54MF^OM]X'  #V)0  &
M        @ 'AL0, 97AH:6)I=#,Q+3%X,#-X,S%X,C(N:'1M4$L! A0#%
M  @ V$VE5 7,A 'D!P  _R4  !@              ( !];D# &5X:&EB:70S
M,2TR># S>#,Q>#(R+FAT;5!+ 0(4 Q0    ( -A-I52')HB2S@0  &<2   8
M              "  0_" P!E>&AI8FET,S(M,7@P,W@S,7@R,BYH=&U02P$"
M% ,4    " #83:54.H*@<-\$  !@$@  &               @ $3QP, 97AH
K:6)I=#,R+3)X,#-X,S%X,C(N:'1M4$L%!@     *  H H@(  "C, P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
